Word,Tag
#1601966-02-Background-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Background,O


,O
DNA,O
microarrays,O
have,O
become,O
a,O
standard,O
tool,O
for,O
the,O
analysis,O
of,O
mRNA,O
expression,O
levels,O
in,O
colorectal,B-body-part
cancer,I-disease
cells,O
.,O
 , 
Most,O
studies,O
focus,O
on,O
the,O
identification,O
of,O
differentially,O
expressed,O
genes,O
in,O
tissues,O
at,O
different,O
tumor,B-disease
stages,O
or,O
on,O
the,O
identification,O
of,O
new,O
tumor,B-disease
subclasses,O
and,O
their,O
diagnostic,O
gene,O
expression,O
signatures,O
[,O
1,O
-,O
6,O
],O
.,O
 , 
In,O
contrast,O
,,O
much,O
less,O
is,O
known,O
about,O
the,O
influence,O
of,O
chromosomal,O
neighborhood,O
on,O
gene,O
expression,O
in,O
tumors,B-disease
.,I-disease
 , 


,O
In,O
tumors,B-disease
different,O
genetic,O
mechanisms,O
are,O
known,O
to,O
affect,O
gene,O
expression,O
in,O
wider,O
chromosomal,O
regions,O
.,O
 , 
Chromosomal,B-mutation
aberrations,I-mutation
,,I-mutation
like,O
homozygous,B-mutation
and,I-mutation
heterozygous,I-mutation
deletions,I-mutation
or,I-mutation
amplifications,I-mutation
,,I-mutation
alter,O
the,O
DNA,O
copy,O
number,O
of,O
large,O
genomic,O
regions,O
or,O
even,O
whole,O
chromosome,O
arms,O
,,O
leading,O
to,O
inactivation,O
of,O
tumor,B-disease
suppressor,O
genes,O
[,O
7,8,O
],O
or,O
to,O
activation,O
of,O
oncogenes,O
.,O
 , 
Another,O
genetic,O
phenomenon,O
that,O
is,O
assumed,O
to,O
have,O
drastic,O
effects,O
on,O
gene,O
expression,O
in,O
cancer,B-disease
cells,O
is,O
the,O
aberrant,B-Physiology
alteration,I-Physiology
of,I-Physiology
chromatin,I-Physiology
structure,I-Physiology
.,I-Physiology
 , 
Methylation,O
of,O
genomic,O
DNA,O
,,O
histone,O
acetylation,O
,,O
and,O
histone,O
methylation,O
are,O
assumed,O
to,O
have,O
a,O
large,O
impact,O
on,O
the,O
accessibility,O
of,O
DNA,O
for,O
transcription,O
initiation,O
[,O
9,O
],O
.,O
 , 
Such,O
epigenetic,O
mechanisms,O
can,O
affect,O
large,O
genomic,O
regions,O
by,O
possibly,O
either,O
silencing,O
or,O
activating,O
large,O
arrays,O
of,O
genes,O
.,O
 , 
However,O
,,O
the,O
regulatory,O
mechanisms,O
governing,O
chromatin,O
assembly,O
and,O
disassembly,O
are,O
only,O
beginning,O
to,O
emerge,O
.,O
 , 
So,O
far,O
,,O
due,O
to,O
methodological,O
limitations,O
it,O
has,O
not,O
been,O
possible,O
to,O
study,O
the,O
role,O
of,O
such,O
phenomena,O
for,O
gene,O
expression,O
in,O
cancer,B-disease
cells,O
on,O
a,O
genome,O
-,O
wide,O
scale,O
.,O
 , 
Nevertheless,O
,,O
evidence,O
from,O
single,O
-,O
gene,O
focused,O
studies,O
suggests,O
that,O
chromatin,O
regulation,O
does,O
play,O
an,O
important,O
role,O
in,O
tumorigenesis,O
[,O
10,11,O
],O
.,O
 , 


,O
Regardless,O
of,O
which,O
mechanism,O
leads,O
to,O
coordinated,O
expression,O
in,O
chromosomal,O
domains,O
,,O
solely,O
the,O
knowledge,O
about,O
such,O
domains,O
is,O
of,O
considerable,O
importance,O
.,O
 , 
Such,O
knowledge,O
could,O
guide,O
further,O
studies,O
that,O
aim,O
to,O
differentiate,O
between,O
those,O
differentially,O
expressed,O
genes,O
that,O
cause,O
tumorigenesis,O
and,O
are,O
the,O
primary,O
targets,O
of,O
regional,O
genomic,O
aberrations,O
and,O
those,O
that,O
are,O
rather,O
the,O
outcome,O
than,O
the,O
cause,O
of,O
tumor,B-disease
development,O
.,O
 , 
The,O
rationale,O
for,O
the,O
existence,O
of,O
such,O
piggy,O
-,O
back,O
genes,O
is,O
the,O
following,O
.,O
 , 
The,O
silencing,O
of,O
genes,O
at,O
close,O
distance,O
to,O
a,O
known,O
tumor,B-disease
suppressor,O
gene,O
(,O
TSGs,O
),O
would,O
in,O
many,O
cases,B-cohort-patient
just,O
be,O
a,O
side,O
effect,O
of,O
TSG,O
silencing,O
.,O
 , 
A,O
similar,O
reasoning,O
applies,O
to,O
oncogenes,O
that,O
can,O
be,O
activated,O
by,O
increased,O
expression,O
:,O
genes,O
that,O
are,O
co,O
-,O
amplified,O
could,O
also,O
be,O
expressed,O
at,O
higher,O
levels,O
although,O
they,O
do,O
not,O
contribute,O
to,O
tumorigenesis,O
.,O
 , 
Typical,O
searches,O
for,O
differentially,O
expressed,O
genes,O
by,O
microarrays,O
usually,O
ignore,O
such,O
piggy,O
-,O
back,O
effects,O
.,O
 , 
This,O
may,O
lead,O
to,O
the,O
identification,O
of,O
large,O
numbers,O
of,O
differentially,O
expressed,O
genes,O
(,O
DEGs,O
),O
,,O
of,O
which,O
only,O
a,O
smaller,O
fraction,O
is,O
causative,O
for,O
tumor,B-disease
development,O
.,O
 , 


,O
 , 
#1334229-04-Results-p02
With,O
respect,O
to,O
the,O
localisation,O
in,O
the,O
colorectal,B-body-part
tract,I-body-part
,,I-body-part
tumours,B-disease
of,O
the,O
rectosigmoid,B-body-part
and,O
rectum,B-body-part
more,O
frequently,O
harboured,O
truncating,B-mutation
APC,B-gene
mutations,I-mutation
when,O
compared,O
to,O
colon,B-body-part
tumours,B-disease
(,O
P,O
=,O
0.001,O
),O
,,O
as,O
shown,O
in,O
table,O
3,O
.,O
 , 
Rectosigmoid,B-body-part
and,O
rectal,B-body-part
tumours,B-disease
have,O
a,O
relatively,B-Concepts_Ideas
higher,I-Concepts_Ideas
frequency,I-Concepts_Ideas
of,I-Concepts_Ideas
K,B-gene
-,I-gene
ras,I-gene
mutations,I-Concepts_Ideas
in,I-Concepts_Ideas
codons,I-Concepts_Ideas
12,I-Concepts_Ideas
and,I-Concepts_Ideas
13,I-Concepts_Ideas
when,O
compared,O
to,O
colon,B-body-part
tumours,B-disease
(,O
P,O
=,O
0.05,O
),O
(,O
Table,O
3,O
),O
.,O
 , 
Nine,B-size
per,I-size
cent,I-size
of,O
tumours,B-cohort-patient
showed,O
hMLH1,B-gene
deficiency,I-Physiology
,,I-Physiology
as,O
determined,O
by,O
immunohistochemistry,O
(,O
Figure,O
2,O
),O
.,O
 , 
Tumours,B-disease
lacking,B-Physiology
hMLH1,B-gene
expression,I-Physiology
occur,O
almost,O
exclusively,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
(,O
P,O
<,O
0.001,O
),O
and,O
relatively,O
more,O
frequently,O
show,O
poor,O
differentiation,O
or,O
are,O
undifferentiated,O
(,O
P,O
<,O
0.001,O
),O
when,O
compared,O
to,O
tumours,B-disease
with,B-Physiology
hMLH1,B-gene
expression,I-Physiology
(,O
Table,O
3,O
),O
.,O
 , 


,O
Next,O
,,O
we,O
compared,O
the,O
patient,B-cohort-patient
and,O
tumour,B-disease
characteristics,O
of,O
tumours,B-disease
harbouring,O
a,O
truncating,B-mutation
APC,B-gene
and/or,O
an,O
activating,B-mutation
K,B-gene
-,I-gene
ras,I-gene
mutation,I-mutation
to,O
those,O
of,O
tumours,B-disease
without,B-Physiology
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
and,O
these,O
results,O
are,O
presented,O
in,O
table,O
4,O
.,O
 , 
Patients,B-cohort-patient
harbouring,O
hMLH1,B-gene
deficient,I-Disorder
tumours,B-disease
were,O
slightly,O
older,O
when,O
diagnosed,O
with,O
colorectal,B-body-part
cancer,B-disease
(,B-age
69.3,I-age
yr,I-age
(,B-age
68.0–70.5,I-age
),I-age
versus,O
67.8,B-age
(,B-age
67.4–68.3,I-age
),I-age
,,O
P,O
=,O
0.03,O
),O
,,O
were,O
relatively,O
less,B-Concepts_Ideas
frequently,I-Concepts_Ideas
men,I-Concepts_Ideas
(,B-cohort-patient
40,I-cohort-patient
%,I-cohort-patient
versus,O
58,B-size
%,I-size
,,I-size
P,O
=,O
0.02,O
),O
.,O
 , 
Tumours,B-disease
without,B-Physiology
hMLH1,B-gene
expression,I-Physiology
occurred,O
relatively,O
more,O
frequently,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
(,O
P,O
<,O
0.001,O
),O
and,O
relatively,O
more,O
frequently,O
showed,B-Physiology
poor,I-Physiology
differentiation,I-Physiology
or,I-Physiology
are,I-Physiology
undifferentiated,I-Physiology
(,O
P,O
<,O
0.001,O
),O
.,O
 , 


,O
When,O
comparing,O
tumours,B-disease
with,O
a,O
missense,B-mutation
(,I-mutation
but,I-mutation
not,I-mutation
a,I-mutation
truncating,I-mutation
),I-mutation
mutation,I-mutation
in,O
APC,B-gene
to,O
tumours,B-disease
with,O
a,O
truncating,B-mutation
mutation,I-mutation
in,O
APC,B-gene
,,I-gene
missense,O
mutations,O
occurred,O
relatively,O
more,O
frequently,O
in,O
the,O
colon,B-body-part
(,O
P,O
=,O
0.002,O
),O
,,O
less,O
often,O
also,O
harboured,O
an,O
activating,B-mutation
K,B-gene
-,I-gene
ras,I-gene
mutation,I-mutation
(,O
P,O
=,O
0.004,O
),O
,,O
and,O
more,O
often,O
also,O
lacked,B-Physiology
hMLH1,I-Physiology
expression,I-Physiology
(,O
P,O
<,O
0.001,O
),O
.,O
 , 
No,O
differences,O
were,O
observed,O
with,O
regard,O
to,O
age,O
at,O
diagnosis,O
,,O
gender,O
,,O
Dukes,O
',O
stage,O
or,O
tumour,B-disease
differentiation,O
(,O
data,O
not,O
shown,O
),O
.,O
 , 


,O
Finally,O
,,O
to,O
assess,O
agreement,O
between,O
hMLH1,B-gene
expression,I-Physiology
and,O
microsatellite,O
instability,O
,,O
both,O
hMLH1,B-gene
expression,I-Physiology
and,O
BAT-26,O
were,O
analysed,O
in,O
162,B-size
tumours,B-cohort-patient
.,I-cohort-patient
 , 
All,B-size
tumours,B-disease
that,O
had,O
normal,B-Disorder
BAT-26,I-Disorder
,,I-Disorder
also,O
showed,B-Physiology
hMLH1,B-gene
expression,I-Physiology
.,I-Physiology
 , 
Fourteen,B-size
tumours,B-cohort-patient
with,O
unstable,B-Disorder
BAT-26,I-Disorder
also,O
lacked,B-Physiology
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
and,O
two,B-size
tumours,B-cohort-patient
with,O
unstable,B-Disorder
BAT-26,I-Disorder
were,O
found,O
to,O
express,B-Physiology
hMLH1,B-gene
,,I-gene
which,O
demonstrates,O
a,O
high,O
agreement,O
between,O
these,O
molecular,O
features,O
of,O
mismatch,O
repair,O
deficiency,O
.,O
 , 


,O
 , 
#2386495-06-Conclusion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Conclusion,O


,O
We,O
want,O
to,O
emphasize,O
the,O
importance,O
of,O
using,O
a,O
combination,O
of,O
techniques,O
to,O
achieve,O
the,O
highest,O
mutation,O
-,O
detection,O
frequency,O
possible,O
and,O
it,O
is,O
also,O
noteworthy,O
that,O
RNA,O
-,O
based,O
screening,O
is,O
of,O
importance,O
when,O
conducting,O
a,O
highly,O
sensitive,O
mutation,O
-,O
detection,O
screening,O
program,O
as,O
a,O
number,O
of,O
mutations,O
might,O
otherwise,O
be,O
overlooked,O
.,O
 , 
The,O
use,O
of,O
mRNA,O
analyses,O
has,O
been,O
crucial,O
in,O
order,O
to,O
detect,O
and,O
characterize,O
splice,O
variants,O
and,O
also,O
to,O
complement,O
MLPA,O
analyses,O
.,O
 , 
The,O
MLPA,O
method,O
has,O
improved,O
and,O
simplified,O
the,O
screening,O
procedure,O
significantly,O
,,O
but,O
it,O
is,O
important,O
to,O
remember,O
the,O
limits,O
of,O
the,O
method,O
,,O
which,O
in,O
our,O
study,O
is,O
exemplified,O
by,O
a,O
possible,O
translocation,O
that,O
is,O
not,O
detectable,O
by,O
MLPA,O
.,O
 , 
Furthermore,O
,,O
the,O
need,O
to,O
detect,O
elusive,O
APC,B-gene
changes,O
such,O
as,O
mosaicism,O
,,O
which,O
are,O
not,O
easily,O
identified,O
using,O
standard,O
techniques,O
,,O
remains,O
.,O
 , 
Such,O
APC,B-gene
mutations,B-mutation
may,O
be,O
the,O
cause,O
of,O
some,O
of,O
the,O
so,O
-,O
far,O
unresolved,O
de,B-Concepts_Ideas
novo,I-Concepts_Ideas
cases,B-cohort-patient
of,O
attenuated,B-Concepts_Ideas
or,O
atypical,B-Concepts_Ideas
FAP,B-disease
.,I-disease
 , 
Clinical,O
data,O
from,O
this,O
study,O
indicate,O
that,O
the,O
risk,O
of,O
having,O
CRC,B-disease
at,O
diagnosis,O
among,O
probands,B-cohort-patient
with,O
mutations,B-mutation
outside,I-mutation
the,I-mutation
region,I-mutation
codon,I-mutation
1250–1464,I-mutation
,,I-mutation
although,O
exhibiting,O
a,O
less,O
-,O
severe,O
phenotype,O
,,O
is,O
high,O
indicating,O
that,O
age,O
at,O
diagnosis,O
rather,O
than,O
severity,O
of,O
the,O
disease,B-disease
predicts,O
CRC,B-disease
morbidity,B-Concepts_Ideas
.,I-Concepts_Ideas
 , 
Early,O
detection,O
of,O
probands,B-cohort-patient
contributes,O
to,O
the,O
decrease,O
in,O
overall,O
CRC,B-disease
morbidity,B-Concepts_Ideas
seen,O
in,O
FAP,B-disease
in,O
recent,O
years,O
.,O
 , 


,O
 , 
#1601966-03-Results-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Whole,O
-,O
chromosome,O
plots,O
of,O
running,O
average,O
of,O
fractions,O
of,O
samples,O
showing,O
up-/down,O
-,O
regulation,O
in,O
tumor,B-disease
versus,O
normal,B-disease
samples,B-cohort-patient
(,O
Chromosome,O
17,18,19,20,21,22,X,O
,,O
Y,O
),O
.,O
 , 
For,O
each,O
chromosome,O
you,O
see,O
a,O
separate,O
figure,O
.,O
 , 
Gray,O
dots,O
denote,O
the,O
number,O
of,O
patients,B-cohort-patient
with,O
up-,O
or,O
down,O
-,O
regulation,O
for,O
a,O
single,O
gene,O
.,O
 , 
Orange,O
/,O
green,O
lines,O
represent,O
a,O
running,O
average,O
of,O
these,O
values,O
.,O
 , 
The,O
plots,O
are,O
made,O
to,O
be,O
easily,O
comparable,O
with,O
whole,O
-,O
genome,O
CGH,O
plots,O
(,O
like,O
e.g.,O
those,O
in,O
Knösel,O
et,O
al,O
.,O
 , 
[,O
21,O
],O
),O
Further,O
details,O
of,O
plot,O
construction,O
are,O
described,O
in,O
the,O
methods,O
section,O
.,O
 , 


,O
Individual,O
chromosomal,O
islands,O
of,O
up-,O
or,O
down,O
-,O
regulation,O
.,O
 , 


,O
These,O
are,O
condensed,O
results,O
of,O
the,O
ChARM,O
analyses,O
:,O
overlapping,O
regions,O
with,O
evidence,O
for,O
up-,O
or,O
down,O
-,O
regulation,O
from,O
various,O
analyses,O
of,O
different,O
cross,O
-,O
correlation,O
window,O
sizes,O
have,O
been,O
fused,O
into,O
single,O
regions,O
.,O
 , 
The,O
original,O
ChARM,O
output,O
including,O
p,O
values,O
for,O
each,O
region,O
and,O
additional,O
annotation,O
can,O
be,O
found,O
in,O
Additional,O
file,O
1,O
.,O
 , 
Hereditary,B-Concepts_Ideas
colorectal,B-body-part
cancer,I-disease
syndromes,O
are,O
indicated,O
along,O
with,O
their,O
OMIM,O
ID,O
.,O
 , 
Gene,O
symbols,O
are,O
official,O
or,O
provisional,O
HUGO,O
symbols,O
if,O
available,O
,,O
otherwise,O
names,O
of,O
Unigene,O
clusters,O
.,O
 , 
Information,O
about,O
known,O
tumor,B-disease
genes,O
in,O
misregulated,O
regions,O
were,O
extracted,O
from,O
the,O
literature,O
.,O
 , 
Tumor,B-disease
-,I-disease
associated,O
genes,O
are,O
located,O
within,O
expression,O
islands,O
or,O
in,O
near,O
vicinity,O
.,O
 , 


,O
Statistics,O
on,O
expression,O
imbalances,O
across,O
human,O
chromosomes,O
.,O
 , 


,O
Here,O
,,O
estimates,O
of,O
portions,O
of,O
chromosomes,O
that,O
are,O
affected,O
by,O
regional,O
regulation,O
of,O
expression,O
are,O
given,O
.,O
 , 
The,O
second,O
column,O
gives,O
the,O
number,O
of,O
genes,O
on,O
a,O
particular,O
chromosome,O
that,O
were,O
included,O
in,O
our,O
analysis,O
.,O
 , 
The,O
following,O
columns,O
contain,O
the,O
numbers,O
of,O
genes,O
that,O
are,O
located,O
in,O
deregulated,O
expression,O
islands,O
(,O
up,O
/,O
down,O
),O
.,O
 , 


,O
Individual,O
chromosomal,O
islands,O
with,O
gain,O
of,O
expression,O


,O
8q11.23,O
-,O
q21.13,O


,O
Gain,O
of,O
expression,O
in,O
region,O
8q11.23,O
-,O
q21.13,O
is,O
strongest,O
in,O
a,O
small,O
interval,O
(,O
8q12.1,O
),O
that,O
spans,O
genes,O
from,O
TCEA1,B-gene
to,O
PLAG1,B-gene
(,O
see,O
Figures,O
6,O
,,O
7,O
,,O
8),O
.,O
 , 
There,O
have,O
been,O
numerous,O
reports,O
of,O
copy,B-mutation
number,I-mutation
gains,I-mutation
of,I-mutation
chromosome,I-mutation
8q,I-mutation
in,O
CRC,B-disease
[,O
18,21,23,25,O
],O
which,O
suggests,O
a,O
possible,O
mechanism,O
leading,O
to,O
over,B-Physiology
-,I-Physiology
expression,I-Physiology
in,O
our,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
The,O
known,O
blood,O
cell,O
oncogene,O
LYN,B-gene
is,O
located,O
in,O
this,O
interval,O
and,O
it,O
is,O
up,O
-,O
regulated,O
in,O
several,O
of,O
our,O
tumor,B-disease
samples,B-cohort-patient
.,I-cohort-patient
 , 
It,O
has,O
been,O
reported,O
before,O
that,O
LYN,B-gene
is,O
expressed,O
in,O
colorectal,B-body-part
tumors,B-disease
[,O
26,O
],O
.,O
 , 
The,O
concerted,O
up,B-Physiology
-,I-Physiology
regulation,I-Physiology
of,I-Physiology
LYN,I-Physiology
along,O
with,O
other,O
genes,O
in,O
this,O
region,O
suggests,O
a,O
role,O
for,O
LYN,B-gene
in,O
CRC,B-disease
.,I-disease
 , 
Another,O
interesting,O
gene,O
in,O
this,O
interval,O
is,O
PLAG1,B-gene
(,B-gene
pleomorphic,I-gene
adenoma,B-disease
gene,I-gene
1,I-gene
),I-gene
for,O
which,O
chromosomal,B-mutation
aberrations,I-mutation
have,O
been,O
described,O
that,O
lead,O
to,O
over,B-Physiology
-,I-Physiology
expression,I-Physiology
in,O
salivary,B-body-part
gland,I-body-part
tumors,B-disease
[,O
27,28,O
],O
.,O
 , 
No,O
informative,O
expression,O
measures,O
were,O
obtained,O
for,O
the,O
MOS,B-gene
protein,O
kinase,O
gene,O
which,O
is,O
located,O
between,O
RPS20,B-gene
and,O
PLAG1,B-gene
,,I-gene
although,O
this,O
may,O
be,O
due,O
to,O
technical,O
limitations,O
.,O
 , 
Genes,O
encoding,O
components,O
of,O
the,O
translation,O
machinery,O
,,O
the,O
mitochondrial,O
ribosomal,O
protein,O
MRPL15,B-gene
and,O
cytosolic,O
ribosomal,O
proteins,O
RPL7,B-gene
and,O
RPS20,B-gene
,,I-gene
are,O
located,O
in,O
this,O
region,O
,,O
highlighting,O
the,O
need,O
for,O
enhanced,O
translation,O
in,O
cancer,B-disease
cells,O
.,O
 , 
The,O
concomitant,O
down,B-Physiology
-,I-Physiology
regulation,I-Physiology
of,I-Physiology
the,I-Physiology
TOX,I-Physiology
and,I-Physiology
ANKTM1,I-Physiology
genes,I-Physiology
in,O
many,O
patients,B-cohort-patient
in,O
an,O
environment,O
of,O
transcriptional,O
activation,O
is,O
remarkable,O
,,O
but,O
the,O
functional,O
significance,O
remains,O
unclear,O
.,O
 , 
Buffart,O
et,O
al,O
.,O
have,O
reported,O
amplifications,B-Disorder
of,I-Disorder
8q11,I-Disorder
-,I-Disorder
q24,I-Disorder
in,O
metastasizing,O
CRC,B-disease
[,O
29,O
],O
,,O
highlighting,O
a,O
possible,O
mechanism,O
for,O
gain,O
of,O
expression,O
in,O
this,O
region,O
.,O
 , 
In,O
summary,O
,,O
our,O
analysis,O
suggests,O
that,O
chromosomal,O
region,O
8q12.1,O
is,O
a,O
candidate,O
target,O
region,O
for,O
genetic,O
alterations,O
that,O
lead,O
to,O
over,O
-,O
expression,O
in,O
CRC,B-disease
.,I-disease
 , 


,O
 , 
#1373649-04-Results-and-discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O
and,O
discussion,O


,O
Our,O
work,O
shows,O
that,O
the,O
absence,O
of,O
proband,B-cohort-patient
's,I-cohort-patient
non,O
-,O
tumor,O
DNA,O
for,O
MSI,O
testing,O
can,O
be,O
overcome,O
by,O
studying,O
the,O
alleles,O
carried,O
by,O
his,B-gender
progenitors,O
avoiding,O
the,O
need,O
for,O
initial,O
sequencing,O
of,O
the,O
obligate,O
carrier,O
.,O
 , 


,O
Although,O
BAT-26,O
has,O
been,O
reported,O
to,O
be,O
sufficient,O
for,O
MSI,O
-,O
H,O
detection,O
even,O
without,O
normal,O
tissue,O
matching,O
[,O
9,O
],O
,,O
careful,O
interpretation,O
is,O
needed,O
if,O
MSI,O
-,O
H,O
detection,O
is,O
based,O
solely,O
on,O
this,O
marker,O
,,O
since,O
polymorphism,O
at,O
the,O
BAT-26,O
locus,O
has,O
been,O
detected,O
[,O
10,O
],O
.,O
 , 


,O
A,O
more,O
sensitive,O
approach,O
has,O
been,O
reported,O
using,O
a,O
quasimonomorphic,O
mononucleotide,O
markers,O
panel,O
(,O
that,O
includes,O
BAT-25,O
and,O
BAT-26,O
),O
without,O
the,O
need,O
to,O
match,O
normal,O
DNA[11,O
],O
.,O
 , 


,O
In,O
the,O
present,O
case,B-cohort-patient
,,I-cohort-patient
we,O
overcame,O
the,O
difficulty,O
of,O
having,O
a,O
proband,B-cohort-patient
post,O
-,O
mortem,O
non,O
-,O
tumor,O
tissue,O
sample,O
for,O
MSI,O
testing,O
by,O
studying,O
the,O
alleles,O
carried,O
by,O
his,B-gender
progenitors,O
.,O
 , 
Microsatellites,O
are,O
inherited,O
according,O
to,O
Mendelian,O
rules,O
like,O
any,O
other,O
genetic,O
markers,O
.,O
 , 
Each,O
progenitor,O
pass,O
one,O
of,O
its,O
two,O
alleles,O
to,O
its,O
offspring,O
and,O
by,O
definition,O
,,O
the,O
alleles,O
present,O
in,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
tumor,B-disease
tissue,O
but,O
absent,O
in,O
his,B-gender
progenitors,O
are,O
the,O
result,O
of,O
somatic,O
mutation,O
.,O
 , 


,O
Three,O
out,O
of,O
five,O
microsatellite,O
markers,O
(,O
BAT-25,O
,,O
BAT-26,O
and,O
D5S346,O
),O
presented,O
alleles,O
in,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
primary,O
tumor,B-disease
(,O
T,O
',O
),O
and,O
its,O
metastasis,O
(,O
T,O
",O
),O
different,O
from,O
those,O
inherited,O
from,O
his,B-gender
parents,O
.,O
 , 
This,O
observation,O
suggested,O
a,O
dysfunction,B-Disorder
of,I-Disorder
the,I-Disorder
mismatch,I-Disorder
repair,I-Disorder
system,I-Disorder
and,O
the,O
tumor,B-disease
was,O
classified,O
as,O
high,B-Disorder
frequency,I-Disorder
MSI,I-Disorder
(,B-Disorder
MSI,I-Disorder
-,I-Disorder
H,I-Disorder
),I-Disorder
according,O
to,O
the,O
NCI,O
workshop,O
[,O
12,O
],O
.,O
 , 
Direct,O
sequencing,O
of,O
the,O
hMSH2,B-gene
and,O
hMLH1,B-gene
genes,O
was,O
indicated,O
,,O
detecting,O
a,O
novel,O
germline,O
mutation,O
,,O
a,B-mutation
c.1864C,I-mutation
>,I-mutation
A,I-mutation
transversion,I-mutation
in,I-mutation
exon,I-mutation
12,I-mutation
of,O
hMSH2,B-gene
gene,O
at,O
the,O
heterozygous,O
state,O
(,O
fig,O
.,O
3,O
),O
leading,O
to,O
a,O
proline,B-mutation
622,I-mutation
to,I-mutation
threonine,I-mutation
(,I-mutation
p.,I-mutation
Pro622Thr,I-mutation
),I-mutation
amino,I-mutation
acid,I-mutation
substitution,I-mutation
.,I-mutation
 , 
This,O
is,O
the,O
second,O
report,O
involving,O
the,O
622,O
codon,O
in,O
HNPCC,B-disease
 , 
[,O
13,O
],O
.,O
 , 


,O
DNA,O
sequence,O
analysis,O
of,O
hMSH2,B-gene
exon,O
12,O
.,O
 , 
Genomic,O
DNA,O
was,O
isolated,O
from,O
leucocytes,O
and,O
PCR,O
amplified,O
with,O
the,O
help,O
of,O
hMSH2,B-gene
exon,O
12,O
flanking,O
primers,O
.,O
 , 
In,O
the,O
image,O
the,O
result,O
of,O
the,O
sequencing,O
using,O
the,O
PCR,O
forward,O
primer,O
.,O
 , 
Panel,O
A,O
:,O
proband,B-cohort-patient
's,I-cohort-patient
mother,I-cohort-patient
(,O
obligate,O
carrier,O
),O
,,O
positive,O
for,O
the,O
mutation,O
.,O
 , 
Panel,O
B,O
:,O
negative,O
control,O
for,O
the,O
mutation,O
.,O
 , 


,O
Evolutionary,O
conservation,O
,,O
examined,O
by,O
alignment,O
of,O
sequences,O
of,O
homologous,O
proteins,O
for,O
several,O
species,O
(,O
fig,O
.,O
4,O
),O
,,O
suggests,O
a,O
functional,O
relevance,O
for,O
the,O
amino,O
acid,O
involved,O
.,O
 , 
This,O
is,O
also,O
supported,O
by,O
the,O
mutator,O
phenotype,O
described,O
for,O
Pro640Leu,B-mutation
mutant,O
yeast,O
[,O
14,O
],O
,,O
homologous,O
to,O
Pro622Leu,B-mutation
hMSH2,B-gene
substitution,O
in,O
humans,O
(,O
fig,O
.,O
4,O
),O
.,O
 , 


,O
Protein,O
sequence,O
alignment,O
for,O
hMSH2,B-gene
and,O
homologues,O
.,O
 , 
Human,O
,,O
Mouse,O
,,O
Rat,O
,,O
Chicken,O
and,O
Saccharomyces,O
cerevisiae,O
(,O
the,O
site,O
of,O
mutation,O
is,O
highlighted,O
),O
protein,O
sequence,O
alignment,O
.,O
 , 
Evolutionary,O
conservation,O
may,O
indicate,O
the,O
functional,O
relevance,O
of,O
the,O
aminoacid,O
involved,O
for,O
the,O
structure,O
or,O
functioning,O
of,O
the,O
protein,O
.,O
 , 
*,O
UniProtKB,O
/,O
Swiss,O
-,O
Prot,O


,O
 , 
#1601966-06-Methods-p05
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Availability,O
and,O
requirements,O


,O
Project,O
name,O
:,O
Colorectal,B-body-part
carcinoma,B-disease
comparative,O
chromosomal,O
gene,O
expression,O
analysis,O
(,O
CC,O
-,O
CCGEA,O
),O
 , 
[,O
41,O
],O
.,O
 , 


,O
Project,O
home,O
page,O
:,O


,O
Operating,O
system(s,O
):,O
all,O


,O
Programming,O
language,O
:,O
Perl,O
-,O
CGI,O


,O
Licence,O
:,O
 , 
GNU,O
GPL,O


,O
Restrictions,O
to,O
use,O
by,O
non,O
-,O
academics,O
:,O
none,O


,O
 , 
#1373649-03-Methods-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Microsatellite,O
instability,O
.,O
 , 
Three,O
of,O
five,O
microsatellite,O
markers,O
(,O
BAT-25,O
,,O
BAT-26,O
and,O
D5S346,O
),O
presented,O
different,O
alleles,O
(,O
*,O
),O
in,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
primary,O
tumor,B-disease
(,O
T,O
',O
),O
and,O
its,O
metastasis,O
(,O
T,O
",O
),O
of,O
those,O
inherited,O
from,O
his,B-gender
biological,O
mother,B-gender
(,O
BM,O
),O
and,O
father,B-cohort-patient
(,O
BF,O
),O
.,O
 , 


,O
DNA,O
sequencing,O
of,O
hMSH2,B-gene
and,O
hMLH1,B-gene
genes,O


,O
A,O
second,O
blood,O
sample,O
was,O
obtained,O
from,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
mother,B-gender
and,O
forwarded,O
to,O
the,O
Department,O
of,O
Clinical,O
Cancer,O
Genetics,O
(,O
City,O
of,O
Hope,O
Cancer,O
Center,O
,,O
Duarte,O
,,O
California,O
,,O
USA,O
),O
to,O
full,O
mutation,O
analysis,O
of,O
the,O
hMSH2,B-gene
and,O
hMLH1,B-gene
genes,O
.,O
 , 
The,O
sample,O
was,O
amplified,O
followed,O
by,O
direct,O
sequencing,O
to,O
screen,O
the,O
coding,O
regions,O
of,O
both,O
the,O
hMSH2,B-gene
and,O
the,O
hMLH1,B-gene
genes,O
for,O
germline,O
mutation,O
in,O
the,O
DNA,O
.,O
 , 


,O
After,O
establishing,O
the,O
familial,O
mutation,B-mutation
in,I-mutation
the,I-mutation
proband,B-cohort-patient
's,I-cohort-patient
mother,B-gender
,,I-gender
located,I-mutation
in,I-mutation
the,I-mutation
exon,I-mutation
12,I-mutation
of,O
hMSH2,B-gene
gene,O
,,O
it,O
was,O
searched,O
in,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
sisters,I-cohort-patient
by,O
direct,O
sequencing,O
using,O
a,O
manual,O
Sequenase,O
PCR,O
products,O
kit,O
(,O
Amersham,O
Biosciences,O
),O
.,O
 , 


,O
 , 
#1557864-05-Discussion-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Another,O
difference,O
between,O
the,O
studies,O
is,O
the,O
distribution,O
of,O
the,O
various,O
histological,O
types,O
of,O
the,O
ovarian,B-body-part
carcinoma,B-disease
tissues,B-cohort-patient
analyzed,O
(,O
Table,O
2,O
),O
.,O
 , 
This,O
difference,O
in,O
the,O
distribution,O
could,O
be,O
a,O
cause,O
for,O
the,O
wide,O
range,O
in,O
the,O
MSI,O
frequency,O
especially,O
since,O
it,O
has,O
been,O
suggested,O
that,O
certain,O
histological,O
types,O
have,O
a,O
higher,O
frequency,O
of,O
MSI,O
.,O
 , 
To,O
determine,O
whether,O
there,O
is,O
a,O
relation,O
between,O
histology,O
and,O
MSI,O
within,O
these,O
studies,O
,,O
we,O
looked,O
at,O
the,O
frequency,O
of,O
MSI,O
per,O
histological,O
type,O
for,O
the,O
628,B-size
patients,B-cohort-patient
with,O
known,O
histology,O
(,O
Table,O
2,O
),O
.,O
 , 
The,O
summary,O
of,O
these,O
studies,O
suggests,O
that,O
the,O
frequency,O
of,O
MSI,O
is,O
higher,O
in,O
the,O
mucinous,B-Disorder
and,O
endometrioid,B-body-part
adenocarcinoma,B-cohort-patient
compared,O
to,O
clear,B-body-part
cell,I-body-part
and,O
serous,B-Concepts_Ideas
adenocarcinoma,B-cohort-patient
(,O
the,O
overall,O
frequencies,O
of,O
MSI,B-Disorder
were,O
22,B-size
%,I-size
,,I-size
16,B-size
%,I-size
,,I-size
9,B-size
%,I-size
and,O
8,B-size
%,I-size
,,I-size
respectively,O
),O
(,O
Table,O
2,O
),O
.,O
 , 
We,O
hypothesize,O
that,O
mucinous,O
and,O
endometrioid,O
histology,O
might,O
be,O
prone,O
to,O
a,O
higher,O
MSI,O
frequency,O
since,O
sporadic,B-Concepts_Ideas
endometrial,B-body-part
carcinoma,B-disease
,,I-disease
which,O
is,O
closely,O
related,O
to,O
endometrioid,B-body-part
ovarian,B-body-part
cancer,I-disease
,,I-disease
has,O
a,O
MSI,B-Concepts_Ideas
frequency,I-Concepts_Ideas
of,I-Concepts_Ideas
20–30,I-Concepts_Ideas
%,I-Concepts_Ideas
[,O
49,O
-,O
51,O
],O
and,O
MSI,B-Disorder
is,O
almost,O
universal,O
present,O
in,O
the,O
colorectal,B-body-part
tumors,B-disease
of,O
the,O
hereditary,B-disease
nonpolyposis,I-disease
colon,I-disease
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
syndrome,O
which,O
all,O
have,O
a,O
mucinous,B-Disorder
histological,O
type,O
.,O
 , 
Therefore,O
,,O
the,O
different,O
histology,O
's,O
of,O
the,O
ovarian,B-body-part
carcinomas,B-disease
included,O
in,O
the,O
several,O
studies,O
seems,O
to,O
be,O
a,O
plausible,O
cause,O
for,O
the,O
wide,O
range,O
in,O
MSI,O
frequency,O
reported,O
in,O
these,O
studies,O
.,O
 , 


,O
Next,O
we,O
addressed,O
the,O
second,O
part,O
of,O
the,O
aim,O
of,O
this,O
study,O
,,O
is,O
MMR,B-gene
inactivation,O
associated,O
with,O
resistance,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
in,O
ovarian,B-body-part
cancer,I-disease
.,I-disease
 , 
Forty,B-size
-,I-size
six,I-size
of,I-size
the,I-size
75,I-size
ovarian,B-body-part
carcinomas,B-disease
we,O
analyzed,O
had,O
been,O
treated,O
with,O
platinum,O
-,O
based,O
chemotherapy,O
,,O
eleven,B-size
did,B-cohort-patient
not,I-cohort-patient
respond,I-cohort-patient
and,O
34,B-size
did,B-cohort-patient
.,I-cohort-patient
 , 
For,O
one,O
patient,B-cohort-patient
the,O
response,O
was,O
not,O
known,O
.,O
 , 
Methylation,B-Physiology
of,I-Physiology
the,I-Physiology
MLH1,B-gene
promoter,I-Physiology
was,O
detected,O
in,O
two,B-size
of,I-size
the,I-size
eleven,I-size
non,B-cohort-patient
-,I-cohort-patient
responders,I-cohort-patient
(,B-size
18,I-size
%,I-size
),I-size
and,O
four,B-size
of,I-size
the,I-size
34,I-size
responders,B-cohort-patient
(,B-size
12,I-size
%,I-size
),I-size
and,O
this,O
was,O
not,O
significantly,O
different,O
(,O
p,O
=,O
0.664,O
),O
.,O
 , 
Since,O
we,O
did,O
not,O
detect,O
any,O
MSI,O
,,O
the,O
resistance,O
seen,O
in,O
the,O
eleven,B-size
patients,B-cohort-patient
could,O
not,O
be,O
associated,O
with,O
MSI,O
and,O
MMR,B-gene
inactivation,I-Disorder
.,I-Disorder
 , 


,O
The,O
relation,O
between,O
MMR,B-gene
deficiency,O
and,O
platinum,O
-,O
drug,O
resistance,O
has,O
been,O
investigated,O
in,O
only,O
a,O
few,O
in,O
vivo,O
studies,O
.,O
 , 
Similarly,O
to,O
our,O
result,O
,,O
no,B-Disorder
MSI,I-Disorder
was,O
detected,O
by,O
Mesquita,O
et,O
al,O
.,O
 , 
[,O
18,O
],O
who,O
studied,O
34,B-size
ovarian,B-body-part
carcinomas,B-disease
of,O
which,O
seven,B-size
did,B-Phenomena
not,I-Phenomena
respond,I-Phenomena
to,I-Phenomena
cisplatin,I-Phenomena
/,I-Phenomena
paclitaxel,I-Phenomena
therapy,I-Phenomena
.,I-Phenomena
 , 
So,O
the,O
resistance,O
seen,O
in,O
these,O
seven,B-size
nonresponding,B-cohort-patient
patients,I-cohort-patient
was,O
also,O
not,O
associated,O
with,O
MMR,B-Disorder
inactivation,I-Disorder
.,I-Disorder
 , 
In,O
contrast,O
,,O
Samimi,O
et,O
al,O
.,O
 , 
[,O
52,O
],O
found,O
an,O
inverse,O
relation,O
between,O
MLH1,B-gene
protein,O
expression,O
and,O
the,O
response,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
in,O
54,B-size
ovarian,B-body-part
carcinomas,B-disease
.,I-disease
 , 
Again,O
,,O
the,O
number,O
of,O
ovarian,B-body-part
carcinomas,B-disease
included,O
in,O
these,O
studies,O
is,O
small,O
and,O
no,O
further,O
conclusion,O
can,O
be,O
drawn,O
from,O
these,O
results,O
.,O
 , 


,O
 , 
#2386495-03-Methods-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Molecular,O
genetic,O
analysis,O
of,O
the,O
APC,B-gene
gene,O


,O
Mutational,O
screening,O
of,O
APC,B-gene
was,O
initialized,O
with,O
DNA,O
(,O
exon,O
15,O
),O
and,O
,,O
whenever,O
possible,O
,,O
RNA,O
-,O
based,O
(,O
exons,O
1–14,O
),O
PTT,O
(,O
protein,O
truncation,O
test,O
),O
.,O
 , 
SSCP,O
/,O
HD,O
(,O
single,O
-,O
strand,O
conformational,O
polymorphism,O
/,O
heteroduplex,O
),O
,,O
D,O
-,O
HPLC,O
(,O
denaturing,O
high,O
-,O
performance,O
liquid,O
chromatography,O
),O
on,O
the,O
Wave,O
instrument,O
(,O
Transgenomic,O
,,O
Omaha,O
,,O
NE,O
),O
,,O
and/or,O
DNA,O
sequencing,O
was,O
applied,O
for,O
screening,O
of,O
exons,O
1–14,O
.,O
 , 
DNA,O
sequencing,O
of,O
exon,O
15,O
was,O
performed,O
when,O
no,O
mutation,O
had,O
been,O
detected,O
in,O
the,O
initial,O
search,O
.,O
 , 
Patients,B-cohort-patient
C107,B-cohort-patient
,,I-cohort-patient
C257,B-cohort-patient
and,O
C505,B-cohort-patient
with,O
no,O
documented,O
inheritance,O
of,O
FAP,B-disease
and,O
where,O
no,O
mutation,B-mutation
in,O
the,O
entire,O
APC,B-gene
or,O
MUTYH,B-gene
genes,O
could,O
be,O
detected,O
,,O
were,O
subjected,O
to,O
analyses,O
for,O
mosaic,O
mutations,O
using,O
SSCP,O
/,O
HD,O
.,O
 , 
PCR,O
,,O
RT,O
-,O
PCR,O
(,O
reverse,O
transcriptase,O
PCR,O
),O
,,O
SSCP,O
/,O
HD,O
,,O
and,O
PTT,O
were,O
carried,O
out,O
as,O
described,O
previously,O
[,O
33,O
],O
with,O
the,O
following,O
changes,O
:,O
the,O
Criterion,O
Tris,O
-,O
HCl,O
8–16,O
%,O
gels,O
and,O
Criterion,O
Gel,O
Electrophoresis,O
System,O
(,O
BioRad,O
Laboratories,O
,,O
Hercules,O
,,O
CA,O
),O
were,O
used,O
for,O
the,O
PTT,O
.,O
 , 
Primers,O
used,O
for,O
PCR,O
amplification,O
of,O
genomic,O
DNA,O
for,O
subsequent,O
DNA,O
sequencing,O
or,O
PTT,O
are,O
available,O
from,O
the,O
authors,O
upon,O
request,O
.,O
 , 
Taq,O
DNA,O
polymerase,O
(,O
Amersham,O
Biosciences,O
Corp,O
,,O
Piscataway,O
,,O
NJ,O
or,O
Promega,O
Corporation,O
,,O
Madison,O
,,O
WI,O
),O
was,O
used,O
for,O
PCR,O
amplification,O
prior,O
to,O
DNA,O
sequencing,O
.,O
 , 
DNA,O
sequencing,O
was,O
performed,O
on,O
PCR,O
products,O
purified,O
with,O
ExoSAP,O
-,O
IT,O
(,O
USB,O
,,O
Cleveland,O
,,O
OH,O
),O
.,O
 , 
Sequence,O
reactions,O
were,O
carried,O
out,O
using,O
ABI,O
Prism,O
Big,O
Dye,O
Terminator,O
Cycle,O
Sequencing,O
kit,O
(,O
Applied,O
Biosystems,O
,,O
Foster,O
City,O
,,O
CA,O
),O
and,O
analyzed,O
on,O
the,O
ABI,O
Prism,O
3100,O
Genetic,O
Analyzer,O
(,O
Applied,O
Biosystems,O
),O
according,O
to,O
the,O
manufacturer,O
's,O
protocol,O
.,O
 , 
MLPA,O
[,O
34,O
],O
was,O
used,O
to,O
detect,O
deletions,O
/,O
duplications,O
of,O
one,O
or,O
more,O
exons,O
and,O
was,O
carried,O
out,O
as,O
described,O
by,O
Meuller,O
et,O
al,O
 , 
[,O
10,O
],O
.,O
 , 
All,O
MLPA,O
analyses,O
were,O
carried,O
out,O
in,O
duplicates,O
and,O
normalized,O
against,O
two,O
different,O
control,O
individuals,B-cohort-patient
.,I-cohort-patient
 , 
All,O
mutations,O
described,O
in,O
this,O
study,O
were,O
verified,O
in,O
a,O
second,O
independent,O
analysis,O
using,O
,,O
as,O
far,O
as,O
possible,O
,,O
an,O
alternative,O
mutation,O
-,O
detection,O
technique,O
.,O
 , 


,O
Analyses,O
of,O
APC,B-gene
expression,O


,O
The,O
level,O
of,O
APC,B-gene
mRNA,O
expression,O
in,O
peripheral,O
blood,O
cells,O
was,O
investigated,O
by,O
TaqMan,O
quantitative,O
real,O
-,O
time,O
PCR,O
(,O
RT,O
-,O
PCR,O
),O
analysis,O
in,O
29,B-size
patients,B-cohort-patient
from,O
18,B-size
families,B-cohort-patient
.,I-cohort-patient
 , 
RT,O
-,O
PCR,O
was,O
carried,O
out,O
using,O
ABI,O
Prism,O
7900HT,O
Sequence,O
Detection,O
System,O
(,O
Applied,O
Biosystems,O
),O
at,O
the,O
Gothenburg,O
Genomics,O
Core,O
Facility,O
.,O
 , 
Primers,O
and,O
probe,O
for,O
the,O
APC,B-gene
gene,O
as,O
well,O
as,O
for,O
GAPD,B-gene
,,I-gene
which,O
was,O
used,O
as,O
internal,O
control,O
,,O
were,O
obtained,O
from,O
[,O
35,O
],O
.,O
 , 
Amplification,O
reactions,O
were,O
performed,O
for,O
the,O
two,O
genes,O
separately,O
in,O
a,O
volume,O
of,O
10,O
μl,O
containing,O
1,O
μl,O
template,O
cDNA,O
diluted,O
1:10,O
,,O
1,O
×,O
FAM,O
-,O
labeled,O
Assay,O
-,O
on,O
-,O
Demand,O
Gene,O
Expression,O
Assay,O
Mix,O
,,O
and,O
1,O
×,O
TaqMan,O
Universal,O
PCR,O
Master,O
Mix,O
(,O
Applied,O
Biosystems,O
),O
.,O
 , 
Thermal,O
cycling,O
was,O
performed,O
according,O
to,O
the,O
standard,O
protocol,O
.,O
 , 
Triple,O
samples,O
of,O
each,O
patient,B-cohort-patient
were,O
analyzed,O
and,O
no,O
-,O
template,O
controls,O
were,O
included,O
in,O
the,O
experiments,O
.,O
 , 
As,O
the,O
standard,O
curve,O
method,O
for,O
quantification,O
of,O
RT,O
-,O
PCR,O
products,O
would,O
be,O
used,O
,,O
a,O
series,O
of,O
dilutions,O
of,O
calibrator,O
cDNA,O
were,O
also,O
included,O
.,O
 , 
The,O
fluorescence,O
intensities,O
detected,O
during,O
the,O
PCR,O
process,O
were,O
analyzed,O
and,O
converted,O
into,O
threshold,O
cycle,O
values,O
(,O
Ct,O
-,O
values,O
),O
using,O
the,O
SDS,O
2.0,O
software,O
(,O
Applied,O
Biosystems,O
),O
.,O
 , 
Using,O
the,O
obtained,O
standard,O
curve,O
for,O
each,O
gene,O
,,O
the,O
concentration,O
of,O
APC,B-gene
and,O
GAPD,B-gene
in,O
each,O
sample,O
was,O
calculated,O
from,O
the,O
mean,O
Ct,O
value,O
of,O
each,O
triplicate,O
.,O
 , 
The,O
APC,B-gene
value,O
was,O
then,O
normalized,O
against,O
the,O
housekeeping,O
gene,O
GAPD,B-gene
to,O
obtain,O
a,O
relative,O
measurement,O
of,O
the,O
level,O
of,O
APC,B-gene
expression,O
in,O
the,O
blood,O
of,O
the,O
patient,B-cohort-patient
.,I-cohort-patient
 , 
The,O
Dunnett,O
t,O
-,O
test,O
was,O
used,O
to,O
calculate,O
statistical,O
significance,O
.,O
 , 
To,O
verify,O
the,O
expression,O
data,O
,,O
cDNA,O
from,O
the,O
positive,O
individuals,B-cohort-patient
was,O
sequenced,O
over,O
an,O
informative,O
heterozygous,O
cSNP,O
position,O
(,B-mutation
c.5465A,I-mutation
>,I-mutation
T,I-mutation
),I-mutation
.,O
 , 
The,O
level,O
of,O
expression,O
of,O
each,O
allele,O
could,O
then,O
be,O
estimated,O
.,O
 , 


,O
 , 
#2275286-03-Methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Methods,O


,B-cohort-patient
Patients,I-cohort-patient


,I-cohort-patient
Data,O
were,O
prospectively,O
collected,O
from,O
158,B-size
consecutive,O
colorectal,B-body-part
cancer,I-disease
patients,B-cohort-patient
who,O
received,O
surgical,O
treatments,O
in,O
the,O
National,O
Colorectal,O
Center,O
of,O
the,O
Third,O
Affiliated,O
Hospital,O
of,O
Nanjing,O
University,O
of,O
Traditional,O
Chinese,B-ethnicity
Medicine,O
(,O
NUTCM,O
),O
from,O
October,O
2004,O
to,O
June,O
2006,O
.,O
 , 
All,O
patients,B-cohort-patient
signed,O
an,O
informed,O
consent,O
before,O
the,O
study,O
.,O
 , 
Patients,B-cohort-patient
who,O
had,O
histologically,O
proven,O
carcinoma,B-disease
and,O
received,O
operative,O
treatment,O
in,O
our,O
hospital,O
were,O
included,O
in,O
the,O
study,O
.,O
 , 
Patients,B-cohort-patient
were,O
excluded,O
if,O
they,O
:,O
(,O
1,O
),O
had,O
evidence,O
of,O
concomitant,O
ulcerative,B-disease
colitis,I-disease
,,I-disease
(,O
2,O
),O
presented,O
with,O
clinically,O
unresectable,O
diseases,B-disease
,,I-disease
(,O
3,O
),O
were,O
diagnosed,O
with,O
FAP,B-disease
and,O
other,O
polyposis,B-disease
syndromes,O
,,O
(,O
4,O
),O
refused,O
operative,O
treatment,O
or,O
refused,O
to,O
participate,O
in,O
the,O
study,O
.,O
 , 
This,O
study,O
was,O
approved,O
by,O
the,O
ethical,O
committee,O
of,O
the,O
NUTCM,O
.,O
 , 


,O
Extraction,O
of,O
genomic,O
DNA,O


,O
Fresh,O
tissue,O
samples,O
of,O
tumor,B-disease
and,O
matched,O
normal,B-disease
mucosa,B-body-part
were,O
obtained,O
from,O
the,O
surgical,O
specimen,O
once,O
it,O
was,O
removed,O
.,O
 , 
DNA,O
was,O
extracted,O
using,O
a,O
tissue,O
DNA,O
extraction,O
kit,O
from,O
the,O
Beijing,O
Bio,O
-,O
lab,O
Materials,O
Institute,O
(,O
Beijing,O
,,O
China,O
),O
and,O
was,O
stored,O
at,O
-80,O
°,O
C,O
until,O
analysis,O
.,O
 , 


,O
Synthesis,O
of,O
fluorescent,O
primer,O


,O
A,O
reference,O
panel,O
of,O
5,O
MSI,O
markers,O
recommended,O
by,O
NCI,O
:,O
BAT-26,O
,,O
BAT-25,O
,,O
D2S123,O
,,O
D5S346,O
and,O
D17S250,O
were,O
used,O
in,O
this,O
study,O
.,O
 , 
The,O
primers,O
of,O
BAT-40,O
and,O
MYCL,O
were,O
also,O
applied,O
.,O
 , 
The,O
fluorescent,O
primers,O
were,O
synthesized,O
at,O
Applied,O
Biosystem,O
Company,O
(,O
Foster,O
City,O
,,O
CA,O
),O
with,O
a,O
previously,O
published,O
method,O
[,O
6,7,O
],O
.,O
 , 


,O
Microsatellite,O
instability,O
analysis,O


,O
Microsatellite,O
instability,O
was,O
analyzed,O
according,O
to,O
a,O
method,O
previously,O
reported,O
[,O
6,7,O
],O
.,O
 , 
Briefly,O
,,O
the,O
5,O
microsatellites,O
were,O
amplified,O
by,O
multiple,O
PCR,O
.,O
 , 
The,O
reaction,O
system,O
consisted,O
of,O
1,O
μL,O
of,O
template,O
(,O
extracted,O
genomic,O
DNA,O
,,O
100,O
ng,O
),O
,,O
4,O
μL,O
of,O
mixed,O
primers,O
(,O
primer,O
mix,O
),O
and,O
15,O
μL,O
of,O
ABI,O
Prism,O
True,O
Allele,O
PCR,O
Premix,O
(,O
containing,O
AmpliTaq,O
Gold,O
DNA,O
Polymerase,O
buffer,O
,,O
magnesium,O
chloride,O
and,O
dNTPs,O
),O
(,O
Applied,O
Biosystems,O
Company,O
),O
.,O
 , 
The,O
reaction,O
initially,O
underwent,O
pre,O
-,O
denature,O
at,O
95,O
°,O
C,O
for,O
15,O
minutes,O
,,O
then,O
30,O
cycles,O
of,O
:,O
denaturation,O
at,O
94,O
°,O
C,O
for,O
1,O
minute,O
,,O
annealing,O
at,O
56,O
°,O
C,O
for,O
1,O
minute,O
and,O
extension,O
at,O
72,O
°,O
C,O
for,O
1,O
minute,O
were,O
performed,O
.,O
 , 
An,O
additional,O
extension,O
at,O
72,O
°,O
C,O
for,O
25,O
minutes,O
was,O
performed,O
subsequently,O
.,O
 , 


,O
PCR,O
reaction,O
product,O
(,O
1,O
μL,O
),O
was,O
then,O
mixed,O
with,O
0.4,O
μL,O
LIZ,O
(,O
internal,O
standard,O
),O
and,O
9,O
μL,O
of,O
formamide,O
.,O
 , 
Heat,O
denaturation,O
was,O
performed,O
on,O
the,O
mixture,O
at,O
95,O
°,O
C,O
for,O
5,O
minutes,O
,,O
and,O
the,O
sample,O
was,O
kept,O
at,O
4,O
°,O
C,O
for,O
5,O
minutes,O
.,O
 , 
Then,O
the,O
product,O
was,O
put,O
in,O
a,O
96,O
well,O
plate,O
,,O
and,O
capillary,O
electrophoresis,O
was,O
performed,O
with,O
an,O
AB13100,O
-,O
Avant,O
sequencer,O
(,O
Applied,O
Biosystem,O
Shanghai,O
Division,O
,,O
Shanghai,O
,,O
China,O
),O
for,O
45,O
minutes,O
.,O
 , 
Data,O
was,O
automatically,O
analyzed,O
with,O
Genotyper,O
2.5,O
software,O
(,O
Applied,O
Biosystem,O
Shanghai,O
Division,O
),O
and,O
the,O
original,O
data,O
was,O
generated,O
.,O
 , 
The,O
electrophoresis,O
was,O
then,O
repeated,O
on,O
the,O
next,O
day,O
to,O
ensure,O
the,O
accuracy,O
of,O
the,O
analysis,O
.,O
 , 


,O
 , 
#2386495-04-Results-p05
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Pedigree,O
presenting,O
a,O
part,O
of,O
family,B-cohort-patient
1,I-cohort-patient
of,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
.,O
 , 
Family,B-cohort-patient
members,O
where,O
positive,O
linkage,O
to,O
APC,B-gene
has,O
been,O
confirmed,O
are,O
indicated,O
with,O
asterisks,O
.,O
 , 


,O
 , 
#1601966-05-Conclusion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Conclusion,O


,O
Roughly,O
a,O
quarter,O
of,O
all,O
human,O
genes,O
is,O
located,O
in,O
islands,O
of,O
misregulated,O
gene,O
expression,O
in,O
colorectal,B-disease
cancer,I-disease
.,I-disease
 , 
There,O
are,O
only,O
slightly,O
more,O
down,O
-,O
regulated,O
than,O
up,O
-,O
regulated,O
genes,O
.,O
 , 
Chromosomal,O
regions,O
that,O
are,O
linked,O
to,O
hereditary,B-Concepts_Ideas
colorectal,B-disease
cancer,I-disease
often,O
exhibit,O
deregulated,O
expression,O
,,O
suggesting,O
that,O
they,O
are,O
implicated,O
in,O
spontaneous,O
CRC,B-disease
not,O
only,O
through,O
collection,O
of,O
mutations,O
.,O
 , 
Thus,O
,,O
genes,O
in,O
these,O
chromosomal,O
hotspots,O
may,O
be,O
systematically,O
tested,O
in,O
patients,B-cohort-patient
with,O
sporadic,B-Concepts_Ideas
CRC,B-disease
for,O
molecular,O
lesions,B-disease
and,O
for,O
transcriptional,O
silencing,O
.,O
 , 


,O
Chromosomal,O
regions,O
that,O
are,O
frequently,O
deleted,O
in,O
CRC,B-disease
very,O
often,O
comprise,O
islands,O
in,O
which,O
we,O
found,O
reduced,O
expression,O
.,O
 , 
Although,O
many,O
regions,O
that,O
are,O
known,O
to,O
be,O
amplified,O
in,O
colorectal,B-body-part
tumors,B-disease
show,O
a,O
gain,O
of,O
expression,O
,,O
there,O
are,O
also,O
a,O
considerable,O
number,O
of,O
amplified,O
islands,O
that,O
show,O
no,O
alterations,O
or,O
even,O
down,O
-,O
regulation,O
.,O
 , 
Comparison,O
of,O
published,O
CGH,O
studies,O
with,O
our,O
expression,O
data,O
suggests,O
that,O
amplified,O
or,O
deleted,O
chromosomal,O
regions,O
are,O
responsible,O
for,O
many,O
islands,O
with,O
aberrant,O
expression,O
.,O
 , 
However,O
,,O
we,O
suggest,O
that,O
it,O
is,O
necessary,O
to,O
invoke,O
other,O
mechanism,O
like,O
epigenetic,O
regulation,O
of,O
chromatin,O
or,O
disruption,O
of,O
enhancer,O
actions,O
to,O
explain,O
the,O
remaining,O
expression,O
imbalances,O
.,O
 , 


,O
 , 
#1601966-06-Methods-p04
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
 , 
Although,O
this,O
analysis,O
is,O
already,O
instructive,O
for,O
the,O
visual,O
identification,O
of,O
general,O
up,O
/,O
down,O
-,O
regulation,O
of,O
a,O
particular,O
region,O
,,O
it,O
does,O
not,O
allow,O
to,O
infer,O
the,O
precise,O
boundaries,O
of,O
deregulated,O
regions,O
.,O
 , 
Several,O
software,O
packages,O
for,O
the,O
analysis,O
of,O
array,O
CGH,O
data,O
exist,O
that,O
have,O
been,O
announced,O
to,O
also,O
be,O
suited,O
for,O
the,O
analysis,O
of,O
expression,O
data,O
 , 
[,O
42,O
-,O
44,O
],O
.,O
 , 
In,O
the,O
following,O
,,O
we,O
used,O
the,O
ChARM,O
software,O
package,O
[,O
44,O
],O
.,O
 , 
ChARM,O
can,O
be,O
used,O
to,O
infer,O
intervals,O
of,O
variable,O
size,O
with,O
significant,O
positive,O
or,O
negative,O
signal,O
amplitudes,O
in,O
ordered,O
data,O
,,O
such,O
as,O
log(intensity,O
),O
values,O
in,O
array,O
CGH,O
data,O
and,O
mRNA,O
expression,O
data,O
.,O
 , 
We,O
applied,O
the,O
ChARM,O
algorithm,O
on,O
different,O
data,O
sets,O
that,O
harbor,O
information,O
about,O
the,O
numbers,O
of,O
patients,B-cohort-patient
with,O
coordinated,O
up-,O
and,O
down,O
-,O
regulation,O
of,O
expression,O
for,O
all,O
genes,O
on,O
human,O
autosomes,O
and,O
the,O
X,O
chromosome,O
.,O
 , 
For,O
each,O
chromosome,O
six,O
separate,O
data,O
sets,O
were,O
prepared,O
,,O
according,O
to,O
scanning,O
window,O
sizes,O
of,O
5,O
,,O
11,O
,,O
21,O
,,O
31,O
,,O
41,O
,,O
51,O
.,O
 , 
Within,O
each,O
window,O
all,O
possible,O
gene,O
pairs,O
(,O
excluding,O
self,O
comparisons,O
),O
were,O
considered,O
.,O
 , 
For,O
each,O
gene,O
pair,O
,,O
the,O
number,O
of,O
coordinated,O
up,O
-,O
regulated,O
(,O
counted,O
as,O
+1,O
),O
and,O
down,O
-,O
regulated,O
(,O
counted,O
as,O
-1,O
),O
was,O
determined,O
.,O
 , 
For,O
each,O
window,O
the,O
sum,O
of,O
these,O
gene,O
pair,O
-,O
specific,O
values,O
divided,O
by,O
the,O
total,O
number,O
of,O
pairs,O
gave,O
the,O
cumulative,O
misregulation,O
score,O
(,O
CMS,O
),O
.,O
 , 
In,O
a,O
sliding,O
window,O
approach,O
,,O
each,O
gene,O
was,O
associated,O
with,O
a,O
CMS,O
value,O
.,O
 , 
CMS,O
values,O
for,O
genes,O
at,O
the,O
edges,O
of,O
chromosomes,O
were,O
calculated,O
with,O
reduced,O
window,O
sizes,O
.,O
 , 
The,O
main,O
theoretical,O
advantage,O
of,O
the,O
use,O
of,O
CMS,O
scores,O
compared,O
to,O
raw,O
up,O
-,O
regulation,O
counts,O
or,O
averaged,O
expression,O
ratios,O
is,O
that,O
it,O
captures,O
only,O
information,O
from,O
co,O
-,O
regulated,O
neighboring,O
gene,O
pairs,O
:,O
Noise,O
signals,O
fluctuate,O
across,O
genes,O
and,O
may,O
more,O
often,O
lead,O
to,O
artificial,O
assignment,O
of,O
high,O
expression,O
ratios,O
between,O
two,O
genes,O
.,O
 , 
In,O
contrast,O
,,O
real,O
signals,O
of,O
regional,O
up-/down,O
-,O
regulation,O
lead,O
to,O
consistent,O
changes,O
in,O
the,O
same,O
patients,B-cohort-patient
for,O
two,O
genes,O
.,O
 , 
For,O
each,O
window,O
size,O
,,O
CMS,O
data,O
sets,O
of,O
each,O
chromosome,O
were,O
subject,O
to,O
ChARM,O
analysis,O
.,O
 , 
ChARM,O
determines,O
borders,O
of,O
regions,O
with,O
high,O
signal,O
amplitudes,O
in,O
ordered,O
data,O
,,O
here,O
regions,O
of,O
expression,O
imbalances,O
along,O
a,O
chromosome,O
,,O
by,O
an,O
expectation,O
-,O
maximization,O
approach,O
.,O
 , 
In,O
addition,O
,,O
ChARM,O
provides,O
different,O
statistical,O
estimates,O
to,O
judge,O
the,O
significance,O
of,O
expression,O
deregulation,O
in,O
a,O
particular,O
chromosomal,O
region,O
[,O
44,O
],O
.,O
 , 
The,O
identified,O
deregulated,O
regions,O
were,O
further,O
evaluated,O
manually,O
using,O
heat,O
maps,O
and,O
the,O
above,O
mentioned,O
gene,O
-,O
versus,O
-,O
gene,O
",O
correlation,O
",O
plots,O
(,O
see,O
above,O
,,O
Figures,O
6,O
,,O
7,O
,,O
8,O
,,O
9,O
,,O
10,O
,,O
11,O
,,O
12,O
,,O
13,O
,,O
14,O
,,O
15,O
,,O
16,O
,,O
17,O
,,O
18,O
,,O
19,O
,,O
20,O
,,O
21,O
,,O
22,O
,,O
23,O
,,O
24,O
,,O
25,O
,,O
26,O
,,O
27,O
,,O
28,O
,,O
29,O
,,O
30,O
,,O
31,O
,,O
32,O
and,O
accompanying,O
website,O
),O
.,O
 , 


,O
 , 
#2386495-04-Results-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O


,B-size
Sixty,I-size
-,I-size
one,I-size
different,O
APC,B-gene
mutations,B-mutation
,,I-mutation
27,O
novel,O
and,O
34,O
recurrent,O
,,O
were,O
detected,O
among,O
81,B-size
of,I-size
the,I-size
96,I-size
Swedish,B-ethnicity
families,B-cohort-patient
studied,O
as,O
shown,O
in,O
Additional,O
files,O
1,O
and,O
2,O
.,O
 , 
A,O
mutation,O
spectrum,O
displaying,O
the,O
distribution,O
between,O
novel,O
and,O
previously,O
reported,O
mutations,O
is,O
shown,O
in,O
Figure,O
1,O
.,O
 , 
The,O
frequency,O
of,O
APC,B-gene
de,B-mutation
novo,I-mutation
mutation,I-mutation
cases,B-cohort-patient
among,O
the,O
families,B-cohort-patient
was,O
16,B-size
%,I-size
.,I-size
 , 
In,O
three,B-size
of,O
the,O
families,B-cohort-patient
parents,I-cohort-patient
were,O
tested,O
negative,O
for,O
the,O
mutation,B-mutation
and,O
in,O
the,O
remaining,O
seven,B-size
families,B-cohort-patient
we,O
where,O
unable,O
to,O
obtain,O
samples,O
to,O
test,O
parents,O
.,O
 , 
Thirty,B-size
-,I-size
two,I-size
of,I-size
the,I-size
81,I-size
patients,B-cohort-patient
with,O
APC,B-gene
mutations,B-mutation
were,O
probands,B-cohort-patient
.,I-cohort-patient
 , 
Probands,B-cohort-patient
with,O
mutations,B-mutation
in,I-mutation
the,I-mutation
region,I-mutation
from,I-mutation
codon,I-mutation
1250,I-mutation
to,I-mutation
1464,I-mutation
of,O
the,O
APC,B-gene
gene,O
which,O
predicts,O
a,O
severe,O
phenotype,O
[,O
36,O
],O
had,O
a,O
median,B-age
age,I-age
at,I-age
diagnosis,I-age
of,I-age
21.8,I-age
(,B-age
range,I-age
,,I-age
11–49,I-age
),I-age
years,O
compared,O
with,O
34.4,B-age
(,B-age
range,I-age
,,I-age
14–57,I-age
),I-age
years,O
among,O
those,B-cohort-patient
with,I-cohort-patient
mutations,I-cohort-patient
outside,I-cohort-patient
this,I-cohort-patient
region,I-cohort-patient
(,O
P,O
<,O
0.017,O
),O
.,O
 , 
Available,O
data,O
on,O
colorectal,B-body-part
polyp,B-disease
number,O
shows,O
that,O
,,O
in,O
spite,O
of,O
higher,B-Concepts_Ideas
age,I-Concepts_Ideas
at,I-Concepts_Ideas
diagnosis,I-Concepts_Ideas
,,I-Concepts_Ideas
dense,B-Disorder
polyposis,I-Disorder
(,B-Concepts_Ideas
>,I-Concepts_Ideas
1000,I-Concepts_Ideas
),I-Concepts_Ideas
only,O
occurred,O
in,O
30,B-size
%,I-size
of,O
the,O
probands,B-cohort-patient
compared,O
with,O
75,B-size
%,I-size
in,O
those,B-cohort-patient
with,O
mutations,B-mutation
between,I-mutation
codon,I-mutation
1250,I-mutation
and,I-mutation
1464,I-mutation
.,I-mutation
 , 
In,O
the,O
former,O
group,B-cohort-patient
29,B-size
%,I-size
(,B-size
7,I-size
out,I-size
of,I-size
24,I-size
),I-size
had,O
CRC,B-disease
at,O
diagnosis,O
compared,O
with,O
25,B-size
%,I-size
(,B-size
2,I-size
out,I-size
of,I-size
8),I-size
in,O
the,O
latter,O
group,B-cohort-patient
.,I-cohort-patient
 , 
The,O
mean,O
age,O
at,O
CRC,B-disease
was,O
46.6,B-age
(,B-age
range,I-age
28–57,I-age
),I-age
and,O
37.5,B-age
(,B-age
range,I-age
26–49,I-age
),I-age
years,O
,,O
respectively,O
.,O
 , 
The,O
total,O
morbidity,B-Concepts_Ideas
in,O
CRC,B-disease
among,O
probands,B-cohort-patient
was,O
34,B-size
%,I-size
(,B-size
11,I-size
out,I-size
of,I-size
32,I-size
),I-size
.,O
 , 
Of,O
all,O
probands,B-cohort-patient
diagnosed,O
after,O
1996,O
,,O
four,B-size
out,I-size
of,I-size
nine,I-size
(,B-size
44,I-size
%,I-size
),I-size
had,O
cancer,B-disease
at,O
diagnosis,O
.,O
 , 
The,O
median,O
age,O
in,O
this,O
group,B-cohort-patient
was,O
47.5,B-age
(,B-age
 , 
range,B-age
45–51,I-age
),I-age
years,O
 , 
and,O
none,B-size
had,O
,,O
despite,O
high,B-age
age,I-age
at,I-age
diagnosis,I-age
of,O
CRC,B-disease
,,I-disease
dense,B-Disorder
colorectal,I-Disorder
polyposis,I-Disorder
at,O
diagnosis,O
indicating,O
a,O
less,B-Physiology
-,I-Physiology
severe,I-Physiology
phenotype,I-Physiology
.,I-Physiology
 , 
A,O
compilation,O
of,O
clinical,O
status,O
of,O
all,O
patients,B-cohort-patient
analyzed,O
in,O
this,O
study,O
is,O
shown,O
in,O
Additional,O
file,O
1,O
.,O
 , 


,O
Mutation,O
spectrum,O
of,O
the,O
APC,B-gene
gene,O
.,O
 , 
(,O
A,O
),O
 , 
The,O
spectrum,O
of,O
APC,B-gene
mutations,B-mutation
identified,O
among,O
families,B-cohort-patient
from,O
the,O
Swedish,B-ethnicity
Polyposis,O
Registry,O
showing,O
the,O
distribution,O
between,O
previously,O
reported,O
and,O
novel,O
mutations,O
in,O
our,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
(,O
B,O
),O
A,O
schematic,O
representation,O
of,O
the,O
APC,B-gene
coding,O
region,O
,,O
shown,O
in,O
the,O
same,O
scale,O
as,O
in,O
(,O
A,O
),O
.,O
 , 
The,O
arrow,O
with,O
an,O
asterisk,O
indicates,O
codon,O
24,O
and,O
the,O
second,O
arrow,O
points,O
at,O
codon,O
184,O
.,O
 , 
(,O
C,O
),O
Distribution,O
of,O
six,B-size
large,B-mutation
deletions,I-mutation
found,O
in,O
seven,B-size
unrelated,B-cohort-patient
patients,I-cohort-patient
of,O
the,O
Swedish,B-ethnicity
Polyposis,O
Registry,O
.,O
 , 
Novel,O
deletions,O
are,O
marked,O
with,O
an,O
asterisk,O
.,O
 , 
Patient,B-cohort-patient
numbers,O
are,O
shown,O
to,O
the,O
left,O
.,O
 , 
Scale,O
as,O
in,O
(,O
A,O
),O
.,O
 , 


,B-mutation
Large,I-mutation
deletions,I-mutation
of,O
the,O
APC,B-gene
gene,O


,O
 , 
#1619718-03-Materials-and-methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Materials,O
and,O
methods,O


,O
Tissues,O


,O
The,O
colorectal,B-body-part
polyps,B-disease
used,O
in,O
this,O
study,O
were,O
from,O
a,O
previously,O
characterized,O
subset,O
of,O
a,O
consecutive,O
series,O
of,O
1250,B-size
colonoscopically,O
derived,O
lesions.24,B-cohort-patient
 , 
The,O
study,O
group,B-cohort-patient
included,O
all,O
SAs,B-disease
(,B-Concepts_Ideas
sessile,I-Concepts_Ideas
and,O
traditional,B-Concepts_Ideas
),I-Concepts_Ideas
and,O
MPs,B-disease
and,O
a,O
subset,O
of,O
conventional,B-Concepts_Ideas
adenomas,B-disease
and,O
HPs,B-disease
.,I-disease
 , 
The,O
previous,O
study,O
analysed,O
proliferative,O
indices,O
and,O
there,O
was,O
therefore,O
selection,O
of,O
HPs,B-disease
that,O
were,O
large,B-Concepts_Ideas
and,O
well,B-Concepts_Ideas
-,I-Concepts_Ideas
oriented,I-Concepts_Ideas
and,O
likely,O
to,O
provide,O
sufficient,O
numbers,O
of,O
longitudinally,O
sectioned,O
crypts,O
.,O
 , 
Polyps,B-disease
were,O
eliminated,O
from,O
the,O
present,O
study,O
if,O
there,O
was,O
insufficient,O
residual,O
tissue,O
,,O
blocks,O
contained,O
more,O
than,O
one,O
polyp,B-disease
,,I-disease
polyps,B-disease
contained,O
foci,O
of,O
invasive,O
cancer,B-disease
,,I-disease
or,O
there,O
was,O
failure,O
of,O
DNA,O
amplification,O
for,O
both,O
the,O
BRAF,B-gene
and,O
KRAS,B-gene
mutation,B-mutation
assays,O
.,O
 , 
Fifteen,B-size
additional,O
polyps,B-cohort-patient
from,O
the,O
parent,O
series,O
generated,O
a,O
total,O
study,O
group,O
of,O
190,B-size
polyps,B-disease
.,I-disease
 , 
These,O
were,O
reviewed,O
by,O
the,O
first,O
author,O
and,O
classified,O
as,O
:,O
HPs,B-cohort-patient
(,O
n,O
=,O
49,B-size
),I-size
,,O
tubular,B-Concepts_Ideas
adenomas,B-disease
(,B-disease
TAs,I-disease
),I-disease
(,O
n,O
=,O
62,B-size
),I-size
,,O
tubulovillous,B-Concepts_Ideas
and,O
villous,B-Concepts_Ideas
adenomas,B-disease
(,B-disease
TVAs,I-disease
/,I-disease
VAs,I-disease
),I-disease
(,O
n,O
=,O
22,B-size
),I-size
,,O
sessile,B-Concepts_Ideas
SAs,B-cohort-patient
(,B-disease
SSAs,I-disease
),I-disease
(,O
n,O
=,O
32,B-size
),I-size
,,O
MPs,B-cohort-patient
(,O
n,O
=,O
10,B-size
),I-size
and,O
traditional,B-Concepts_Ideas
SAs,B-cohort-patient
(,O
n,O
=,O
15,B-size
),I-size
.,O
 , 
SSA,B-disease
has,O
also,O
been,O
termed,O
sessile,B-Concepts_Ideas
serrated,B-Concepts_Ideas
polyp,B-disease
and,O
serrated,B-Concepts_Ideas
polyp,B-disease
with,O
atypical,B-Disorder
proliferation.17,25–27,I-Disorder
SSA,B-disease
is,O
distinguished,O
from,O
HP,B-disease
on,O
the,O
basis,O
of,O
greater,B-Concepts_Ideas
size,I-Concepts_Ideas
,,I-Concepts_Ideas
aberrant,B-Disorder
architecture,I-Disorder
,,I-Disorder
atypical,B-Disorder
proliferation,I-Disorder
,,I-Disorder
hypermucinous,B-Disorder
epithelium,I-Disorder
,,I-Disorder
predilection,B-Concepts_Ideas
for,I-Concepts_Ideas
proximal,I-Concepts_Ideas
colon25,I-Concepts_Ideas
and,O
molecular,O
features,O
including,O
a,O
higher,O
frequency,O
of,O
BRAF,B-gene
mutation,B-mutation
and,O
more,O
extensive,O
DNA,O
methylation.14,16,17,O
However,O
,,O
the,O
combination,O
of,O
architectural,O
and,O
cytological,O
changes,O
is,O
insufficient,O
for,O
a,O
diagnosis,O
of,O
dysplasia,O
.,O
 , 
Serrated,B-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
include,O
MPs,B-disease
and,O
SAs,B-disease
.,I-disease
 , 
MPs,B-disease
may,O
be,O
conceived,O
as,O
a,O
combined,B-Concepts_Ideas
lesion,B-disease
that,O
includes,O
:,O
(,O
i,O
),O
a,O
serrated,B-Concepts_Ideas
component,O
that,O
is,O
non,B-Disorder
-,I-Disorder
dysplastic,I-Disorder
and,O
resembles,B-Concepts_Ideas
HP,B-disease
or,I-Concepts_Ideas
SSA,B-disease
,,I-disease
and,O
(,O
ii,O
),O
a,O
dysplastic,B-Disorder
component,O
that,O
may,O
resemble,B-Concepts_Ideas
either,I-Concepts_Ideas
SA,B-disease
or,I-Concepts_Ideas
conventional,I-Concepts_Ideas
adenoma.28,B-disease
 , 
For,O
the,O
purposes,O
of,O
this,O
study,O
,,O
lesions,B-disease
were,O
also,O
included,O
as,O
MPs,B-disease
if,O
they,O
comprised,O
separate,O
serrated,B-Concepts_Ideas
and,O
non,B-Concepts_Ideas
-,I-Concepts_Ideas
serrated,I-Concepts_Ideas
components,O
that,O
were,O
both,O
dysplastic,B-Disorder
.,I-Disorder
 , 
SAs,B-disease
are,O
homogeneous,B-Concepts_Ideas
lesions,B-disease
in,O
which,O
there,O
is,O
epithelial,B-Concepts_Ideas
serration,I-Concepts_Ideas
reminiscent,O
of,O
a,O
HP,B-disease
or,O
SSA,B-disease
together,O
with,O
architectural,O
and,O
cytological,O
changes,O
warranting,O
a,O
diagnosis,O
of,O
dysplasia,B-Disorder
.,I-Disorder
 , 
The,O
cytological,B-Disorder
atypia,I-Disorder
of,O
SA,B-disease
may,O
appear,O
similar,O
to,O
that,O
of,O
conventional,B-Concepts_Ideas
adenoma,B-disease
in,O
which,O
nuclei,B-body-part
are,I-body-part
elongated,I-body-part
,,I-body-part
hyperchromatic,I-body-part
and,I-body-part
pseudostratified,I-body-part
.,I-body-part
 , 
However,O
,,O
some,O
SAs,B-disease
may,O
be,O
characterized,O
by,O
non,B-Disorder
-,I-Disorder
adenomatous,I-Disorder
forms,I-Disorder
of,I-Disorder
dysplasia,I-Disorder
in,I-Disorder
which,I-Disorder
the,I-Disorder
nuclei,I-Disorder
are,I-Disorder
enlarged,I-Disorder
,,I-Disorder
ovoid,I-Disorder
,,I-Disorder
vesicular,I-Disorder
and,I-Disorder
contain,I-Disorder
a,I-Disorder
prominent,I-Disorder
nucleolus,I-Disorder
,,I-Disorder
while,O
the,O
cytoplasm,O
is,O
relatively,O
abundant,O
and,O
eosinophilic,O
.,O
 , 
The,O
anatomical,O
site,O
of,O
polyps,B-disease
was,O
grouped,O
as,O
proximal,B-body-part
colon,I-body-part
(,O
up,O
to,O
splenic,B-body-part
flexure,I-body-part
),I-body-part
versus,O
distal,B-body-part
colon,I-body-part
and,O
rectum,B-body-part
combined,O
.,O
 , 
The,O
study,O
was,O
approved,O
by,O
the,O
Institutional,O
Review,O
Board,O
of,O
the,O
Faculty,O
of,O
Medicine,O
,,O
McGill,O
University,O
.,O


,O
 , 
#2275286-02-Background-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Background,O


,B-disease
HNPCC,I-disease
is,O
an,O
autosomal,B-Concepts_Ideas
dominant,I-Concepts_Ideas
syndrome,O
,,O
which,O
accounts,O
for,O
about,O
1–5,B-size
%,I-size
of,O
colorectal,B-disease
cancer,I-disease
 , 
[,O
1,O
],O
.,O
 , 
HNPCC,B-disease
patients,B-cohort-patient
are,O
characterized,O
by,O
earlier,B-Disorder
symptoms,I-Disorder
,,I-Disorder
more,B-Disorder
mucinous,I-Disorder
carcinoma,I-Disorder
,,I-Disorder
more,B-Concepts_Ideas
synchronous,I-Concepts_Ideas
and,I-Concepts_Ideas
metachronous,I-Concepts_Ideas
colorectal,I-Concepts_Ideas
tumors,I-Concepts_Ideas
and,O
more,O
extra,B-body-part
-,I-body-part
colonic,I-body-part
tumors,B-disease
,,I-disease
but,O
have,O
better,B-Concepts_Ideas
survival,I-Concepts_Ideas
 , 
[,O
1,2,O
],O
.,O
 , 
It,O
is,O
believed,O
that,O
HNPCC,B-disease
is,O
secondary,O
to,O
a,O
germline,B-mutation
mutation,I-mutation
resulting,O
in,O
a,O
defective,B-Concepts_Ideas
MMR,I-Concepts_Ideas
gene,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
A,O
defective,B-Concepts_Ideas
MMR,I-Concepts_Ideas
gene,I-Concepts_Ideas
results,O
in,O
increased,O
DNA,O
replication,O
errors,O
and,O
MSI,B-Disorder
,,I-Disorder
which,O
causes,O
the,O
occurrence,O
of,O
tumors,B-disease
in,O
different,O
organs,O
,,O
especially,O
in,O
the,O
colorectum,B-body-part
.,I-body-part
 , 
Identification,O
of,O
HPNCC,B-disease
families,B-cohort-patient
is,O
important,O
because,O
the,O
diagnosis,O
,,O
treatment,O
and,O
follow,O
up,O
of,O
these,O
individuals,B-cohort-patient
should,O
be,O
different,O
from,O
those,O
with,O
sporadic,B-Concepts_Ideas
colorectal,B-disease
cancer,I-disease
 , 
[,O
2,O
],O
.,O
 , 
However,O
,,O
the,O
clinical,O
diagnosis,O
of,O
HNPCC,B-disease
patients,B-cohort-patient
is,O
very,O
difficult,O
for,O
lack,O
of,O
specific,O
clinical,O
phenotype,O
.,O
 , 
Though,O
Amsterdam,O
criteria,O
I,O
and,O
II,O
were,O
established,O
for,O
HNPCC,B-disease
diagnosis[3,4,O
],O
,,O
many,O
HNPCC,B-disease
families,B-cohort-patient
still,O
do,O
not,O
meet,O
the,O
criteria,O
.,O
 , 


,O
MSI,O
is,O
an,O
important,O
phenotype,O
of,O
MMR,B-gene
gene,O
mutation,B-mutation
.,I-mutation
 , 
In,O
1997,O
,,O
the,O
National,O
Cancer,O
Institute,O
(,O
NCI,O
),O
recommended,O
screening,O
MSI,B-Disorder
CRCs,B-disease
using,O
the,O
Bethesda,O
guidelines,O
[,O
5,O
],O
.,O
 , 
After,O
compiling,O
evidence,O
from,O
years,O
of,O
global,O
studies,O
and,O
follow,O
up,O
,,O
NCI,O
revised,O
the,O
Bethesda,O
guidelines,O
in,O
2004,O
,,O
which,O
is,O
called,O
the,O
revised,O
Bethesda,O
standard,O
[,O
6,O
],O
.,O
 , 
NCI,O
recommended,O
screening,O
of,O
HNPCC,B-disease
based,O
on,O
detection,O
of,O
MSI,B-Disorder
in,O
the,O
tumor,B-disease
and,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
a,I-Physiology
MMR,B-gene
gene,I-Physiology
using,O
immunohistochemistry,O
(,O
IHC,O
),O
staining,O
[,O
6,O
],O
.,O
 , 
However,O
,,O
until,O
now,O
,,O
there,O
has,O
been,O
no,O
research,O
about,O
the,O
applicability,O
of,O
the,O
NCI,O
recommendations,O
to,O
the,O
Chinese,B-ethnicity
population,B-cohort-patient
with,O
colorectal,B-disease
cancers,I-disease
.,O
 , 
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
detect,O
and,O
study,O
MSI,B-Disorder
carrier,I-Disorder
and,O
mismatch,B-gene
repair,I-gene
(,B-gene
MMR,I-gene
),I-gene
gene,O
germline,B-mutation
mutation,I-mutation
carriers,B-cohort-patient
among,O
a,O
Chinese,B-ethnicity
population,B-cohort-patient
with,O
colorectal,B-body-part
cancer,I-disease
.,I-disease
 , 


,O
 , 
#1557864-03-Methods-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Microsatellite,O
analysis,O
was,O
standard,O
performed,O
in,O
our,O
laboratory,O
as,O
described,O
by,O
Westenend,O
et,O
al,O
 , 
[,O
40,O
],O
using,O
the,O
two,O
mononucleotide,O
markers,O
,,O
BAT25,O
and,O
BAT26,O
.,O
 , 
In,O
addition,O
,,O
the,O
75,B-size
ovarian,B-body-part
carcinomas,B-disease
were,O
also,O
analysed,O
with,O
the,O
mononucleotide,O
marker,O
BAT40,O
(,O
n,O
=,O
42,O
),O
or,O
with,O
the,O
dinucleotide,O
marker,O
D2S123,O
(,O
n,O
=,O
40,O
),O
.,O
 , 
So,O
all,O
ovarian,B-body-part
carcinomas,B-disease
were,O
analysed,O
with,O
three,O
or,O
four,O
MSI,O
markers,O
.,O
 , 
A,O
PCR,O
containing,O
α-32PdATP,O
,,O
was,O
performed,O
on,O
100,O
ng,O
DNA,O
.,O
 , 
PCR,O
products,O
were,O
separated,O
on,O
a,O
denaturing,O
6,O
%,O
polyacrylamide,O
gel,O
.,O
 , 
After,O
electrophoresis,O
,,O
gels,O
were,O
dried,O
on,O
blotting,O
paper,O
on,O
a,O
vacuum,O
gel,O
dryer,O
and,O
exposed,O
to,O
x,O
-,O
ray,O
film,O
.,O
 , 
The,O
films,O
were,O
evaluated,O
by,O
visual,O
inspection,O
.,O
 , 


,O
The,O
methylation,O
specific,O
PCR,O
(,O
MSP,O
),O
was,O
used,O
to,O
determine,O
the,O
promoter,O
methylation,O
of,O
MLH1,B-gene
after,O
the,O
DNAs,O
were,O
modified,O
with,O
sodium,O
bisulfite,O
using,O
the,O
Ez,O
DNA,O
methylation,O
kit,O
(,O
Zymo,O
research,O
),O
.,O
 , 
We,O
designed,O
and,O
optimized,O
primers,O
that,O
are,O
specific,O
for,O
methylated,O
and,O
unmethylated,O
CpG,O
islands,O
within,O
the,O
MLH1,B-gene
promoter,O
(,O
methylated,O
:,O
Forward,O
5'-CGAATTAATAGGAAGAGCGGATAGC-3,O
',O
,,O
Reverse,O
5'-ACCTCAATACCTCGTACTCACG-3,O
',O
;,O
unmethylated,O
:,O
Forward,O
5'-TGAATTAATAGGAAGAGTGGATAGT-3,O
',O
,,O
Reverse,O
5'-CCTCAATACCTCATACTCACA-3,O
',O
),O
.,O
 , 
Both,O
primers,O
are,O
located,O
within,O
a,O
region,O
important,O
for,O
a,O
maximal,O
transcription,O
of,O
MLH1,B-gene
(,O
including,O
the,O
binding,O
site,O
for,O
the,O
transcription,O
factor,O
CBF,O
),O
 , 
[,O
41,42,O
],O
,,O
since,O
methylation,O
at,O
this,O
region,O
is,O
most,O
likely,O
to,O
inhibit,O
transcription,O
of,O
the,O
gene,O
.,O
 , 
The,O
PCR,O
mixture,O
contained,O
1×,O
PCR,O
buffer,O
(,O
as,O
described,O
by,O
Herman,O
et,O
al,O
 , 
[,O
43,O
],O
),O
,,O
dNTPs,O
(,O
each,O
at,O
5,O
mM,O
),O
,,O
primers,O
(,O
1,O
pmol,O
/,O
μl,O
each,O
per,O
reaction,O
),O
,,O
Taq,O
polymerase,O
(,O
0.05,O
U,O
/,O
μl,O
),O
and,O
100,O
ng,O
modified,O
DNA,O
in,O
a,O
volume,O
of,O
25,O
μl,O
.,O
 , 
Amplification,O
was,O
carried,O
out,O
for,O
35,O
cycles,O
(,O
30,O
sec,O
95,O
°,O
C,O
,,O
30,O
sec,O
58,O
°,O
C,O
for,O
methylated,O
and,O
55,O
°,O
C,O
for,O
unmethylated,O
and,O
30,O
sec,O
72,O
°,O
C,O
),O
followed,O
by,O
a,O
final,O
4,O
minutes,O
extension,O
at,O
72,O
°,O
C,O
.,O
 , 
Controls,O
without,O
DNA,O
were,O
performed,O
and,O
in,O
addition,O
,,O
the,O
colon,B-disease
cancer,B-disease
cell,B-cohort-patient
lines,I-cohort-patient
SW48,B-cohort-patient
with,O
a,O
methylated,B-Physiology
MLH1,I-Physiology
promoter,I-Physiology
and,O
SW480,B-cohort-patient
with,O
an,O
unmethylated,B-Physiology
MLH1,I-Physiology
promoter,I-Physiology
,,I-Physiology
were,O
used,O
as,O
positive,O
and,O
negative,O
control,O
respectively,O
.,O
 , 


,O
Quantitative,O
RT,O
-,O
PCR,O


,O
Quantitative,O
RT,O
-,O
PCR,O
analysis,O
was,O
used,O
to,O
measure,O
the,O
mRNA,O
expression,O
levels,O
of,O
MLH1,B-gene
,,I-gene
MSH2,B-gene
,,I-gene
MSH3,B-gene
,,I-gene
MSH6,B-gene
and,O
PMS2,B-gene
in,O
the,O
eight,B-size
ovarian,B-disease
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
and,O
50,B-size
of,I-size
the,I-size
75,I-size
ovarian,B-disease
cancer,I-disease
specimens,B-cohort-patient
of,O
which,O
RNA,O
was,O
available,O
.,O
 , 
Thirty,B-size
-,I-size
six,I-size
of,I-size
these,I-size
50,I-size
patients,B-cohort-patient
received,O
platinum,O
-,O
based,O
chemotherapy,O
(,B-size
7,I-size
non,B-cohort-patient
-,I-cohort-patient
responders,I-cohort-patient
,,I-cohort-patient
28,B-size
responders,B-cohort-patient
and,O
one,O
patients,B-cohort-patient
with,O
unknown,O
response,O
),O
.,O
 , 
The,O
following,O
20×,O
assay,O
-,O
on,O
-,O
demand,O
primers,O
and,O
FAM,O
-,O
TAMRA,O
labeled,O
probe,O
-,O
mix,O
from,O
Applied,O
Biosystems,O
were,O
used,O
;,O
for,O
MLH1,B-gene
(,O
Hs00179866_m1,O
),O
,,O
MSH2,B-gene
(,O
Hs00179887_m1,O
),O
,,O
MSH3,B-gene
(,O
Hs00267239_m1,O
),O
,,O
MSH6,B-gene
(,O
Hs00264721_m1,O
),O
and,O
PMS2,B-gene
(,O
Hs00241053_m1,O
),O
.,O
 , 


,O
 , 
#1360090-03-Results-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O


,O
Figure,O
1A,O
shows,O
representative,O
Fluorescent,O
-,O
SSCP,O
results,O
for,O
the,O
screening,O
of,O
BRAF,B-gene
mutations,B-mutation
in,O
this,O
CRC,B-disease
series,O
,,O
while,O
Figure,O
1B,O
shows,O
DNA,O
sequencing,O
confirmation,O
of,O
the,O
1799,B-mutation
T,I-mutation
to,I-mutation
A,I-mutation
transversion,O
resulting,O
in,O
the,O
V600E,B-mutation
mutation,O
.,O
 , 
The,O
overall,O
frequency,O
of,O
BRAF,B-gene
mutation,B-mutation
was,O
8.4,B-cohort-patient
%,I-cohort-patient
(,B-size
23/275,I-size
),I-size
,,O
comparing,O
favourably,O
with,O
frequencies,O
of,O
9–11,O
%,O
reported,O
for,O
other,O
large,O
studies,O
of,O
this,O
tumor,B-disease
type,O
[,O
6,16,17,O
],O
.,O
 , 
The,O
mean,O
age,O
of,O
patients,B-cohort-patient
with,O
and,O
without,O
BRAF,B-gene
mutation,B-mutation
was,O
identical,O
(,O
Table,O
1,O
),O
.,O
 , 
Strong,O
associations,O
were,O
observed,O
between,O
BRAF,B-gene
mutation,B-mutation
and,O
tumor,B-disease
origin,O
in,O
the,O
proximal,B-body-part
side,I-body-part
of,I-body-part
the,I-body-part
large,I-body-part
bowel,I-body-part
,,I-body-part
poor,B-Concepts_Ideas
histological,I-Concepts_Ideas
grade,I-Concepts_Ideas
,,I-Concepts_Ideas
mucinous,B-Concepts_Ideas
appearance,I-Concepts_Ideas
and,O
the,O
presence,O
of,O
infiltrating,B-body-part
lymphocytes,I-body-part
.,I-body-part
 , 
Higher,O
frequencies,O
of,O
BRAF,B-gene
mutation,B-mutation
were,O
also,O
observed,O
in,O
females,B-cohort-patient
and,O
in,O
node,B-Phenomena
negative,I-Phenomena
tumors,B-cohort-patient
but,O
these,O
did,O
not,O
reach,O
significance,O
.,O
 , 


,O
(,O
A,O
),O
Representative,O
F,O
-,O
SSCP,O
gel,O
used,O
to,O
detect,O
BRAF,B-gene
mutationsin,B-mutation
colorectal,B-disease
cancer,I-disease
.,I-disease
 , 
WT,O
,,O
wild,O
-,O
type,O
;,O
M,O
,,O
mutation,O
.,O
 , 
(,O
B,O
),O
DNA,O
sequencing,O
gel,O
resultconfirms,O
the,O
presence,O
of,O
a,O
1799,B-mutation
T,I-mutation
to,I-mutation
A,I-mutation
mutation,I-mutation
giving,O
rise,O
to,O
the,O
V600E,B-mutation
mutation,O
.,O
 , 


,O
Associations,O
between,O
BRAF,B-gene
mutation,B-mutation
and,O
clinicopathological,O
features,O
of,O
colorectal,B-disease
cancer,B-disease
.,I-disease
 , 


,O
a,O
Data,O
was,O
unavailable,O
for,O
gender,O
in,O
43,B-size
cases,B-cohort-patient
,,I-cohort-patient
infiltrating,O
lymphocytes,O
in,O
55,B-size
cases,B-cohort-patient
,,I-cohort-patient
nodal,O
involvement,O
in,O
77,B-size
cases,B-cohort-patient
,,I-cohort-patient
tumor,B-disease
site,O
in,O
56,B-size
cases,B-cohort-patient
,,I-cohort-patient
grade,O
in,O
106,B-size
cases,B-cohort-patient
and,O
mucinous,O
appearance,O
in,O
89,B-size
cases,B-cohort-patient
.,I-cohort-patient
 , 


,B-gene
BRAF,I-gene
mutations,B-mutation
showed,O
no,O
association,O
with,O
TP53,B-gene
mutations,B-mutation
and,O
were,O
mutually,O
exclusive,O
with,O
the,O
presence,O
of,O
KRAS,B-gene
mutations,B-mutation
(,O
Table,O
2,O
),O
.,O
 , 
In,O
contrast,O
,,O
BRAF,B-gene
mutations,B-mutation
were,O
approximately,O
10,O
-,O
fold,O
more,O
frequent,O
in,O
MSI+,B-Disorder
and,O
CIMP+,B-Physiology
tumors,B-disease
compared,O
to,O
tumors,B-disease
without,O
these,O
phenotypes,O
.,O
 , 
A,O
strong,O
association,O
was,O
also,O
seen,O
with,O
methylation,B-Physiology
of,I-Physiology
the,I-Physiology
MLH1,B-gene
gene,I-Physiology
promoter,I-Physiology
and,O
in,O
particular,O
with,O
methylation,O
of,O
its,O
proximal,O
region,O
.,O
 , 
We,O
have,O
previously,O
examined,O
the,O
methylation,O
status,O
of,O
7,O
different,O
CpG,O
islands,O
in,O
this,O
CRC,B-disease
series,O
[,O
18,O
],O
.,O
 , 
The,O
mean,O
number,O
of,O
these,O
methylated,O
sites,O
was,O
3,O
-,O
fold,O
higher,O
in,O
tumors,B-cohort-patient
with,O
BRAF,B-gene
mutation,B-mutation
compared,O
to,O
those,O
without,O
(,O
2.6,O
±,O
1.7,O
vs,O
0.8,O
±,O
1.0,O
;,O
P,O
<,O
0.001,O
),O
.,O
 , 
Multivariate,O
analysis,O
revealed,O
that,O
MSI+,O
was,O
the,O
only,O
significant,O
independent,O
predictor,O
of,O
BRAF,B-gene
mutation,B-mutation
(,O
RR,O
=,O
6.3,O
,,O
95%CI,O
 , 
[,O
1.2–32.3,O
],O
;,O
P,O
=,O
0.028,O
),O
in,O
a,O
model,O
that,O
included,O
CIMP+,O
,,O
tumor,B-disease
site,O
,,O
histological,O
grade,O
,,O
presence,O
of,O
infiltrating,O
lymphocytes,O
and,O
mucinous,O
appearance,O
.,O
 , 


,O
Associations,O
between,O
BRAF,B-gene
mutation,B-mutation
and,O
molecular,O
features,O
of,O
colorectal,B-body-part
cancer,B-disease
.,I-disease
 , 


,O
a,O
Data,O
was,O
unavailable,O
for,O
MSI,O
status,O
in,O
40,B-size
cases,B-cohort-patient
,,I-cohort-patient
methylation,O
status,O
in,O
83,B-size
cases,B-cohort-patient
,,I-cohort-patient
KRAS,B-gene
mutation,B-mutation
in,O
26,B-size
cases,B-cohort-patient
and,O
TP53,B-gene
mutation,B-mutation
in,O
26,B-size
cases,B-cohort-patient


,I-cohort-patient
We,O
next,O
examined,O
whether,O
the,O
characteristic,O
features,O
of,O
tumors,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
were,O
still,O
apparent,O
following,O
stratification,O
into,O
MSI,O
and,O
CIMP,O
phenotypes,O
.,O
 , 
Although,O
the,O
statistical,O
power,O
of,O
this,O
subgroup,O
analysis,O
was,O
limited,O
,,O
the,O
morphological,O
features,O
of,O
infiltrating,B-body-part
lymphocytes,I-body-part
,,I-body-part
poor,B-Concepts_Ideas
histological,I-Concepts_Ideas
grade,I-Concepts_Ideas
and,O
mucinous,B-Concepts_Ideas
appearance,I-Concepts_Ideas
were,O
clearly,O
associated,O
with,O
BRAF,B-gene
mutation,B-mutation
regardless,O
of,O
tumor,B-disease
MSI,O
status,O
(,O
Table,O
3,O
),O
.,O
 , 
Similarly,O
,,O
these,O
features,O
were,O
each,O
more,O
common,O
in,O
tumors,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
in,O
both,O
the,O
CIMP-,B-Physiology
and,O
CIMP+,B-Physiology
subgroups,O
(,O
Table,O
4,O
),O
.,O
 , 
Similar,O
to,O
previous,O
observations,O
in,O
a,O
separate,O
CRC,B-disease
cohort,B-cohort-patient
[,O
20,O
],O
,,O
the,O
frequency,O
of,O
KRAS,B-gene
mutation,B-mutation
was,O
lower,O
in,O
MSI+,B-Disorder
compared,O
to,O
MSI-,B-Disorder
tumors,B-disease
(,O
P,O
=,O
0.034,O
;,O
Table,O
3,O
),O
,,O
while,O
the,O
frequency,O
of,O
TP53,B-gene
mutation,B-mutation
was,O
also,O
considerably,O
lower,O
in,O
MSI+,B-Disorder
tumors,B-disease
with,O
wildtype,O
BRAF,B-gene
than,O
in,O
MSI-,B-Disorder
tumors,B-disease
with,O
wildtype,O
BRAF,B-gene
 , 
(,O
P,O
=,O
0.014,O
),O
.,O
 , 


,O
 , 
#2386495-03-Methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Methods,O


,B-cohort-patient
Patients,I-cohort-patient


,I-cohort-patient
Between,O
1957,O
and,O
31,O
December,O
2004,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
included,O
data,O
on,O
196,B-size
families,B-cohort-patient
with,O
verified,O
FAP,B-disease
(,O
defined,O
as,O
more,O
than,O
100,O
colorectal,B-body-part
adenomas,B-disease
or,O
if,O
less,O
with,O
a,O
family,O
history,O
of,O
FAP,B-disease
),I-disease
.,O
 , 
Sixty,B-size
-,I-size
one,I-size
of,O
these,O
families,B-cohort-patient
are,O
now,O
extinct,O
but,O
135,B-size
families,B-cohort-patient
with,O
at,O
least,O
one,O
living,B-cohort-patient
disease,B-disease
-,I-disease
affected,I-cohort-patient
member,I-cohort-patient
remain,O
.,O
 , 
Presently,O
,,O
315,B-size
disease,B-disease
-,I-disease
affected,O
living,O
patients,B-cohort-patient
are,O
included,O
in,O
the,O
registry,O
.,O
 , 
The,O
geographical,O
catchment,O
area,O
comprises,O
the,O
whole,O
of,O
Sweden,B-ethnicity
.,I-ethnicity
 , 
Details,O
of,O
how,O
patients,B-cohort-patient
have,O
been,O
eligible,O
for,O
accession,O
into,O
the,O
registry,O
are,O
given,O
in,O
[,O
30,O
],O
.,O
 , 
In,O
this,O
study,O
we,O
have,O
analyzed,O
96,B-size
families,B-cohort-patient
included,O
in,O
the,O
registry,O
for,O
mutations,B-mutation
in,O
the,O
APC,B-gene
gene,O
.,O
 , 
Twenty,B-size
-,I-size
four,I-size
of,I-size
the,I-size
remaining,I-size
39,I-size
families,B-cohort-patient
have,O
been,O
analyzed,O
for,O
APC,B-gene
gene,O
mutations,B-mutation
at,O
other,O
genetic,O
laboratories,O
and,O
15,B-size
families,B-cohort-patient
remain,O
to,O
be,O
tested,O
.,O
 , 
We,O
have,O
previously,O
reported,O
six,B-size
of,I-size
these,I-size
patients,B-cohort-patient
who,O
carried,O
bi,B-mutation
-,I-mutation
allelic,I-mutation
MUTYH,B-gene
mutations,I-mutation
[,O
31,O
],O
.,O
 , 
Probands,B-cohort-patient
were,O
defined,O
as,O
those,O
diagnosed,O
on,O
the,O
basis,O
of,O
the,O
occurrence,O
of,O
symptoms,O
and,O
irrespective,O
of,O
other,O
cases,B-cohort-patient
in,O
the,O
family,B-cohort-patient
and,O
call,O
-,O
up,O
patients,B-cohort-patient
,,I-cohort-patient
as,O
those,O
identified,O
as,O
subjects,O
at,O
risk,O
on,O
the,O
basis,O
of,O
studies,O
of,O
pedigrees,O
and,O
found,O
to,O
have,O
FAP,B-disease
.,I-disease
 , 
De,O
novo,O
mutations,O
were,O
defined,O
in,O
those,O
individuals,B-cohort-patient
where,O
none,O
of,O
the,O
parents,O
carried,O
the,O
mutation,O
or,O
where,O
the,O
parents,O
had,O
a,O
negative,O
colonoscopy,O
after,O
the,O
age,B-age
of,I-age
50,I-age
or,O
died,O
of,O
a,O
non,O
-,B-disease
FAP,I-disease
related,O
cause,O
after,O
the,O
age,B-age
of,I-age
75,I-age
.,I-age
 , 
All,O
patients,B-cohort-patient
have,O
given,O
their,O
consent,O
and,O
the,O
local,O
ethics,O
committees,O
have,O
approved,O
the,O
study,O
.,O
 , 
The,O
clinical,O
features,O
of,O
index,B-cohort-patient
patients,I-cohort-patient
of,O
each,O
of,O
the,O
families,B-cohort-patient
analyzed,O
are,O
listed,O
in,O
Additional,O
file,O
1,O
and,O
Table,O
1,O
.,O
 , 


,B-cohort-patient
Patients,I-cohort-patient
without,O
any,O
detected,O
mutation,B-mutation
in,O
APC,B-gene
or,O
MUTYH,B-gene


,I-gene
Age,O
,,O
age,O
at,O
diagnosis,O
;,O
DL,B-disease
,,I-disease
duodenal,B-body-part
lesion,B-disease
;,I-disease
dom,O
,,O
dominant,O
;,O
FGP,B-disease
,,I-disease
fundic,B-body-part
gland,I-body-part
polyps,B-disease
;,I-disease
NA,O
,,O
no,O
available,O
data,O
;,O
NI,O
,,O
no,O
inheritance,O
;,O
Number,O
of,O
polyps,B-disease
,,I-disease
number,O
of,O
polyps,B-disease
at,O
diagnosis,O
;,O
rec,O
,,O
recessive,O


,B-cohort-patient
Patient,I-cohort-patient
C896,B-cohort-patient
,,I-cohort-patient
with,O
only,O
five,O
adenomas,B-disease
,,I-disease
was,O
included,O
because,O
of,O
a,O
family,B-Disorder
history,I-Disorder
of,I-Disorder
FAP,B-disease
.,I-disease
 , 
Patient,B-cohort-patient
C107,B-cohort-patient
underwent,O
her,B-gender
first,O
colonoscopy,O
due,O
to,O
intestinal,B-Disorder
bleeding,I-Disorder
at,O
age,B-age
47,I-age
.,I-age
 , 
At,O
diagnosis,O
,,O
10–20,B-Concepts_Ideas
small,I-Concepts_Ideas
(,I-Concepts_Ideas
less,I-Concepts_Ideas
than,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
),I-Concepts_Ideas
polyps,B-disease
were,O
found,O
in,O
most,O
colorectal,B-body-part
parts,O
.,O
 , 
Tubular,B-Concepts_Ideas
and,O
tubulovillous,B-Concepts_Ideas
adenomas,B-disease
were,O
removed,O
yearly,O
.,O
 , 
At,O
age,B-age
50,I-age
,,I-age
carcinoma,B-disease
(,B-Phenomena
Dukes,I-Phenomena
A,I-Phenomena
),I-Phenomena
was,O
diagnosed,O
4,O
cm,O
from,O
valvula,B-body-part
Bauhini,I-body-part
in,O
conjunction,O
with,O
several,O
new,O
adenomas,B-disease
.,I-disease
 , 
At,O
that,O
time,O
the,O
patient,B-cohort-patient
underwent,O
total,O
colectomy,O
with,O
ileorectal,O
anastomosis,O
(,O
IRA,O
),O
.,O
 , 


,O
DNA,O
,,O
RNA,O
and,O
cDNA,O
preparation,O


,O
Genomic,O
DNA,O
was,O
isolated,O
from,O
samples,O
of,O
venous,O
blood,O
,,O
anti,O
-,O
coagulated,O
in,O
ethylenediaminetetraacetic,O
acid,O
(,O
EDTA,O
),O
.,O
 , 
DNA,O
purification,O
was,O
performed,O
using,O
the,O
PuregeneR,O
DNA,O
Isolation,O
Kit,O
(,O
Gentra,O
Systems,O
,,O
Minneapolis,O
,,O
MN,O
),O
according,O
to,O
the,O
manufacturer,O
's,O
recommendations,O
.,O
 , 
DNA,O
was,O
extracted,O
from,O
paraffin,O
-,O
embedded,O
tissue,O
as,O
described,O
previously,O
[,O
32,O
],O
.,O
 , 
Histopaque,O
(,O
Sigma,O
,,O
St,O
Louis,O
,,O
MO,O
),O
or,O
Lymphoprep,O
(,O
Axis,O
-,O
Shield,O
PoC,O
 , 
AS,O
,,O
Oslo,O
,,O
Norway,O
),O
was,O
used,O
for,O
purification,O
of,O
the,O
lymphocytes,O
,,O
and,O
total,O
RNA,O
was,O
extracted,O
using,O
RNA,O
-,O
Stat,O
60,O
(,O
Tel,O
-,O
Test,O
,,O
Friendswood,O
,,O
TX,O
),O
.,O
 , 
cDNA,O
was,O
synthesized,O
as,O
described,O
previously,O
[,O
33,O
],O
.,O
 , 


,O
 , 
#2386495-02-Background-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
In,O
the,O
present,O
study,O
patients,B-cohort-patient
included,O
in,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
were,O
subjected,O
to,O
a,O
thorough,O
clinical,O
characterization,O
and,O
mutational,O
screening,O
of,O
the,O
APC,B-gene
gene,O
including,O
screening,O
for,O
large,O
deletions,O
and,O
detection,O
of,O
low,O
-,O
frequency,O
alleles,O
caused,O
by,O
germline,O
mosaicism,O
.,O
 , 
Sixty,B-size
-,I-size
one,I-size
mutations,B-mutation
,,I-mutation
including,O
27,O
not,O
described,O
previously,O
,,O
are,O
reported,O
.,O
 , 
Among,O
the,O
characterized,O
mutations,O
are,O
elusive,O
changes,O
such,O
as,O
a,O
case,O
of,O
mosaicism,B-mutation
,,I-mutation
splicing,B-mutation
defects,I-mutation
,,I-mutation
and,O
a,O
mutation,B-mutation
in,I-mutation
APC,I-mutation
exon,I-mutation
1,I-mutation
which,O
is,O
the,O
most,O
5,B-mutation
',I-mutation
APC,I-mutation
mutation,I-mutation
hitherto,O
reported,O
.,O
 , 
The,O
detection,O
of,O
reduced,B-Physiology
APC,I-Physiology
expression,I-Physiology
in,O
one,B-size
family,B-cohort-patient
is,O
also,O
described,O
.,O
 , 
A,O
combination,O
of,O
mutation,O
screening,O
techniques,O
was,O
used,O
to,O
achieve,O
as,O
high,O
a,O
mutation,O
-,O
detection,O
frequency,O
as,O
possible,O
.,O
 , 


,O
 , 
#3034663-04-Results-p01
Results,O


,O
No,O
discordances,O
were,O
detected,O
in,O
the,O
genotyping,O
quality,O
control,O
.,O
 , 
The,O
genotype,O
distributions,O
in,O
the,O
control,B-cohort-patient
,,I-cohort-patient
sporadic,B-Concepts_Ideas
and,O
familial,B-Concepts_Ideas
CRC,B-disease
populations,B-cohort-patient
did,O
not,O
deviate,O
significantly,O
from,O
that,O
expected,O
for,O
a,O
population,O
in,O
Hardy,O
-,O
Weinberg,O
equilibrium,O
(,O
Table,O
1,O
),O
.,O
 , 


,O
Allelic,O
and,O
genotypic,O
frequencies,O
and,O
Hardy,O
-,O
Weinberg,O
equilibrium,O


,O
*,O
Individuals,O
from,O
apparently,O
unrelated,O
families,O


,B-size
Twenty,I-size
-,I-size
seven,I-size
individuals,B-cohort-patient
were,O
heterozygous,O
for,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
(,O
Figure,O
1,O
),O
;,O
11,B-size
were,O
controls,B-cohort-patient
(,B-size
11/411,I-size
,,I-size
2.68,B-size
%,I-size
),I-size
,,O
nine,B-size
were,O
CRC,B-disease
patients,B-cohort-patient
from,O
the,O
sporadic,B-cohort-patient
group,I-cohort-patient
(,B-size
9/373,I-size
,,I-size
2.41,B-size
%,I-size
),I-size
and,O
seven,B-size
were,O
CRC,B-disease
patients,B-cohort-patient
from,O
the,O
familial,B-cohort-patient
group,I-cohort-patient
(,B-size
7/250,I-size
,,I-size
2.8,B-size
%,I-size
),I-size
.,O
 , 
None,B-size
of,O
the,O
individuals,B-cohort-patient
was,O
homozygous,O
for,O
the,O
minor,O
allele,O
.,O
 , 


,O
Results,O
of,O
genotyping,O
for,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
using,O
the,O
iPLEX,O
Sequenom,O
(,O
A,O
),O
and,O
sequencing,O
(,O
B,O
),O
methods,O
.,O
 , 


,O
There,O
were,O
no,O
significant,O
associations,O
in,O
the,O
case,O
-,O
control,O
and,O
case,O
-,O
case,O
studies,O
(,O
80,O
%,O
detection,O
power,O
,,O
OR,O
=,O
3.0,O
;,O
two,O
-,O
sided,O
test,O
,,O
alpha,O
level,O
=,O
5,O
%,O
),O
(,O
Table,O
2,O
),O
and,O
no,O
statistically,O
significant,O
associations,O
when,O
the,O
OR,O
was,O
adjusted,O
for,O
age,O
and,O
sex,O
.,O
 , 


,O
Results,O
of,O
case,O
-,O
control,O
and,O
case,O
-,O
case,O
analyses,O
.,O
 , 
Odds,O
ratios,O
(,O
ORs,O
),O
and,O
95,O
%,O
confidence,O
intervals,O
(,O
95,O
%,O
CIs,O
),O
for,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
 , 
variant,O


,O
In,O
one,B-size
of,O
the,O
families,B-cohort-patient
with,O
LS,B-disease
,,I-disease
the,O
index,B-cohort-patient
subject,I-cohort-patient
was,O
heterozygous,O
for,O
a,O
pathogenic,O
MLH1,B-gene
variant,O
(,B-mutation
c.767C,I-mutation
>,I-mutation
T,I-mutation
;,I-mutation
p.,B-mutation
Arg226X,I-mutation
),I-mutation
and,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
.,O
 , 
Two,B-size
of,O
his,B-cohort-patient
offspring,B-cohort-patient
,,I-cohort-patient
who,O
were,O
diagnosed,O
with,O
CRC,B-disease
at,O
the,O
ages,O
of,O
36,B-age
and,I-age
39,I-age
years,I-age
,,I-age
carried,O
the,O
deleterious,O
variant,O
but,O
not,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
.,O
 , 
An,O
unaffected,B-disease
daughter,B-cohort-patient
(,B-cohort-patient
III-12,I-cohort-patient
),I-cohort-patient
carried,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
but,O
not,O
the,O
deleterious,O
variant,O
.,O
 , 
Two,B-size
nephews,B-gender
(,B-cohort-patient
III-3,I-cohort-patient
;,I-cohort-patient
III-4,B-cohort-patient
),I-cohort-patient
were,O
also,O
diagnosed,O
with,O
CRC,B-disease
at,O
the,O
ages,O
of,O
30,B-age
and,I-age
42,I-age
years,I-age
and,O
they,O
carried,O
only,O
the,O
deleterious,O
variant,O
.,O
 , 
Two,B-size
other,O
healthy,B-disease
nephews,B-cohort-patient
(,B-cohort-patient
III-6,I-cohort-patient
;,I-cohort-patient
III-7,B-cohort-patient
),I-cohort-patient
had,O
the,O
wild,O
types,O
of,O
the,O
two,O
variants,O
(,B-cohort-patient
Family,I-cohort-patient
#,I-cohort-patient
1,I-cohort-patient
,,I-cohort-patient
Figure,O
2,O
),O
.,O
 , 


,O
Pedigree,O
for,O
Family,B-cohort-patient
#,I-cohort-patient
1,I-cohort-patient
(,B-disease
CRC,I-disease
:,I-disease
Colorectal,B-body-part
cancer,I-disease
;,I-disease
GC,B-disease
:,I-disease
Gastric,B-body-part
cancer,I-disease
;,I-disease
DC,B-disease
:,I-disease
Duodenal,B-disease
cancer,I-disease
),I-disease
.,O
 , 


,O
In,O
the,O
second,B-cohort-patient
LS,B-disease
family,I-cohort-patient
,,I-cohort-patient
the,O
index,B-cohort-patient
subject,I-cohort-patient
,,I-cohort-patient
one,O
sister,B-cohort-patient
and,O
one,O
brother,B-cohort-patient
with,O
CRC,B-disease
(,B-cohort-patient
II-5,I-cohort-patient
;,I-cohort-patient
II-6,B-cohort-patient
;,I-cohort-patient
II-7,B-cohort-patient
,,I-cohort-patient
respectively,O
),O
had,O
a,O
deleterious,O
variant,O
in,O
MSH6,B-gene
(,B-mutation
c.3013C,I-mutation
>,I-mutation
T,I-mutation
;,I-mutation
p.,B-mutation
Arg1005X,I-mutation
),I-mutation
but,O
did,O
not,O
have,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
.,O
 , 
This,O
variant,O
was,O
present,O
in,O
only,O
three,B-size
of,I-size
four,I-size
unaffected,B-disease
nephews,B-gender
(,B-cohort-patient
III-2,I-cohort-patient
;,I-cohort-patient
III-3,B-cohort-patient
;,I-cohort-patient
III-4,B-cohort-patient
),I-cohort-patient
and,O
was,O
inherited,O
from,O
the,O
parental,O
branch,O
,,O
in,O
which,O
there,O
was,O
no,O
familial,O
history,O
of,O
cancer,B-disease
.,I-disease
 , 
Individuals,O
III-3,B-cohort-patient
and,O
III-4,B-cohort-patient
inherited,O
also,O
the,O
deleterious,B-mutation
variant,I-mutation
.,I-mutation
 , 
No,O
genetic,O
testing,O
was,O
available,O
from,O
the,O
father,B-gender
or,O
paternal,B-gender
relatives,I-cohort-patient
(,B-cohort-patient
Family,I-cohort-patient
#,I-cohort-patient
2,I-cohort-patient
,,I-cohort-patient
Figure,O
3,O
),O
.,O
 , 


,O
Pedigree,O
for,O
Family,B-cohort-patient
#,I-cohort-patient
2,I-cohort-patient
(,B-disease
CRC,I-disease
:,I-disease
Colorectal,B-body-part
cancer,I-disease
;,I-disease
EC,B-disease
:,I-disease
Endometrial,B-body-part
cancer,I-disease
),I-disease
.,O
 , 


,O
The,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
was,O
present,O
in,O
the,O
third,B-cohort-patient
family,I-cohort-patient
that,O
fulfilled,O
the,O
Amsterdam,O
II,O
Criteria,O
.,O
 , 
A,O
first,B-cohort-patient
-,I-cohort-patient
grade,I-cohort-patient
familiar,I-cohort-patient
non,I-cohort-patient
-,I-cohort-patient
carrier,I-cohort-patient
of,O
this,O
variant,O
was,O
diagnosed,O
with,O
a,O
colonic,B-body-part
polyp,B-disease
with,O
a,O
high,B-Disorder
grade,I-Disorder
of,I-Disorder
dysplasia,I-Disorder
at,O
the,O
age,B-age
of,I-age
39,I-age
years,I-age
and,O
with,O
four,O
colonic,B-body-part
polyps,B-disease
at,O
the,O
age,B-age
of,I-age
42,I-age
years,I-age
(,B-cohort-patient
Family,I-cohort-patient
#,I-cohort-patient
3,I-cohort-patient
,,I-cohort-patient
Figure,O
4,O
),O
.,O
 , 


,O
 , 
#1334229-02-Background-p01
Background,O


,O
Carcinogenesis,O
is,O
a,O
multi,O
-,O
step,O
process,O
that,O
involves,O
the,O
accumulation,O
of,O
numerous,O
genetic,O
and,O
epigenetic,O
changes,O
in,O
cells,O
[,O
1,O
],O
.,O
 , 
These,O
genetic,O
aberrations,O
affect,O
a,O
limited,O
number,O
of,O
identified,O
pathways,O
that,O
are,O
involved,O
in,O
(,B-body-part
colorectal,I-body-part
),I-body-part
carcinogenesis,B-disease
[,O
2,O
],O
.,O
 , 
A,O
genetic,O
model,O
for,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancer,B-disease
has,O
been,O
proposed,O
,,O
which,O
describes,O
the,O
sequential,O
accumulation,O
of,O
specific,O
genetic,O
alterations,O
in,O
various,O
pathways,O
,,O
involving,O
tumour,B-disease
suppressor,O
genes,O
(,O
e.g.,O
APC,B-gene
,,I-gene
SMAD4,B-gene
,,I-gene
TP53,B-gene
),I-gene
and,O
oncogenes,O
(,O
e.g.,O
CTNNB1,B-gene
,,I-gene
K,B-gene
-,I-gene
ras,I-gene
),I-gene
 , 
[,O
3,4,O
],O
.,O
 , 
Important,O
molecular,O
pathways,O
that,O
upon,O
activation,O
affect,O
the,O
early,O
and,O
intermediate,O
stages,O
of,O
colorectal,B-body-part
carcinogenesis,B-disease
are,O
the,O
Wnt,O
and,O
Ras,O
signalling,O
pathways,O
,,O
whereas,O
TP53,B-gene
inactivation,I-Physiology
is,O
considered,O
a,O
late,O
event,O
.,O
 , 


,B-Physiology
Activation,I-Physiology
of,I-Physiology
the,I-Physiology
Wnt,I-Physiology
pathway,I-Physiology
plays,O
a,O
central,O
role,O
in,O
the,O
aetiology,O
of,O
most,O
colorectal,B-disease
cancers,I-disease
and,O
is,O
often,O
the,O
result,O
of,O
mutations,B-mutation
in,I-mutation
the,I-mutation
N,I-mutation
-,I-mutation
terminal,I-mutation
domain,I-mutation
of,I-mutation
the,I-mutation
APC,B-gene
gene,I-mutation
,,I-mutation
that,O
lead,O
to,O
partial,O
or,O
complete,O
loss,O
of,O
this,O
region,O
and,O
thereby,O
to,O
loss,B-Physiology
of,I-Physiology
the,I-Physiology
β,I-Physiology
-,I-Physiology
catenin,I-Physiology
regulating,I-Physiology
function,I-Physiology
 , 
[,O
5,6,O
],O
.,O
 , 
Conversely,O
,,O
in,O
tumours,B-disease
lacking,O
these,O
APC,B-gene
mutations,B-mutation
[,O
7,O
],O
,,O
activating,B-mutation
missense,I-mutation
mutations,I-mutation
at,I-mutation
one,I-mutation
of,I-mutation
the,I-mutation
phosphorylation,I-mutation
sites,I-mutation
at,I-mutation
codons,I-mutation
31,I-mutation
,,I-mutation
33,I-mutation
,,I-mutation
37,I-mutation
and,I-mutation
45,I-mutation
of,I-mutation
exon,I-mutation
3,I-mutation
of,O
the,O
CTNNB1,B-gene
gene,O
(,O
encoding,O
the,O
β,O
-,O
catenin,O
protein,O
),O
can,O
render,O
it,O
stable,O
as,O
it,O
can,O
no,O
longer,O
be,O
tagged,O
for,O
cellular,O
degradation,O
.,O
 , 
Activation,B-Physiology
of,I-Physiology
the,I-Physiology
Ras,I-Physiology
pathway,I-Physiology
in,O
cancer,B-disease
is,O
marked,O
by,O
the,O
loss,O
of,O
the,O
intrinsic,O
GTPase,O
activity,O
of,O
the,O
Ras,O
protein,O
,,O
which,O
can,O
be,O
ascribed,O
to,O
missense,B-mutation
mutations,I-mutation
in,I-mutation
codons,I-mutation
12,I-mutation
and,I-mutation
13,I-mutation
of,I-mutation
exon,I-mutation
1,I-mutation
,,I-mutation
which,O
are,O
responsible,O
for,O
90,O
%,O
activating,B-mutation
mutations,I-mutation
in,O
the,O
of,O
the,O
K,B-gene
-,I-gene
ras,I-gene
gene,O
[,O
8,O
],O
.,O
 , 


,O
According,O
to,O
the,O
paradigm,O
for,O
colorectal,B-disease
cancer,I-disease
development,O
,,O
mutations,B-mutation
in,O
the,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
are,O
thought,O
to,O
contribute,O
to,O
the,O
early,O
developmental,O
stages,O
of,O
colorectal,B-disease
cancer,B-disease
[,O
3,O
],O
.,O
 , 
However,O
,,O
a,O
recent,O
study,O
based,O
on,O
the,O
analysis,O
of,O
APC,B-gene
,,I-gene
K,B-gene
-,I-gene
ras,I-gene
and,O
TP53,B-gene
genes,O
concluded,O
that,O
simultaneous,O
occurrence,O
of,O
all,O
three,O
genetic,O
alterations,O
is,O
rare,O
and,O
that,O
multiple,O
genetic,O
pathways,O
may,O
be,O
relevant,O
to,O
colorectal,B-disease
cancer,B-disease
 , 
[,O
9,O
],O
.,O
 , 


,O
Genetic,O
instability,O
is,O
seen,O
in,O
most,O
types,O
of,O
cancer,B-disease
[,O
10,O
],O
.,O
 , 
Two,O
distinct,O
types,O
of,O
genetic,O
instability,O
appear,O
to,O
occur,O
in,O
colorectal,B-disease
cancer,I-disease
[,O
11,O
],O
:,O
chromosomal,B-Physiology
and,I-Physiology
microsatellite,I-Physiology
instability,I-Physiology
.,I-Physiology
 , 
Chromosomal,B-Disorder
instability,I-Disorder
results,O
in,O
gains,O
or,O
losses,O
of,O
entire,O
chromosomes,O
or,O
parts,O
of,O
them,O
,,O
and,O
gives,O
rise,O
to,O
aneuploid,B-Physiology
tumours,B-disease
and,O
occurs,O
in,O
the,O
majority,O
of,O
cancers,B-disease
.,I-disease
 , 
A,O
smaller,O
proportion,O
of,O
colorectal,B-disease
cancers,I-disease
displays,O
microsatellite,B-Disorder
instability,I-Disorder
,,I-Disorder
represented,O
by,O
diploid,O
cells,O
acquiring,O
high,O
mutation,O
rates,O
,,O
and,O
was,O
found,O
to,O
be,O
associated,O
with,O
defective,B-Disorder
mismatch,I-Disorder
repair,I-Disorder
[,O
12,O
],O
.,O
 , 
These,O
tumours,B-disease
are,O
less,O
likely,O
to,O
harbour,O
mutations,B-mutation
in,O
genes,O
associated,O
with,O
chromosomally,B-Disorder
instable,I-Disorder
and,O
generally,O
aneuploid,B-Physiology
tumours,B-disease
,,I-disease
such,O
as,O
APC,B-gene
,,I-gene
K,B-gene
-,I-gene
ras,I-gene
and,O
TP53,B-gene
[,O
13,O
-,O
21,O
],O
,,O
suggesting,O
that,O
these,O
tumours,B-disease
form,O
a,O
distinct,O
group,B-cohort-patient
.,I-cohort-patient
 , 
Moreover,O
,,O
microsatellite,B-Disorder
instable,I-Disorder
tumours,B-disease
are,O
found,O
predominantly,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
[,O
22,23,O
],O
,,O
are,O
more,O
likely,O
to,O
occur,O
in,O
patients,B-cohort-patient
with,O
a,O
positive,B-Disorder
family,I-Disorder
history,I-Disorder
of,O
colorectal,B-body-part
cancer,B-disease
[,O
22,23,O
],O
,,O
are,O
often,O
less,O
differentiated,O
than,O
microsatellite,B-Disorder
stable,I-Disorder
tumours,B-disease
[,O
22,O
],O
,,O
and,O
occur,O
more,O
frequently,O
in,O
women,B-gender
[,O
24,O
],O
and,O
at,O
older,O
age,O
[,O
25,O
],O
.,O
 , 
Moreover,O
,,O
in,O
tumours,B-disease
displaying,O
microsatellite,B-Disorder
instability,I-Disorder
,,I-Disorder
mutations,B-mutation
the,O
CTNNB1,B-gene
gene,O
were,O
more,O
frequent,O
[,O
26,O
],O
.,O
 , 


,O
 , 
#2386495-02-Background-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Background,O


,O
The,O
dominantly,B-Concepts_Ideas
inherited,I-Concepts_Ideas
condition,O
familial,B-Concepts_Ideas
adenomatous,I-disease
polyposis,I-disease
(,B-disease
FAP,I-disease
),I-disease
is,O
caused,O
by,O
germline,B-mutation
mutations,I-mutation
in,O
the,O
APC,B-gene
gene,O
(,B-mutation
5q21,I-mutation
-,I-mutation
q22,I-mutation
;,I-mutation
MIM#175100,O
),O
 , 
[,O
1,2,O
],O
.,O
 , 
The,O
classical,B-Concepts_Ideas
FAP,B-disease
phenotype,O
is,O
defined,O
by,O
hundreds,B-Concepts_Ideas
to,I-Concepts_Ideas
thousands,I-Concepts_Ideas
of,I-Concepts_Ideas
adenomatous,B-disease
polyps,I-disease
that,O
develop,O
in,O
the,O
large,B-body-part
intestine,I-body-part
,,I-body-part
conferring,O
a,O
high,O
risk,O
of,O
colorectal,B-disease
cancer,I-disease
(,B-disease
CRC,I-disease
),I-disease
.,O
 , 
A,O
variety,O
of,O
extra,B-body-part
-,I-body-part
colonic,I-body-part
manifestations,O
exist,O
in,O
FAP,B-disease
.,I-disease
 , 
Duodenal,B-body-part
adenomas,B-disease
are,O
common,O
and,O
carcinomas,B-disease
of,O
the,O
duodenum,B-body-part
are,O
a,O
main,O
cause,O
of,O
death,O
in,O
FAP,B-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 
Patients,B-cohort-patient
also,O
have,O
an,O
increased,O
risk,O
of,O
developing,O
extra,B-body-part
-,I-body-part
intestinal,I-body-part
tumors,B-disease
,,I-disease
for,O
example,O
,,O
desmoids,B-disease
.,I-disease
 , 
Recently,O
,,O
a,O
new,O
type,O
of,O
colorectal,B-body-part
adenomatous,B-disease
polyposis,I-disease
has,O
been,O
described,O
,,O
MUTYH,B-gene
-,I-gene
associated,I-disease
polyposis,I-disease
(,B-disease
MAP,I-disease
),I-disease
 , 
[,O
3,O
],O
or,O
MUTYH,B-gene
-,I-gene
associated,I-disease
CRC,I-disease
(,O
MIM#608456,O
),O
.,O
 , 
MAP,B-disease
is,O
caused,O
by,O
biallelic,B-mutation
mutations,I-mutation
in,O
the,O
MUTYH,B-gene
(,B-mutation
mutY,I-mutation
homologue,I-mutation
;,I-mutation
MIM*604933,O
),O
gene,O
(,B-mutation
1p32.1,I-mutation
-,I-mutation
p34.3,I-mutation
),I-mutation
and,O
is,O
inherited,B-Physiology
in,I-Physiology
a,I-Physiology
recessive,I-Physiology
manner,I-Physiology
[,O
4,5,O
],O
.,O
 , 


,O
The,O
majority,O
of,O
germline,B-mutation
APC,I-mutation
mutations,I-mutation
identified,O
in,O
FAP,B-disease
families,B-cohort-patient
cause,O
truncations,O
in,O
this,O
multifunctional,O
protein,O
[,O
6,7,O
],O
.,O
 , 
The,O
APC,B-gene
truncations,B-mutation
most,O
often,O
occur,O
as,O
the,O
result,O
of,O
nonsense,B-mutation
APC,B-gene
mutations,I-mutation
or,O
frameshifts,B-mutation
caused,I-mutation
by,I-mutation
small,I-mutation
deletions,I-mutation
/,I-mutation
insertions,I-mutation
.,I-mutation
 , 
Large,O
APC,B-gene
deletions,B-mutation
are,O
found,O
in,O
a,O
limited,O
number,O
of,O
FAP,B-disease
cases,B-cohort-patient
.,I-cohort-patient
 , 
By,O
using,O
methods,O
such,O
as,O
quantitative,O
real,O
-,O
time,O
PCR,O
(,O
polymerase,O
chain,O
reaction,O
),O
or,O
MLPA,O
(,O
multiplex,O
ligation,O
-,O
dependent,O
probe,O
amplification,O
),O
rather,O
than,O
conventional,O
mutation,O
-,O
detection,O
techniques,O
,,O
we,O
can,O
achieve,O
higher,O
detection,O
rates,O
of,O
large,O
deletions,O
[,O
8,O
-,O
12,O
],O
.,O
 , 
The,O
number,O
of,O
reported,O
characterized,O
APC,B-gene
splice,B-mutation
-,I-mutation
site,I-mutation
mutations,I-mutation
is,O
comparatively,O
low,O
 , 
[,O
13,O
-,O
17,O
],O
.,O
 , 
Approximately,O
10–15,B-size
%,I-size
of,O
the,O
FAP,B-disease
patients,B-cohort-patient
could,O
have,O
a,O
reduced,B-Physiology
or,I-Physiology
absent,I-Physiology
APC,B-gene
expression,I-Physiology
[,O
18,O
],O
.,O
 , 
The,O
cause,O
of,O
the,O
reduced,O
expression,O
is,O
not,O
known,O
but,O
the,O
patients,B-cohort-patient
show,O
a,O
similar,O
phenotype,O
to,O
those,O
with,O
an,O
identified,O
truncating,B-mutation
APC,B-gene
mutation,I-mutation
[,O
19,O
-,O
21,O
],O
.,O
 , 
It,O
has,O
been,O
shown,O
that,O
a,O
decrease,O
of,O
approximately,O
50,O
%,O
of,O
the,O
expression,O
of,O
an,O
allele,O
can,O
result,O
in,O
a,O
predisposition,O
to,O
FAP,B-disease
[,O
20,O
],O
.,O
 , 
Germline,B-mutation
APC,B-gene
-,I-gene
mutation,I-mutation
mosaicism,O
in,O
FAP,B-disease
patients,B-cohort-patient
has,O
been,O
reported,O
[,O
22,O
-,O
25,O
],O
but,O
is,O
not,O
generally,O
included,O
in,O
the,O
mutation,O
screening,O
procedure,O
provided,O
by,O
most,O
labs,O
owing,O
to,O
the,O
technical,O
difficulties,O
encountered,O
with,O
these,O
analyses,O
.,O
 , 


,O
Different,O
genotype,O
-,O
phenotype,O
correlations,O
in,O
FAP,B-disease
have,O
been,O
suggested,O
[,O
26,O
-,O
28,O
],O
.,O
 , 
The,O
classic,O
phenotype,O
is,O
primarily,O
caused,O
by,O
mutations,B-mutation
in,I-mutation
the,I-mutation
central,I-mutation
part,I-mutation
of,I-mutation
the,I-mutation
APC,B-gene
gene,I-mutation
.,I-mutation
 , 
Mutations,B-mutation
around,I-mutation
codon,I-mutation
1309,I-mutation
cause,O
a,O
severe,B-Concepts_Ideas
course,I-Concepts_Ideas
of,O
disease,B-disease
with,O
early,B-Disorder
onset,I-Disorder
and,O
profuse,B-Disorder
polyposis,I-Disorder
.,I-Disorder
 , 
The,O
milder,B-Concepts_Ideas
,,I-Concepts_Ideas
attenuated,I-Concepts_Ideas
form,I-Concepts_Ideas
of,O
disease,B-disease
(,B-disease
AFAP,I-disease
),I-disease
,,O
characterized,O
by,O
less,B-Concepts_Ideas
than,I-Concepts_Ideas
100,I-Concepts_Ideas
adenomas,B-disease
and,O
later,B-Disorder
onset,I-Disorder
of,I-Disorder
adenomatosis,I-Disorder
and,I-Disorder
CRC,B-disease
,,I-disease
is,O
often,O
caused,O
by,O
mutations,B-mutation
in,I-mutation
the,I-mutation
far,I-mutation
5,I-mutation
',I-mutation
and,I-mutation
3,I-mutation
',I-mutation
regions,I-mutation
of,O
the,O
APC,B-gene
gene,O
,,O
as,O
well,O
as,O
in,B-mutation
the,I-mutation
part,I-mutation
excluded,I-mutation
by,I-mutation
alternative,I-mutation
splicing,I-mutation
of,I-mutation
exon,I-mutation
9,I-mutation
[,O
29,O
],O
.,O
 , 


,O
 , 
#1373649-05-Conclusion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Conclusion,O


,O
We,O
overcame,O
the,O
absence,O
of,O
proband,B-cohort-patient
's,I-cohort-patient
non,O
-,O
tumor,O
DNA,O
for,O
MSI,O
testing,O
by,O
studying,O
the,O
alleles,O
carried,O
by,O
his,B-gender
progenitors,O
,,O
the,O
natural,O
approach,O
for,O
the,O
research,O
team,O
due,O
its,O
paternity,O
testing,O
background,O
.,O
 , 


,O
This,O
strategy,O
allowed,O
us,O
to,O
perform,O
the,O
screening,O
for,O
HNPCC,B-disease
using,O
the,O
recommended,O
NCI,O
microsatellite,O
panel,O
before,O
sequencing,O
the,O
obligate,O
carrier,O
.,O
 , 


,O
We,O
consider,O
highly,O
probable,O
the,O
disease,O
-,O
causing,O
nature,O
of,O
the,O
germline,B-mutation
mutation,I-mutation
in,O
the,O
hMSH2,B-gene
gene,O
found,O
in,O
the,O
family,B-cohort-patient
.,I-cohort-patient
 , 
To,O
establish,O
it,O
undoubtedly,O
,,O
both,O
immunohistochemical,O
data,O
of,O
the,O
investigated,O
tumor,O
and,O
screening,O
of,O
at,O
least,O
100,O
chromosomes,O
in,O
healthy,B-disease
controls,B-cohort-patient
should,O
be,O
performed,O
.,O
 , 
This,O
is,O
the,O
second,O
report,O
of,O
an,O
HNPCC,B-disease
related,O
mutation,B-mutation
in,O
Argentina,B-ethnicity
,,I-ethnicity
involving,O
the,O
hMSH2,B-gene
gene,O
[,O
15,O
],O
.,O
 , 
According,O
to,O
the,O
Human,O
Gene,O
Mutation,O
Database,O
(,O
HGMD,O
),O
 , 
[,O
16,O
],O
and,O
the,O
International,O
Society,O
for,O
Gastrointestinal,O
Hereditary,O
Tumors,O
(,O
InSiGHT,O
),O
[,O
17,O
],O
Database,O
we,O
are,O
the,O
first,O
to,O
report,O
the,O
mutation,O
.,O
 , 


,O
 , 
#1557864-05-Discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Discussion,O


,O
In,O
this,O
study,O
we,O
aimed,O
to,O
address,O
two,O
questions,O
;,O
1,O
),O
what,O
is,O
the,O
frequency,O
of,O
MMR,B-Disorder
inactivation,I-Disorder
in,O
ovarian,B-body-part
cancer,I-disease
,,I-disease
and,O
2,O
),O
is,O
it,O
associated,O
with,O
platinum,O
-,O
based,O
chemotherapy,O
response,O
.,O
 , 


,O
First,O
we,O
analyzed,O
eight,B-size
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
,,I-cohort-patient
i.e.,O
SKOV6,B-cohort-patient
,,I-cohort-patient
HOC7,B-cohort-patient
,,I-cohort-patient
SKOV3,B-cohort-patient
,,I-cohort-patient
2774,B-cohort-patient
,,I-cohort-patient
OVCAR3,B-cohort-patient
,,I-cohort-patient
KB3.1,B-cohort-patient
,,I-cohort-patient
CAOV3,B-cohort-patient
and,O
A2780,B-cohort-patient
.,I-cohort-patient
 , 
Microsatellite,B-Disorder
instability,I-Disorder
(,O
MSI,O
),O
,,O
which,O
is,O
a,O
marker,O
for,O
MMR,B-Disorder
inactivation,I-Disorder
,,I-Disorder
was,O
detected,O
in,O
three,B-size
out,I-size
of,I-size
eight,I-size
cell,B-cohort-patient
lines,I-cohort-patient
i.e.,O
SKOV3,B-cohort-patient
,,I-cohort-patient
2774,B-cohort-patient
and,O
A2780,B-cohort-patient
.,I-cohort-patient
 , 
This,O
results,O
in,O
a,O
frequency,O
of,O
MMR,B-gene
inactivation,I-Disorder
in,O
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
of,O
38,B-size
%,I-size
.,I-size
 , 
The,O
MSI,B-Disorder
in,O
SKOV3,B-cohort-patient
can,O
be,O
explained,O
by,O
the,O
loss,B-Physiology
of,I-Physiology
MLH1,B-gene
mRNA,I-Physiology
expression,I-Physiology
which,O
,,O
however,O
,,O
was,O
not,O
caused,O
by,O
promoter,O
methylation,O
.,O
 , 
This,O
is,O
in,O
agreement,O
with,O
the,O
loss,B-Physiology
of,I-Physiology
MLH1,B-gene
protein,I-Physiology
expression,I-Physiology
seen,O
in,O
SKOV3,B-cohort-patient
described,O
in,O
a,O
study,O
of,O
the,O
60,B-size
NCI,O
cancer,B-disease
cell,B-cohort-patient
lines,I-cohort-patient
[,O
44,O
],O
.,O
 , 
In,O
concordance,O
with,O
our,O
findings,O
,,O
2774,B-cohort-patient
was,O
also,O
described,O
to,O
be,O
MSI,B-Disorder
 , 
[,O
45,O
],O
.,O
 , 
One,B-size
of,O
the,O
MSI,B-Disorder
positive,I-Disorder
A2780,B-cohort-patient
sublines,B-cohort-patient
showed,O
a,O
strong,B-Physiology
methylation,I-Physiology
of,I-Physiology
the,I-Physiology
MLH1,B-gene
promoter,I-Physiology
without,B-Physiology
MLH1,B-gene
mRNA,I-Physiology
expression,I-Physiology
,,I-Physiology
while,O
the,O
other,O
subline,B-cohort-patient
showed,O
a,O
low,B-Physiology
level,I-Physiology
of,I-Physiology
methylation,I-Physiology
and,O
relative,O
high,B-Physiology
mRNA,I-Physiology
expression,I-Physiology
.,I-Physiology
 , 
Strathdee,O
et,O
al,O
.,O
described,O
that,O
one,B-Physiology
MLH1,B-gene
allele,I-Physiology
was,I-Physiology
methylated,I-Physiology
in,O
A2780,B-cohort-patient
 , 
[,O
12,O
],O
which,O
is,O
comparable,O
with,O
the,O
methylation,O
status,O
we,O
saw,O
in,O
A2780,B-cohort-patient
,,I-cohort-patient
moreover,O
one,B-size
of,O
our,O
A2780,B-cohort-patient
sublines,B-cohort-patient
showed,O
complete,O
methylation,B-Physiology
.,I-Physiology
 , 
On,O
the,O
other,O
hand,O
,,O
another,O
study,O
did,O
not,O
detect,O
MSI,O
in,O
A2780,B-cohort-patient
[,O
11,O
],O
.,O
 , 
Interestingly,O
,,O
Aquilina,O
and,O
colleagues,O
suggested,O
there,O
is,O
a,O
subpopulation,O
of,O
A2780,B-cohort-patient
cells,B-cohort-patient
,,I-cohort-patient
estimated,O
to,O
be,O
around,O
one,B-size
per,I-size
106,I-size
cells,O
[,O
46,O
],O
,,O
which,O
are,O
MLH1,B-gene
deficient,I-Disorder
and,O
heterozygous,B-Physiology
for,I-Physiology
the,I-Physiology
p53phe172,B-mutation
mutation,I-Physiology
 , 
[,O
46,47,O
],O
.,O
 , 
Since,O
these,O
cells,O
have,O
a,O
growth,O
advantage,O
,,O
prolonged,O
culturing,O
of,O
the,O
A2780,B-cohort-patient
cell,B-cohort-patient
line,I-cohort-patient
can,O
result,O
in,O
selection,O
of,O
this,O
subpopulation,O
.,O
 , 
Thus,O
over,O
time,O
,,O
separately,O
cultured,O
A2780,B-cohort-patient
can,O
have,O
varying,O
percentages,O
of,O
cells,O
belonging,O
to,O
this,O
subpopulation,O
which,O
may,O
explain,O
the,O
discrepancies,O
in,O
MMR,B-gene
status,O
seen,O
in,O
the,O
A2780,B-cohort-patient
cell,B-cohort-patient
lines,I-cohort-patient
analyzed,O
by,O
us,O
.,O
 , 


,O
Next,O
we,O
studied,O
the,O
association,O
between,O
MMR,B-gene
inactivation,O
and,O
cisplatin,O
resistance,O
in,O
these,O
cell,O
lines,O
.,O
 , 
MMR,B-Disorder
inactivation,I-Disorder
seen,O
in,O
SKOV3,B-cohort-patient
and,O
2774,B-cohort-patient
might,O
result,O
in,O
the,O
relative,O
resistance,O
to,O
cisplatin,O
compared,O
to,O
the,O
other,O
cell,O
lines,O
.,O
 , 
On,O
the,O
other,O
hand,O
,,O
A2780,B-cohort-patient
which,O
has,O
clearly,O
an,O
inactive,B-Concepts_Ideas
MMR,I-Concepts_Ideas
,,I-Concepts_Ideas
was,O
most,O
sensitive,O
to,O
cisplatin,O
.,O
 , 
Overall,O
,,O
there,O
seems,O
to,O
be,O
no,O
association,O
between,O
the,O
response,O
to,O
cisplatin,O
and,O
MMR,B-gene
status,O
in,O
these,O
eight,B-size
cell,B-cohort-patient
lines,I-cohort-patient
.,I-cohort-patient
 , 
This,O
is,O
similar,O
to,O
a,O
study,O
in,O
the,O
60,B-size
NCI,O
cell,B-cohort-patient
lines,I-cohort-patient
which,O
also,O
showed,O
no,O
association,O
between,O
response,O
to,O
cisplatin,O
and,O
MMR,B-gene
status,O
based,O
on,O
the,O
MLH1,B-gene
and/or,O
MSH2,B-gene
protein,O
expression,O
[,O
44,O
],O
.,O
 , 


,O
 , 
#1601966-03-Results-p04
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
8q11.23,O
-,O
q21.13,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,O
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,O
;,O
red,O
:,O
up,O
in,O
tumor,O
),O
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
7,O
and,O
8,O
.,O
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
8q11.23,O
-,O
q21.13,O
(,O
patient,O
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
plot,O
of,O
cross,O
-,O
comparison,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
for,O
gene,O
pairs,O
in,O
a,O
particular,O
region,O
.,O
 , 
Both,O
,,O
horizontal,O
and,O
vertical,O
axes,O
comprise,O
the,O
same,O
genes,O
in,O
chromosomal,O
order,O
.,O
 , 
In,O
each,O
square,O
total,O
counts,O
of,O
patients,B-cohort-patient
with,O
consistent,O
up,O
-,O
regulation,O
in,O
two,O
genes,O
are,O
coded,O
by,O
different,O
shades,O
of,O
gray,O
.,O
 , 
Dark,O
squared,O
regions,O
along,O
the,O
diagonal,O
indicate,O
coordinated,O
regulation,O
in,O
patient,O
subgroups,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
figure,O
than,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
8,O
.,O
 , 
The,O
left,O
region,O
of,O
exceptionally,O
strong,O
up,O
-,O
regulation,O
spans,O
TCEA1,B-gene
,,I-gene
LYPLA1,B-gene
,,I-gene
MRPL15,B-gene
,,I-gene
the,O
known,O
tumor,O
gene,O
LYN,B-gene
,,I-gene
and,O
PLAG1,B-gene
.,I-gene
 , 
Note,O
that,O
TOX,B-Physiology
and,I-Physiology
ANKTM1,I-Physiology
are,I-Physiology
down,I-Physiology
-,I-Physiology
regulated,I-Physiology
in,O
approximately,O
half,B-size
of,O
the,O
tumor,B-disease
samples,B-cohort-patient
.,I-cohort-patient
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
8q11.23,O
-,O
q21.13,O
(,O
patient,O
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
plot,O
of,O
cross,O
-,O
comparison,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
for,O
gene,O
pairs,O
in,O
a,O
particular,O
region,O
.,O
 , 
Both,O
,,O
horizontal,O
and,O
vertical,O
axes,O
comprise,O
the,O
same,O
genes,O
in,O
chromosomal,O
order,O
.,O
 , 
In,O
each,O
square,O
total,O
counts,O
of,O
patients,B-cohort-patient
with,O
consistent,O
down,O
-,O
regulation,O
in,O
two,O
genes,O
are,O
coded,O
by,O
different,O
shades,O
of,O
gray,O
.,O
 , 
Dark,O
squared,O
regions,O
along,O
the,O
diagonal,O
indicate,O
coordinated,O
regulation,O
in,O
patient,B-cohort-patient
subgroups,O
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
6,O
and,O
7,O
.,O
 , 


,O
20q11.22,O
-,O
q11.23,O


,O
The,O
region,O
20q11.22,O
-,O
q11.23,O
was,O
among,O
the,O
most,O
frequently,O
up,O
-,O
regulated,O
regions,O
(,O
see,O
Figures,O
12,O
,,O
13,O
,,O
14,O
),O
.,O
 , 
Amplifications,O
of,O
regions,O
on,O
chromosome,O
20q,O
have,O
been,O
identified,O
independently,O
by,O
several,O
groups,B-cohort-patient
in,O
CRCs,B-disease
[,O
19,21,23,24,O
],O
.,O
 , 
The,O
interval,O
comprises,O
the,O
known,O
tumor,B-disease
gene,O
SRC,B-gene
(,O
located,O
between,O
MANBAL,B-gene
and,O
BLCAP,B-gene
in,O
Figures,O
12,O
,,O
13,O
,,O
14,O
),O
for,O
which,O
no,O
informative,O
expression,O
measures,O
were,O
obtained,O
.,O
 , 
We,B-gene
note,O
that,O
it,O
is,O
possible,O
that,O
the,O
SRC,B-gene
gene,O
is,O
the,O
primary,O
target,O
of,O
up,O
-,O
regulation,O
in,O
our,O
CRC,B-disease
patients,B-cohort-patient
,,I-cohort-patient
the,O
up,O
-,O
regulation,O
of,O
other,O
genes,O
being,O
just,O
piggy,O
-,O
back,O
effects,O
.,O
 , 
However,O
,,O
also,O
the,O
up,B-Physiology
-,I-Physiology
regulation,I-Physiology
of,I-Physiology
the,I-Physiology
CTNN1L1,I-Physiology
transcript,I-Physiology
could,O
be,O
of,O
potential,O
functional,O
significance,O
for,O
CRC,B-disease
development,O
.,O
 , 
CTNN1L1,B-gene
shows,O
partial,O
homology,O
to,O
the,O
known,O
colorectal,B-body-part
cancer,I-disease
gene,O
beta,O
-,O
catenin,O
in,O
the,O
armadillo,O
repeat,O
region,O
and,O
has,O
a,O
nuclear,O
localization,O
signal,O
,,O
suggesting,O
that,O
it,O
could,O
play,O
an,O
important,O
role,O
in,O
signal,O
transduction,O
to,O
the,O
nucleus,O
in,O
CRC,B-disease
.,I-disease
 , 
Also,O
up,B-Physiology
-,I-Physiology
regulation,I-Physiology
of,I-Physiology
the,I-Physiology
E3,I-Physiology
ubiquitin,I-Physiology
ligase,I-Physiology
Itchy,I-Physiology
(,I-Physiology
ITCH,I-Physiology
),I-Physiology
could,O
be,O
of,O
potential,O
importance,O
as,O
selective,O
ubiquitin,O
-,O
tagging,O
of,O
signaling,O
proteins,O
for,O
destruction,O
is,O
an,O
emerging,O
mechanism,O
in,O
cancer,B-disease
biology,O
.,O
 , 
The,O
need,O
for,O
accelerated,O
protein,O
synthesis,O
in,O
cancer,B-disease
cells,O
is,O
reflected,O
by,O
the,O
up,B-Physiology
-,I-Physiology
regulation,I-Physiology
of,I-Physiology
the,I-Physiology
translation,I-Physiology
initiation,I-Physiology
factor,I-Physiology
EIF2S2,I-Physiology
.,I-Physiology
 , 
Remarkably,O
,,O
we,O
found,O
dramatic,O
down,O
-,O
regulation,O
against,O
the,O
regional,O
trend,O
of,O
C20orf110,O
alias,O
p53,B-gene
-,I-gene
inducible,O
protein,O
2,O
(,B-gene
TP53INP2,B-mutation
),I-gene
whose,O
expression,O
is,O
usually,O
positively,O
controlled,O
by,O
the,O
p53,B-gene
protein,O
.,O
 , 
For,O
unknown,O
reasons,O
p53,B-gene
seems,O
to,O
be,O
unable,O
to,O
induce,O
TP53INP2,B-gene
expression,O
in,O
the,O
majority,O
of,O
CRCs,B-disease
studied,O
here,O
.,O
 , 


,O
 , 
#2275286-05-Discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Discussion,O


,O
Identification,O
of,O
mismatch,B-gene
repair,I-gene
gene,I-gene
germline,B-mutation
mutations,I-mutation
in,O
sporadic,B-Concepts_Ideas
colorectal,B-disease
cancer,I-disease
is,O
the,O
most,O
important,O
method,O
to,O
screen,O
HNPCC,B-disease
.,I-disease
 , 
In,O
2004,O
,,O
the,O
NCI,O
recommended,O
the,O
revised,O
Bethesda,O
criteria,O
as,O
a,O
HNPCC,B-disease
screening,O
guideline,O
and,O
established,O
the,O
HNPCC,B-disease
diagnostic,O
procedures,O
.,O
 , 
These,O
guidelines,O
stated,O
that,O
MSI,B-Disorder
should,O
firstly,O
be,O
identified,O
in,O
colorectal,B-body-part
tumor,B-disease
tissue,O
,,O
and,O
then,O
genetic,O
tests,O
would,O
be,O
performed,O
to,O
confirm,O
MMR,B-gene
gene,O
germline,B-mutation
mutations,I-mutation
in,O
a,O
blood,B-body-part
sample,O
[,O
6,O
],O
.,O
 , 


,O
At,O
present,O
,,O
a,O
number,O
of,O
publications,O
have,O
studied,O
the,O
value,O
of,O
the,O
revised,O
Bethesda,O
criteria,O
and,O
the,O
relevant,O
diagnostic,O
procedures,O
[,O
13,14,O
],O
.,O
 , 
However,O
,,O
there,O
has,O
not,O
been,O
any,O
systematic,O
report,O
on,O
germline,B-mutation
mutations,I-mutation
of,O
MMR,B-gene
genes,O
in,O
the,O
Chinese,B-ethnicity
population,B-cohort-patient
.,I-cohort-patient
 , 
Moreover,O
,,O
we,O
found,O
that,O
research,O
from,O
some,O
countries,O
have,O
results,O
that,O
,,O
if,O
applied,O
to,O
the,O
NCI,O
recommendations,O
,,O
may,O
have,O
resulted,O
in,O
a,O
missed,O
HNPCC,B-disease
family,B-cohort-patient
or,O
low,O
pick,O
-,O
up,O
rate,O
of,O
HNPCC,B-disease
.,I-disease
 , 
In,O
a,O
study,O
by,O
Pinol,O
et,O
al,O
.,O
 , 
from,O
Spain,B-ethnicity
[,O
13,O
],O
,,O
287,B-size
out,I-size
of,I-size
1222,I-size
patients,B-cohort-patient
(,B-size
23.5,I-size
%,I-size
),I-size
complied,O
with,O
the,O
revised,O
Bethesda,O
standard,O
.,O
 , 
Ninety,B-size
-,I-size
one,I-size
patients,B-cohort-patient
(,B-size
7.4,I-size
%,I-size
),I-size
were,O
MSI,B-cohort-patient
carriers,I-cohort-patient
,,I-cohort-patient
but,O
only,O
11,B-size
patients,B-cohort-patient
(,B-size
0.9,I-size
%,I-size
),I-size
had,O
germline,B-mutation
mutations,I-mutation
of,O
MSH2,B-gene
or,O
MLH1,B-gene
.,I-gene
 , 
This,O
means,O
that,O
among,O
this,O
group,B-cohort-patient
,,I-cohort-patient
only,O
0.9,B-size
%,I-size
of,O
patients,B-cohort-patient
could,O
be,O
diagnosed,O
as,O
HNPCC,B-disease
.,I-disease
 , 
In,O
a,O
study,O
by,O
Yearsley,O
et,O
al,O
.,O
 , 
[,O
14,O
],O
,,O
out,O
of,O
482,B-size
US,B-ethnicity
patients,B-cohort-patient
with,O
colorectal,B-body-part
cancers,B-disease
,,I-disease
87,B-size
patients,B-cohort-patient
(,B-size
18,I-size
%,I-size
),I-size
were,O
MSI,B-cohort-patient
carriers,I-cohort-patient
and,O
only,O
12,B-size
cases,B-cohort-patient
(,B-size
2.5,I-size
%,I-size
),I-size
 , 
had,O
MMR,B-gene
gene,O
germline,B-mutation
mutations,I-mutation
.,I-mutation
 , 
These,O
results,O
may,O
be,O
explained,O
by,O
different,O
case,B-cohort-patient
selections,O
and,O
sensitivity,O
of,O
the,O
tests,O
used,O
.,O
 , 
On,O
the,O
other,O
hand,O
,,O
in,O
their,O
study,O
of,O
HNPCC,B-Disorder
related,I-Disorder
tumors,B-disease
in,O
young,B-age
patients,B-cohort-patient
(,B-age
<,I-age
50,I-age
years,I-age
old,I-age
),I-age
,,O
Niessen,O
et,O
al,O
.,O
 , 
[,O
15,O
],O
found,O
that,O
the,O
rate,O
of,O
MSH2,B-gene
,,I-gene
MSH6,B-gene
and,O
MLH1,B-gene
germline,B-mutation
mutations,I-mutation
in,O
MSI,B-cohort-patient
carriers,I-cohort-patient
was,O
82,B-size
%,I-size
.,I-size
 , 
In,O
our,O
146,B-size
patients,B-cohort-patient
with,O
colorectal,B-body-part
cancers,B-disease
,,I-disease
34,B-size
patients,B-cohort-patient
(,B-size
23.3,I-size
%,I-size
),I-size
had,O
MSI,B-Disorder
colorectal,B-disease
cancer,I-disease
.,I-disease
 , 
This,O
is,O
comparable,O
to,O
the,O
studies,O
by,O
Pinol,O
et,O
al,O
.,O
 , 
[,O
13,O
],O
and,O
Yearsley,O
et,O
al,O
.,O
 , 
[,O
16,O
],O
.,O
 , 
Wong,O
et,O
al,O
.,O
 , 
[,O
17,O
],O
showed,O
that,O
in,O
the,O
case,O
of,O
sporadic,B-Concepts_Ideas
endometrial,B-body-part
carcinoma,B-disease
,,I-disease
MSI,B-Disorder
endometrial,B-body-part
carcinoma,B-disease
accounted,O
for,O
26,B-size
%,I-size
of,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
Our,O
results,O
showed,O
that,O
there,O
were,O
15,B-size
(,B-size
10.3,I-size
%,I-size
),I-size
CRCs,B-disease
with,O
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
and,O
19,B-size
(,B-size
13.0,I-size
%,I-size
),I-size
CRCs,B-cohort-patient
with,O
MSL,B-Disorder
-,I-Disorder
H,I-Disorder
,,I-Disorder
respectively,O
.,O
 , 
Lamberti,O
et,O
al,O
.,O
 , 
[,O
18,O
],O
reported,O
that,O
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
and,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
accounted,O
for,O
6,B-size
%,I-size
and,O
17,B-size
%,I-size
,,I-size
respectively,O
,,O
of,O
German,B-ethnicity
patients,B-cohort-patient
.,I-cohort-patient
 , 
These,O
results,O
are,O
similar,O
to,O
ours,O
.,O
 , 
Unexpectedly,O
,,O
in,O
the,O
present,O
study,O
,,O
the,O
age,O
of,O
patients,B-cohort-patient
with,O
MSS,B-Disorder
colorectal,B-disease
cancers,I-disease
(,B-age
60,I-age
yrs,I-age
),I-age
was,O
similar,O
to,O
the,O
age,O
of,O
patients,B-cohort-patient
with,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
(,B-age
61,I-age
yrs,I-age
),I-age
.,O
 , 
In,O
contrast,O
,,O
the,O
average,O
age,O
of,O
patients,B-cohort-patient
with,O
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
colorectal,B-disease
cancer,I-disease
was,O
71,B-age
,,I-age
which,O
was,O
quite,O
different,O
from,O
the,O
reports,O
of,O
other,O
research,O
groups,O
[,O
13,15,18,O
],O
.,O
 , 
In,O
a,O
study,O
of,O
1263,B-size
patients,B-cohort-patient
with,O
colorectal,B-body-part
cancers,B-disease
,,I-disease
Benatti,O
et,O
al,O
.,O
 , 
[,O
19,O
],O
found,O
that,O
those,O
who,O
were,O
MSI,B-cohort-patient
carriers,I-cohort-patient
tended,O
to,O
have,O
mucinous,B-body-part
and,O
right,B-body-part
colonic,I-body-part
tumours,B-disease
.,I-disease
 , 
Noda,O
et,O
al,O
.,O
 , 
[,O
20,O
],O
also,O
found,O
that,O
MSI,B-cohort-patient
carriers,I-cohort-patient
have,O
more,O
right,B-body-part
colonic,I-body-part
tumors,B-disease
.,I-disease
 , 
However,O
,,O
in,O
our,O
study,O
,,O
tumors,B-disease
in,O
the,O
MSI,B-Disorder
group,B-cohort-patient
were,O
most,O
commonly,O
located,O
at,O
the,O
rectum,B-body-part
,,I-body-part
and,O
mucinous,B-Disorder
carcinoma,B-disease
was,O
not,O
the,O
most,O
common,O
pathological,O
type,O
,,O
as,O
it,O
only,O
accounted,O
for,O
29,B-size
%,I-size
.,I-size
 , 
Interestingly,O
,,O
patients,B-cohort-patient
in,O
our,O
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
group,B-cohort-patient
were,O
older,B-age
than,O
the,O
MSS,B-Disorder
group,B-cohort-patient
.,I-cohort-patient
 , 
The,O
reason,O
for,O
these,O
findings,O
is,O
uncertain,O
.,O
 , 
Bettstetter,O
et,O
al,O
.,O
 , 
[,O
20,O
],O
reported,O
that,O
the,O
average,O
age,O
of,O
MSI,B-Disorder
CRCs,B-cohort-patient
with,O
MLH1,B-Phenomena
negative,I-Phenomena
staining,I-Phenomena
was,O
80,B-age
yrs,I-age
,,I-age
which,O
was,O
similar,O
to,O
our,O
results,O
.,O
 , 
Most,O
of,O
these,O
MSI,B-Disorder
CRCs,B-disease
were,O
caused,O
by,O
MLH1,B-Physiology
promoter,I-Physiology
hypermethylation,I-Physiology
.,I-Physiology
 , 
In,O
our,O
group,B-cohort-patient
,,I-cohort-patient
out,O
of,O
34,B-size
MSI,B-Disorder
CRCs,B-disease
,,I-disease
19,B-size
CRCs,B-disease
(,B-size
55.9,I-size
%,I-size
),I-size
were,O
hypermethylated,B-Physiology
at,I-Physiology
the,I-Physiology
MLH1,I-Physiology
promoter,I-Physiology
,,I-Physiology
which,O
accounted,O
for,O
73.7,B-size
%,I-size
of,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
CRCs,B-disease
and,O
33.3,B-size
%,I-size
of,O
MSI,B-Disorder
CRCs,B-disease
.,I-disease
 , 
Anacleto,O
et,O
al,O
.,O
 , 
[,O
21,O
],O
reported,O
that,O
8,B-size
out,I-size
of,I-size
15,I-size
MSI,B-Disorder
CRCs,B-disease
had,O
MLH1,B-gene
promoter,I-Physiology
hypermethylation,I-Physiology
,,I-Physiology
which,O
was,O
similar,O
to,O
our,O
results,O
.,O
 , 
Kim,O
et,O
al,O
.,O
 , 
[,O
10,O
],O
found,O
that,O
in,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
gastric,B-body-part
cancers,B-disease
,,I-disease
the,O
MLH1,B-gene
hypermethylation,I-Physiology
occurred,O
in,O
89,B-size
%,I-size
of,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
Bettstetter,O
et,O
al,O
.,O
 , 
[,O
20,O
],O
showed,O
that,O
all,O
sporadic,B-Concepts_Ideas
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
CRCs,B-disease
were,O
hypermethylated,B-Physiology
at,I-Physiology
the,I-Physiology
MLH1,I-Physiology
promoter,I-Physiology
.,I-Physiology
 , 
These,O
results,O
were,O
similar,O
to,O
ours,O
.,O
 , 
Fourteen,B-size
out,I-size
of,I-size
16,I-size
MLH1,B-Phenomena
negatively,I-Phenomena
staining,I-Phenomena
CRCs,B-cohort-patient
were,O
hypermethylated,B-Physiology
at,I-Physiology
the,I-Physiology
MLH1promoter,B-gene
.,I-Physiology
 , 
Mutation,O
analysis,O
revealed,O
that,O
8,B-size
patients,B-cohort-patient
(,B-size
23.5,I-size
%,I-size
),I-size
had,O
MMR,B-gene
gene,O
germline,B-mutation
mutations,I-mutation
out,O
of,O
34,B-size
MSI,B-Disorder
patients,B-cohort-patient
.,I-cohort-patient
 , 
Five,B-size
patients,B-cohort-patient
had,O
MSH2,B-gene
mutations,B-mutation
and,O
3,B-cohort-patient
had,O
MSH6,B-gene
mutations,B-mutation
,,I-mutation
while,O
no,B-size
MLH1,B-gene
mutation,B-mutation
was,O
found,O
.,O
 , 
There,O
were,O
2,B-size
and,O
6,B-size
patients,B-cohort-patient
who,O
had,O
mutations,B-mutation
in,O
MSH2,B-gene
and,O
MSH6,B-gene
in,O
the,O
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
and,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
groups,B-cohort-patient
,,I-cohort-patient
respectively,O
.,O
 , 
Yearsley,O
et,O
al,O
.,O
 , 
[,O
15,O
],O
,,O
in,O
their,O
study,O
of,O
87,B-size
patients,B-cohort-patient
with,O
MSI,B-Disorder
colorectal,B-body-part
cancers,B-disease
,,I-disease
found,O
12,B-size
patients,B-cohort-patient
(,B-size
13.8,I-size
%,I-size
),I-size
with,O
MLH1,B-gene
and,O
MSH2,B-gene
germline,B-mutation
mutations,I-mutation
.,I-mutation
 , 
Niessen,O
et,O
al,O
.,O
 , 
[,O
16,O
],O
,,O
however,O
,,O
found,O
that,O
the,O
rate,O
of,O
MSH2,B-gene
,,I-gene
MSH6,B-gene
and,O
MLH1,B-gene
germline,B-mutation
mutations,I-mutation
was,O
82,B-size
%,I-size
in,O
the,O
young,B-age
age,O
group,B-cohort-patient
(,B-age
<,I-age
50,I-age
years,I-age
old,I-age
),I-age
.,O
 , 
This,O
was,O
quite,O
different,O
from,O
our,O
group,B-cohort-patient
.,I-cohort-patient
 , 
This,O
difference,O
might,O
be,O
due,O
to,O
different,O
case,B-cohort-patient
selections,O
of,O
the,O
two,O
groups,B-cohort-patient
.,I-cohort-patient
 , 
Our,O
study,O
was,O
more,O
representative,O
of,O
the,O
patient,B-cohort-patient
population,O
because,O
it,O
was,O
a,O
successive,O
cohort,B-cohort-patient
study,O
.,O
 , 
Most,O
importantly,O
,,O
the,O
above,O
differences,O
may,O
also,O
be,O
explained,O
by,O
underlying,O
differences,O
in,O
genetic,O
background,O
between,O
Chinese,B-ethnicity
and,O
Western,B-ethnicity
populations,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1619718-04-Results-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,B-gene
BRAF,I-gene
and,O
KRAS,B-gene
mutations,B-mutation
were,O
distributed,O
in,O
roughly,O
similar,O
proportions,O
across,O
MPs,B-disease
(,B-size
90,I-size
%,I-size
had,O
either,O
BRAF,B-gene
or,O
KRAS,B-gene
mutation,B-mutation
),I-mutation
and,O
SAs,B-disease
(,B-size
60,I-size
%,I-size
had,O
either,O
BRAF,B-gene
or,O
KRAS,B-gene
mutation,B-mutation
),I-mutation
(,O
Table,O
1,O
),O
.,O
 , 
The,O
frequent,O
finding,O
of,O
either,O
BRAF,B-gene
or,O
KRAS,B-gene
mutations,B-mutation
in,O
both,O
types,O
of,O
serrated,B-Concepts_Ideas
polyp,B-disease
indicated,O
that,O
MPs,B-disease
and,O
SAs,B-disease
might,O
be,O
heterogeneous,B-Concepts_Ideas
lesions,B-disease
.,I-disease
 , 
These,O
25,B-size
serrated,B-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
were,O
therefore,O
grouped,O
differently,O
.,O
 , 
Group,B-cohort-patient
A,I-cohort-patient
polyps,B-disease
(,O
n,O
=,O
16,B-size
),I-size
included,O
a,O
non,B-Disorder
-,I-Disorder
dysplastic,I-Disorder
serrated,B-Concepts_Ideas
component,O
and/or,O
dysplastic,B-Disorder
epithelium,B-body-part
in,O
which,O
the,O
architectural,O
and,O
cytological,O
changes,O
were,O
more,O
reminiscent,O
of,O
HP,B-disease
than,O
adenoma,B-disease
(,O
Figure,O
1A,O
,,O
B,O
),O
.,O
 , 
Group,B-cohort-patient
B,I-cohort-patient
polyps,B-disease
(,O
n,O
=,O
9,B-size
),I-size
comprised,O
serrated,B-Concepts_Ideas
polyps,B-disease
in,O
which,O
the,O
epithelial,B-body-part
dysplasia,I-Disorder
appeared,I-Disorder
adenomatous,I-Disorder
(,O
Figure,O
1C,O
,,O
D,O
),O
.,O
 , 
BRAF,B-gene
mutation,B-mutation
occurred,O
in,O
10/16,B-size
Group,B-cohort-patient
A,I-cohort-patient
polyps,B-disease
but,O
only,O
1/9,B-size
Group,B-cohort-patient
B,I-cohort-patient
polyps,B-disease
(,O
P,O
<,O
0.03,O
),O
.,O
 , 
KRAS,B-gene
mutation,B-mutation
occurred,O
in,O
only,O
3/16,B-size
Group,B-cohort-patient
A,I-cohort-patient
polyps,B-disease
but,O
in,O
5/9,B-size
Group,B-cohort-patient
B,I-cohort-patient
polyps,B-disease
(,O
P,O
=,O
0.06,O
),O
.,O
 , 
In,O
each,O
of,O
the,O
five,B-size
Group,B-cohort-patient
B,I-cohort-patient
polyps,B-disease
with,O
KRAS,B-gene
mutation,B-mutation
,,I-mutation
the,O
adenomatous,O
component,O
showed,O
both,O
villous,B-Concepts_Ideas
change,I-Concepts_Ideas
and,O
serration,B-Concepts_Ideas
.,I-Concepts_Ideas
 , 


,O
A,O
,,O
Serrated,B-Concepts_Ideas
adenoma,B-disease
(,B-cohort-patient
SA,I-cohort-patient
),I-cohort-patient
(,B-gene
BRAF,I-gene
mutation,B-mutation
),I-mutation
with,O
a,O
‘,B-Disorder
hyperplastic,I-Disorder
’,I-Disorder
appearance,O
but,O
with,O
architectural,O
and,O
cytological,O
features,O
of,O
a,O
non,O
-,O
adenomatous,O
form,O
of,O
dysplasia,O
.,O
 , 
The,O
latter,O
include,O
marked,O
epithelial,B-Concepts_Ideas
serration,I-Concepts_Ideas
and,O
surface,O
papillarity,O
and,O
nuclei,O
that,O
are,O
ovoid,O
,,O
vesicular,O
and,O
contain,O
a,O
prominent,O
nucleolus,O
(,O
inset,O
),O
.,O
 , 
The,O
columnar,O
cells,O
(,O
inset,O
),O
contain,O
apical,O
mucin,O
droplets,O
,,O
similar,O
to,O
sessile,B-Concepts_Ideas
SA,B-disease
(,B-disease
SSA,I-disease
),I-disease
.,O
 , 
B,O
,,O
Mixed,B-Concepts_Ideas
polyp,B-disease
(,B-gene
BRAF,I-gene
mutation,B-mutation
),I-mutation
comprising,O
SSA,B-disease
(,O
left,O
),O
and,O
SA,B-disease
with,O
high,B-Disorder
-,I-Disorder
grade,I-Disorder
dyplasia,I-Disorder
showing,O
back,O
-,O
to,O
-,O
back,O
glands,B-body-part
(,O
right,O
),O
and,O
aberrant,B-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
(,O
inset,O
),O
.,O
 , 
C,O
,,O
D,O
,,O
Two,B-size
mixed,B-Concepts_Ideas
polyps,B-disease
(,B-disease
MPs,I-disease
),I-disease
(,O
both,O
SA,B-disease
/,I-disease
tubulo,I-Concepts_Ideas
-,I-Concepts_Ideas
villous,I-Concepts_Ideas
adenoma,B-disease
and,O
with,O
KRAS,B-gene
mutation,B-mutation
),I-mutation
in,O
which,O
the,O
serrated,O
epithelium,B-body-part
has,O
an,O
adenomatous,O
appearance,O
as,O
evidenced,O
by,O
elongated,O
hyperchomatic,O
nuclei,O
with,O
marked,O
stratification,O
and,O
a,O
dark,O
amphophilic,O
cytoplasm,O
.,O
 , 
The,O
pure,O
adenomatous,O
component,O
is,O
not,O
shown,O
.,O
 , 
E,O
,,O
F,O
,,O
Low-,O
and,O
medium,O
-,O
power,O
images,O
of,O
a,O
SA,B-disease
(,B-gene
KRAS,I-gene
mutation,B-mutation
),I-mutation
in,O
which,O
complex,O
microacini,O
have,O
resulted,O
in,O
markedly,O
serrated,O
epithelial,B-body-part
contours,O
.,O
 , 
The,O
epithelium,O
comprises,O
numerous,O
goblet,O
cells,O
and,O
absorptive,O
-,O
type,O
columnar,O
cells,O
with,O
eosinophilic,O
cytoplasm,O
and,O
is,O
reminiscent,O
of,O
the,O
goblet,O
cell,O
variant,O
of,O
hyperplastic,B-Disorder
polyp,B-disease
.,I-disease
 , 
These,O
examples,O
illustrate,O
the,O
range,O
of,O
appearances,O
and,O
genetic,O
changes,O
that,O
are,O
encompassed,O
by,O
‘,B-Concepts_Ideas
traditional,I-Concepts_Ideas
’,I-Concepts_Ideas
SA,B-disease
.,I-disease
 , 


,O
With,O
respect,O
to,O
the,O
25,B-size
serrated,B-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
,,I-Disorder
only,O
five,B-size
occurred,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
(,O
up,O
to,O
the,O
splenic,B-body-part
flexure,I-body-part
),I-body-part
.,O
 , 
Two,B-size
of,O
these,O
had,O
BRAF,B-gene
mutation,B-mutation
(,O
both,O
Group,B-cohort-patient
A,I-cohort-patient
),I-cohort-patient
and,O
two,B-size
had,O
KRAS,B-gene
mutation,B-mutation
(,O
both,O
Group,B-cohort-patient
B,I-cohort-patient
),I-cohort-patient
.,O
 , 
Seven,B-size
of,I-size
the,I-size
11,I-size
BRAF,B-gene
mutations,B-mutation
occurred,O
in,O
polyps,B-cohort-patient
derived,O
from,O
the,O
left,B-body-part
colon,I-body-part
or,O
rectum,B-body-part
(,O
remaining,O
two,B-size
polyps,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
from,O
site,O
unknown,O
),O
.,O
 , 
The,O
three,B-size
Group,B-cohort-patient
A,I-cohort-patient
SAs,B-disease
with,O
KRAS,B-gene
mutation,B-mutation
(,O
all,O
from,O
the,O
left,B-body-part
colon,I-body-part
or,O
rectum,B-body-part
),I-body-part
comprised,O
numerous,B-body-part
goblet,I-body-part
cells,I-body-part
and,O
adjacent,B-body-part
cells,I-body-part
with,I-body-part
eosinophilic,I-body-part
cytoplasm,I-body-part
and,O
no,B-Physiology
mucin,I-Physiology
production,I-Physiology
or,I-Physiology
microvesicular,I-Physiology
appearance,I-Physiology
(,O
Figure,O
1E,O
,,O
F,O
),O
.,O
 , 
These,O
SAs,B-disease
therefore,O
resembled,O
the,O
goblet,B-Concepts_Ideas
cell,I-Concepts_Ideas
variant,I-Concepts_Ideas
of,O
HP,B-disease
.,I-disease
 , 


,O
 , 
#2275286-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Detection,O
of,O
mismatch,O
repair,O
gene,O
germline,O
mutation,O
carrier,O
among,O
Chinese,B-ethnicity
population,B-cohort-patient
with,O
colorectal,B-body-part
cancer,B-disease


,I-disease
Abstract,O


,O
Background,O


,B-disease
Hereditary,I-disease
nonpolyposis,I-disease
colorectal,B-body-part
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
is,O
an,O
autosomal,B-Concepts_Ideas
dominant,I-Concepts_Ideas
syndrome,O
.,O
 , 
The,O
National,O
Cancer,O
Institute,O
(,O
NCI,O
),O
has,O
recommended,O
the,O
Revised,O
Bethesda,O
guidelines,O
for,O
screening,O
HNPCC,B-disease
.,I-disease
 , 
There,O
has,O
been,O
a,O
great,O
deal,O
of,O
research,O
on,O
the,O
value,O
of,O
these,O
tests,O
in,O
other,O
countries,O
.,O
 , 
However,O
,,O
literature,O
about,O
the,O
Chinese,B-ethnicity
population,B-cohort-patient
is,O
scarce,O
.,O
 , 
Our,O
objective,O
is,O
to,O
detect,O
and,O
study,O
microsatellite,O
instability,O
(,O
MSI,O
),O
and,O
mismatch,B-gene
repair,I-gene
(,I-gene
MMR,I-gene
),I-gene
gene,I-gene
germline,B-mutation
mutation,I-mutation
carriers,O
among,O
a,O
Chinese,B-ethnicity
population,B-cohort-patient
with,O
colorectal,B-body-part
cancer,B-disease
.,I-disease
 , 


,O
Methods,O


,O
In,O
146,B-size
prospectively,O
recruited,O
consecutive,O
patients,B-cohort-patient
with,O
clinically,O
proven,O
colorectal,B-body-part
cancer,B-disease
,,I-disease
MSI,B-Disorder
carriers,B-cohort-patient
were,O
identified,O
by,O
analysis,O
of,O
tumor,B-disease
tissue,O
using,O
multiplex,O
fluorescence,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
using,O
the,O
NCI,O
recommended,O
panel,O
and,O
classified,O
into,O
microsatellite,B-Disorder
instability,I-Disorder
-,I-Disorder
low,I-Disorder
(,B-Disorder
MSI,I-Disorder
-,I-Disorder
L,I-Disorder
),I-Disorder
,,O
microsatellite,B-Disorder
instability,I-Disorder
-,I-Disorder
high,I-Disorder
(,B-Disorder
MSI,I-Disorder
-,I-Disorder
H,I-Disorder
),I-Disorder
and,O
microsatellite,B-Disorder
stable,I-Disorder
(,B-Disorder
MSS,I-Disorder
),I-Disorder
groups,B-cohort-patient
.,I-cohort-patient
 , 
Immunohistochemical,O
staining,O
for,O
MSH2,B-gene
,,I-gene
MSH6,B-gene
and,O
MLH1,B-gene
on,O
tissue,O
microarrays,O
(,O
TMAs,O
),O
was,O
performed,O
,,O
and,O
methylation,O
of,O
the,O
MLH1,B-gene
promoter,O
was,O
analyzed,O
by,O
quantitative,O
methylation,O
specific,O
PCR,O
(,O
MSP,O
),O
.,O
 , 
Germline,O
mutation,O
analysis,O
of,O
blood,O
samples,O
was,O
performed,O
for,O
MSH2,B-gene
,,I-gene
MSH6,B-gene
and,O
MLH1,B-gene
genes,O
.,O
 , 


,O
Results,O


,B-size
Thirty,I-size
-,I-size
four,I-size
out,I-size
of,I-size
the,I-size
146,I-size
colorectal,B-body-part
cancers,B-cohort-patient
(,B-disease
CRCs,I-disease
,,I-disease
23.2,B-size
%,I-size
),I-size
were,O
MSI,B-Disorder
,,I-Disorder
including,O
19,B-size
MSI,B-cohort-patient
-,I-cohort-patient
H,I-cohort-patient
CRCs,I-cohort-patient
and,O
15,B-size
MSI,B-cohort-patient
-,I-cohort-patient
L,I-cohort-patient
CRCS,I-cohort-patient
.,I-cohort-patient
 , 
Negative,B-Phenomena
staining,I-Phenomena
for,I-Phenomena
MSH2,B-gene
was,O
found,O
in,O
8,B-size
CRCs,B-cohort-patient
,,I-cohort-patient
negative,B-Phenomena
staining,I-Phenomena
for,I-Phenomena
MSH6,B-gene
was,O
found,O
in,O
6,B-size
CRCs,B-cohort-patient
.,I-cohort-patient
 , 
One,B-size
MSI,B-cohort-patient
-,I-cohort-patient
H,I-cohort-patient
CRC,I-cohort-patient
was,O
negative,B-Phenomena
for,I-Phenomena
both,I-Phenomena
MSH6,B-gene
and,I-Phenomena
MSH2,B-gene
.,I-gene
 , 
Seventeen,B-size
CRCs,B-cohort-patient
stained,B-Phenomena
negatively,I-Phenomena
for,I-Phenomena
MLH1,B-gene
.,I-gene
 , 
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
was,O
determined,O
in,O
34,B-size
MSI,B-Disorder
CRCs,B-disease
.,I-disease
 , 
Hypermethylation,B-Physiology
of,I-Physiology
the,I-Physiology
MLH1,B-gene
promoter,I-Physiology
occurred,O
in,O
14,B-size
(,I-size
73.7,I-size
%,I-size
),I-size
out,I-size
of,I-size
19,I-size
MSI,B-cohort-patient
-,I-cohort-patient
H,I-cohort-patient
CRCs,I-cohort-patient
and,O
5,B-size
(,I-size
33.3,I-size
%,I-size
),I-size
out,I-size
of,I-size
15,I-size
MSI,B-cohort-patient
-,I-cohort-patient
L,I-cohort-patient
CRCs,I-cohort-patient
.,I-cohort-patient
 , 
Among,O
the,O
34,B-size
MSI,B-cohort-patient
carriers,I-cohort-patient
and,O
one,B-size
MSS,B-Disorder
CRC,I-cohort-patient
with,O
MLH1,B-gene
negative,I-Phenomena
staining,I-Phenomena
,,I-Phenomena
8,B-size
had,O
a,O
MMR,B-gene
gene,O
germline,B-mutation
mutation,I-mutation
,,I-mutation
which,O
accounted,O
for,O
23.5,B-size
%,I-size
of,O
all,O
MSI,B-Disorder
colorectal,B-disease
cancers,I-disease
and,O
5.5,B-size
%,I-size
of,O
all,O
the,O
colorectal,B-disease
cancers,I-disease
.,I-disease
 , 
Five,B-size
patients,B-cohort-patient
harbored,O
MSH2,B-gene
germline,B-mutation
mutations,I-mutation
,,I-mutation
and,O
three,B-size
patients,B-cohort-patient
harbored,O
MSH6,B-gene
germline,B-mutation
mutations,I-mutation
.,I-mutation
 , 
None,B-size
of,O
the,O
patients,B-cohort-patient
had,O
an,O
MLH1,B-gene
mutation,B-mutation
.,I-mutation
 , 
Mutations,B-mutation
were,I-mutation
commonly,I-mutation
located,I-mutation
in,I-mutation
exon,I-mutation
7,I-mutation
and,I-mutation
12,I-mutation
of,I-mutation
MSH2,B-gene
and,I-mutation
exon,I-mutation
5,I-mutation
of,I-mutation
MSH6,I-mutation
.,I-mutation
 , 
Right,B-body-part
colonic,I-body-part
lesions,B-disease
and,O
mucinous,B-body-part
carcinoma,B-disease
were,O
not,B-Concepts_Ideas
common,I-Concepts_Ideas
in,I-Concepts_Ideas
MSI,I-Concepts_Ideas
carriers,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 


,O
Conclusion,O


,O
Our,O
data,O
may,O
imply,O
that,O
the,O
characteristics,O
of,O
HNPCC,B-disease
in,O
the,O
Chinese,B-ethnicity
population,B-cohort-patient
are,O
probably,O
different,O
from,O
those,O
of,O
Western,B-ethnicity
countries,I-ethnicity
.,I-ethnicity
 , 
Application,O
of,O
NCI,O
recommended,O
criteria,O
may,O
not,O
be,O
effective,O
enough,O
to,O
identify,O
Chinese,B-ethnicity
HNPCC,B-disease
families,B-cohort-patient
.,I-cohort-patient
 , 
Further,O
studies,O
are,O
necessary,O
to,O
echo,O
or,O
refute,O
our,O
results,O
so,O
as,O
to,O
make,O
the,O
NCI,O
recommendation,O
more,O
universally,O
applicable,O
.,O
 , 


,O
 , 
#1266026-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Numbers,O
of,O
mutations,O
to,O
different,O
types,O
of,O
colorectal,B-body-part
cancer,I-disease


,I-disease
Abstract,O


,O
Background,O


,O
The,O
numbers,O
of,O
oncogenic,O
mutations,O
required,O
for,O
transformation,O
are,O
uncertain,O
but,O
may,O
be,O
inferred,O
from,O
how,O
cancer,B-disease
frequencies,O
increase,O
with,O
aging,O
.,O
 , 
Cancers,B-disease
requiring,O
more,O
mutations,O
will,O
tend,O
to,O
appear,O
later,O
in,O
life,O
.,O
 , 
This,O
type,O
of,O
approach,O
may,O
be,O
confounded,O
by,O
biologic,O
heterogeneity,O
because,O
different,O
cancer,B-disease
subtypes,O
may,O
require,O
different,O
numbers,O
of,O
mutations,O
.,O
 , 
For,O
example,O
,,O
a,O
sporadic,B-Concepts_Ideas
cancer,B-disease
should,O
require,O
at,O
least,O
one,O
more,O
somatic,O
mutation,O
relative,O
to,O
its,O
hereditary,O
counterpart,O
.,O
 , 


,O
Methods,O


,O
To,O
better,O
estimate,O
numbers,O
of,O
mutations,O
before,O
transformation,O
,,O
1,022,B-size
colorectal,B-disease
cancers,B-cohort-patient
were,O
classified,O
with,O
respect,O
to,O
microsatellite,O
instability,O
(,O
MSI,O
),O
and,O
germline,B-mutation
DNA,I-mutation
mismatch,I-mutation
repair,I-mutation
mutations,I-mutation
characteristic,O
of,O
hereditary,B-disease
nonpolyposis,I-disease
colorectal,I-disease
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
.,O
 , 
MSI-,B-Disorder
cancers,B-disease
were,O
also,O
classified,O
with,O
respect,O
to,O
clinical,O
stage,O
.,O
 , 
Ages,O
at,O
cancer,B-disease
and,O
a,O
Bayesian,O
algorithm,O
were,O
used,O
to,O
estimate,O
the,O
numbers,O
of,O
oncogenic,O
mutations,O
required,O
for,O
transformation,O
for,O
each,O
cancer,B-disease
subtype,O
.,O
 , 


,O
Results,O


,O
Ages,O
at,O
MSI+,B-Disorder
cancers,B-disease
were,O
consistent,O
with,O
five,B-size
or,I-size
six,I-size
oncogenic,B-mutation
mutations,I-mutation
for,O
hereditary,B-Concepts_Ideas
(,B-disease
HNPCC,I-disease
),I-disease
cancers,B-cohort-patient
,,I-cohort-patient
and,O
seven,B-size
or,I-size
eight,I-size
mutations,B-mutation
for,O
its,O
sporadic,B-Concepts_Ideas
counterpart,O
.,O
 , 
Ages,O
at,O
cancer,B-disease
were,O
consistent,O
with,O
seven,B-size
mutations,B-mutation
for,O
sporadic,B-Concepts_Ideas
MSI-,B-Disorder
cancers,B-cohort-patient
,,I-cohort-patient
and,O
were,O
similar,O
(,B-size
six,I-size
to,I-size
eight,I-size
mutations,B-mutation
),I-mutation
regardless,O
of,O
clinical,O
cancer,B-disease
stage,O
.,O
 , 


,O
Conclusion,O


,O
Different,O
biologic,O
subtypes,O
of,O
colorectal,B-body-part
cancer,I-disease
appear,O
to,O
require,O
different,O
numbers,O
of,O
oncogenic,O
mutations,O
before,O
transformation,O
.,O
 , 
Sporadic,B-Concepts_Ideas
MSI+,B-Disorder
 , 
cancers,B-disease
may,O
require,O
more,O
than,O
a,O
single,O
additional,O
somatic,O
alteration,O
compared,O
to,O
hereditary,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
because,O
the,O
epigenetic,B-Physiology
inactivation,I-Physiology
of,I-Physiology
MLH1,I-Physiology
commonly,O
observed,O
in,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
may,O
be,O
a,O
multistep,O
process,O
.,O
 , 
Interestingly,O
,,O
estimated,O
numbers,O
of,O
MSI-,B-Disorder
cancer,B-disease
mutations,B-mutation
were,O
similar,O
(,B-size
six,I-size
to,I-size
eight,I-size
mutations,B-mutation
),I-mutation
regardless,O
of,O
clinical,O
cancer,B-disease
stage,O
,,O
suggesting,O
a,O
propensity,O
to,O
spread,O
or,O
metastasize,O
does,O
not,O
require,O
additional,O
mutations,O
after,O
transformation,O
.,O
 , 
Estimates,O
of,O
oncogenic,O
mutation,O
numbers,O
may,O
help,O
explain,O
some,O
of,O
the,O
biology,O
underlying,O
different,O
cancer,B-disease
subtypes,O
.,O
 , 


,O
 , 
#1557864-05-Discussion-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Furthermore,O
,,O
we,O
analyzed,O
MMR,B-gene
status,O
in,O
75,B-size
ovarian,B-body-part
carcinomas,B-disease
to,O
determine,O
the,O
frequency,O
of,O
MMR,B-gene
inactivation,I-Disorder
in,O
ovarian,B-body-part
cancer,I-disease
in,O
vivo,O
.,O
 , 
Seven,B-size
of,I-size
the,I-size
75,I-size
ovarian,B-body-part
carcinomas,B-disease
showed,O
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
.,I-Physiology
 , 
We,O
confirmed,O
whether,O
the,O
observed,O
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
results,O
in,O
the,O
inactivation,O
of,O
the,O
gene,O
by,O
determining,O
the,O
MLH1,B-gene
mRNA,O
expression,O
with,O
quantitative,O
RT,O
-,O
PCR,O
.,O
 , 
The,O
six,B-size
tumors,B-cohort-patient
with,O
low,B-Physiology
level,I-Physiology
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
appeared,O
to,O
express,O
MLH1,B-gene
at,O
mRNA,O
levels,O
similar,O
to,O
that,O
of,O
the,O
unmethylated,B-Physiology
tumors,B-disease
.,I-disease
 , 
Thus,O
a,O
low,O
level,O
of,O
methylation,O
does,O
not,O
result,O
in,O
an,O
altered,O
expression,O
of,O
the,O
MLH1,B-gene
gene,O
.,O
 , 
In,O
contrast,O
,,O
the,O
abundant,B-Physiology
methylation,I-Physiology
seen,O
in,O
the,O
remaining,O
carcinoma,B-disease
was,O
associated,O
with,O
the,O
lowest,O
MLH1,B-gene
mRNA,O
expression,O
level,O
of,O
all,O
50,B-size
ovarian,B-body-part
carcinomas,B-disease
tested,O
.,O
 , 
However,O
,,O
none,B-size
of,O
the,O
ovarian,B-body-part
carcinomas,B-disease
showed,O
MSI,O
for,O
BAT25,O
,,O
BAT26,O
and,O
for,O
BAT40,O
or,O
D2S123,O
which,O
suggests,O
a,O
frequency,O
of,O
MMR,B-gene
inactivation,O
of,O
0,O
%,O
.,O
 , 
The,O
low,B-Physiology
MLH1,I-Physiology
mRNA,I-Physiology
expression,I-Physiology
seen,O
in,O
the,O
abundant,B-Physiology
methylated,I-Physiology
carcinoma,B-disease
might,O
be,O
sufficient,O
enough,O
for,O
a,O
functional,B-Concepts_Ideas
MMR,I-Concepts_Ideas
which,O
results,O
in,O
the,O
observed,O
absence,B-Disorder
of,I-Disorder
MSI,I-Disorder
.,I-Disorder
 , 


,O
Since,O
ovarian,B-body-part
cancer,I-disease
is,O
a,O
heterogeneous,B-Concepts_Ideas
disease,B-disease
characterized,O
by,O
various,O
histological,O
types,O
which,O
may,O
have,O
different,O
MSI,O
frequencies,O
,,O
the,O
number,O
of,O
specimens,O
analyzed,O
is,O
very,O
important,O
in,O
characterizing,O
a,O
feature,O
that,O
may,O
be,O
uncommon,O
such,O
as,O
MSI,O
.,O
 , 
We,O
therefore,O
,,O
made,O
a,O
summary,O
of,O
20,O
studies,O
totaling,O
1315,B-size
ovarian,B-body-part
carcinomas,B-disease
,,I-disease
to,O
compare,O
the,O
findings,O
of,O
these,O
studies,O
with,O
our,O
results,O
(,O
Table,O
2,O
),O
.,O
 , 
The,O
MSI,O
frequencies,O
determined,O
in,O
these,O
studies,O
ranged,O
from,O
0,O
%,O
to,O
39,O
%,O
.,O
 , 
Overall,O
,,O
MSI,B-Disorder
was,O
detected,O
in,O
165,B-size
of,I-size
the,I-size
1315,I-size
ovarian,B-body-part
carcinomas,B-cohort-patient
tested,O
,,O
suggesting,O
an,O
overall,O
incidence,O
of,O
13,B-size
%,I-size
[,O
18,O
-,O
37,O
],O
.,O
 , 


,O
Multiple,O
differences,O
between,O
these,O
studies,O
could,O
have,O
caused,O
the,O
wide,O
range,O
in,O
the,O
MSI,O
frequency,O
(,O
0–39,O
%,O
),O
.,O
 , 
One,O
of,O
these,O
is,O
the,O
number,O
and,O
variety,O
of,O
microsatellite,O
markers,O
analyzed,O
to,O
determine,O
the,O
MSI,O
.,O
 , 
The,O
NCI,O
recommended,O
five,O
markers,O
comprising,O
the,O
National,O
Cancer,O
Institute,O
Consensus,O
Panel,O
(,O
NCI,O
-,O
CP,O
),O
for,O
the,O
detection,O
of,O
MSI,O
,,O
i.e.,O
markers,O
for,O
the,O
mononucleotide,O
repeats,O
BAT25,O
and,O
BAT26,O
and,O
the,O
dinucleotide,O
repeats,O
D2S123,O
,,O
D5S346,O
and,O
D17S250,O
[,O
48,O
],O
.,O
 , 
Table,O
2,O
shows,O
per,O
study,O
the,O
number,O
of,O
MS,O
markers,O
used,O
and,O
specifies,O
how,O
many,O
of,O
these,O
are,O
part,O
of,O
the,O
NCI,O
-,O
CP,O
.,O
 , 
Interestingly,O
,,O
the,O
studies,O
that,O
used,O
all,O
NCI,O
-,O
CP,O
markers,O
to,O
determine,O
the,O
MS,O
status,O
also,O
showed,O
a,O
wide,O
range,O
in,O
MSI,O
frequency,O
(,O
8–39,O
%,O
),O
which,O
is,O
similar,O
to,O
the,O
overall,O
range,O
(,O
0–39,O
%,O
),O
.,O
 , 
Therefore,O
,,O
the,O
various,O
MS,O
markers,O
used,O
can,O
not,O
be,O
the,O
sole,O
cause,O
for,O
the,O
wide,O
range,O
.,O
 , 
Moreover,O
,,O
Gras,O
et,O
al,O
.,O
suggest,O
that,O
the,O
reliability,O
of,O
the,O
mononucleotide,O
markers,O
BAT25,O
and,O
BAT26,O
is,O
so,O
high,O
that,O
most,O
MSI,O
can,O
be,O
predicted,O
by,O
evaluating,O
these,O
two,O
markers,O
exclusively,O
[,O
27,O
],O
,,O
confirming,O
the,O
less,O
stringent,O
role,O
for,O
the,O
various,O
markers,O
used,O
for,O
the,O
analysis,O
.,O
 , 


,O
 , 
#2386495-05-Discussion-p04
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Owing,O
to,O
the,O
fact,O
that,O
RNA,O
-,O
based,O
PTT,O
was,O
used,O
at,O
the,O
initial,O
stage,O
of,O
the,O
mutational,O
screening,O
,,O
detection,O
of,O
the,O
disease,B-disease
-,I-disease
causing,O
splice,O
-,O
site,O
mutations,O
was,O
straightforward,O
.,O
 , 
Sequencing,O
of,O
genomic,O
DNA,O
was,O
then,O
used,O
to,O
pinpoint,O
the,O
genetic,O
alteration,O
causing,O
the,O
aberrant,O
mRNA,O
sequence,O
that,O
was,O
visualized,O
in,O
the,O
PTT,O
experiments,O
.,O
 , 
The,O
use,O
of,O
both,O
DNA-,O
and,O
mRNA,O
-,O
based,O
methods,O
is,O
a,O
prerequisite,O
for,O
high,O
-,O
quality,O
investigation,O
of,O
splice,O
-,O
site,O
mutations,O
.,O
 , 


,O
A,O
case,B-cohort-patient
of,O
reduced,B-Physiology
APC,B-gene
expression,I-Physiology


,I-Physiology
The,O
study,O
of,O
mRNA,O
levels,O
was,O
the,O
next,O
step,O
in,O
the,O
line,O
of,O
investigation,O
of,O
the,O
cause,O
of,O
disease,B-disease
in,O
patients,B-cohort-patient
with,O
no,B-Phenomena
detected,I-Phenomena
APC,B-gene
mutation,B-mutation
.,I-mutation
 , 
Family,B-cohort-patient
1,I-cohort-patient
is,O
the,O
largest,O
kindred,O
in,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
;,O
this,O
family,B-cohort-patient
includes,O
150,B-size
individuals,B-cohort-patient
of,O
whom,O
57,B-size
are,O
affected,B-disease
by,O
the,O
disease,B-disease
(,O
Figure,O
6,O
shows,O
part,O
of,O
the,O
pedigree,O
),O
.,O
 , 
However,O
,,O
no,O
pathogenic,O
mutation,O
had,O
been,O
detected,O
after,O
screening,O
the,O
whole,O
coding,O
region,O
of,O
the,O
APC,B-gene
gene,O
but,O
as,O
the,O
family,B-cohort-patient
did,O
show,O
positive,O
linkage,O
to,O
the,O
APC,B-gene
locus,O
we,O
decided,O
to,O
perform,O
expression,O
analyses,O
and,O
evidence,O
of,O
lowered,B-Physiology
APC,I-Physiology
expression,I-Physiology
was,O
obtained,O
by,O
quantitative,O
real,O
-,O
time,O
PCR,O
(,O
Figure,O
5A,O
),O
.,O
 , 
The,O
result,O
was,O
supported,O
by,O
the,O
indication,O
of,O
a,O
lower,O
expression,O
from,O
the,O
T,O
-,O
allele,O
from,O
analysis,O
of,O
the,O
APC,B-gene
c.5465A,B-mutation
>,I-mutation
T,I-mutation
polymorphism,O
in,O
the,O
cDNA,O
sequencing,O
diagram,O
of,O
two,B-size
affected,B-disease
family,B-cohort-patient
members,I-cohort-patient
(,O
Figure,O
5B,O
),O
.,O
 , 
The,O
search,O
for,O
mutations,O
in,O
the,O
DNA,O
sequence,O
of,O
the,O
APC,B-gene
promoters,O
has,O
been,O
initiated,O
,,O
but,O
no,O
pathogenic,O
change,O
has,O
been,O
detected,O
to,O
this,O
date,O
.,O
 , 
The,O
possibility,O
of,O
the,O
pathogenic,O
change,O
being,O
epigenetic,O
will,O
have,O
to,O
be,O
investigated,O
further,O
.,O
 , 
Hypermethylation,B-Physiology
of,I-Physiology
CpG,I-Physiology
sites,I-Physiology
in,I-Physiology
the,I-Physiology
promoter,I-Physiology
of,I-Physiology
APC,I-Physiology
has,O
been,O
reported,O
as,O
a,O
means,O
of,O
gene,O
silencing,O
in,O
colorectal,B-body-part
tumors,B-disease
[,O
46,O
-,O
49,O
],O
.,O
 , 
To,O
the,O
best,O
of,O
the,O
authors,O
',O
knowledge,O
no,O
germ,B-Physiology
-,I-Physiology
line,I-Physiology
inactivation,I-Physiology
of,I-Physiology
APC,I-Physiology
caused,I-Physiology
by,I-Physiology
promoter,I-Physiology
hypermethylation,I-Physiology
has,O
been,O
reported,O
.,O
 , 
However,O
,,O
cases,B-cohort-patient
of,O
pathogenic,O
germline,B-mutation
epimutations,I-mutation
have,O
been,O
identified,O
in,O
the,O
MLH1,B-gene
gene,O
,,O
which,O
causes,O
hereditary,B-disease
non,I-disease
-,I-disease
polyposis,I-disease
CRC,I-disease
[,O
50,51,O
],O
.,O
 , 


,O
Mutation,O
-,O
detection,O
frequency,O


,O
The,O
61,B-size
different,O
APC,B-gene
mutations,B-mutation
listed,O
in,O
Additional,O
file,O
2,O
were,O
identified,O
among,O
81,B-size
of,I-size
the,I-size
96,I-size
families,B-cohort-patient
of,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
that,O
were,O
screened,O
for,O
APC,B-gene
mutations,B-mutation
.,I-mutation
 , 
Fifteen,B-size
of,O
the,O
cases,B-cohort-patient
shown,O
to,O
be,O
APC,B-Disorder
-,I-Disorder
mutation,I-Disorder
negative,I-Disorder
where,O
all,O
subjected,O
to,O
mutational,O
screening,O
of,O
the,O
MUTYH,B-gene
gene,O
and,O
six,B-cohort-patient
of,O
them,B-cohort-patient
were,O
shown,O
to,O
carry,O
biallelic,B-mutation
MUTYH,I-mutation
mutations,I-mutation
(,O
reported,O
in,O
Kanter,O
Smoler,O
et,O
al[31,O
],O
),O
.,O
 , 
The,O
overall,O
mutation,B-mutation
-,I-mutation
detection,O
rate,O
in,O
APC,B-gene
and,O
MUTYH,B-gene
among,O
the,O
families,B-cohort-patient
in,O
our,O
study,O
was,O
thus,O
90,B-size
%,I-size
.,I-size
 , 
In,O
total,O
,,O
84,B-size
%,I-size
of,O
the,O
families,B-cohort-patient
carried,O
APC,B-gene
mutations,B-mutation
while,O
6,B-size
%,I-size
where,O
positive,O
for,O
biallelic,B-mutation
MUTYH,B-gene
mutations,I-mutation
.,I-mutation
 , 
The,O
mutation,O
-,O
detection,O
rate,O
we,O
have,O
reached,O
in,O
this,O
study,O
is,O
notably,O
high,O
.,O
 , 
In,O
fact,O
,,O
a,O
disease,B-disease
-,I-disease
causing,O
mutation,O
was,O
detected,O
in,O
all,O
cases,B-cohort-patient
who,O
presented,O
with,O
a,O
classical,B-Concepts_Ideas
FAP,B-disease
phenotype,O
(,O
except,O
for,O
family,B-cohort-patient
1,I-cohort-patient
(,B-cohort-patient
C152,I-cohort-patient
),I-cohort-patient
,,O
where,O
we,O
have,O
clear,O
indications,O
for,O
inactivation,B-Physiology
of,I-Physiology
the,I-Physiology
APC,B-gene
transcription,I-Physiology
),I-Physiology
.,O
 , 
The,O
mutation,B-cohort-patient
-,I-cohort-patient
negative,I-cohort-patient
patients,I-cohort-patient
all,O
display,O
an,O
attenuated,B-Concepts_Ideas
form,O
of,O
disease,B-disease
.,I-disease
 , 
However,O
,,O
as,O
we,O
have,O
also,O
found,O
subtle,O
mutations,B-mutation
in,O
the,O
APC,B-gene
gene,O
in,O
patients,B-cohort-patient
with,O
attenuated,B-Concepts_Ideas
FAP,B-disease
,,I-disease
we,O
have,O
to,O
consider,O
inactivation,B-Physiology
of,I-Physiology
APC,B-gene
to,O
be,O
responsible,O
for,O
some,O
of,O
these,O
FAP,B-disease
cases,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1557864-02-Background-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Background,O


,B-body-part
Ovarian,I-body-part
cancer,I-disease
is,O
the,O
leading,O
cause,O
of,O
death,O
from,O
gynecological,B-body-part
cancer,B-disease
in,O
the,O
Western,O
world,O
[,O
1,O
],O
.,O
 , 
The,O
treatment,O
of,O
ovarian,B-body-part
adenocarcinoma,B-disease
has,O
improved,O
over,O
the,O
last,O
20,O
years,O
owing,O
to,O
the,O
combined,O
treatment,O
of,O
cytoreductive,O
surgery,O
and,O
chemotherapy,O
 , 
[,O
2,O
],O
.,O
 , 
Although,O
the,O
response,O
of,O
the,O
primary,O
tumor,B-disease
to,O
taxane,O
and,O
platinum,O
-,O
based,O
chemotherapy,O
is,O
high,O
,,O
about,O
20,B-size
%,I-size
of,O
patients,B-cohort-patient
never,O
achieve,O
a,O
clinical,O
response,O
and,O
the,O
majority,O
of,O
the,O
patients,B-cohort-patient
will,O
relapse,O
and,O
eventually,O
die,O
of,O
drug,B-Concepts_Ideas
-,I-Concepts_Ideas
resistant,I-Concepts_Ideas
disease,B-disease
[,O
3,O
],O
.,O
 , 


,O
If,O
it,O
would,O
be,O
possible,O
to,O
predict,O
primary,O
platinum,O
resistance,O
,,O
patients,B-cohort-patient
might,O
be,O
spared,O
an,O
ineffective,O
but,O
toxic,O
platinum,O
-,O
containing,O
therapy,O
and,O
might,O
benefit,O
from,O
an,O
early,O
therapy,O
with,O
different,O
drugs,O
.,O
 , 
Recently,O
,,O
several,O
molecular,O
profiling,O
studies,O
,,O
including,O
our,O
study,O
,,O
have,O
revealed,O
gene,O
sets,O
that,O
can,O
predict,O
response,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
in,O
ovarian,B-body-part
cancer,I-disease
[,O
4,O
-,O
6,O
],O
.,O
 , 
We,O
discovered,O
a,O
nine,O
-,O
gene,O
set,O
which,O
predicts,O
response,O
with,O
a,O
sensitivity,O
of,O
89,O
%,O
and,O
a,O
specificity,O
of,O
59,O
%,O
[,O
5,O
],O
.,O
 , 
One,O
of,O
these,O
nine,O
genes,O
was,O
proliferating,B-gene
cell,I-gene
nuclear,I-gene
antigen,I-gene
(,B-gene
PCNA,I-gene
),I-gene
.,O
 , 
PCNA,B-gene
is,O
a,O
DNA,O
sliding,O
clamp,O
that,O
interacts,O
with,O
several,O
proteins,O
involved,O
in,O
cell,O
cycle,O
control,O
,,O
DNA,O
methylation,O
,,O
DNA,O
replication,O
and,O
DNA,O
repair,O
including,O
mismatch,O
repair,O
[,O
7,O
],O
.,O
 , 
In,O
this,O
study,O
,,O
we,O
have,O
focused,O
on,O
DNA,O
mismatch,O
repair,O
and,O
its,O
role,O
in,O
platinum,O
-,O
based,O
chemotherapy,O
resistance,O
in,O
ovarian,B-body-part
cancer,I-disease
.,I-disease
 , 


,O
DNA,O
mismatch,O
repair,O
(,B-gene
MMR,I-gene
),I-gene
is,O
divided,O
into,O
three,O
steps,O
:,O
initiation,O
,,O
excision,O
and,O
resynthesis,O
(,O
Figure,O
1,O
),O
.,O
 , 
Several,O
proteins,O
are,O
involved,O
in,O
the,O
initiation,O
of,O
MMR,B-gene
including,O
the,O
three,O
MutS,O
-,O
homologs,O
,,O
MSH2,B-gene
,,I-gene
MSH3,B-gene
and,O
MSH6,B-gene
.,I-gene
 , 
The,O
MutS,O
homologs,O
form,O
a,O
heterodimer,O
that,O
recognizes,O
DNA,O
damage,O
;,O
the,O
MSH2,B-gene
and,O
MSH6,B-gene
dimer,O
(,O
the,O
hMutSα,O
complex,O
),O
recognizes,O
base,O
-,O
base,O
mismatches,O
and,O
single,O
base,O
loops,O
whereas,O
the,O
MSH2,B-gene
and,O
MSH3,B-gene
dimer,O
(,O
hMutSβ,O
complex,O
),O
recognizes,O
insertion,O
/,O
deletion,O
loops,O
of,O
more,O
then,O
one,O
base,O
.,O
 , 
After,O
the,O
recognition,O
of,O
the,O
DNA,O
damage,O
the,O
binding,O
of,O
a,O
heterodimer,O
of,O
the,O
MutS,O
-,O
homologs,O
MLH1,B-gene
and,O
PMS2,B-gene
(,O
the,O
hMutLα,O
complex,O
),O
leads,O
to,O
the,O
further,O
initiation,O
of,O
MMR,B-gene
.,I-gene
 , 
Other,O
known,O
and,O
still,O
unknown,O
proteins,O
involved,O
in,O
the,O
last,O
two,O
steps,O
of,O
MMR,B-gene
,,I-gene
the,O
excision,O
of,O
the,O
damaged,O
strand,O
and,O
the,O
resynthesis,O
,,O
are,O
recruited,O
subsequently,O
.,O
 , 
Proteins,O
known,O
to,O
be,O
involved,O
are,O
exonuclease,O
ExoI,B-gene
,,I-gene
proliferating,O
cell,O
nuclear,O
antigen,O
(,B-gene
PCNA,I-gene
),I-gene
,,O
DNA,O
polymerase,O
δ,O
and,O
perhaps,O
ε,O
and,O
in,O
addition,O
based,O
on,O
its,O
association,O
with,O
DNA,O
polymerase,O
δ,O
and,O
PCNA,B-gene
,,I-gene
DNA,O
ligase,O
I,O
[,O
8,9,O
],O
.,O
 , 


,O
Inactivation,O
of,O
MMR,B-gene
leads,O
to,O
the,O
occurrence,O
of,O
unrepaired,O
deletions,O
in,O
mono-,O
and,O
dinucleotide,O
repeats,O
resulting,O
in,O
variable,O
lengths,O
of,O
these,O
repeats,O
.,O
 , 
This,O
is,O
called,O
microsatellite,O
instability,O
(,O
MSI,O
),O
and,O
MSI,O
is,O
therefore,O
used,O
as,O
a,O
marker,O
for,O
MMR,B-gene
deficiency,O
.,O
 , 
MSI,O
can,O
be,O
caused,O
by,O
genetic,O
or,O
epigenetic,O
inactivation,O
of,O
several,O
genes,O
involved,O
in,O
MMR,B-gene
.,I-gene
 , 
Mouse,O
knockout,O
models,O
have,O
demonstrated,O
that,O
MSH2-/-,B-gene
,,I-mutation
MSH3-/-,B-gene
,,I-mutation
MLH1-/-,B-mutation
and,O
PMS2-/-,B-mutation
leads,O
to,O
a,O
high,O
frequency,O
of,O
MSI,O
while,O
MSH6-/-,B-mutation
and,O
PMS1-/-,B-mutation
cause,O
a,O
low,O
frequency,O
(,O
reviewed,O
by,O
Wei,O
et,O
al,O
.,O
 , 
[,O
10,O
],O
),O
.,O
 , 
However,O
,,O
in,O
hereditary,B-disease
nonpolyposis,I-disease
colon,I-disease
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
families,B-cohort-patient
(,O
which,O
are,O
known,O
to,O
have,O
a,O
high,O
frequency,O
of,O
MSI,B-Disorder
),I-Disorder
germline,B-mutation
mutations,I-mutation
in,O
MSH2,B-gene
and,O
MLH1,B-gene
are,O
responsible,O
for,O
the,O
MSI,B-Disorder
,,I-Disorder
while,O
MSH6,B-gene
and,O
PMS2,B-gene
are,O
less,O
frequently,O
involved,O
 , 
[,O
9,O
],O
.,O
 , 
The,O
lesser,O
role,O
for,O
MSH6,B-gene
,,I-gene
PMS2,B-gene
,,I-gene
PMS1,B-gene
and,O
especially,O
MSH3,B-gene
inactivation,I-Physiology
in,O
MSI,B-Disorder
seen,O
in,O
HNPCC,B-disease
patients,B-cohort-patient
could,O
be,O
due,O
to,O
functional,O
redundancy,O
of,O
these,O
genes,O
.,O
 , 


,O
 , 
#1619718-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,B-Concepts_Ideas
Advanced,I-Concepts_Ideas
colorectal,B-body-part
polyps,B-disease
with,O
the,O
molecular,O
and,O
morphological,O
features,O
of,O
serrated,B-Concepts_Ideas
polyps,B-disease
and,O
adenomas,B-disease
:,I-disease
concept,O
of,O
a,O
‘,O
fusion,O
’,O
pathway,O
to,O
colorectal,B-body-part
cancer,I-disease


,I-disease
Abstract,O


,O
Jass,O
J,O
R,O
,,O
Baker,O
K,O
,,O
Zlobec,O
I,O
,,O
Higuchi,O
T,O
,,O
Barker,O
M,O
,,O
Buchanan,O
D,O
&,O
Young,O
J,O
(,O
2006,O
),O
Histopathology,O
49,O
,,O
121–131,O


,B-Concepts_Ideas
Advanced,I-Concepts_Ideas
colorectal,B-body-part
polyps,B-disease
with,O
the,O
molecular,O
and,O
morphological,O
features,O
of,O
serrated,B-Concepts_Ideas
polyps,B-disease
and,O
adenomas,B-disease
:,I-disease
concept,O
of,O
a,O
‘,O
fusion,O
’,O
pathway,O
to,O
colorectal,B-disease
cancer,I-disease


,I-disease
Aim,O


,O
To,O
establish,O
and,O
explain,O
the,O
pattern,O
of,O
molecular,O
signatures,O
across,O
colorectal,B-body-part
polyps,B-disease
.,I-disease
 , 


,O
Methods,O
and,O
results,O


,B-size
Thirty,I-size
-,I-size
two,I-size
sessile,B-Concepts_Ideas
serrated,B-Concepts_Ideas
adenomas,B-disease
(,B-disease
SSA,I-disease
),I-disease
,,O
10,B-size
mixed,B-Concepts_Ideas
polyps,B-disease
(,B-disease
MP,I-disease
),I-disease
,,O
15,B-size
traditional,B-Concepts_Ideas
serrated,B-Concepts_Ideas
adenomas,B-disease
(,B-disease
SA,I-disease
),I-disease
,,O
49,B-size
hyperplastic,B-Disorder
polyps,B-cohort-patient
(,B-disease
HP,I-disease
),I-disease
and,O
84,B-size
adenomas,B-disease
were,O
assessed,O
for,O
mutation,O
of,O
KRAS,B-gene
and,O
BRAF,B-gene
and,O
aberrant,O
expression,O
of,O
p53,O
.,O
 , 
The,O
findings,O
were,O
correlated,O
with,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
O-6,I-Physiology
-,I-Physiology
methylguanine,I-Physiology
DNA,I-Physiology
methyltransferase,I-Physiology
(,B-gene
MGMT,I-gene
),I-gene
.,O
 , 
KRAS,B-gene
mutation,B-mutation
occurred,O
more,O
frequently,O
(,B-size
26.5,I-size
%,I-size
),I-size
than,O
BRAF,B-gene
mutation,B-mutation
(,B-size
4.8,I-size
%,I-size
),I-size
in,O
adenomas,B-disease
(,O
P,O
<,O
0.001,O
),O
and,O
particularly,O
in,O
adenomas,B-disease
with,O
villous,B-Concepts_Ideas
architecture,I-Concepts_Ideas
(,B-size
50,I-size
%,I-size
),I-size
.,O
 , 
Loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,I-Physiology
correlated,O
with,O
KRAS,B-gene
mutation,B-mutation
in,O
small,B-Concepts_Ideas
tubular,B-Concepts_Ideas
adenomas,B-disease
(,O
P,O
<,O
0.04,O
),O
.,O
 , 
BRAF,B-gene
mutation,B-mutation
was,O
frequent,O
in,O
HPs,B-disease
(,B-size
67,I-size
%,I-size
),I-size
and,O
SSAs,B-disease
(,B-size
81,I-size
%,I-size
),I-size
,,O
while,O
KRAS,B-gene
mutation,B-mutation
was,O
infrequent,O
(,B-size
4,I-size
%,I-size
and,O
3,B-size
%,I-size
,,I-size
respectively,O
),O
.,O
 , 
Of,O
MPs,B-disease
and,O
SAs,B-disease
,,I-disease
72,B-size
%,I-size
had,O
either,O
BRAF,B-gene
or,O
KRAS,B-gene
mutation,B-mutation
.,I-mutation
 , 
Aberrant,B-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
was,O
uncommon,O
overall,O
,,O
but,O
occurred,O
more,O
frequently,O
in,O
MPs,B-disease
and,O
SAs,B-disease
(,B-size
12,I-size
%,I-size
),I-size
than,O
adenomas,B-disease
(,B-size
1,I-size
%,I-size
),I-size
(,O
P,O
<,O
0.04,O
),O
and,O
there,O
was,O
concordant,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,I-Physiology
.,I-Physiology
 , 


,O
Conclusions,O


,O
Molecular,O
alterations,O
that,O
are,O
characteristic,O
of,O
the,O
serrated,O
pathway,O
and,O
adenoma,B-disease
–,I-disease
carcinoma,I-disease
sequence,O
can,O
co,O
-,O
occur,O
in,O
a,O
minority,O
of,O
advanced,B-Concepts_Ideas
colorectal,B-body-part
polyps,B-disease
that,O
then,O
show,O
morphological,O
features,O
of,O
both,O
pathways,O
.,O
 , 
These,O
lesions,B-disease
account,O
for,O
only,O
2,B-size
%,I-size
of,O
colorectal,B-body-part
polyps,B-disease
,,I-disease
but,O
may,O
be,O
relatively,O
aggressive,O
.,O
 , 


,O
 , 
#1601966-03-Results-p10
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
18q21.2,O
-,O
18q23,O
–,O
the,O
BCL2,O
region,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
25,O
and,O
26,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
18q21.2,O
-,O
18q23,O
–,O
the,O
BCL2,B-gene
region,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
7,O
,,O
10,O
,,O
13,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
24,O
and,O
26,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
18q21.2,O
-,O
18q23,O
–,O
the,O
BCL2,O
region,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
8,O
,,O
11,O
,,O
14,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
24,O
and,O
25,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
25,O
.,O
 , 
This,O
region,O
has,O
been,O
reported,O
in,O
other,O
studies,O
to,O
be,O
frequently,O
deleted,O
in,O
colon,B-body-part
cancer,B-disease
(,O
see,O
Table,O
4,O
),O
.,O
 , 
Note,O
the,O
expression,O
down,O
-,O
regulation,O
of,O
BCL2,B-gene
.,I-gene
 , 
SMAD4,B-gene
(,O
Hs.298320,O
),O
and,O
TCF4,B-gene
are,O
only,O
weakly,O
down,O
-,O
regulated,O
.,O
 , 
The,O
DCC,B-gene
gene,O
is,O
also,O
located,O
in,O
this,O
region,O
between,O
LOC51320,B-gene
and,O
MBD2,B-gene
but,O
no,O
informative,O
expression,O
measures,O
were,O
obtained,O
.,O
 , 


,O
5q22.2,O
-,O
5q23.1,O


,O
Not,O
unexpected,O
,,O
we,O
found,O
loss,O
of,O
expression,O
in,O
region,O
5q22.2,O
-,O
5q23.1,O
(,O
see,O
Figures,O
27,O
,,O
28,O
,,O
29,O
),O
.,O
 , 
This,O
interval,O
harbors,O
two,O
known,O
TSGs,O
in,O
colon,B-body-part
cancer,I-disease
,,I-disease
the,O
adenomatous,O
polyposis,O
coli,O
gene,O
(,B-gene
APC,I-gene
),I-gene
gene,O
and,O
the,O
mutated,O
in,O
colorectal,B-body-part
cancer,B-disease
(,O
MCC,O
),O
.,O
 , 
We,O
were,O
not,O
able,O
to,O
obtain,O
expression,O
values,O
for,O
APC,B-gene
.,I-gene
 , 
APC,B-gene
is,O
located,O
at,O
the,O
border,O
of,O
a,O
region,O
at,O
5q22.2,O
-,O
5q22.3,O
that,O
harbors,O
several,O
drastically,O
down,O
-,O
regulated,O
genes,O
.,O
 , 
Central,O
in,O
this,O
region,O
is,O
the,O
MCC,B-gene
gene,O
.,O
 , 
The,O
distal,O
border,O
is,O
the,O
CDO1,B-gene
gene,O
.,O
 , 
We,O
assume,O
that,O
deletion,O
or,O
epigenetic,O
silencing,O
of,O
this,O
region,O
is,O
a,O
frequent,O
mechanism,O
contributing,O
to,O
colorectal,B-body-part
tumorigenesis,O
.,O
 , 
It,O
is,O
possible,O
that,O
also,O
APC,B-gene
or,O
MCC,B-gene
show,O
reduced,O
expression,O
,,O
that,O
genes,O
in,O
this,O
region,O
other,O
than,O
APC,B-gene
and,O
MCC,B-gene
are,O
piggy,O
-,O
back,O
genes,O
,,O
and,O
that,O
their,O
misregulation,O
is,O
not,O
of,O
functional,O
significance,O
for,O
tumorigenesis,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
5q22.2,O
-,O
5q23.1,O
–,O
the,O
APC,B-gene
region,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
28,O
and,O
29,O
.,O
 , 


,O
 , 
#1601966-03-Results-p08
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
1p36.13,O
-,O
1p36.11,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
plot,O
of,O
cross,O
-,O
comparison,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
for,O
gene,O
pairs,O
in,O
a,O
particular,O
region,O
.,O
 , 
Both,O
,,O
horizontal,O
and,O
vertical,O
axes,O
comprise,O
the,O
same,O
genes,O
in,O
chromosomal,O
order,O
.,O
 , 
In,O
each,O
square,O
total,O
counts,O
of,O
patients,B-cohort-patient
with,O
consistent,O
up,O
-,O
regulation,O
in,O
two,O
genes,O
are,O
coded,O
by,O
different,O
shades,O
of,O
gray,O
.,O
 , 
Dark,O
squared,O
regions,O
along,O
the,O
diagonal,O
indicate,O
coordinated,O
regulation,O
in,O
patient,B-cohort-patient
subgroups,O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
9,O
and,O
11,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
1p36.13,O
-,O
1p36.11,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
plot,O
of,O
cross,O
-,O
comparison,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
for,O
gene,O
pairs,O
in,O
a,O
particular,O
region,O
.,O
 , 
Both,O
,,O
horizontal,O
and,O
vertical,O
axes,O
comprise,O
the,O
same,O
genes,O
in,O
chromosomal,O
order,O
.,O
 , 
In,O
each,O
square,O
total,O
counts,O
of,O
patients,B-cohort-patient
with,O
consistent,O
down,O
-,O
regulation,O
in,O
two,O
genes,O
are,O
coded,O
by,O
different,O
shades,O
of,O
gray,O
.,O
 , 
Dark,O
squared,O
regions,O
along,O
the,O
diagonal,O
indicate,O
coordinated,O
regulation,O
in,O
patient,B-cohort-patient
subgroups,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
10,O
.,O
 , 
This,O
region,O
has,O
been,O
reported,O
in,O
other,O
studies,O
to,O
be,O
frequently,O
deleted,O
in,O
colorectal,B-disease
cancer,I-disease
(,O
see,O
Table,O
4,O
),O
.,O
 , 
This,O
is,O
the,O
most,O
significantly,O
down,O
-,O
regulated,O
region,O
of,O
our,O
analysis,O
.,O
 , 
Note,O
the,O
expression,O
of,O
potential,O
tumor,B-disease
genes,O
PLA2G2A,B-gene
,,I-gene
E2F2,B-gene
,,I-gene
and,O
CDC42,B-gene
.,I-gene
 , 


,O
4p15.31,O
-,O
4p15.2,O


,O
The,O
region,O
4p15.31,O
-,O
4p15.2,O
is,O
part,O
of,O
a,O
larger,O
region,O
(,O
see,O
Table,O
1,O
),O
that,O
showed,O
marked,O
down,O
-,O
regulation,O
of,O
expression,O
in,O
our,O
tumor,B-disease
samples,O
(,O
see,O
Figures,O
21,O
,,O
22,O
,,O
23,O
),O
.,O
 , 
Full,O
or,O
partial,O
losses,O
of,O
chromosome,O
4,O
are,O
well,O
known,O
phenomena,O
in,O
the,O
development,O
of,O
CRC,B-disease
[,O
18,19,23,24,O
],O
.,O
 , 
One,O
of,O
the,O
strongly,O
down,O
-,O
regulated,O
genes,O
in,O
this,O
region,O
is,O
the,O
SLIT2,B-gene
gene,O
at,O
4p15.31,O
that,O
encodes,O
a,O
membrane,O
protein,O
regulating,O
cellular,O
migration,O
.,O
 , 
It,O
has,O
recently,O
been,O
described,O
as,O
a,O
new,O
tumor,B-disease
suppressor,O
gene,O
in,O
CRC,B-disease
,,I-disease
gliomas,B-disease
,,I-disease
lung,B-body-part
and,O
breast,B-body-part
tumors,B-disease
and,O
seems,O
to,O
be,O
transcriptionally,O
inactivated,O
by,O
epigenetic,O
silencing,O
[,O
31,O
-,O
33,O
],O
.,O
 , 
In,O
addition,O
,,O
several,O
other,O
genes,O
of,O
this,O
region,O
could,O
serve,O
as,O
candidate,O
class,O
II,O
tumor,B-disease
suppressor,O
genes,O
.,O
 , 
The,O
GPR125,B-gene
gene,O
encodes,O
an,O
orphan,O
G,O
-,O
protein,O
coupled,O
receptor,O
that,O
has,O
a,O
large,O
extracellular,O
N,O
-,O
terminus,O
with,O
an,O
immunoglobulin,O
domain,O
and,O
leucine,O
-,O
rich,O
repeats,O
,,O
similar,O
to,O
GPR49,B-gene
described,O
above,O
.,O
 , 
The,O
PCDH7,B-gene
gene,O
belongs,O
to,O
the,O
protocadherin,O
gene,O
family,B-cohort-patient
.,I-cohort-patient
 , 
It,O
encodes,O
a,O
transmembrane,O
protein,O
that,O
has,O
seven,O
extracellular,O
cadherin,O
repeats,O
,,O
suggesting,O
that,O
it,O
is,O
involved,O
in,O
cellular,O
adhesion,O
and,O
adhesion,O
-,O
dependent,O
intracellular,O
signaling,O
.,O
 , 
The,O
functions,O
of,O
genes,O
in,O
this,O
region,O
suggest,O
that,O
this,O
regional,O
expression,O
loss,O
influences,O
adhesion,O
and,O
migration,O
properties,O
of,O
cancer,B-disease
cells,O
.,O
 , 
Both,O
,,O
epigenetic,O
silencing,O
and,O
chromosomal,O
aberrations,O
are,O
potential,O
mechanisms,O
leading,O
to,O
expression,O
loss,O
in,O
this,O
region,O
.,O
 , 


,O
 , 
#2386495-05-Discussion-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
The,O
phenotype,O
of,O
the,O
patient,B-cohort-patient
(,B-cohort-patient
C157,I-cohort-patient
),I-cohort-patient
,,O
carrying,O
the,O
c.70C,B-mutation
>,I-mutation
T,I-mutation
mutation,O
,,O
is,O
in,O
agreement,O
with,O
the,O
suggested,O
genotype,O
-,O
phenotype,O
correlation,O
where,O
a,O
milder,O
form,O
of,O
polyposis,B-disease
is,O
proposed,O
to,O
be,O
caused,O
by,O
mutations,O
in,O
the,O
5,O
',O
end,O
of,O
the,O
gene,O
.,O
 , 
A,O
model,O
for,O
the,O
attenuated,O
phenotype,O
in,O
patients,B-cohort-patient
carrying,O
mutations,B-mutation
in,I-mutation
the,I-mutation
first,I-mutation
four,I-mutation
exons,I-mutation
of,O
APC,B-gene
have,O
been,O
suggested,O
by,O
Heppner,O
Goss,O
et,O
al,O
 , 
[,O
42,O
],O
,,O
in,O
which,O
the,O
internal,O
ATG,O
at,O
codon,O
184,O
could,O
be,O
used,O
as,O
an,O
alternative,O
translation,O
initiation,O
codon,O
in,O
the,O
allele,O
carrying,O
a,O
truncating,O
mutation,O
upstream,O
of,O
this,O
site,O
(,O
Figure,O
1,O
),O
.,O
 , 
Such,O
an,O
alternative,O
start,O
of,O
translation,O
would,O
supply,O
the,O
cell,O
with,O
an,O
APC,B-gene
protein,O
of,O
almost,O
full,O
length,O
,,O
thus,O
explaining,O
the,O
attenuated,O
phenotype,O
.,O
 , 
Patient,B-cohort-patient
C159,B-cohort-patient
,,I-cohort-patient
with,O
the,O
most,O
3,B-mutation
',I-mutation
localized,I-mutation
mutation,I-mutation
was,O
a,O
case,B-cohort-patient
of,O
attenuated,B-Concepts_Ideas
FAP,B-disease
(,B-Concepts_Ideas
100–1000,I-Concepts_Ideas
polyps,I-Concepts_Ideas
,,I-Concepts_Ideas
46,B-age
years,I-age
of,O
age,O
at,O
diagnosis,O
),O
.,O
 , 
In,O
family,B-cohort-patient
1,I-cohort-patient
(,B-Physiology
reduced,I-Physiology
expression,I-Physiology
of,I-Physiology
APC,B-gene
),I-gene
,,O
patient,B-cohort-patient
C152,B-cohort-patient
displayed,O
a,O
classical,B-Concepts_Ideas
FAP,B-disease
phenotype,O
including,O
a,O
large,B-Disorder
number,I-Disorder
of,I-Disorder
polyps,I-Disorder
,,I-Disorder
duodenal,B-body-part
adenomas,B-disease
,,I-disease
and,O
fundic,B-body-part
gland,I-body-part
polyps,B-disease
(,O
Additional,O
file,O
1,O
),O
.,O
 , 


,O
The,O
APC-,B-gene
and,I-Disorder
MUTYH,B-gene
-,I-gene
mutation,I-mutation
negative,I-Disorder
patients,B-cohort-patient
all,O
display,O
an,O
attenuated,B-Concepts_Ideas
form,O
of,O
disease,B-disease
with,O
a,O
low,B-Concepts_Ideas
number,I-Concepts_Ideas
of,I-Concepts_Ideas
polyps,I-Concepts_Ideas
,,I-Concepts_Ideas
comparably,O
high,B-age
age,I-age
at,I-age
diagnosis,I-age
,,I-age
and,O
a,O
low,O
frequency,O
of,O
extracolonic,B-body-part
manifestations,O
.,O
 , 
Whether,O
these,O
patients,B-cohort-patient
really,O
are,O
affected,O
by,O
APC,B-gene
-,I-gene
associated,O
FAP,B-disease
can,O
(,O
of,O
course,O
),O
be,O
called,O
into,O
question,O
.,O
 , 
However,O
,,O
among,O
attenuated,B-Concepts_Ideas
cases,B-cohort-patient
of,O
FAP,B-disease
in,O
these,O
study,O
we,O
have,O
found,O
very,O
subtle,O
mutations,O
such,O
as,O
the,O
mosaic,B-Physiology
case,B-cohort-patient
as,O
well,O
as,O
the,O
c.70C,B-mutation
>,I-mutation
T,I-mutation
mutation,O
and,O
splice,B-mutation
-,I-mutation
site,I-mutation
mutations,I-mutation
.,I-mutation
 , 
Considering,O
these,O
facts,O
,,O
at,O
least,O
some,O
of,O
the,O
cases,B-cohort-patient
could,O
be,O
caused,O
by,O
mutations,B-mutation
in,O
APC,B-gene
resulting,O
in,O
only,O
partially,O
inactivation,O
of,O
the,O
gene,O
function,O
.,O
 , 
Since,O
the,O
main,O
purpose,O
of,O
this,O
study,O
was,O
to,O
achieve,O
as,O
high,O
mutation,O
-,O
detection,O
rate,O
as,O
possible,O
in,O
families,B-cohort-patient
with,O
colorectal,B-body-part
polyposis,I-disease
syndromes,I-disease
,,I-disease
using,O
a,O
range,O
of,O
different,O
molecular,O
genetic,O
techniques,O
,,O
we,O
have,O
not,O
yet,O
performed,O
any,O
further,O
analyses,O
of,O
the,O
relatively,O
few,O
mutation,O
negative,O
cases,B-cohort-patient
to,O
determine,O
if,O
they,O
belong,O
to,O
non,B-disease
-,I-disease
polyposis,I-disease
CRC,I-disease
syndromes,I-disease
.,I-disease
 , 


,B-mutation
Large,I-mutation
deletions,I-mutation
of,O
the,O
APC,B-gene
gene,O


,O
The,O
fraction,O
of,O
large,B-mutation
deletions,I-mutation
of,O
all,O
APC,B-gene
mutations,O
identified,O
in,O
the,O
Swedish,B-ethnicity
patients,B-cohort-patient
was,O
9,B-size
%,I-size
,,I-size
which,O
is,O
higher,O
than,O
the,O
5,B-size
%,I-size
of,O
large,B-mutation
deletions,I-mutation
reported,O
in,O
[,O
38,O
],O
.,O
 , 
The,O
relatively,O
large,O
number,O
of,O
gross,O
deletions,O
identified,O
could,O
be,O
a,O
result,O
of,O
the,O
thorough,O
analysis,O
applied,O
for,O
every,O
patient,B-cohort-patient
,,I-cohort-patient
including,O
the,O
use,O
of,O
the,O
MLPA,O
technique,O
.,O
 , 
It,O
is,O
noteworthy,O
that,O
no,O
deletion,B-mutation
of,I-mutation
APC,B-gene
exon,I-mutation
4,I-mutation
in,O
patient,B-cohort-patient
3765,B-cohort-patient
was,O
detected,O
using,O
MLPA,O
although,O
it,O
had,O
been,O
identified,O
and,O
confirmed,O
by,O
other,O
methods,O
.,O
 , 
A,O
still,O
untested,O
possibility,O
is,O
that,O
exon,O
4,O
has,O
been,O
translocated,O
to,O
another,O
chromosomal,O
locus,O
and,O
thus,O
generates,O
the,O
positive,O
MLPA,O
result,O
.,O
 , 


,O
 , 
#3034663-02-Background-p01
Background,O


,O
Genetic,O
testing,O
is,O
conducted,O
for,O
diverse,O
purposes,O
,,O
including,O
confirmation,O
of,O
diagnosis,O
,,O
risk,O
prediction,O
,,O
carrier,O
testing,O
and,O
reproductive,O
decision,O
-,O
making,O
.,O
 , 
The,O
identification,O
of,O
germ,B-mutation
-,I-mutation
line,I-mutation
mutations,I-mutation
in,O
patients,B-cohort-patient
with,O
inherited,B-Concepts_Ideas
cancer,B-disease
syndromes,O
enables,O
them,O
to,O
be,O
included,O
in,O
cancer,B-disease
surveillance,O
programmes,O
.,O
 , 
Such,O
programmes,O
are,O
effective,O
in,O
reducing,O
cancer,B-disease
mortality,O
in,O
the,O
families,B-cohort-patient
concerned,O
.,O
 , 
Moreover,O
,,O
family,B-cohort-patient
members,O
who,O
do,O
not,O
carry,O
the,O
mutation,O
can,O
be,O
treated,O
safely,O
as,O
low,O
-,O
risk,O
individuals,O
,,O
avoiding,O
unnecessary,O
screening,O
and,O
preventing,O
anxiety,O
in,O
the,O
individuals,O
concerned,O
.,O
 , 
Unfortunately,O
,,O
the,O
number,O
of,O
suspected,O
familial,B-Concepts_Ideas
cancer,B-disease
cases,B-cohort-patient
in,O
which,O
a,O
causative,O
mutation,O
is,O
identified,O
is,O
far,O
from,O
ideal,O
.,O
 , 
All,O
members,O
from,O
a,O
family,B-cohort-patient
with,O
a,O
strong,B-Disorder
history,I-Disorder
of,I-Disorder
cancer,B-disease
and,O
no,O
causative,O
mutation,O
detected,O
are,O
included,O
in,O
a,O
surveillance,O
program,O
.,O
 , 
Identification,O
of,O
mutations,O
depends,O
on,O
the,O
specific,O
syndrome,O
and,O
the,O
criteria,O
applied,O
to,O
select,O
patients,B-cohort-patient
for,O
genetic,O
analyses,O
.,O
 , 


,O
The,O
results,O
of,O
sequence,O
-,O
based,O
genetic,O
tests,O
may,O
be,O
reported,O
to,O
physicians,O
as,O
:,O
1,O
),O
positive,O
,,O
in,O
which,O
a,O
mutation,O
that,O
clearly,O
disrupts,O
gene,O
function,O
is,O
detected,O
and,O
is,O
highly,O
likely,O
to,O
have,O
clinical,O
consequences,O
;,O
2,O
),O
a,O
genetic,O
variant,O
is,O
detected,O
but,O
it,O
is,O
not,O
known,O
whether,O
the,O
variant,O
has,O
any,O
effect,O
on,O
gene,O
function,O
that,O
might,O
confer,O
an,O
increased,O
cancer,B-disease
risk,O
(,O
these,O
variants,O
are,O
known,O
as,O
variants,O
of,O
uncertain,O
/,O
unclassified,O
significance,O
or,O
unclassified,O
variants,O
 , 
[,O
UVs,O
],O
),O
;,O
and,O
3,O
),O
negative,O
,,O
in,O
which,O
deleterious,O
variant,O
or,O
UV,O
is,O
detected,O
[,O
1,O
],O
.,O
 , 


,O
The,O
majority,O
of,O
UVs,O
are,O
missense,B-mutation
mutations,I-mutation
or,O
small,B-mutation
in,I-mutation
-,I-mutation
frame,I-mutation
deletions,I-mutation
.,I-mutation
 , 
The,O
human,O
gene,O
pool,O
harbours,O
a,O
vast,O
number,O
of,O
rare,O
missense,B-mutation
substitutions,I-mutation
,,I-mutation
70,O
%,O
of,O
which,O
are,O
at,O
least,O
mildly,O
deleterious,O
[,O
2,O
],O
.,O
 , 
Integration,O
of,O
various,O
lines,O
of,O
evidence,O
may,O
help,O
to,O
classify,O
UVs,O
.,O
 , 
Information,O
on,O
:,O
1,O
),O
frequencies,O
in,O
cases,B-cohort-patient
and,O
controls,B-cohort-patient
,,I-cohort-patient
2,O
),O
co,O
-,O
occurrence,O
(,O
in,O
trans,O
),O
with,O
deleterious,O
mutations,O
,,O
3,O
),O
co,O
-,O
segregation,O
with,O
disease,B-disease
in,O
pedigrees,O
,,O
4,O
),O
pathological,O
factors,O
,,O
5,O
),O
amino,O
acid,O
polarity,O
or,O
size,O
,,O
6,O
),O
evolutionary,O
conservation,O
of,O
the,O
residue,O
,,O
7,O
),O
splice,O
predictions,O
and,O
8),O
in,O
vitro,O
and/or,O
in,O
vivo,O
functional,O
assays,O
may,O
enable,O
UVs,O
to,O
be,O
classified,O
as,O
pathogenic,O
or,O
non,O
-,O
pathogenic,O
[,O
3,O
],O
.,O
 , 


,B-disease
Lynch,I-disease
syndrome,I-disease
(,O
MIM,O
#,O
120435,O
),O
(,B-disease
LS,I-disease
),I-disease
is,O
an,O
autosomal,B-Concepts_Ideas
dominant,I-Concepts_Ideas
inherited,B-Concepts_Ideas
cancer,I-disease
syndrome,I-disease
characterized,O
by,O
early,B-Disorder
onset,I-Disorder
colorectal,B-disease
cancer,I-disease
(,B-disease
CRC,I-disease
),I-disease
,,O
cancer,B-disease
of,O
the,O
endometrium,B-body-part
and,O
tumours,B-disease
of,O
the,O
stomach,B-body-part
,,I-body-part
pancreas,B-body-part
,,I-body-part
small,B-body-part
intestine,I-body-part
,,I-body-part
ovary,B-body-part
,,I-body-part
bladder,B-body-part
and,O
bile,B-body-part
duct,I-body-part
[,O
4,O
],O
.,O
 , 
LS,B-disease
-,I-disease
associated,I-Disorder
tumours,B-disease
are,O
characterized,O
by,O
DNA,B-Physiology
mismatch,I-Physiology
repair,I-Physiology
(,B-gene
MMR,I-gene
),I-gene
deficiency,I-Physiology
,,I-Physiology
which,O
may,O
be,O
evidenced,O
by,O
microsatellite,B-Disorder
instability,I-Disorder
(,B-Disorder
MSI,I-Disorder
),I-Disorder
or,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MMR,I-Physiology
proteins,I-Physiology
using,O
immunohistochemistry,O
[,O
5,O
],O
.,O
 , 
The,O
proportion,O
of,O
genetic,O
UVs,O
in,O
LS,B-disease
varies,O
from,O
1/5,O
to,O
1/3,O
of,O
all,O
unique,O
variants,O
detected,O
[,O
6,O
],O
.,O
 , 


,O
 , 
#1601966-02-Background-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Though,O
some,O
experimental,O
data,O
recently,O
became,O
available,O
linking,O
microarray,O
expression,O
with,O
DNA,O
copy,O
number,O
analyses,O
in,O
some,O
solid,O
tumors,O
 , 
[,O
12,O
-,O
16,O
],O
the,O
knowledge,O
about,O
the,O
existence,O
of,O
genomic,O
islands,O
of,O
coordinated,O
expression,O
in,O
colorectal,B-body-part
carcinoma,B-disease
(,B-disease
CRC,I-disease
),I-disease
is,O
still,O
limited,O
.,O
 , 
During,O
the,O
preparation,O
of,O
this,O
manuscript,O
a,O
first,O
assessment,O
of,O
chromosomal,O
expression,O
patterns,O
in,O
CRC,B-disease
in,O
conjunction,O
with,O
genome,O
-,O
wide,O
DNA,O
copy,O
number,O
analyses,O
became,O
available,O
[,O
17,O
],O
.,O
 , 
Tsafrir,O
et,O
al,O
.,O
described,O
a,O
correlation,O
of,O
gene,O
copy,O
number,O
and,O
expression,O
for,O
both,O
,,O
deleted,O
and,O
amplified,O
genes,O
.,O
 , 
They,O
claimed,O
that,O
the,O
described,O
alterations,O
become,O
more,O
frequent,O
as,O
the,O
tumors,B-disease
progress,O
from,O
benign,O
to,O
metastatic,O
forms,O
,,O
highlighting,O
the,O
need,O
for,O
a,O
more,O
precise,O
characterization,O
of,O
regions,O
of,O
coordinate,O
expression,O
and,O
gene,O
copy,O
number,O
change,O
.,O
 , 
In,O
addition,O
to,O
this,O
most,O
recent,O
work,O
,,O
a,O
substantial,O
body,O
of,O
literature,O
on,O
chromosomal,O
aberrations,O
in,O
CRC,B-disease
has,O
accumulated,O
[,O
7,15,18,O
-,O
25,O
],O
that,O
could,O
help,O
to,O
interpret,O
findings,O
on,O
islands,O
of,O
coordinated,O
chromosomal,O
expression,O
.,O
 , 


,O
The,O
need,O
for,O
a,O
more,O
precise,O
definition,O
of,O
chromosomal,O
regions,O
of,O
altered,O
gene,O
expression,O
prompted,O
us,O
to,O
find,O
a,O
new,O
approach,O
to,O
investigate,O
chromosomal,O
co,O
-,O
expression,O
domains,O
in,O
CRC,B-disease
.,I-disease
 , 
The,O
focus,O
of,O
our,O
study,O
was,O
the,O
identification,O
of,O
up-,O
or,O
down,O
-,O
regulated,O
gene,O
expression,O
in,O
primary,B-Concepts_Ideas
colon,B-body-part
carcinoma,B-disease
cells,O
compared,O
to,O
normal,B-disease
colon,B-body-part
epithelia,O
of,O
the,O
same,O
patient,B-cohort-patient
.,I-cohort-patient
 , 
By,O
using,O
laser,O
capture,O
microdissection,O
(,O
LCM,O
),O
we,O
aimed,O
to,O
investigate,O
transcript,O
abundance,O
in,O
relatively,O
pure,O
cell,O
populations,O
,,O
trying,O
to,O
minimize,O
the,O
influence,O
of,O
contaminating,O
stroma,O
tissue,O
or,O
infiltrating,O
peripheral,O
blood,O
cells,O
on,O
expression,O
measurements,O
.,O
 , 
The,O
use,O
of,O
Affymetrix,O
DNA,O
microarray,O
technology,O
allowed,O
us,O
to,O
simultaneously,O
assess,O
mRNA,O
levels,O
of,O
all,O
known,O
human,O
genes,O
using,O
only,O
small,O
amounts,O
of,O
cells,O
obtained,O
by,O
LCM,O
.,O
 , 
Finally,O
,,O
we,O
developed,O
a,O
new,O
bioinformatic,O
approach,O
to,O
identify,O
regions,O
of,O
chromosomal,O
deregulation,O
which,O
enabled,O
the,O
most,O
precise,O
survey,O
of,O
chromosomal,O
expression,O
domains,O
in,O
colon,B-body-part
cancer,B-disease
available,O
today,O
.,O
 , 
In,O
particular,O
,,O
we,O
were,O
interested,O
in,O
the,O
question,O
whether,O
our,O
data,O
correlated,O
with,O
the,O
data,O
of,O
Tsafrir,O
et,O
al,O
.,O
 , 
who,O
performed,O
genome,O
scale,O
arrayCGH,O
and,O
chip,O
-,O
based,O
expression,O
analyses,O
on,O
a,O
different,O
set,O
of,O
colorectal,B-body-part
cancer,I-disease
patients,B-cohort-patient
[,O
17,O
],O
.,O
 , 
In,O
contrast,O
to,O
Tsafrir,O
et,O
al,O
.,O
 , 
we,O
put,O
more,O
emphasis,O
on,O
the,O
identification,O
of,O
precise,O
boundaries,O
of,O
expression,O
domains,O
and,O
therefore,O
we,O
consider,O
our,O
work,O
as,O
complementary,O
to,O
their,O
pioneering,O
study,O
.,O
 , 


,O
 , 
#1557864-06-Conclusion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Conclusion,O


,B-Physiology
No,I-Physiology
MMR,I-Physiology
inactivation,I-Physiology
was,O
detected,O
in,O
75,B-size
ovarian,B-body-part
carcinoma,B-disease
specimens,B-cohort-patient
and,O
no,O
association,O
was,O
seen,O
between,O
MMR,B-gene
inactivation,O
and,O
resistance,O
in,O
the,O
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
as,O
well,O
as,O
the,O
ovarian,B-body-part
carcinomas,B-disease
.,I-disease
 , 
We,O
hypothesize,O
that,O
MMR,B-gene
inactivation,O
is,O
not,O
clearly,O
associated,O
with,O
intrinsic,O
resistance,O
in,O
ovarian,B-body-part
cancer,I-disease
.,I-disease
 , 
However,O
,,O
it,O
might,O
play,O
a,O
role,O
in,O
acquired,O
resistance,O
due,O
to,O
selection,O
of,O
MMR,B-gene
deficient,O
cells,O
during,O
platinum,O
-,O
based,O
chemotherapy,O
,,O
but,O
this,O
needs,O
further,O
investigation,O
.,O
 , 


,O
 , 
#1334229-03-Methods-p02
K,B-gene
-,I-gene
ras,I-gene
mutation,B-mutation
analysis,O


,O
Mutation,O
analysis,O
of,O
the,O
exon,B-mutation
1,I-mutation
fragment,I-mutation
of,I-mutation
the,I-mutation
K,B-gene
-,I-gene
ras,I-gene
oncogene,I-mutation
,,I-mutation
spanning,I-mutation
codons,I-mutation
8–29,I-mutation
,,I-mutation
was,O
performed,O
on,O
archival,O
colorectal,B-body-part
adenocarcinoma,B-disease
specimens,O
of,O
737,B-size
patients,B-cohort-patient
,,I-cohort-patient
using,O
nested,O
PCR,O
,,O
followed,O
by,O
direct,O
sequencing,O
of,O
purified,O
fragments,O
[,O
27,O
],O
.,O
 , 
The,O
detection,O
limit,O
was,O
5,O
%,O
mutated,O
DNA,O
and,O
duplicate,O
experiments,O
revealed,O
a,O
good,O
reproducibility,O
(,O
88,O
%,O
),O
 , 
[,O
27,O
],O
.,O
 , 


,B-gene
APC,I-gene
mutation,B-mutation
analysis,O


,O
The,O
majority,O
of,O
somatic,B-mutation
mutations,I-mutation
in,O
the,O
APC,B-gene
gene,O
are,O
found,O
within,O
the,O
mutation,O
cluster,O
region,O
(,O
codons,O
1286–1520,O
),O
.,O
 , 
Mutation,O
analysis,O
of,O
the,O
mutation,O
cluster,O
region,O
was,O
performed,O
on,O
adenocarcinoma,B-disease
DNA,O
using,O
nested,O
PCR,O
for,O
amplification,O
of,O
the,O
mutation,O
cluster,O
region,O
as,O
four,O
overlapping,O
DNA,O
fragments,O
followed,O
by,O
direct,O
sequencing,O
of,O
purified,O
fragments,O
,,O
as,O
previously,O
described,O
[,O
28,O
],O
.,O
 , 
An,O
alternative,O
nested,O
PCR,O
strategy,O
was,O
performed,O
when,O
nested,O
PCR,O
failed,O
for,O
any,O
of,O
the,O
fragments,O
,,O
using,O
different,O
primers,O
.,O
 , 
The,O
detection,O
limit,O
was,O
5,O
%,O
mutated,O
DNA,O
and,O
duplicate,O
experiments,O
revealed,O
good,O
reproducibility,O
(,O
85%)[28,O
],O
.,O
 , 
From,O
72,B-size
of,I-size
the,I-size
737,I-size
patients,B-cohort-patient
with,O
sufficient,O
DNA,O
yield,O
,,O
one,O
or,O
more,O
fragments,O
of,O
the,O
mutation,O
cluster,O
region,O
could,O
not,O
be,O
amplified,O
and,O
these,O
patients,B-cohort-patient
were,O
not,O
included,O
in,O
this,O
study,O
.,O
 , 


,B-gene
CTNNB1,I-gene
mutation,B-mutation
analysis,O


,O
All,O
464,B-size
samples,B-cohort-patient
without,B-Physiology
a,I-Physiology
truncating,I-Physiology
APC,B-gene
mutation,I-Physiology
(,O
n,O
=,O
411,B-size
),I-size
and,O
all,O
samples,B-cohort-patient
with,O
absent,B-Physiology
hMLH1,B-gene
expression,I-Physiology
(,O
n,O
=,O
58,B-size
),I-size
were,O
analysed,O
for,O
mutations,B-mutation
in,I-mutation
the,I-mutation
phosphorylation,I-mutation
sites,I-mutation
at,I-mutation
codons,I-mutation
33,I-mutation
,,I-mutation
37,I-mutation
,,I-mutation
41,I-mutation
and,I-mutation
45,I-mutation
in,I-mutation
exon,I-mutation
3,I-mutation
of,O
the,O
CTNNB1,B-gene
gene,O
.,O
 , 
This,O
selection,O
was,O
made,O
,,O
since,O
most,O
mutations,O
are,O
expected,O
in,O
these,O
samples,O
.,O
 , 
Tumours,B-disease
lacking,O
truncating,B-mutation
APC,B-gene
mutations,I-mutation
may,O
harbour,O
CTNNB1,B-gene
mutations,B-mutation
[,O
7,O
],O
,,O
and,O
microsatellite,B-Disorder
instable,I-Disorder
tumours,B-disease
are,O
also,O
expected,O
to,O
more,O
frequently,O
have,O
mutations,B-mutation
in,O
CTNNB1,B-gene
[,O
26,O
],O
.,O
 , 


,O
Amplification,O
of,O
exon,O
3,O
of,O
the,O
CTNNB1,B-gene
gene,O
entailed,O
a,O
semi,O
-,O
nested,O
PCR,O
strategy,O
,,O
which,O
covered,O
codons,O
33,O
,,O
37,O
,,O
41,O
and,O
45,O
.,O
 , 
Flank,O
PCR,O
was,O
performed,O
to,O
generate,O
a,O
308,O
bp,O
fragment,O
(,O
primers,O
,,O
forward,O
:,O
5'-CCAATCTACTAATGCTAATACTG-3,O
',O
,,O
reverse,O
:,O
5'-GCATTCTGACTTTCAGTAAGGC-3,O
',O
),O
that,O
was,O
used,O
in,O
a,O
1:100,O
dilution,O
for,O
amplification,O
of,O
the,O
final,O
PCR,O
product,O
(,O
primers,O
,,O
forward,O
:,O
5'-CCAATCTACTAATGCTAATACTG-3,O
',O
,,O
reverse,O
:,O
5'-CTTCCTCAGGATTGCCTTTACC-3,O
',O
),O
.,O
 , 
In,O
each,O
PCR,O
,,O
one,O
round,O
of,O
35,O
cycles,O
was,O
performed,O
.,O
 , 


,O
The,O
semi,O
-,O
nested,O
PCR,O
products,O
from,O
samples,O
without,O
a,O
truncating,B-mutation
APC,B-gene
mutation,I-mutation
were,O
screened,O
for,O
mutations,O
using,O
denaturing,O
high,O
-,O
pressure,O
liquid,O
chromatography,O
(,O
dHPLC,O
),O
on,O
a,O
WAVE,O
3500,O
HT,O
system,O
(,O
Transgenomic,O
Inc.,O
,,O
UK,O
),O
.,O
 , 
WAVE,O
analysis,O
was,O
optimised,O
and,O
validated,O
using,O
specific,O
mutations,O
in,O
cell,O
line,O
DNA,O
,,O
i.e.,O
HCT116,O
(,B-mutation
codon,I-mutation
45,I-mutation
:,I-mutation
3,I-mutation
bp,I-mutation
deletion,I-mutation
),I-mutation
and,O
SW48,O
(,B-mutation
codon,I-mutation
33,I-mutation
:,I-mutation
C→A,I-mutation
),I-mutation
as,O
well,O
as,O
DNA,O
derived,O
from,O
desmoid,B-Disorder
tumours,B-disease
from,O
patients,B-cohort-patient
(,B-mutation
codon,I-mutation
41,I-mutation
:,I-mutation
A→G,I-mutation
and,O
codon,B-mutation
45,I-mutation
:,I-mutation
C→T,I-mutation
),I-mutation
as,O
positive,B-cohort-patient
controls,I-cohort-patient
.,I-cohort-patient
 , 
All,O
of,O
these,O
mutations,O
were,O
repeatedly,O
confirmed,O
by,O
sequencing,O
.,O
 , 
WAVE,O
analysis,O
was,O
carried,O
out,O
at,O
two,O
different,O
temperatures,O
(,O
57.7,O
en,O
60,O
°,O
C,O
),O
.,O
 , 
Samples,O
showing,O
an,O
aberrant,O
elution,O
profile,O
were,O
re,O
-,O
amplified,O
and,O
re,O
-,O
screened,O
.,O
 , 
When,O
an,O
aberrant,O
elution,O
profile,O
was,O
confirmed,O
,,O
direct,O
sequencing,O
was,O
performed,O
.,O
 , 
All,O
samples,B-cohort-patient
without,B-Physiology
hMLH1,B-gene
expression,I-Physiology
were,O
analysed,O
by,O
direct,O
sequencing,O
without,O
screening,O
.,O
 , 
The,O
sequence,O
profile,O
was,O
analysed,O
on,O
an,O
ALFexpress,O
II,O
DNA,O
analysis,O
system,O
using,O
ALFwin,O
software,O
(,O
Amersham,O
Biosciences,O
,,O
Roosendaal,O
,,O
the,O
Netherlands,O
),O
.,O
 , 


,O
 , 
#1334229-03-Methods-p03
hMLH1,B-gene
expression,O


,O
Formalin,O
-,O
fixed,O
,,O
paraffin,O
-,O
embedded,O
tissue,O
sections,O
cut,O
at,O
4,O
μm,O
,,O
which,O
included,O
tumour,B-disease
tissue,O
with,O
normal,O
adjacent,O
mucosa,O
,,O
were,O
used,O
for,O
immunohistochemistry,O
.,O
 , 
Endogenous,O
peroxidase,O
activity,O
was,O
blocked,O
by,O
3,O
%,O
H2O2,O
.,O
 , 
Slides,O
were,O
submitted,O
to,O
microwave,O
antigen,O
retrieval,O
in,O
1,O
mM,O
EDTA,O
buffer,O
(,O
pH,O
8.0,O
),O
and,O
incubated,O
with,O
10,O
%,O
normal,O
horse,O
serum,O
for,O
ten,O
min,O
at,O
room,O
temperature,O
.,O
 , 
Then,O
,,O
sections,O
were,O
incubated,O
overnight,O
at,O
4,O
°,O
C,O
with,O
mouse,O
monoclonal,O
antibodies,O
against,O
hMLH1,B-gene
protein,O
(,O
clone,O
G168,O
-,O
15,O
,,O
PharMingen,O
,,O
San,O
Diego,O
,,O
CA,O
),O
at,O
a,O
1:100,O
dilution,O
.,O
 , 
Antibody,O
binding,O
was,O
detected,O
by,O
incubating,O
the,O
sections,O
at,O
room,O
temperature,O
with,O
the,O
peroxidase,O
-,O
labelled,O
DAKO,O
Envision,O
System,O
(,O
DAKO,O
,,O
Carpinteris,O
,,O
CA,O
),O
,,O
using,O
DAB,O
as,O
a,O
chromogen,O
.,O
 , 
Sections,O
were,O
counterstained,O
with,O
diluted,O
haematoxylin,O
.,O
 , 


,B-disease
Lesions,I-disease
were,O
considered,O
to,O
lack,B-Physiology
hMLH1,B-gene
protein,I-Physiology
expression,I-Physiology
when,O
unequivocal,O
absence,B-Phenomena
of,I-Phenomena
nuclear,I-Phenomena
staining,I-Phenomena
of,O
the,O
tumour,B-disease
epithelial,O
cells,O
was,O
observed,O
.,O
 , 
Nuclear,O
staining,O
of,O
normal,O
epithelial,O
and,O
stromal,O
cells,O
or,O
lymphocytes,O
served,O
as,O
an,O
internal,O
positive,O
control,O
.,O
 , 
Staining,O
was,O
scored,O
independently,O
by,O
at,O
least,O
two,O
observers,O
and,O
in,O
case,O
of,O
discordant,O
results,O
discussed,O
with,O
a,O
pathologist,O
until,O
consensus,O
was,O
reached,O
.,O
 , 
hMLH1,B-Physiology
expression,I-Physiology
could,O
be,O
determined,O
in,O
724,B-size
of,I-size
737,I-size
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
BAT-26,O


,O
Analysis,O
of,O
the,O
BAT-26,O
mononucleotide,O
repeat,O
was,O
performed,O
in,O
a,O
random,O
sample,O
of,O
tumour,B-disease
specimens,O
from,O
114,B-size
patients,B-cohort-patient
,,I-cohort-patient
and,O
a,O
series,O
of,O
48,B-size
of,I-size
58,I-size
tumours,B-cohort-patient
that,O
lacked,B-Physiology
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
to,O
assess,O
the,O
concordance,O
between,O
the,O
microsatellite,O
instability,O
marker,O
BAT-26,O
and,O
hMLH1,B-Physiology
expression,I-Physiology
.,I-Physiology
 , 
The,O
primer,O
sequences,O
and,O
PCR,O
conditions,O
for,O
the,O
BAT-26,O
mononucleotide,O
repeat,O
were,O
used,O
as,O
described,O
previously,O
[,O
31,O
],O
.,O
 , 


,O
Statistical,O
analysis,O


,O
In,O
the,O
statistical,O
analysis,O
,,O
data,O
from,O
656,B-size
patients,B-cohort-patient
for,O
whom,O
information,O
on,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
mutation,B-mutation
status,O
as,O
well,O
as,O
hMLH1,B-Physiology
expression,I-Physiology
was,O
complete,O
were,O
included,O
.,O
 , 


,O
The,O
χ2,O
test,O
and,O
Cramérs,O
V,O
test,O
were,O
used,O
to,O
estimate,O
the,O
association,O
of,O
the,O
co,O
-,O
occurrence,O
of,O
K,B-gene
-,I-gene
ras,I-gene
and,O
APC,B-gene
gene,O
mutations,B-mutation
.,I-mutation
 , 
Characteristics,O
of,O
patients,B-cohort-patient
(,O
age,O
at,O
diagnosis,O
,,O
sex,O
,,O
family,O
history,O
of,O
colorectal,B-body-part
cancer,B-disease
),I-disease
and,O
tumours,B-disease
(,B-disease
tumour,I-disease
sub,O
-,O
localisation,O
,,O
Dukes,O
',O
stage,O
and,O
tumour,B-disease
differentiation,O
),O
were,O
compared,O
between,O
patients,B-cohort-patient
with,O
and,O
without,O
an,O
activating,B-mutation
K,B-gene
-,I-gene
ras,I-gene
or,O
a,O
truncating,B-mutation
APC,I-mutation
mutation,I-mutation
as,O
well,O
as,O
patients,B-cohort-patient
harbouring,O
tumours,B-disease
with,B-Physiology
and,I-Physiology
without,I-Physiology
hMLH1,I-Physiology
expression,I-Physiology
,,I-Physiology
using,O
Students,O
T,O
-,O
test,O
(,O
age,O
at,O
diagnosis,O
),O
and,O
χ2,O
tests,O
(,O
sex,O
,,O
family,O
history,O
of,O
colorectal,B-body-part
cancer,B-disease
,,I-disease
tumour,B-disease
sub,O
-,O
localisation,O
,,O
Dukes,O
',O
stage,O
and,O
differentiation,O
),O
.,O
 , 
Additionally,O
,,O
patient,B-cohort-patient
and,O
tumour,B-disease
characteristics,O
of,O
tumours,B-disease
with,O
an,O
activating,B-mutation
K,B-gene
-,I-gene
ras,I-gene
and/or,O
a,O
truncating,B-mutation
APC,I-mutation
mutation,I-mutation
were,O
compared,O
to,O
tumours,B-disease
lacking,B-Physiology
hMLH1,I-Physiology
expression,I-Physiology
.,I-Physiology
 , 
All,O
P,O
-,O
values,O
are,O
reported,O
for,O
a,O
two,O
-,O
sided,O
test,O
;,O
P,O
-,O
values,O
of,O
less,O
than,O
0.05,O
were,O
considered,O
to,O
be,O
statistically,O
significant,O
.,O
 , 


,O
 , 
#3034663-03-Methods-p01
Methods,O


,B-cohort-patient
Controls,I-cohort-patient
and,O
sporadic,B-Concepts_Ideas
and,O
familial,B-Concepts_Ideas
CRC,B-disease
cases,B-cohort-patient


,I-cohort-patient
We,O
genotyped,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
in,O
MLH1,B-gene
in,O
1034,B-size
individuals,B-cohort-patient
(,B-size
373,I-size
sporadic,B-Concepts_Ideas
CRC,B-disease
patients,B-cohort-patient
,,I-cohort-patient
250,B-size
index,B-cohort-patient
subjects,I-cohort-patient
from,O
families,O
suspected,O
of,O
having,O
LS,B-disease
[,O
revised,O
Bethesda,O
Guidelines,O
],O
and,O
411,B-size
controls,B-cohort-patient
),I-cohort-patient
.,O
 , 
The,O
controls,B-cohort-patient
were,O
selected,O
from,O
the,O
same,O
hospitals,O
,,O
had,O
no,O
personal,O
histories,O
of,O
cancer,B-disease
and,O
had,O
diagnoses,O
unrelated,O
to,O
the,O
variables,O
of,O
interest,O
.,O
 , 
They,O
were,O
matched,O
for,O
age,O
,,O
gender,O
and,O
race,O
/,O
ethnicity,O
with,O
the,O
sporadic,B-Concepts_Ideas
CRC,B-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
No,O
familial,O
history,O
of,O
cancer,B-disease
was,O
available,O
from,O
the,O
control,B-cohort-patient
group,I-cohort-patient
.,I-cohort-patient
 , 
Patients,B-cohort-patient
diagnosed,O
at,O
an,O
age,O
over,B-age
50,I-age
years,I-age
and,O
not,O
referred,O
to,O
Genetic,O
Counselling,O
Units,O
were,O
considered,O
as,O
sporadic,B-Concepts_Ideas
CRC,B-disease
.,I-disease
 , 
Samples,O
from,O
sporadic,B-Concepts_Ideas
CRC,B-disease
patients,B-cohort-patient
were,O
obtained,O
from,O
the,O
Elche,O
University,O
Hospital,O
BioBank,O
and,O
the,O
Castellon,O
Provincial,O
Hospital,O
BioBank,O
.,O
 , 
Written,O
consent,O
to,O
be,O
included,O
in,O
the,O
respective,O
biobanks,O
was,O
obtained,O
from,O
each,O
patient,B-cohort-patient
.,I-cohort-patient
 , 
CRC,B-disease
patients,B-cohort-patient
,,I-cohort-patient
as,O
index,B-cohort-patient
subjects,I-cohort-patient
from,O
families,O
with,O
suspicion,O
of,O
LS,B-disease
that,O
attended,O
Genetic,O
Counselling,O
at,O
the,O
Cancer,O
Units,O
of,O
the,O
Elche,O
and,O
La,O
Fe,O
Hospitals,O
,,O
were,O
recruited,O
.,O
 , 
The,O
study,O
was,O
approved,O
by,O
the,O
Ethics,O
Committee,O
of,O
the,O
Elche,O
University,O
Hospital,O
.,O
 , 


,O
The,O
median,O
age,O
of,O
patients,B-cohort-patient
in,O
the,O
sporadic,B-Concepts_Ideas
CRC,B-disease
group,B-cohort-patient
was,O
70,B-age
years,I-age
(,B-age
range,I-age
,,I-age
52,I-age
-,I-age
93,I-age
years,I-age
),I-age
,,O
47,B-age
years,I-age
(,B-age
range,I-age
,,I-age
21,I-age
-,I-age
87,I-age
years,I-age
),I-age
for,O
the,O
familial,B-Concepts_Ideas
group,I-cohort-patient
and,O
71,B-age
years,I-age
(,B-age
range,I-age
,,I-age
25,I-age
-,I-age
96,I-age
years,I-age
),I-age
for,O
the,O
controls,B-cohort-patient
.,I-cohort-patient
 , 
The,O
sex,O
distribution,O
was,O
58,B-size
%,I-size
men,B-cohort-patient
and,O
42,B-size
%,I-size
women,B-gender
for,O
the,O
sporadic,B-Concepts_Ideas
CRC,B-disease
group,B-cohort-patient
and,O
53.3,B-size
%,I-size
men,B-gender
and,O
46.7,B-size
%,I-size
women,B-cohort-patient
for,O
the,O
controls,B-cohort-patient
.,I-cohort-patient
 , 


,B-cohort-patient
Families,I-cohort-patient
carrying,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
 , 
variant,O


,B-size
Three,I-size
characterized,O
LS,B-disease
families,B-cohort-patient
that,O
fulfilled,O
the,O
Amsterdam,O
II,O
Criteria,O
and,O
that,O
consisted,O
of,O
members,O
with,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
were,O
included,O
to,O
assess,O
co,O
-,O
occurrence,O
and,O
co,O
-,O
segregation,O
.,O
 , 
Two,B-size
families,B-cohort-patient
attended,O
the,O
Genetic,O
Counselling,O
in,O
Cancer,O
Units,O
of,O
the,O
Elche,O
and,O
La,O
Fe,O
Hospitals,O
and,O
one,B-size
family,B-cohort-patient
was,O
a,O
member,O
of,O
the,O
EPICOLON,O
cohort,O
 , 
[,O
7,O
],O
.,O
 , 


,O
Concomitant,O
deleterious,O
variants,O
were,O
detected,O
in,O
two,B-size
of,O
the,O
families,B-cohort-patient
:,I-cohort-patient
one,O
in,O
the,O
MLH1,B-gene
gene,O
(,B-mutation
c.676C,I-mutation
>,I-mutation
T,I-mutation
;,I-mutation
p.,B-mutation
Arg226X,I-mutation
),I-mutation
and,O
the,O
other,O
in,O
the,O
MSH6,B-gene
gene,O
(,B-mutation
c.3013C,I-mutation
>,I-mutation
T,I-mutation
;,I-mutation
p.,B-mutation
Arg1005X,I-mutation
),I-mutation
.,O
 , 
Seventeen,B-size
affected,B-disease
and,O
unaffected,B-disease
family,B-cohort-patient
members,O
from,O
these,O
two,B-size
families,B-cohort-patient
were,O
tested,O
for,O
the,O
pathogenic,O
and,O
p.,B-mutation
Lys618Ala,I-mutation
variants,O
.,O
 , 


,O
Genotyping,O
of,O
the,O
MLH1,B-gene
p.,B-mutation
Lys618Ala,I-mutation
variant,O


,O
DNA,O
from,O
blood,B-body-part
cells,I-body-part
(,B-Concepts_Ideas
familial,I-Concepts_Ideas
cancer,B-disease
cases,B-cohort-patient
and,O
controls,B-cohort-patient
),I-cohort-patient
or,O
colorectal,B-body-part
mucosa,O
of,O
normal,O
appearance,O
(,B-Concepts_Ideas
sporadic,I-Concepts_Ideas
cases,I-cohort-patient
),I-cohort-patient
was,O
used,O
for,O
the,O
c.1852_1853AA,B-mutation
>,I-mutation
GC,I-mutation
variant,O
genotyping,O
.,O
 , 
This,O
was,O
assessed,O
using,O
the,O
iPLEX,O
Gold,O
method,O
(,O
Sequenom,O
,,O
CA,O
,,O
USA,O
),O
,,O
in,O
which,O
single,O
-,O
base,O
extension,O
and,O
MALDI,O
-,O
TOF,O
technology,O
are,O
employed,O
for,O
allelic,O
discrimination,O
.,O
 , 
These,O
experiments,O
were,O
carried,O
out,O
at,O
the,O
Centro,O
Español,O
de,O
Genotipado,O
(,O
CEGEN,O
),O
genotyping,O
platform,O
facilities,O
.,O
 , 
Quality,O
control,O
for,O
genotyping,O
was,O
conducted,O
by,O
direct,O
sequencing,O
of,O
familial,B-Concepts_Ideas
cancer,B-disease
subjects,B-cohort-patient
who,O
underwent,O
genetic,O
analysis,O
for,O
MLH1,B-gene
(,B-size
49/1034,I-size
,,I-size
4.7,B-size
%,I-size
),I-size
.,O
 , 


,O
 , 
#1619718-04-Results-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O


,B-gene
KRAS,I-gene
and,O
BRAF,B-gene
mutation,B-mutation


,I-mutation
DNA,O
failed,O
to,O
amplify,O
in,O
the,O
KRAS,B-gene
assay,O
for,O
one,B-size
SSA,B-disease
and,O
one,B-size
TA,B-cohort-patient
<,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
Overall,O
,,O
34,B-size
of,I-size
188,I-size
polyps,B-cohort-patient
(,B-size
18,I-size
%,I-size
),I-size
had,O
mutation,B-mutation
of,O
KRAS,B-gene
.,I-gene
 , 
Twenty,B-size
-,I-size
eight,I-size
mutations,I-mutation
were,I-mutation
in,I-mutation
codon,I-mutation
12,I-mutation
(,I-mutation
20,I-mutation
G→A,I-mutation
,,I-mutation
seven,I-mutation
G→T,I-mutation
and,I-mutation
one,I-mutation
G→C,I-mutation
),I-mutation
and,I-mutation
six,B-size
mutations,I-mutation
were,I-mutation
in,I-mutation
codon,I-mutation
13,I-mutation
(,I-mutation
all,I-mutation
G→A,I-mutation
),I-mutation
.,I-mutation
 , 
One,B-size
serrated,B-Concepts_Ideas
adenoma,B-disease
had,O
two,B-size
KRAS,B-gene
mutations,O
in,O
codon,B-mutation
12,I-mutation
(,I-mutation
G→T,I-mutation
at,I-mutation
position,I-mutation
35,I-mutation
and,I-mutation
T→G,I-mutation
at,I-mutation
position,I-mutation
36,I-mutation
),I-mutation
.,I-mutation
 , 
BRAF,B-gene
mutation,O
at,O
V600E,B-mutation
could,O
be,O
assessed,O
in,O
all,O
polyps,B-disease
except,O
for,O
a,O
single,B-size
TA,B-disease
<,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
BRAF,B-gene
mutation,B-mutation
was,O
found,O
in,O
82,B-size
of,I-size
189,I-size
polyps,B-disease
(,B-size
43,I-size
%,I-size
),I-size
.,O
 , 
BRAF,B-gene
and,O
KRAS,B-gene
mutations,B-mutation
were,O
negatively,O
correlated,O
,,O
with,O
only,O
four,B-size
polyps,B-cohort-patient
having,O
both,B-mutation
mutations,I-mutation
(,B-size
two,I-size
TAs,B-disease
,,I-disease
one,B-size
TVA,B-cohort-patient
and,O
one,B-size
SSA,B-cohort-patient
),I-cohort-patient
.,O
 , 
The,O
three,B-size
conventional,B-Concepts_Ideas
adenomas,B-disease
with,O
mutations,B-mutation
of,O
both,O
BRAF,B-gene
and,O
KRAS,B-gene
were,O
among,O
only,O
four,B-size
adenomas,B-disease
that,O
had,O
any,O
BRAF,B-gene
mutations,B-mutation
at,O
all,O
.,O
 , 
Mutation,B-mutation
frequencies,O
for,O
both,O
KRAS,B-gene
and,O
BRAF,B-gene
were,O
distributed,O
differently,O
across,O
the,O
seven,B-size
polyp,B-disease
groups,B-cohort-patient
(,O
Table,O
1,O
),O
.,O
 , 


,O
Frequency,O
of,O
KRAS,B-gene
and,O
BRAF,B-gene
mutation,B-mutation
and,O
loss,O
of,O
expression,O
of,O
O-6,B-gene
-,I-gene
methylguanine,I-gene
DNA,I-gene
methyltransferase,I-gene
(,B-gene
MGMT,I-gene
),I-gene
by,O
polyp,B-disease
type,O


,O
Mutation,O
frequencies,O
for,O
both,O
KRAS,B-gene
(,O
P,O
<,O
0.0001,O
),O
and,O
BRAF,B-gene
(,O
P,O
<,O
0.0001,O
),O
are,O
distributed,O
differently,O
across,O
the,O
seven,B-size
classes,B-cohort-patient
of,O
polyp,B-disease
(,O
see,O
Results,O
for,O
individual,O
comparisons,O
),O
.,O
 , 
Distribution,O
of,O
MGMT,B-gene
loss,I-Physiology
differs,O
across,O
the,O
seven,B-size
classes,B-cohort-patient
of,O
polyp,B-disease
(,O
P,O
<,O
0.001,O
),O
.,O
 , 


,O
Note,O
:,O
no,O
result,O
for,O
KRAS,B-gene
in,O
one,B-size
sessile,B-Concepts_Ideas
serrated,B-Concepts_Ideas
adenoma,B-cohort-patient
(,B-disease
SSA,I-disease
),I-disease
and,O
one,B-size
tubular,B-Concepts_Ideas
adenoma,B-cohort-patient
(,B-disease
TA,I-disease
),I-disease
or,O
for,O
BRAF,B-gene
in,O
one,B-size
TA,B-disease
.,I-disease
 , 
MGMT,B-gene
immunstaining,O
not,O
performed,O
in,O
15,B-size
polyps,B-disease
(,B-size
seven,I-size
HPs,B-disease
,,I-disease
one,B-size
SSA,B-disease
,,I-disease
one,B-size
MP,B-disease
and,O
six,B-size
TAs,B-disease
),I-disease
.,O
 , 


,B-gene
KRAS,I-gene
mutation,B-mutation
occurred,O
in,O
26.5,B-size
%,I-size
and,O
BRAF,B-gene
mutation,B-mutation
in,O
4.8,B-size
%,I-size
of,O
adenomas,B-disease
(,O
all,O
types,O
),O
 , 
(,O
Table,O
1,O
),O
(,O
P,O
<,O
0.0001,O
),O
.,O
 , 
TVAs,B-cohort-patient
/,I-cohort-patient
VAs,I-cohort-patient
were,O
more,O
likely,O
to,O
have,O
KRAS,B-gene
mutation,B-mutation
(,B-size
50,I-size
%,I-size
),I-size
than,O
TAs,B-cohort-patient
<,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
(,B-size
18,I-size
%,I-size
),I-size
 , 
(,O
P,O
<,O
0.004,O
),O
or,O
TAS,B-cohort-patient
>,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
in,O
diameter,O
(,B-size
17,I-size
%,I-size
),I-size
 , 
(,O
P,O
<,O
0.02,O
),O
.,O
 , 
In,O
the,O
case,O
of,O
TAs,B-disease
there,O
was,O
a,O
trend,O
for,O
KRAS,B-gene
mutation,B-mutation
to,O
occur,O
more,O
frequently,O
in,O
polyps,B-disease
from,O
the,O
proximal,B-body-part
colon,I-body-part
(,O
P,O
=,O
0.08,O
),O
and,O
in,O
females,B-gender
(,O
P,O
=,O
0.07,O
),O
.,O
 , 


,B-disease
SSAs,I-disease
were,O
more,O
likely,O
to,O
have,O
BRAF,B-gene
mutation,B-mutation
(,B-size
81,I-size
%,I-size
),I-size
than,O
either,O
SAs,B-cohort-patient
(,B-size
33,I-size
%,I-size
),I-size
(,O
P,O
<,O
0.001,O
),O
or,O
MPs,B-cohort-patient
(,B-size
40,I-size
%,I-size
),I-size
(,O
P,O
<,O
0.02,O
),O
.,O
 , 
KRAS,B-gene
mutation,B-mutation
was,O
infrequent,O
among,O
both,O
SSAs,B-cohort-patient
(,B-size
3,I-size
%,I-size
),I-size
and,O
HPs,B-disease
(,B-size
4,I-size
%,I-size
),I-size
(,O
Table,O
1,O
),O
.,O
 , 
Patient,O
age,O
,,O
gender,O
and,O
anatomical,O
location,O
were,O
not,O
predictors,O
of,O
BRAF,B-gene
mutation,B-mutation
in,O
either,O
SSAs,B-disease
or,O
HPs,B-disease
.,I-disease
 , 
The,O
mean,O
age,O
of,O
subjects,B-cohort-patient
with,O
SSAs,B-disease
(,B-age
64,I-age
years,I-age
),I-age
differed,O
from,O
that,O
of,O
subjects,B-cohort-patient
with,O
HPs,B-disease
(,B-age
55,I-age
years,I-age
),I-age
(,O
P,O
<,O
0.001,O
),O
.,O
 , 


,O
 , 
#1334229-05-Discussion-p01
Discussion,O


,O
In,O
this,O
study,O
,,O
the,O
occurrence,O
of,O
mutations,B-mutation
in,O
the,O
APC,B-gene
,,I-gene
CTNNB1,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
genes,O
as,O
well,O
as,O
expression,B-Physiology
of,I-Physiology
the,I-Physiology
hMLH1,B-gene
protein,I-Physiology
in,O
tumour,B-disease
tissue,O
of,O
656,B-size
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancer,B-disease
cases,B-cohort-patient
were,O
investigated,O
.,O
 , 
The,O
occurrence,O
of,O
mutations,B-mutation
in,O
the,O
CTNNB1,B-gene
gene,O
,,O
which,O
codes,O
for,O
β,O
-,O
catenin,O
,,O
was,O
rare,O
:,O
only,O
five,B-size
of,I-size
464,I-size
tumours,B-cohort-patient
analysed,O
were,O
found,O
to,O
have,O
a,O
mutation,B-mutation
at,I-mutation
one,I-mutation
of,I-mutation
the,I-mutation
phosphorylation,I-mutation
sites,I-mutation
in,I-mutation
exon,I-mutation
3,I-mutation
.,I-mutation
 , 
Truncating,B-mutation
mutations,I-mutation
in,O
APC,B-gene
and,O
activating,B-mutation
mutations,I-mutation
in,O
K,B-gene
-,I-gene
ras,I-gene
appeared,O
to,O
occur,O
at,O
similar,O
frequencies,O
.,O
 , 
Although,O
tumours,B-disease
harbouring,O
both,O
mutations,O
were,O
relatively,O
rare,O
,,O
mutations,B-mutation
in,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
seemed,O
to,O
occur,O
co,O
-,O
dependently,O
.,O
 , 
Nine,B-size
percent,I-size
of,O
all,O
tumours,B-cohort-patient
(,B-size
58/656,I-size
),I-size
lacked,B-Physiology
hMLH1,I-Physiology
expression,I-Physiology
,,I-Physiology
and,O
in,O
these,O
tumours,B-disease
almost,O
no,O
APC,B-gene
or,O
K,B-gene
-,I-gene
ras,I-gene
mutations,B-mutation
was,O
detected,O
.,O
 , 
Patients,B-cohort-patient
harbouring,O
a,O
tumour,B-disease
with,O
absent,B-Physiology
hMLH1,I-Physiology
expression,I-Physiology
were,O
older,B-age
,,I-age
more,B-Concepts_Ideas
often,I-Concepts_Ideas
women,I-Concepts_Ideas
,,I-Concepts_Ideas
more,O
often,O
had,O
proximal,B-body-part
colon,I-body-part
tumours,B-disease
that,O
showed,O
poorer,O
differentiation,O
when,O
compared,O
to,O
patients,B-cohort-patient
who,O
harboured,O
a,O
tumour,B-disease
with,O
an,O
APC,B-gene
and/or,O
K,B-gene
-,I-gene
ras,I-gene
mutation,B-mutation
.,I-mutation
 , 


,O
The,O
selection,O
of,O
patients,B-cohort-patient
included,O
in,O
this,O
study,O
was,O
based,O
on,O
the,O
completeness,O
of,O
analyses,O
of,O
both,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
genes,O
as,O
well,O
as,O
hMLH1,B-Physiology
expression,I-Physiology
and,O
this,O
led,O
to,O
a,O
considerable,O
reduction,O
in,O
the,O
number,O
of,O
cases,B-cohort-patient
that,O
could,O
be,O
included,O
in,O
the,O
analyses,O
presented,O
in,O
this,O
study,O
.,O
 , 
The,O
largest,O
reduction,O
(,B-size
72,I-size
cases,B-cohort-patient
),I-cohort-patient
was,O
due,O
to,O
incompleteness,O
of,O
the,O
analysis,O
of,O
all,O
fragments,O
comprising,O
the,O
APC,B-gene
mutation,O
cluster,O
region,O
.,O
 , 
Tumour,B-disease
DNA,O
was,O
derived,O
from,O
formalin,O
-,O
fixed,O
,,O
paraffin,O
-,O
embedded,O
tumour,B-disease
tissue,O
blocks,O
.,O
 , 
Depending,O
on,O
the,O
conditions,O
of,O
fixation,O
and,O
storage,O
,,O
the,O
extracted,O
DNA,O
is,O
more,O
or,O
less,O
fragmented,O
,,O
which,O
may,O
have,O
impaired,O
the,O
analysis,O
of,O
mutations,O
in,O
the,O
APC,B-gene
gene,O
more,O
than,O
in,O
the,O
K,B-gene
-,I-gene
ras,I-gene
gene,O
,,O
since,O
the,O
analysis,O
of,O
the,O
latter,O
is,O
based,O
on,O
the,O
amplification,O
of,O
a,O
smaller,O
gene,O
fragment,O
.,O
 , 
It,O
should,O
be,O
emphasized,O
that,O
characteristics,O
of,O
patients,B-cohort-patient
(,O
age,O
,,O
sex,O
,,O
family,O
history,O
of,O
colorectal,B-body-part
cancer,I-disease
),I-disease
and,O
tumours,B-disease
(,O
sub,O
-,O
localisation,O
,,O
Dukes,O
',O
stage,O
and,O
differentiation,O
),O
of,O
the,O
group,B-cohort-patient
under,O
study,O
are,O
similar,O
to,O
the,O
737,B-size
patients,B-cohort-patient
for,O
whom,O
tumour,B-disease
material,O
was,O
available,O
and,O
to,O
all,O
819,B-size
patients,B-cohort-patient
initially,O
recognized,O
within,O
the,O
cohort,B-cohort-patient
(,O
data,O
not,O
shown,O
),O
.,O
 , 
Moreover,O
,,O
the,O
K,B-gene
-,I-gene
ras,I-gene
and,O
hMLH1data,B-gene
presented,O
here,O
are,O
similar,O
to,O
the,O
data,O
for,O
K,B-gene
-,I-gene
ras,I-gene
and,O
hMLH1,B-gene
based,O
on,O
the,O
complete,O
groups,B-cohort-patient
(,B-size
737,I-size
and,O
724,B-size
cases,B-cohort-patient
,,I-cohort-patient
respectively,O
),O
(,O
data,O
not,O
shown,O
),O
.,O
 , 


,B-mutation
Mutations,I-mutation
in,I-mutation
exon,I-mutation
3,I-mutation
of,O
the,O
CTNNB1,B-gene
gene,O
leading,O
to,O
loss,O
of,O
one,O
of,O
the,O
phosphorylation,O
sites,O
were,O
rare,O
.,O
 , 
Strikingly,O
,,O
all,O
five,B-size
of,O
these,O
mutations,B-mutation
occurred,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
and,O
three,B-size
of,I-size
these,I-size
also,O
had,O
absent,B-Physiology
hMLH1,I-Physiology
expression,I-Physiology
.,I-Physiology
 , 
This,O
may,O
indicate,O
that,O
these,O
proximal,B-body-part
colon,I-body-part
tumours,B-disease
,,I-disease
which,O
often,O
also,O
show,O
mismatch,B-Physiology
repair,I-Physiology
deficiency,I-Physiology
,,I-Physiology
are,O
more,O
likely,O
to,O
harbour,O
CTNNB1,B-gene
mutations,B-mutation
.,I-mutation
 , 
This,O
was,O
also,O
found,O
in,O
a,O
study,O
of,O
microsatellite,B-Disorder
instable,I-Disorder
colorectal,B-body-part
tumours,B-disease
[,O
26,O
],O
.,O
 , 
The,O
WAVE,O
screening,O
technique,O
has,O
not,O
been,O
used,O
previously,O
for,O
formalin,O
-,O
fixed,O
,,O
paraffin,O
-,O
embedded,O
tissue,O
,,O
and,O
therefore,O
it,O
seems,O
plausible,O
that,O
samples,O
harbouring,O
a,O
CTNNB1,B-gene
mutation,B-mutation
have,O
escaped,O
detection,O
.,O
 , 
However,O
,,O
all,O
58,B-size
hMLH1,B-gene
deficient,I-Disorder
samples,B-cohort-patient
were,O
analysed,O
by,O
direct,O
sequencing,O
without,O
a,O
prior,O
screening,O
step,O
,,O
and,O
only,O
three,B-size
of,I-size
these,I-size
samples,B-cohort-patient
harboured,O
a,O
CTNNB1,B-gene
mutation,B-mutation
,,I-mutation
indicating,O
the,O
low,O
frequency,O
of,O
such,O
mutations,O
.,O
 , 


,O
 , 
#1619718-03-Materials-and-methods-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Dna,O
extraction,O


,O
Genomic,O
DNA,O
was,O
extracted,O
from,O
archival,O
paraffin,O
-,O
embedded,O
tissue,O
sections,O
using,O
DNeasy,O
Tissue,O
Kit,O
(,O
Qiagen,O
,,O
Hilden,O
,,O
Germany,O
),O
according,O
to,O
the,O
manufacturer,O
's,O
instructions,O
except,O
for,O
the,O
omission,O
of,O
xylene,O
treatment,O
.,O
 , 
Briefly,O
,,O
five,O
4-µm,O
non,O
-,O
microdissected,O
sections,O
(,B-disease
polyps,I-disease
were,O
generally,O
accompanied,O
by,O
little,O
normal,B-disease
mucosa,B-body-part
),I-body-part
and,O
180,O
µl,O
of,O
ATL,O
buffer,O
were,O
dissolved,O
at,O
80,O
°,O
C,O
and,O
then,O
digested,O
overnight,O
with,O
20,O
µl,O
of,O
proteinase,O
K,O
at,O
55,O
°,O
C,O
.,O
 , 
Following,O
centrifugation,O
at,O
2000,O
r.p.m,O
.,O
 , 
(,O
300,O
g,O
),O
for,O
5,O
min,O
,,O
the,O
lower,O
phase,O
was,O
applied,O
to,O
a,O
DNeasy,O
tissue,O
column,O
.,O
 , 
Bound,O
DNA,O
was,O
washed,O
by,O
centrifugation,O
through,O
ethanol,O
and,O
then,O
eluted,O
from,O
the,O
column,O
using,O
AE,O
buffer,O
.,O
 , 


,B-gene
KRAS,I-gene
and,O
BRAF,B-gene
mutations,B-mutation


,B-gene
KRAS,I-gene
mutation,B-mutation
analysis,O
at,O
codons,O
12,O
and,O
13,O
was,O
performed,O
using,O
direct,O
automated,O
sequencing,O
of,O
a,O
fragment,O
containing,O
codon,O
12,O
and,O
13,O
in,O
exon,O
1,O
of,O
the,O
KRAS,B-gene
gene,O
,,O
amplified,O
using,O
a,O
touchdown,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
cycle,O
and,O
hotstart,O
protocol,O
.,O
 , 
PCR,O
products,O
were,O
initially,O
purified,O
and,O
then,O
directly,O
sequenced,O
using,O
BigDye,O
version,O
3.1,O
dye,O
terminators,O
and,O
an,O
ABI,O
3100,O
DNA,O
fragment,O
analyser,O
.,O
 , 
The,O
sequence,O
at,O
codon,O
12,O
and,O
13,O
was,O
determined,O
using,O
Mutation,O
Surveyor,O
(,O
SoftGenetics,O
,,O
State,O
College,O
,,O
PA,O
,,O
USA,O
),O
software,O
.,O
 , 


,B-gene
BRAF,I-gene
mutation,B-mutation
analysis,O
at,O
codon,O
600,O
(,B-mutation
V600E,I-mutation
;,I-mutation
formerly,O
V599E,B-mutation
),I-mutation
was,O
performed,O
by,O
a,O
real,O
-,O
time,O
PCR,O
-,O
based,O
allelic,O
discrimination,O
method,O
as,O
previously,O
described.29,O
Briefly,O
,,O
real,O
-,O
time,O
PCR,O
was,O
performed,O
using,O
allele,O
-,O
specific,O
primers,O
designed,O
to,O
amplify,O
selectively,O
the,O
wild,O
-,O
type,O
(,O
T1796,O
),O
and,O
mutant,O
(,B-mutation
A1796,I-mutation
),I-mutation
BRAF,B-gene
alleles,O
.,O
 , 
The,O
primer,O
sequences,O
were,O
as,O
follows,O
:,O
V,O
,,O
5′-GTGATTTTGGTCTAGCTACtGT,O
;,O
E,O
,,O
5′-CGCGGCCGGCCGCGGCGGTGATTTTGGTCTAGCTACcGA,O
;,O
AS,O
,,O
5′-TAGCCTCAATTCTTACCATCCAC,O
.,O
 , 
PCR,O
amplification,O
and,O
melting,O
curve,O
analysis,O
were,O
performed,O
on,O
a,O
Rotor,O
-,O
gene,O
3000,O
(,O
Corbett,O
Research,O
,,O
NSW,O
,,O
Australia,O
),O
.,O
 , 
Genomic,O
DNA,O
was,O
amplified,O
in,O
a,O
15-µl,O
volume,O
containing,O
1,O
×,O
Platinum,O
SYBR,O
Green,O
qPCR,O
 , 
SuperMix,O
-,O
UDG,O
(,O
Invitrogen,O
,,O
Carlsbad,O
,,O
CA,O
,,O
USA,O
),O
,,O
forward,O
primer,O
V,O
(,O
300,O
nm,O
),O
,,O
forward,O
primer,O
E,O
(,O
900,O
nm,O
),O
and,O
reverse,O
primer,O
 , 
AS,O
(,O
300,O
nm,O
),O
.,O
 , 
The,O
cycling,O
conditions,O
were,O
as,O
follows,O
:,O
50,O
°,O
C,O
for,O
2,O
min,O
,,O
95,O
°,O
C,O
for,O
2,O
min,O
,,O
40,O
cycles,O
of,O
95,O
°,O
C,O
for,O
15,O
s,O
and,O
60,O
°,O
C,O
for,O
60,O
s.,O
After,O
amplification,O
,,O
samples,O
were,O
subjected,O
to,O
a,O
temperature,O
ramp,O
from,O
60,O
°,O
C,O
to,O
99,O
°,O
C,O
,,O
rising,O
1,O
°,O
C,O
each,O
step,O
.,O
 , 
For,O
wild,O
-,O
type,O
samples,O
,,O
single,O
peaks,O
were,O
observed,O
at,O
80,O
°,O
C,O
while,O
samples,O
containing,O
mutant,O
alleles,O
produced,O
single,O
peaks,O
at,O
85,O
°,O
C,O
.,O
 , 


,O
p53,O
immunohistochemistry,O
and,O
scoring,O


,O
This,O
was,O
undertaken,O
on,O
all,O
adenomas,B-disease
and,O
all,O
serrated,B-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
(,B-Concepts_Ideas
traditional,I-Concepts_Ideas
SA,B-disease
and,O
MP,B-disease
),I-disease
.,O
 , 
Most,O
of,O
these,O
polyps,B-disease
had,O
been,O
immunostained,O
previously,O
for,O
MGMT.24,B-gene
Following,O
deparaffinization,O
and,O
rehydration,O
of,O
4-µm,O
sections,O
and,O
antigen,O
retrieval,O
using,O
ethylene,O
diamine,O
tetra,O
-,O
acetic,O
acid,O
and,O
microwaving,O
,,O
the,O
sections,O
were,O
subjected,O
to,O
peroxidase,O
blockade,O
(,O
Dako,O
EnVision,O
bottle,O
1,O
;,O
Mississauga,O
,,O
Canada,O
),O
and,O
then,O
incubated,O
in,O
10,O
%,O
goat,O
serum,O
to,O
minimize,O
non,O
-,O
specific,O
staining,O
.,O
 , 
They,O
were,O
subsequently,O
incubated,O
with,O
the,O
primary,O
anti,O
-,O
p53,O
antibody,O
(,O
DO-7,O
,,O
from,O
DakoCytomation,O
,,O
Mississauga,O
,,O
Canada,O
),O
at,O
a,O
dilution,O
of,O
1,O
:,O
100,O
for,O
60,O
min,O
at,O
37,O
°,O
C,O
.,O
 , 
After,O
washing,O
,,O
the,O
sections,O
were,O
incubated,O
with,O
secondary,O
antibody,O
(,O
EnVision,O
bottle,O
2,O
),O
for,O
30,O
min,O
,,O
washed,O
again,O
and,O
then,O
developed,O
with,O
the,O
chromogen,O
AEC,O
for,O
30,O
min,O
.,O
 , 
Finally,O
,,O
the,O
sections,O
were,O
counterstained,O
with,O
Gill,O
's,O
haematoxylin,O
.,O
 , 
Polyps,B-disease
were,O
scored,O
as,O
showing,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,I-Physiology
if,O
there,O
was,O
complete,O
absence,O
of,O
nuclear,O
expression,O
throughout,O
one,O
or,O
more,O
crypts,O
.,O
 , 
Polyps,B-disease
were,O
scored,O
as,O
positive,O
for,O
aberrant,B-Physiology
p53,B-gene
expression,I-Physiology
if,O
there,O
were,O
distinct,O
subclones,O
characterized,O
by,O
strong,O
nuclear,O
expression,O
that,O
implicated,O
at,O
least,O
50,O
%,O
of,O
nuclei,O
.,O
 , 


,O
 , 
#1601966-03-Results-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Global,O
search,O
for,O
chromosomal,O
islands,O
with,O
up-,O
or,O
down,O
-,O
regulation,O


,O
Chromosome,O
-,O
scale,O
analysis,O
of,O
gene,O
expression,O
(,O
see,O
Figures,O
2,O
,,O
3,O
,,O
4,O
,,O
5,O
),O
already,O
suggested,O
that,O
there,O
are,O
many,O
regions,B-Physiology
of,I-Physiology
misregulated,I-Physiology
expression,I-Physiology
in,O
our,O
CRC,B-disease
samples,B-cohort-patient
.,I-cohort-patient
 , 
The,O
detailed,O
analysis,O
of,O
expression,O
along,O
the,O
chromosome,O
in,O
windows,O
of,O
sizes,O
5,O
,,O
11,O
,,O
21,O
,,O
31,O
,,O
41,O
,,O
51,O
genes,O
resulted,O
in,O
the,O
identification,O
of,O
251,O
partially,O
overlapping,O
intervals,O
of,O
up-,O
or,O
down,O
-,O
regulation,O
(,O
see,O
Additional,O
file,O
1,O
),O
.,O
 , 
These,O
intervals,O
were,O
condensed,O
in,O
81,O
non,O
-,O
overlapping,O
regions,O
of,O
expression,O
imbalance,O
:,O
43,O
regions,O
with,O
loss,O
of,O
expression,O
and,O
38,O
regions,O
with,O
gain,O
of,O
expression,O
(,O
see,O
Table,O
1,O
),O
.,O
 , 
We,O
determined,O
the,O
fraction,O
of,O
affected,O
genes,O
on,O
each,O
chromosome,O
(,O
see,O
Table,O
2,O
),O
.,O
 , 
In,O
total,O
,,O
25.3,O
%,O
of,O
all,O
genes,O
under,O
consideration,O
show,O
expression,O
imbalance,O
.,O
 , 
Slightly,O
more,O
genes,O
lie,O
in,O
chromosomal,O
regions,O
that,O
show,O
loss,O
of,O
expression,O
(,O
13.3,O
%,O
),O
than,O
gain,O
(,O
12,O
%,O
),O
of,O
expression,O
.,O
 , 
The,O
fractions,O
of,O
genes,O
with,O
gain,O
or,O
loss,O
of,O
expression,O
vary,O
strikingly,O
from,O
chromosome,O
to,O
chromosome,O
.,O
 , 
Chromosomes,O
9,O
,,O
10,O
,,O
15,O
,,O
18,O
,,O
and,O
22,O
showed,O
only,O
regional,O
expression,O
loss,O
,,O
whereas,O
8,O
,,O
13,O
,,O
20,O
,,O
and,O
X,O
showed,O
only,O
regional,O
increase,O
in,O
expression,O
.,O
 , 
There,O
were,O
too,O
few,O
informative,O
genes,O
on,O
chromosome,O
Y,O
to,O
carry,O
out,O
a,O
full,O
analysis,O
using,O
all,O
window,O
sizes,O
,,O
but,O
small,O
window,O
sizes,O
did,O
not,O
reveal,O
significant,O
deregulation,O
.,O
 , 


,O
Whole,O
-,O
chromosome,O
plots,O
of,O
running,O
average,O
of,O
fractions,O
of,O
samples,O
showing,O
up-/down,O
-,O
regulation,O
in,O
tumor,B-disease
versus,O
normal,B-disease
samples,B-cohort-patient
(,O
Chromosomes,O
1,O
,,O
2,O
,,O
3,O
,,O
4,O
),O
.,O
 , 
For,O
each,O
chromosome,O
you,O
see,O
a,O
separate,O
figure,O
.,O
 , 
Gray,O
dots,O
denote,O
the,O
number,O
of,O
patients,B-cohort-patient
with,O
up-,O
or,O
down,O
-,O
regulation,O
for,O
a,O
single,O
gene,O
.,O
 , 
Orange,O
/,O
green,O
lines,O
represent,O
a,O
running,O
average,O
of,O
these,O
values,O
.,O
 , 
The,O
plots,O
are,O
made,O
to,O
be,O
easily,O
comparable,O
with,O
whole,O
-,O
genome,O
CGH,O
plots,O
(,O
like,O
e.g.,O
those,O
in,O
Knösel,O
et,O
al,O
.,O
 , 
[,O
21,O
],O
),O
Further,O
details,O
of,O
plot,O
construction,O
are,O
described,O
in,O
the,O
methods,O
section,O
.,O
 , 


,O
Whole,O
-,O
chromosome,O
plots,O
of,O
running,O
average,O
of,O
fractions,O
of,O
samples,O
showing,O
up-/down,O
-,O
regulation,O
in,O
tumor,B-disease
versus,O
normal,B-disease
samples,B-cohort-patient
(,O
Chromosomes,O
5,O
,,O
6,O
,,O
7,O
,,O
8,O
,,O
9,O
,,O
10,O
),O
.,O
 , 
For,O
each,O
chromosome,O
you,O
see,O
a,O
separate,O
figure,O
.,O
 , 
Gray,O
dots,O
denote,O
the,O
number,O
of,O
patients,B-cohort-patient
with,O
up-,O
or,O
down,O
-,O
regulation,O
for,O
a,O
single,O
gene,O
.,O
 , 
Orange,O
/,O
green,O
lines,O
represent,O
a,O
running,O
average,O
of,O
these,O
values,O
.,O
 , 
The,O
plots,O
are,O
made,O
to,O
be,O
easily,O
comparable,O
with,O
whole,O
-,O
genome,O
CGH,O
plots,O
(,O
like,O
e.g.,O
those,O
in,O
Knösel,O
et,O
al,O
.,O
 , 
[,O
21,O
],O
),O
Further,O
details,O
of,O
plot,O
construction,O
are,O
described,O
in,O
the,O
methods,O
section,O
.,O
 , 


,O
Whole,O
-,O
chromosome,O
plots,O
of,O
running,O
average,O
of,O
fractions,O
of,O
samples,O
showing,O
up-/down,O
-,O
regulation,O
in,O
tumor,B-disease
versus,O
normal,B-disease
samples,B-cohort-patient
(,O
Chromosomes,O
11,O
,,O
12,O
,,O
13,O
,,O
14,O
,,O
15,O
,,O
16,O
),O
.,O
 , 
For,O
each,O
chromosome,O
you,O
see,O
a,O
separate,O
figure,O
.,O
 , 
Gray,O
dots,O
denote,O
the,O
number,O
of,O
patients,B-cohort-patient
with,O
up-,O
or,O
down,O
-,O
regulation,O
for,O
a,O
single,O
gene,O
.,O
 , 
Orange,O
/,O
green,O
lines,O
represent,O
a,O
running,O
average,O
of,O
these,O
values,O
.,O
 , 
The,O
plots,O
are,O
made,O
to,O
be,O
easily,O
comparable,O
with,O
whole,O
-,O
genome,O
CGH,O
plots,O
(,O
like,O
e.g.,O
those,O
in,O
Knösel,O
et,O
al,O
.,O
 , 
[,O
21,O
],O
),O
Further,O
details,O
of,O
plot,O
construction,O
are,O
described,O
in,O
the,O
methods,O
section,O
.,O
 , 


,O
 , 
#1334229-05-Discussion-p02
The,O
model,O
describing,O
the,O
accumulation,O
of,O
genetic,O
alterations,O
of,O
the,O
APC,B-gene
,,I-gene
K,B-gene
-,I-gene
ras,I-gene
,,I-gene
TP53,B-gene
and,O
SMAD4,B-gene
genes,O
that,O
drive,O
the,O
development,O
of,O
a,O
carcinoma,B-disease
,,I-disease
has,O
become,O
generally,O
accepted,O
as,O
a,O
paradigm,O
for,O
the,O
genetic,O
basis,O
of,O
colorectal,B-disease
carcinogenesis,I-disease
[,O
3,32,O
],O
.,O
 , 
The,O
relatively,O
low,O
frequency,O
of,O
simultaneous,O
occurrence,O
of,O
mutations,B-mutation
in,O
both,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
observed,O
in,O
this,O
study,O
seems,O
to,O
argue,O
against,O
this,O
synergy,O
.,O
 , 
This,O
contention,O
is,O
in,O
accordance,O
with,O
observations,O
from,O
another,O
cohort,O
study,O
,,O
in,O
which,O
APC,B-gene
,,I-gene
K,B-gene
-,I-gene
ras,I-gene
and,O
TP53,B-gene
gene,O
mutations,B-mutation
were,O
studied,O
in,O
109,B-size
tumours,B-cohort-patient
and,O
these,O
mutations,O
were,O
found,O
to,O
rarely,O
occur,O
together,O
in,O
the,O
same,O
tumour,B-disease
[,O
9,O
],O
.,O
 , 
However,O
,,O
the,O
simultaneous,O
occurrence,O
of,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
mutations,B-mutation
observed,O
in,O
our,O
study,O
occurs,O
more,O
frequently,O
than,O
expected,O
based,O
on,O
chance,O
alone,O
and,O
therefore,O
mutations,B-mutation
in,O
the,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
genes,O
do,O
not,O
seem,O
to,O
occur,O
independently,O
.,O
 , 
When,O
data,O
on,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
mutations,B-mutation
are,O
derived,O
from,O
the,O
study,O
by,O
Smith,O
et,O
al,O
.,O
 , 
[,O
9,O
],O
,,O
similar,O
results,O
,,O
although,O
not,O
statistically,O
significant,O
,,O
could,O
be,O
obtained,O
.,O
 , 


,O
The,O
K,B-gene
-,I-gene
ras,I-gene
mutation,B-mutation
frequency,O
of,O
37,O
%,O
is,O
in,O
accordance,O
with,O
reported,O
frequencies,O
of,O
30,O
to,O
60,O
%,O
 , 
[,O
33,O
-,O
43,O
],O
.,O
 , 
The,O
frequency,O
of,O
37,B-size
%,I-size
of,O
truncating,B-cohort-patient
mutations,I-cohort-patient
in,I-mutation
the,I-mutation
mutation,I-mutation
cluster,I-mutation
region,I-mutation
of,I-mutation
APC,B-gene
in,O
this,O
study,O
,,O
however,O
,,O
seems,O
low,O
in,O
comparison,O
to,O
the,O
general,O
assumption,O
that,O
most,O
colorectal,B-body-part
tumours,B-disease
harbour,O
a,O
mutation,B-mutation
in,O
the,O
APC,B-gene
gene,O
.,O
 , 
When,O
only,O
reports,O
from,O
studies,O
on,O
sporadic,B-Concepts_Ideas
rather,O
than,O
familial,B-Concepts_Ideas
colorectal,B-body-part
cancer,B-disease
or,O
colorectal,B-body-part
cancer,I-disease
cell,O
lines,O
are,O
considered,O
,,O
the,O
mutation,O
frequencies,O
are,O
lower,O
and,O
vary,O
between,O
30,O
and,O
70,O
%,O
[,O
17,44,O
-,O
49,O
],O
,,O
and,O
a,O
population,O
-,O
based,O
case,O
-,O
control,O
study,O
in,O
the,O
Netherlands,B-ethnicity
reported,O
a,O
32,O
%,O
mutation,O
frequency,O
[,O
50,O
],O
.,O
 , 


,O
The,O
method,O
for,O
mutation,O
analysis,O
of,O
the,O
APC,B-gene
mutation,O
cluster,O
region,O
and,O
exon,O
1,O
of,O
K,B-gene
-,I-gene
ras,I-gene
is,O
based,O
on,O
nested,O
amplification,O
and,O
direct,O
sequencing,O
of,O
purified,O
PCR,O
fragments,O
,,O
a,O
highly,O
sensitive,O
method,O
.,O
 , 
Since,O
no,O
screening,O
step,O
was,O
performed,O
prior,O
to,O
the,O
sequencing,O
of,O
the,O
gene,O
fragments,O
,,O
it,O
is,O
unlikely,O
that,O
mutations,O
would,O
have,O
escaped,O
detection,O
.,O
 , 
The,O
reproducibility,O
of,O
the,O
applied,O
assays,O
was,O
good,O
,,O
with,O
a,O
reproducibility,O
of,O
85,O
%,O
and,O
88,O
%,O
for,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
,,I-gene
respectively,O
.,O
 , 
Arguably,O
,,O
this,O
indicates,O
the,O
extent,O
of,O
heterogeneity,O
present,O
in,O
the,O
tumour,B-disease
samples,O
.,O
 , 


,O
In,O
103,B-size
sporadic,B-Concepts_Ideas
colorectal,B-disease
cancers,B-disease
no,B-Physiology
alterations,I-Physiology
were,I-Physiology
found,I-Physiology
in,I-Physiology
the,I-Physiology
K,B-gene
-,I-gene
ras,I-gene
,,I-gene
APC,B-gene
or,I-Physiology
hMLH1,B-gene
genes,I-Physiology
.,I-Physiology
 , 
It,O
is,O
plausible,O
that,O
these,O
tumours,B-disease
have,O
harboured,O
mutations,O
in,O
other,O
components,O
of,O
the,O
Wnt,O
signalling,O
pathway,O
,,O
e.g.,O
mutations,B-mutation
in,O
the,O
Axin,B-gene
genes,O
,,O
which,O
are,O
essential,O
for,O
the,O
degradation,O
of,O
β,O
-,O
catenin,O
,,O
and,O
were,O
observed,O
in,O
11,B-size
%,I-size
of,O
patient,B-cohort-patient
samples,I-cohort-patient
[,O
51,O
],O
.,O
 , 
In,O
addition,O
,,O
an,O
epi,O
-,O
genetic,O
change,O
,,O
i.e.,O
promotor,B-Physiology
hypermethylation,I-Physiology
of,I-Physiology
the,I-Physiology
APC,B-gene
gene,O
that,O
leads,O
to,O
impaired,B-Physiology
APC,B-gene
function,I-Physiology
has,O
been,O
observed,O
in,O
18,B-size
%,I-size
of,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
adenomas,B-disease
and,I-cohort-patient
carcinomas,B-disease
[,O
52,O
],O
.,O
 , 


,O
 , 
#1334229-03-Methods-p01
Methods,O


,O
Study,O
population,O


,O
The,O
prospective,O
Netherlands,B-ethnicity
Cohort,O
Study,O
on,O
diet,O
and,O
cancer,B-disease
was,O
initiated,O
in,O
September,O
1986,O
.,O
 , 
The,O
study,O
design,O
has,O
been,O
described,O
in,O
detail,O
elsewhere,O
[,O
29,O
],O
.,O
 , 
The,O
study,B-cohort-patient
population,I-cohort-patient
originated,O
from,O
204,O
municipal,O
population,O
registries,O
throughout,O
the,O
Netherlands,B-ethnicity
,,I-ethnicity
and,O
included,O
a,O
total,O
of,O
58,279,B-size
men,B-gender
and,O
62,573,B-size
women,B-gender
between,B-age
the,I-age
ages,I-age
of,I-age
55,I-age
and,I-age
69,I-age
years,I-age
at,O
baseline,O
.,O
 , 


,B-cohort-patient
Incident,I-cohort-patient
cancer,I-cohort-patient
cases,I-cohort-patient
are,O
identified,O
by,O
monitoring,O
of,O
the,O
entire,O
cohort,B-cohort-patient
for,O
cancer,B-disease
occurrence,O
through,O
annual,O
record,O
linkage,O
to,O
the,O
Netherlands,B-ethnicity
Cancer,O
Registry,O
,,O
i.e.,O
nine,O
regional,O
cancer,B-disease
registries,O
throughout,O
the,O
Netherlands,B-ethnicity
,,I-ethnicity
and,O
to,O
PALGA,O
,,O
a,O
nationwide,O
network,O
and,O
registry,O
of,O
histo-,O
and,O
cytopathology,O
[,O
30,O
],O
.,O
 , 
Together,O
,,O
the,O
NCR,O
and,O
PALGA,O
provide,O
a,O
near,O
100,O
%,O
coverage,O
of,O
the,O
municipalities,O
included,O
in,O
the,O
NLCS,O
.,O
 , 
The,O
first,O
2.3,O
years,O
of,O
follow,O
up,O
were,O
excluded,O
because,O
of,O
possible,O
pre,O
-,O
clinical,O
disease,O
affecting,O
exposure,O
status,O
and,O
because,O
of,O
incomplete,O
nationwide,O
coverage,O
of,O
PALGA,O
in,O
some,O
of,O
the,O
municipalities,O
included,O
in,O
the,O
NLCS,O
in,O
that,O
period,O
.,O
 , 
From,O
1989,O
until,O
1994,O
,,O
929,B-size
incident,B-cohort-patient
cases,I-cohort-patient
with,O
histologically,O
confirmed,O
colorectal,B-body-part
cancer,B-disease
were,O
identified,O
within,O
the,O
cohort,B-cohort-patient
,,I-cohort-patient
of,O
whom,O
819,O
could,O
also,O
be,O
linked,O
to,O
a,O
PALGA,O
report,O
of,O
the,O
lesion,O
.,O
 , 


,O
The,O
PALGA,O
reports,O
were,O
used,O
to,O
identify,O
and,O
locate,O
tumour,B-disease
tissue,O
from,O
eligible,O
colorectal,B-disease
cancer,I-disease
patients,B-cohort-patient
in,O
Dutch,B-ethnicity
pathology,O
laboratories,O
.,O
 , 
Colon,B-body-part
and,O
rectal,B-body-part
cancer,I-disease
were,O
classified,O
according,O
to,O
site,O
as,O
follows,O
,,O
colon,B-body-part
:,I-body-part
cecum,B-body-part
through,I-body-part
sigmoid,I-body-part
colon,I-body-part
(,O
ICD,O
-,O
O,O
codes,O
153.0,O
,,O
153.1,O
,,O
153.2,O
,,O
153.3,O
,,O
153.4,O
,,O
153.5,O
,,O
153.6,O
,,O
153.7,O
),O
,,O
rectosigmoid,B-body-part
(,O
ICD,O
-,O
O,O
code,O
154.0,O
),O
,,O
and,O
rectum,B-body-part
(,O
ICD,O
-,O
O,O
code,O
154.1,O
),O
.,O
 , 


,O
Tissue,O
samples,O


,B-disease
Tumour,I-disease
material,O
of,O
colorectal,B-disease
cancer,I-disease
patients,B-cohort-patient
was,O
collected,O
after,O
approval,O
by,O
the,O
Ethical,O
Review,O
Board,O
of,O
Maastricht,O
University,O
,,O
PALGA,O
and,O
the,O
NCR,O
.,O
 , 
Tissue,O
samples,O
from,O
819,B-size
colorectal,B-body-part
cancer,I-disease
patients,B-cohort-patient
were,O
localized,O
in,O
54,O
pathology,O
laboratories,O
throughout,O
the,O
Netherlands,B-ethnicity
.,I-ethnicity
 , 
Forty,B-size
-,I-size
four,I-size
(,B-size
5,I-size
%,I-size
),I-size
tumour,B-disease
tissue,B-cohort-patient
samples,I-cohort-patient
could,O
not,O
be,O
retrieved,O
from,O
the,O
pathology,O
archives,O
.,O
 , 
Of,O
775,B-size
available,O
tissue,B-cohort-patient
samples,I-cohort-patient
,,I-cohort-patient
737,B-size
(,B-size
95,I-size
%,I-size
),I-size
contained,O
sufficient,O
tumour,B-disease
material,O
for,O
molecular,O
analyses,O
.,O
 , 
Tissue,O
sections,O
were,O
cut,O
from,O
each,O
sample,O
,,O
which,O
were,O
used,O
for,O
DNA,O
isolation,O
and,O
immunohistochemical,O
analysis,O
.,O
 , 


,O
DNA,O
isolation,O


,O
DNA,O
isolation,O
was,O
described,O
in,O
detail,O
elsewhere,O
[,O
27,O
],O
.,O
 , 
Briefly,O
,,O
a,O
4,O
μm,O
section,O
,,O
cut,O
from,O
each,O
paraffin,O
-,O
embedded,O
tumour,B-disease
tissue,O
block,O
,,O
was,O
stained,O
with,O
haematoxylin,O
and,O
eosin,O
(,O
HE,O
),O
for,O
histopathological,O
examination,O
by,O
a,O
pathologist,O
.,O
 , 
Five,O
20,O
μm,O
sections,O
of,O
tumour,B-disease
tissue,O
were,O
cut,O
from,O
each,O
sample,O
for,O
DNA,O
isolation,O
.,O
 , 
Tumour,B-disease
tissue,O
was,O
separated,O
from,O
normal,O
colon,B-body-part
epithelium,O
using,O
the,O
HE,O
section,O
as,O
a,O
reference,O
.,O
 , 
Genomic,O
DNA,O
was,O
extracted,O
from,O
macrodissected,O
tumour,B-disease
tissue,O
using,O
proteinase,O
K,O
(,O
Qiagen,O
,,O
St.,O
Louis,O
,,O
MO,O
,,O
USA,O
),O
and,O
the,O
Puregene,O
DNA,O
isolation,O
kit,O
(,O
Gentra,O
Systems,O
,,O
Minneapolis,O
,,O
MN,O
,,O
USA,O
),O
.,O
 , 
DNA,O
concentration,O
and,O
purity,O
was,O
measured,O
at,O
260,O
and,O
280,O
nm,O
.,O
 , 


,O
 , 
#3034663-04-Results-p02
Pedigree,O
for,O
Family,B-cohort-patient
#,I-cohort-patient
3,I-cohort-patient
(,B-disease
CRC,I-disease
:,I-disease
Colorectal,B-disease
cancer,I-disease
;,I-disease
ESC,B-disease
:,I-disease
Oesophageal,B-disease
cancer,I-disease
;,I-disease
LC,B-disease
:,I-disease
Lung,B-body-part
cancer,I-disease
),I-disease
.,O
 , 


,O
Of,O
the,O
17,B-size
CRC,B-disease
patients,B-cohort-patient
with,O
the,O
Lys618Ala,B-mutation
variant,O
,,O
two,B-cohort-patient
had,O
MSI,B-Disorder
(,B-size
11.8,I-size
%,I-size
),I-size
,,O
one,B-cohort-patient
in,O
the,O
familial,B-Concepts_Ideas
CRC,B-disease
group,B-cohort-patient
(,B-size
1/8,I-size
),I-size
and,O
one,B-cohort-patient
in,O
the,O
sporadic,B-Concepts_Ideas
CRC,B-disease
group,B-cohort-patient
(,B-size
1/9,I-size
),I-size
.,O
 , 


,O
The,O
MSI,B-Disorder
-,I-Disorder
positive,I-Disorder
patient,B-cohort-patient
from,O
the,O
familial,B-Concepts_Ideas
CRC,B-disease
group,B-cohort-patient
showed,O
loss,B-Physiology
of,I-Physiology
immunohistochemical,I-Physiology
expression,I-Physiology
of,I-Physiology
MLH1,I-Physiology
.,I-Physiology
 , 
This,O
is,O
the,O
index,B-cohort-patient
subject,I-cohort-patient
(,B-cohort-patient
II-3,I-cohort-patient
),I-cohort-patient
for,O
the,O
third,B-cohort-patient
family,I-cohort-patient
(,O
Figure,O
4,O
),O
and,O
no,B-Physiology
hypermethylation,I-Physiology
of,I-Physiology
MLH1,I-Physiology
gene,I-Physiology
promoter,I-Physiology
;,I-Physiology
no,B-Physiology
BRAF,B-gene
p.,B-mutation
Val600Glu,I-mutation
 , 
mutation,B-Physiology
were,O
detected,O
in,O
this,O
case,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1266026-05-Discussion-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,B-body-part
Colorectal,I-body-part
cancers,I-disease
also,O
differ,O
by,O
their,O
extent,O
of,O
spread,O
.,O
 , 
Progression,O
to,O
metastasis,O
may,O
involve,O
a,O
long,O
sequence,O
of,O
potentially,O
rate,O
limiting,O
steps,O
[,O
21,O
],O
.,O
 , 
If,O
invasion,O
or,O
metastasis,O
depends,O
on,O
mutations,O
that,O
arise,O
after,O
transformation,O
,,O
advanced,O
cancers,B-disease
should,O
require,O
more,O
oncogenic,O
mutations,O
and,O
more,O
time,O
for,O
progression,O
(,O
Figure,O
2,O
),O
.,O
 , 
However,O
,,O
ages,O
at,O
diagnosis,O
and,O
estimated,O
mutation,O
numbers,O
did,O
not,O
markedly,O
differ,O
between,O
cancers,B-disease
of,O
different,O
clinical,O
stages,O
.,O
 , 


,O
Equivalent,O
numbers,O
of,O
mutations,O
regardless,O
of,O
clinical,O
stage,O
are,O
consistent,O
with,O
recent,O
speculation,O
that,O
an,O
invasive,O
potential,O
is,O
acquired,O
early,O
in,O
progression,O
[,O
22,O
],O
,,O
albeit,O
only,O
rare,O
cells,O
actually,O
form,O
visible,O
metastases,O
.,O
 , 
Primary,O
breast,B-body-part
cancer,I-disease
expression,O
patterns,O
correlate,O
with,O
clinical,O
outcomes,O
or,O
metastases,O
[,O
22,O
-,O
25,O
],O
,,O
suggesting,O
that,O
a,O
propensity,O
to,O
spread,O
is,O
already,O
present,O
at,O
the,O
time,O
of,O
transformation,O
.,O
 , 
Alternatively,O
,,O
all,O
cancers,B-disease
may,O
have,O
the,O
same,O
abilities,O
to,O
invade,O
and,O
metastasize,O
,,O
with,O
clinical,O
stage,O
dependent,O
on,O
random,O
events,O
that,O
occur,O
rapidly,O
after,O
transformation,O
.,O
 , 
A,O
short,O
interval,O
between,O
transformation,O
and,O
detection,O
may,O
help,O
limit,O
spread,O
because,O
clinical,O
surveillance,O
tends,O
to,O
detect,O
localized,O
colorectal,B-body-part
cancers,I-disease
[,O
26,O
-,O
28,O
],O
.,O
 , 


,O
Multistage,O
models,O
are,O
mechanistically,O
different,O
from,O
tumor,B-disease
progression,O
models,O
and,O
more,O
consistent,O
with,O
a,O
hypothesis,O
that,O
mutations,O
acquired,O
early,O
during,O
progression,O
help,O
determine,O
extent,O
of,O
invasion,O
(,O
Figure,O
3,O
),O
.,O
 , 
Mutations,O
sequentially,O
accumulate,O
before,O
transformation,O
in,O
both,O
models,O
,,O
but,O
the,O
adenoma,B-disease
-,B-disease
cancer,I-disease
sequence,O
suggests,O
most,O
cancer,B-disease
mutations,B-mutation
start,O
to,O
accumulate,O
after,B-age
the,I-age
age,I-age
of,I-age
50,I-age
years,I-age
in,O
adenomas,B-disease
[,O
7,O
],O
.,O
 , 
Such,O
tumor,B-disease
progression,O
imposes,O
purpose,O
to,O
early,O
mutations,O
because,O
each,O
additional,O
mutation,O
confers,O
incremental,O
changes,O
to,O
a,O
non,O
-,O
invasive,O
adenoma,B-disease
phenotype,O
.,O
 , 
Therefore,O
,,O
tumor,O
progression,O
models,O
would,O
likely,O
differ,O
between,O
MSI+,B-Disorder
and,O
MSI-,B-Disorder
cancers,B-disease
because,O
their,O
biology,O
and,O
types,O
of,O
mutations,O
are,O
quite,O
different,O
[,O
7,8,O
],O
.,O
 , 


,O
In,O
contrast,O
,,O
mutations,O
accumulate,O
throughout,O
life,O
in,O
multistage,O
models,O
.,O
 , 
Genetically,O
engineered,O
mice,O
and,O
familial,B-Concepts_Ideas
cancer,B-disease
syndromes,O
reveal,O
that,O
many,O
oncogenic,O
mutations,O
are,O
also,O
compatible,O
with,O
normal,O
phenotypes,O
[,O
11,O
],O
,,O
allowing,O
for,O
the,O
possibility,O
that,O
many,O
",B-disease
cancer,I-disease
",I-disease
mutations,B-mutation
may,O
first,O
accumulate,O
in,O
normal,B-disease
-,I-disease
appearing,I-disease
colon,B-body-part
very,O
early,O
in,O
life,O
.,O
 , 
Such,O
pretumor,O
progression,O
[,O
11,O
],O
more,O
readily,O
allows,O
for,O
an,O
invasive,B-Concepts_Ideas
or,O
metastatic,B-Disorder
cancer,B-disease
phenotype,O
at,O
transformation,O
because,O
genetic,O
progression,O
is,O
uncoupled,O
from,O
tumor,B-disease
progression,O
(,O
Figure,O
2,O
),O
.,O
 , 
Rather,O
than,O
incremental,O
stepwise,O
changes,O
in,O
phenotype,O
after,O
each,O
new,O
mutation,O
,,O
a,O
tumor,B-disease
phenotype,O
may,O
only,O
emerge,O
after,O
several,O
initially,O
occult,O
mutations,O
accumulate,O
in,O
a,O
single,O
normal,O
appearing,O
cell,O
.,O
 , 
In,O
this,O
way,O
our,O
multistage,O
model,O
can,O
apply,O
to,O
both,O
MSI+,B-Disorder
and,O
MSI-,B-Disorder
cancers,B-disease
despite,O
their,O
marked,O
differences,O
in,O
types,O
of,O
mutations,O
because,O
early,O
critical,O
mutations,O
(,O
whatever,O
they,O
are,O
),O
do,O
not,O
visibly,O
change,O
phenotype,O
but,O
instead,O
accumulate,O
in,O
normal,B-disease
appearing,I-disease
colon,B-body-part
.,I-body-part
 , 
Early,B-Disorder
or,I-Disorder
advanced,I-Disorder
sporadic,B-Concepts_Ideas
MSI-,B-Disorder
colorectal,B-disease
cancers,I-disease
appeared,O
to,O
require,O
similar,O
numbers,O
of,O
mutations,B-mutation
,,I-mutation
consistent,O
with,O
the,O
phenotype,O
at,O
cancer,B-disease
diagnosis,O
contingent,O
on,O
mutations,B-mutation
acquired,O
much,O
earlier,O
in,O
life,O
and,O
present,O
at,O
the,O
time,O
of,O
transformation,O
.,O
 , 
However,O
,,O
ascertainment,O
bias,O
may,O
also,O
be,O
responsible,O
for,O
the,O
similar,O
frequency,O
-,O
age,O
distributions,O
of,O
colorectal,B-disease
cancers,I-disease
of,O
different,O
clinical,O
stages,O
.,O
 , 


,O
 , 
#1373649-04-Results-and-discussion-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Mutation,O
screening,O
was,O
done,O
in,O
both,O
sisters,B-gender
to,O
assign,O
their,O
risk,O
to,O
develop,O
HNPCC,B-disease
and,O
other,O
related,O
cancers,B-disease
.,I-disease
 , 
We,O
found,O
the,O
mutation,O
in,O
one,O
of,O
them,O
and,O
opportune,O
recommendations,O
for,O
surveillance,O
and,O
prophylaxis,O
were,O
given,O
.,O
 , 
Two,O
years,O
after,O
that,O
,,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
mother,B-gender
,,I-gender
unaffected,B-disease
during,O
this,O
study,O
,,O
developed,O
an,O
endometrial,B-body-part
adenocarcinoma,B-disease
.,I-disease
 , 


,O
 , 
#2275286-06-Conclusion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Conclusion,O


,O
Our,O
results,O
imply,O
that,O
HNPCC,B-disease
in,O
the,O
Chinese,B-ethnicity
population,B-cohort-patient
may,O
have,O
distinct,O
clinicopathological,O
characteristics,O
and,O
underlying,O
MMR,B-gene
germline,B-mutation
mutations,I-mutation
,,I-mutation
as,O
compared,O
to,O
patients,B-cohort-patient
from,O
Western,B-ethnicity
countries,O
.,O
 , 
Application,O
of,O
NCI,O
recommendations,O
on,O
the,O
Chinese,B-ethnicity
population,B-cohort-patient
may,O
not,O
enable,O
the,O
screening,O
of,O
all,O
HNPCC,B-disease
families,B-cohort-patient
.,I-cohort-patient
 , 
Further,O
studies,O
are,O
necessary,O
to,O
echo,O
or,O
refute,O
our,O
results,O
so,O
as,O
to,O
make,O
the,O
NCI,O
recommendation,O
more,O
universally,O
applicable,O
.,O
 , 


,O
 , 
#1619718-05-Discussion-p05
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
In,O
summary,O
,,O
MPs,B-disease
and,O
SAs,B-disease
account,O
for,O
only,O
about,O
2,B-size
%,I-size
of,O
colorectal,B-body-part
polyps,B-cohort-patient
.,I-cohort-patient
 , 
Nevertheless,O
,,O
those,O
serrated,B-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
show,O
frequent,O
mutation,B-mutation
of,O
either,O
KRAS,B-gene
or,O
BRAF,B-gene
and,O
frequent,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,B-gene
(,O
particularly,O
MP,B-disease
),I-disease
.,O
 , 
Additionally,O
,,O
four,B-cohort-patient
of,I-cohort-patient
25,I-cohort-patient
(,B-size
16,I-size
%,I-size
),I-size
showed,O
high,B-Disorder
-,I-Disorder
grade,I-Disorder
dysplasia,I-Disorder
and,O
in,O
three,B-cohort-patient
of,O
these,O
there,O
was,O
concordant,O
aberrant,B-Physiology
nuclear,I-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
.,I-Physiology
 , 
Along,O
with,O
SSAs,B-disease
,,I-disease
these,O
rare,O
polyps,B-disease
may,O
serve,O
as,O
the,O
precursors,O
of,O
sporadic,B-Concepts_Ideas
CRCs,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
and,O
DNA,B-Physiology
methylation,I-Physiology
(,B-Disorder
with,I-Disorder
and,I-Disorder
without,I-Disorder
DNA,I-Disorder
MSI,I-Disorder
),I-Disorder
and,O
a,O
subset,O
of,O
CRCs,B-disease
with,O
KRAS,B-gene
mutation,B-mutation
.,I-mutation
 , 
Their,O
malignant,O
potential,O
is,O
explained,O
by,O
the,O
accumulation,O
of,O
genetic,O
alterations,O
that,O
may,O
in,O
turn,O
depend,O
upon,O
the,O
inactivation,B-Physiology
of,I-Physiology
the,I-Physiology
DNA,I-Physiology
repair,I-Physiology
gene,I-Physiology
MGMT.28,B-gene
 , 
The,O
importance,O
of,O
these,O
‘,B-Physiology
fusion,I-Physiology
’,I-Physiology
polyps,B-disease
as,O
cancer,B-disease
precursors,O
may,O
be,O
under,O
-,O
appreciated,O
because,O
critical,O
rate,O
-,O
limiting,O
changes,O
governing,O
malignant,O
transition,O
,,O
particularly,O
in,O
association,O
with,O
loss,B-Physiology
of,I-Physiology
function,I-Physiology
of,I-Physiology
MLH1,I-Physiology
of,I-Physiology
p53,I-Physiology
,,I-Physiology
occur,O
rapidly,O
and,O
can,O
rarely,O
be,O
‘,O
caught,O
in,O
the,O
act,O
’,O
.,O
 , 


,O
 , 
#1557864-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Mismatch,O
repair,O
and,O
treatment,O
resistance,O
in,O
ovarian,B-body-part
cancer,I-disease


,I-disease
Abstract,O


,O
Background,O


,O
The,O
treatment,O
of,O
ovarian,B-body-part
cancer,I-disease
is,O
hindered,O
by,O
intrinsic,O
or,O
acquired,O
resistance,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
.,O
 , 
The,O
aim,O
of,O
this,O
study,O
is,O
to,O
determine,O
the,O
frequency,O
of,O
mismatch,O
repair,O
(,B-gene
MMR,I-gene
),I-gene
inactivation,O
in,O
ovarian,B-body-part
cancer,I-disease
and,O
its,O
association,O
with,O
resistance,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
.,O
 , 


,O
Methods,O


,O
We,O
determined,O
,,O
microsatellite,O
instability,O
(,O
MSI,O
),O
as,O
a,O
marker,O
for,O
MMR,B-gene
inactivation,O
(,O
analysis,O
of,O
BAT25,O
and,O
BAT26,O
),O
,,O
MLH1,B-gene
promoter,O
methylation,O
status,O
(,O
methylation,O
specific,O
PCR,O
on,O
bisulfite,O
treated,O
DNA,O
),O
and,O
mRNA,O
expression,O
of,O
MLH1,B-gene
,,I-gene
MSH2,B-gene
,,I-gene
MSH3,B-gene
,,I-gene
MSH6,B-gene
and,O
PMS2,B-gene
(,O
quantitative,O
RT,O
-,O
PCR,O
),O
in,O
75,B-size
ovarian,B-body-part
carcinomas,B-cohort-patient
and,O
eight,B-size
ovarian,B-disease
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient


,I-cohort-patient
Results,O


,B-Disorder
MSI,I-Disorder
was,O
detected,O
in,O
three,B-size
of,I-size
the,I-size
eight,I-size
cell,B-cohort-patient
lines,I-cohort-patient
i.e.,O
A2780,B-cohort-patient
(,B-Physiology
no,I-Physiology
MLH1,B-gene
mRNA,I-Physiology
expression,I-Physiology
due,I-Physiology
to,I-Physiology
promoter,I-Physiology
methylation,I-Physiology
),I-Physiology
,,O
SKOV3,B-cohort-patient
(,B-Physiology
no,I-Physiology
MLH1,B-gene
mRNA,I-Physiology
expression,I-Physiology
),I-Physiology
and,O
2774,B-cohort-patient
(,B-Physiology
no,I-Physiology
altered,I-Physiology
expression,I-Physiology
of,I-Physiology
MMR,I-Physiology
genes,I-Physiology
),I-Physiology
.,O
 , 
Overall,O
,,O
there,O
was,O
no,O
association,O
between,O
cisplatin,O
response,O
and,O
MMR,B-gene
status,O
in,O
these,O
eight,B-size
cell,B-cohort-patient
lines,I-cohort-patient
.,I-cohort-patient
 , 


,B-size
Seven,I-size
of,I-size
the,I-size
75,I-size
ovarian,B-body-part
carcinomas,B-disease
showed,O
MLH1,B-Physiology
promoter,I-Physiology
methylation,I-Physiology
,,I-Physiology
however,O
,,O
none,B-Concepts_Ideas
of,I-Concepts_Ideas
these,I-Concepts_Ideas
showed,I-Concepts_Ideas
MSI,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
Forty,B-size
-,I-size
six,I-size
of,O
these,O
patients,B-cohort-patient
received,O
platinum,O
-,O
based,O
chemotherapy,O
(,B-size
11,I-size
non,B-cohort-patient
-,I-cohort-patient
responders,I-cohort-patient
,,I-cohort-patient
34,B-size
responders,B-cohort-patient
,,I-cohort-patient
one,O
unknown,O
response,O
),O
.,O
 , 
The,O
resistance,O
seen,O
in,O
the,O
eleven,B-size
non,B-cohort-patient
-,I-cohort-patient
responders,I-cohort-patient
was,O
not,B-Disorder
related,I-Disorder
to,I-Disorder
MSI,I-Disorder
and,O
therefore,O
also,O
not,B-Physiology
to,I-Physiology
MMR,I-Physiology
inactivation,I-Physiology
.,I-Physiology
 , 


,O
Conclusion,O


,B-Physiology
No,I-Physiology
MMR,B-gene
inactivation,I-Physiology
was,O
detected,O
in,O
75,B-size
ovarian,B-body-part
carcinoma,B-disease
specimens,B-cohort-patient
and,O
no,O
association,O
was,O
seen,O
between,O
MMR,B-gene
inactivation,I-Disorder
and,O
resistance,O
in,O
the,O
ovarian,B-disease
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
as,O
well,O
as,O
the,O
ovarian,B-body-part
carcinomas,B-disease
.,I-disease
 , 
In,O
the,O
discussion,O
,,O
the,O
results,O
were,O
compared,O
to,O
that,O
of,O
twenty,O
similar,O
studies,O
in,O
the,O
literature,O
including,O
in,O
total,O
1315,B-size
ovarian,B-disease
cancer,I-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 
Although,O
no,O
association,O
between,O
response,O
and,O
MMR,B-gene
status,O
was,O
seen,O
in,O
the,O
primary,O
tumor,B-disease
the,O
possible,O
role,O
of,O
MMR,B-gene
inactivation,O
in,O
acquired,O
resistance,O
deserves,O
further,O
investigation,O
.,O
 , 


,O
 , 
#2275286-05-Discussion-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Regarding,O
the,O
location,O
of,O
gene,O
mutations,O
,,O
we,O
found,O
that,O
3,B-size
patients,B-cohort-patient
bore,O
mutations,B-mutation
in,I-mutation
exon,I-mutation
7,I-mutation
of,O
MSH2,B-gene
,,I-gene
2,B-cohort-patient
had,O
mutations,B-mutation
in,I-mutation
exon,I-mutation
12,I-mutation
of,O
MSH2,B-gene
,,I-gene
1,B-size
had,O
a,O
mutation,B-mutation
in,I-mutation
exon,I-mutation
2,I-mutation
of,O
MSH6,B-gene
,,I-gene
and,O
2,B-size
had,O
mutations,B-mutation
in,I-mutation
exon,I-mutation
5,I-mutation
of,O
MSH6,B-gene
.,I-gene
 , 
No,B-size
MLH1,B-gene
mutations,B-mutation
were,O
found,O
in,O
our,O
cohort,B-cohort-patient
.,I-cohort-patient
 , 
All,O
8,O
mutations,O
were,O
considered,O
pathogenic,O
mutations,O
.,O
 , 
The,O
mutation,O
of,O
C1886,B-mutation
A,I-mutation
>,I-mutation
G,I-mutation
,,I-mutation
C1668,B-mutation
C,I-mutation
>,I-mutation
T,I-mutation
was,O
reported,O
as,O
a,O
pathogenic,O
mutation,O
previously,O
[,O
22,O
-,O
25,O
],O
.,O
 , 
However,O
,,O
the,O
other,O
six,O
mutations,O
have,O
not,O
been,O
reported,O
in,O
other,O
publications,O
and,O
are,O
likely,O
to,O
be,O
novel,O
mutations,O
.,O
 , 
We,O
also,O
attempted,O
to,O
screen,O
for,O
the,O
presence,O
of,O
all,O
these,O
mutations,O
in,O
50,B-size
randomly,O
selected,O
patients,B-cohort-patient
in,O
the,O
MSS,B-Disorder
group,B-cohort-patient
and,O
in,O
50,B-size
normal,B-disease
people,B-cohort-patient
.,I-cohort-patient
 , 
The,O
result,O
of,O
this,O
screen,O
was,O
negative,O
,,O
and,O
all,O
these,O
CRCs,B-cohort-patient
with,B-Physiology
mutations,I-Physiology
stained,B-Phenomena
negatively,I-Phenomena
for,I-Phenomena
MSH2,I-Phenomena
or,I-Phenomena
/,I-Phenomena
and,I-Phenomena
MSH6,I-Phenomena
,,I-Phenomena
indicating,O
that,O
these,O
6,O
mutations,O
may,O
be,O
pathogenic,O
mutations,O
but,O
not,O
polymorphisms,O
.,O
 , 
In,O
terms,O
of,O
the,O
clinical,O
features,O
of,O
the,O
8,B-size
cases,B-cohort-patient
with,O
mutations,B-mutation
,,I-mutation
only,O
1,O
conformed,O
to,O
the,O
Amsterdam,O
criteria,O
II,O
;,O
all,O
the,O
others,O
did,O
not,O
have,O
any,O
family,B-cohort-patient
history,O
of,O
malignancy,O
.,O
 , 
Moreover,O
,,O
the,O
median,B-age
age,I-age
was,I-age
59,I-age
with,O
4,B-size
patients,B-cohort-patient
that,O
were,O
older,B-age
than,I-age
60,I-age
years,I-age
old,I-age
.,I-age
 , 


,O
One,O
limitation,O
of,O
this,O
study,O
is,O
that,O
it,O
is,O
a,O
single,O
-,O
center,O
study,O
with,O
a,O
relatively,O
small,O
sample,O
size,O
.,O
 , 
Therefore,O
,,O
the,O
results,O
of,O
this,O
study,O
need,O
to,O
be,O
confirmed,O
by,O
a,O
well,O
designed,O
multi,O
-,O
center,O
study,O
,,O
which,O
is,O
one,O
of,O
our,O
ongoing,O
studies,O
in,O
China,B-ethnicity
.,I-ethnicity
 , 


,O
 , 
#1334229-02-Background-p02
Considering,O
the,O
aforementioned,O
issues,O
,,O
there,O
is,O
a,O
need,O
for,O
studies,O
addressing,O
the,O
heterogeneity,O
of,O
affected,O
genes,O
involved,O
in,O
early,O
to,O
intermediate,O
colorectal,B-body-part
cancer,I-disease
development,O
in,O
large,O
groups,O
of,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
We,O
have,O
previously,O
studied,O
the,O
occurrence,O
of,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
mutations,B-mutation
separately,O
[,O
27,28,O
],O
.,O
 , 
In,O
the,O
current,O
study,O
,,O
in,O
addition,O
to,O
investigating,O
mutations,B-mutation
in,O
the,O
APC,B-gene
,,I-gene
CTNNB1,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
genes,O
as,O
well,O
as,O
mismatch,O
repair,O
deficiency,O
by,O
means,O
of,O
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
and,O
combinations,O
of,O
these,O
aberrations,O
,,O
their,O
relation,O
with,O
various,O
tumour,B-disease
and,O
patient,B-cohort-patient
characteristics,O
were,O
studied,O
in,O
a,O
large,O
,,O
unselected,O
group,O
of,O
incident,O
colorectal,B-disease
cancer,I-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1334229-01-Abstract-p01
Mutations,O
in,O
,,O
and,O
genes,O
and,O
expression,O
of,O
hMLH1,B-gene
in,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
carcinomas,B-disease
from,O
the,O
Netherlands,B-ethnicity
Cohort,O
Study,O


,O
Abstract,O


,O
Background,O


,O
The,O
early,O
to,O
intermediate,O
stages,O
of,O
the,O
majority,O
of,O
colorectal,B-body-part
tumours,B-disease
are,O
thought,O
to,O
be,O
driven,O
by,O
aberrations,O
in,O
the,O
Wnt,B-gene
(,B-gene
APC,I-gene
,,I-gene
CTNNB1,B-gene
),I-gene
and,O
Ras,B-gene
(,B-gene
K,I-gene
-,I-gene
ras,I-gene
),I-gene
pathways,O
.,O
 , 
A,O
smaller,O
proportion,O
of,O
cancers,B-disease
shows,O
mismatch,B-Physiology
repair,I-Physiology
deficiency,I-Physiology
.,I-Physiology
 , 
The,O
aim,O
of,O
this,O
study,O
was,O
to,O
analyse,O
the,O
co,O
-,O
occurrence,O
of,O
these,O
genetic,O
alterations,O
in,O
relation,O
to,O
tumour,B-disease
and,O
patient,B-cohort-patient
characteristics,O
.,O
 , 


,O
Methods,O


,O
In,O
a,O
group,B-cohort-patient
of,O
656,B-size
unselected,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancer,B-disease
patients,B-cohort-patient
,,I-cohort-patient
aberrations,O
in,O
the,O
APC,B-gene
,,I-gene
K,B-gene
-,I-gene
ras,I-gene
,,I-gene
CTNNB1,B-gene
genes,O
,,O
and,O
expression,O
of,O
hMLH1,B-gene
were,O
investigated,O
.,O
 , 
Additionally,O
,,O
tumours,B-disease
were,O
divided,O
in,O
groups,O
based,O
on,O
molecular,O
features,O
and,O
compared,O
with,O
respect,O
to,O
patient,O
's,O
age,O
at,O
diagnosis,O
,,O
sex,O
,,O
family,O
history,O
of,O
colorectal,B-body-part
cancer,B-disease
,,I-disease
tumour,B-disease
sub,O
-,O
localisation,O
,,O
Dukes,O
',O
stage,O
and,O
differentiation,O
.,O
 , 


,O
Results,O


,B-mutation
Mutations,I-mutation
at,I-mutation
the,I-mutation
phosphorylation,I-mutation
sites,I-mutation
(,I-mutation
codons,I-mutation
31,I-mutation
,,I-mutation
33,I-mutation
,,I-mutation
37,I-mutation
,,I-mutation
and,I-mutation
45,I-mutation
),I-mutation
in,O
the,O
CTNNB1,B-gene
gene,O
were,O
observed,O
in,O
tumours,B-disease
from,O
only,O
5/464,B-size
patients,B-cohort-patient
.,I-cohort-patient
 , 
Tumours,B-cohort-patient
with,O
truncating,B-mutation
APC,I-mutation
mutations,I-mutation
and,O
activating,B-mutation
K,B-gene
-,I-gene
ras,I-gene
mutations,I-mutation
in,I-mutation
codons,I-mutation
12,I-mutation
and,I-mutation
13,I-mutation
occurred,O
at,O
similar,O
frequencies,O
(,B-size
37,I-size
%,I-size
(,B-size
245/656,I-size
),I-size
and,O
36,B-size
%,I-size
(,B-size
235/656,I-size
),I-size
,,O
respectively,O
),O
.,O
 , 
Seventeen,B-size
percent,I-size
of,O
tumours,B-cohort-patient
harboured,O
both,O
an,O
APC,B-gene
and,O
a,O
K,B-gene
-,I-gene
ras,I-gene
mutation,B-mutation
(,B-size
109/656,I-size
),I-size
.,O
 , 
Nine,B-size
percent,I-size
of,O
all,O
tumours,B-disease
(,B-size
58/656,I-size
),I-size
lacked,B-Physiology
hMLH1,B-gene
expression,I-Physiology
.,I-Physiology
 , 
Patients,B-cohort-patient
harbouring,O
a,O
tumour,B-disease
with,O
absent,B-Physiology
hMLH1,I-Physiology
expression,I-Physiology
were,O
older,B-age
,,I-age
more,O
often,O
women,B-gender
,,I-gender
more,O
often,O
had,O
proximal,B-body-part
colon,I-body-part
tumours,B-disease
that,O
showed,O
poorer,B-Physiology
differentiation,I-Physiology
when,O
compared,O
to,O
patients,B-cohort-patient
harbouring,O
tumours,B-disease
with,O
an,O
APC,B-gene
and/or,O
K,B-gene
-,I-gene
ras,I-gene
mutation,B-mutation
.,I-mutation
 , 


,O
Conclusion,O


,B-gene
CTNNB1,I-gene
mutations,B-mutation
seem,O
to,O
be,O
of,O
minor,O
importance,O
in,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancer,I-disease
.,I-disease
 , 
The,O
main,O
differences,O
in,O
tumour,B-disease
and,O
patient,O
characteristics,O
are,O
found,O
between,O
groups,O
of,O
patients,O
based,O
on,O
mismatch,O
repair,O
deficiency,O
.,O
 , 


,O
 , 
#1601966-03-Results-p05
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
20q11.22,O
-,O
q11.23,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,B-disease
-,I-disease
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
13,O
and,O
14,O
.,O
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
20q11.22,O
-,O
q11.23,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
plot,O
of,O
cross,O
-,O
comparison,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
for,O
gene,O
pairs,O
in,O
a,O
particular,O
region,O
.,O
 , 
Both,O
,,O
horizontal,O
and,O
vertical,O
axes,O
comprise,O
the,O
same,O
genes,O
in,O
chromosomal,O
order,O
.,O
 , 
In,O
each,O
square,O
total,O
counts,O
of,O
patients,B-cohort-patient
with,O
consistent,O
up,O
-,O
regulation,O
in,O
two,O
genes,O
are,O
coded,O
by,O
different,O
shades,O
of,O
gray,O
.,O
 , 
Dark,O
squared,O
regions,O
along,O
the,O
diagonal,O
indicate,O
coordinated,O
regulation,O
in,O
patient,B-cohort-patient
subgroups,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
14,O
.,O
 , 
The,O
known,O
most,O
frequently,O
up,O
-,O
regulated,O
genes,O
in,O
this,O
region,O
are,O
EIF2S2,B-gene
,,I-gene
AHCY,B-gene
,,I-gene
ITCH,B-gene
,,I-gene
DNCL2A,B-gene
,,I-gene
ITG4BP,B-gene
,,I-gene
C20orf24,B-gene
,,I-gene
NDRGL3,B-gene
,,I-gene
RPN2,B-gene
and,O
CTNNBL1,B-gene
.,I-gene
 , 
Also,O
note,O
the,O
gene,O
C20orf110,O
alias,O
TP53INP2,B-mutation
which,O
is,O
down,O
-,O
regulated,O
in,O
the,O
majority,O
of,O
tumors,O
.,O
 , 


,O
Up,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
20q11.22,O
-,O
q11.23,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
plot,O
of,O
cross,O
-,O
comparison,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
for,O
gene,O
pairs,O
in,O
a,O
particular,O
region,O
.,O
 , 
Both,O
,,O
horizontal,O
and,O
vertical,O
axes,O
comprise,O
the,O
same,O
genes,O
in,O
chromosomal,O
order,O
.,O
 , 
In,O
each,O
square,O
total,O
counts,O
of,O
patients,B-cohort-patient
with,O
consistent,O
down,O
-,O
regulation,O
in,O
two,O
genes,O
are,O
coded,O
by,O
different,O
shades,O
of,O
gray,O
.,O
 , 
Dark,O
squared,O
regions,O
along,O
the,O
diagonal,O
indicate,O
coordinated,O
regulation,O
in,O
patient,B-cohort-patient
subgroups,O
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
12,O
and,O
13,O
.,O
 , 


,O
12q14.2,O
-,O
12q22,O


,O
We,O
observed,O
increased,O
expression,O
of,O
genes,O
in,O
chromosomal,O
region,O
12q14.2,O
-,O
12q22,O
(,O
see,O
Figures,O
15,O
,,O
16,O
,,O
17,O
),O
.,O
 , 
The,O
MDM2,B-gene
gene,O
at,O
12q15,O
is,O
a,O
possible,O
target,O
of,O
this,O
misregulation,O
.,O
 , 
However,O
,,O
within,O
this,O
large,O
region,O
there,O
is,O
a,O
smaller,O
region,O
at,O
12q21.1,O
-,O
q21.2,O
spanning,O
eight,O
genes,O
that,O
exhibit,O
exceptionally,O
high,O
expression,O
in,O
our,O
tumor,O
samples,O
.,O
 , 
Among,O
these,O
is,O
LGR5,B-gene
alias,O
GPR49,B-gene
,,I-gene
a,O
G,O
-,O
protein,O
coupled,O
receptor,O
that,O
has,O
large,O
leucine,O
-,O
rich,O
repeats,O
in,O
its,O
N,O
-,O
terminus,O
.,O
 , 
We,O
could,O
confirm,O
the,O
up,O
-,O
regulation,O
of,O
GPR49,B-gene
in,O
CRC,B-disease
by,O
quantitative,O
PCR,O
and,O
in,O
-,O
situ,O
hybridization,O
(,O
data,O
not,O
shown,O
),O
.,O
 , 
This,O
finding,O
and,O
the,O
exceptional,O
suitability,O
of,O
G,O
-,O
protein,O
-,O
coupled,O
receptors,O
as,O
drug,O
targets,O
make,O
the,O
LGR5,B-gene
/,B-gene
GPR49,I-gene
protein,O
a,O
potential,O
target,O
for,O
future,O
therapeutical,O
approaches,O
.,O
 , 
We,O
do,O
not,O
know,O
of,O
any,O
other,O
reports,O
that,O
link,O
this,O
region,O
to,O
CRC,B-disease
.,I-disease
 , 


,O
 , 
#1601966-03-Results-p12
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
14q24.1,O
-,O
14q24.3,O
–,O
the,O
FOS,B-gene
region,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
7,O
,,O
10,O
,,O
13,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
30,O
and,O
32,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
14q24.1,O
-,O
14q24.3,O
–,O
the,O
FOS,B-gene
region,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
8,O
,,O
11,O
,,O
14,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
30,O
and,O
31,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
31,O
.,O
 , 
This,O
region,O
has,O
been,O
reported,O
in,O
other,O
studies,O
to,O
be,O
frequently,O
deleted,O
in,O
colon,B-body-part
cancer,I-disease
metastases,O
(,O
see,O
Table,O
1,O
),O
.,O
 , 
The,O
FOS,B-gene
oncogene,O
is,O
the,O
5th,O
gene,O
from,O
the,O
right,O
and,O
is,O
one,O
of,O
the,O
most,O
strongly,O
down,O
-,O
regulated,O
genes,O
in,O
this,O
region,O
.,O
 , 
Note,O
the,O
expression,O
of,O
MLH3,B-gene
,,I-gene
KIAA0317,B-gene
,,I-gene
KIAA0440,B-gene
/,I-gene
SIPA1L1,I-gene
,,I-gene
NUMB,B-gene
,,I-gene
SYNJ2BP,B-gene
and,O
PSEN1,B-gene
.,I-gene
 , 


,O
 , 
#1360090-04-Discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Discussion,O


,O
The,O
BRAF,B-gene
V600E,B-mutation
mutation,O
has,O
already,O
been,O
proposed,O
as,O
a,O
convenient,O
marker,O
to,O
discriminate,O
between,O
MSI+,B-Disorder
tumors,B-disease
that,O
are,O
sporadic,B-Concepts_Ideas
or,O
HNPCC,B-disease
in,O
origin,O
[,O
5,8,O
-,O
10,O
],O
.,O
 , 
This,O
is,O
a,O
very,O
important,O
issue,O
for,O
population,O
-,O
based,O
screening,O
programs,O
that,O
aim,O
to,O
identify,O
CRC,B-disease
associated,O
with,O
the,O
HNPCC,B-disease
syndrome,O
.,O
 , 
Compared,O
to,O
the,O
analysis,O
of,O
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
,,I-Physiology
mutation,O
at,O
the,O
BRAF,B-gene
V600E,B-mutation
hotspot,O
is,O
relatively,O
simple,O
to,O
detect,O
using,O
DNA,O
sequencing,O
,,O
RFLP,O
or,O
the,O
SSCP,O
method,O
used,O
in,O
the,O
present,O
work,O
(,O
Figure,O
1,O
),O
.,O
 , 


,O
Similar,O
to,O
other,O
studies,O
[,O
4,5,10,16,17,O
],O
we,O
observed,O
BRAF,B-gene
mutation,B-mutation
frequencies,O
of,O
4,B-size
%,I-size
in,O
MSI-,B-Disorder
tumors,B-cohort-patient
and,O
39,B-size
%,I-size
in,O
MSI+,B-Disorder
tumors,B-cohort-patient
(,O
Table,O
1,O
),O
.,O
 , 
The,O
highest,O
frequencies,O
were,O
seen,O
in,O
tumors,B-cohort-patient
showing,O
methylation,B-Physiology
of,I-Physiology
the,I-Physiology
MLH1,B-gene
promoter,I-Physiology
proximal,I-Physiology
region,I-Physiology
(,B-size
46,I-size
%,I-size
),I-size
and,O
in,O
tumors,B-disease
with,O
infiltrating,B-body-part
lymphocytes,I-body-part
(,B-size
48,I-size
%,I-size
),I-size
.,O
 , 
BRAF,B-gene
mutation,B-mutation
frequencies,O
of,O
up,O
to,O
70–80,B-size
%,I-size
have,O
been,O
reported,O
in,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
,,I-Disorder
CIMP+,B-Physiology
and,O
MLH1,B-gene
-,I-gene
methylated,I-Physiology
CRC,B-disease
and,O
polyps,B-disease
[,O
7,8,15,16,O
],O
.,O
 , 
For,O
reasons,O
that,O
are,O
still,O
unclear,O
,,O
BRAF,B-gene
mutations,B-mutation
are,O
approximately,O
5–10,O
-,O
fold,O
more,O
frequent,O
in,O
tumors,B-disease
that,O
have,O
characteristic,O
features,O
of,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
(,O
ie,O
.,O
 , 
MLH1,B-gene
methylated,I-Physiology
),I-Physiology
and,O
CIMP+,B-Physiology
phenotypes,O
.,O
 , 
These,O
include,O
proximal,B-body-part
colon,I-body-part
location,O
,,O
poor,O
differentiation,O
,,O
mucinous,O
histology,O
and,O
infiltrating,O
lymphocytes,O
[,O
13,19,20,O
],O
.,O
 , 
Interestingly,O
however,O
,,O
in,O
the,O
present,O
study,O
BRAF,B-gene
mutations,B-mutation
never,O
occurred,O
in,O
association,O
with,O
KRAS,B-gene
mutation,B-mutation
,,I-mutation
were,O
present,O
in,O
only,O
3,B-size
%,I-size
of,O
CIMP-,B-Physiology
tumors,B-disease
and,O
showed,O
no,O
association,O
with,O
TP53,B-gene
mutation,B-mutation
(,O
Table,O
2,O
),O
.,O
 , 
The,O
observation,O
that,O
BRAF,B-gene
mutations,B-mutation
occur,O
only,O
very,O
rarely,O
in,O
HNPCC,B-disease
-,I-disease
related,I-Disorder
MSI+,B-Disorder
CRC,B-disease
demonstrates,O
that,O
defective,O
DNA,O
mismatch,O
repair,O
is,O
not,O
involved,O
in,O
causing,O
this,O
genetic,O
alteration,O
.,O
 , 


,O
In,O
order,O
to,O
determine,O
whether,O
the,O
characteristic,O
clinicopathological,O
features,O
of,O
tumors,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
were,O
due,O
to,O
their,O
close,O
association,O
with,O
MSI+,B-Disorder
and,O
CIMP+,B-Physiology
,,I-Physiology
we,O
stratified,O
tumours,B-disease
according,O
to,O
these,O
phenotypes,O
.,O
 , 
Despite,O
having,O
only,O
9,B-size
MSI-/BRAF,B-Disorder
mutant,I-mutation
and,O
5,B-size
CIMP-/BRAF,B-gene
mutant,B-mutation
tumors,B-disease
,,I-disease
the,O
results,O
showed,O
that,O
associations,O
between,O
BRAF,B-gene
mutation,B-mutation
and,O
the,O
morphological,O
properties,O
of,O
tumor,O
-,O
infiltrating,O
infiltrating,O
lymphocytes,O
,,O
poor,O
histological,O
grade,O
and,O
mucinous,O
phenotype,O
were,O
retained,O
(,O
Tables,O
3,O
and,O
4,O
),O
.,O
 , 


,O
The,O
frequencies,O
of,O
BRAF,B-gene
mutation,B-mutation
observed,O
in,O
MSI-,B-Disorder
(,B-size
4,I-size
%,I-size
),I-size
and,O
MSI+,B-Disorder
(,B-size
39,I-size
%,I-size
),I-size
tumors,B-disease
in,O
the,O
present,O
study,O
compare,O
favourably,O
(,B-size
5,I-size
%,I-size
and,O
52,B-size
%,I-size
,,I-size
respectively,O
),O
to,O
those,O
reported,O
recently,O
in,O
another,O
large,O
,,O
population,O
-,O
based,O
study,O
[,O
17,O
],O
.,O
 , 
Although,O
BRAF,B-gene
mutations,B-mutation
are,O
much,O
more,O
frequent,O
in,O
MSI+,B-Disorder
tumors,B-disease
,,I-disease
the,O
comparative,O
rarity,O
of,O
this,O
phenotype,O
means,O
that,O
a,O
considerable,O
proportion,O
occur,O
in,O
MSI-,B-Disorder
tumors,B-disease
.,I-disease
 , 
In,O
the,O
present,O
study,O
,,O
43,B-size
%,I-size
of,O
all,O
BRAF,B-cohort-patient
mutations,I-cohort-patient
occurred,O
in,O
MSI-,B-Disorder
tumors,B-disease
compared,O
to,O
48,O
%,O
in,O
the,O
study,O
by,O
Samowitz,O
et,O
al,O
 , 
[,O
17,O
],O
.,O
 , 
BRAF,B-gene
mutations,B-mutation
were,O
reported,O
to,O
show,O
prognostic,O
significance,O
in,O
MSI-,B-Disorder
but,O
not,O
in,O
MSI+,B-Disorder
CRC,B-disease
[,O
17,O
],O
.,O
 , 
The,O
lack,O
of,O
follow,O
-,O
up,O
information,O
on,O
CRC,B-disease
patients,B-cohort-patient
in,O
the,O
current,O
study,O
and,O
the,O
small,O
number,O
of,O
BRAF,B-gene
mutations,B-mutation
(,O
n,O
=,O
21,B-size
),I-size
meant,O
that,O
we,O
were,O
unable,O
to,O
evaluate,O
the,O
prognostic,O
significance,O
of,O
BRAF,B-gene
mutation,B-mutation
according,O
to,O
MSI,O
status,O
.,O
 , 


,O
 , 
#1601966-06-Methods-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Preprocessing,O
of,O
expression,O
data,O


,O
We,O
used,O
our,O
own,O
algorithm,O
to,O
condensate,O
the,O
probe,O
level,O
data,O
provided,O
by,O
Affymetrix,O
CEL,O
-,O
files,O
per,O
chip,O
experiment,O
:,O
Background,O
intensity,O
was,O
computed,O
as,O
the,O
mean,O
of,O
the,O
2,O
%,O
darkest,O
feature,O
intensities,O
.,O
 , 
This,O
background,O
value,O
was,O
subtracted,O
from,O
each,O
feature,O
value,O
.,O
 , 
Subsequently,O
,,O
each,O
feature,O
value,O
was,O
divided,O
by,O
the,O
median,O
of,O
all,O
feature,O
values,O
.,O
 , 
As,O
a,O
representative,O
expression,O
value,O
(,O
PMQ,O
),O
for,O
each,O
probe,O
set,O
,,O
the,O
third,O
quartile,O
(,O
75,O
%,O
),O
of,O
all,O
intensities,O
of,O
all,O
perfect,O
match,O
oligonucleotides,O
was,O
used,O
.,O
 , 
Furthermore,O
,,O
to,O
distinguish,O
real,O
expression,O
signals,O
from,O
noise,O
the,O
Wilcoxon,O
signed,O
rank,O
test,O
was,O
applied,O
to,O
each,O
probe,O
set,O
.,O
 , 
A,O
probe,O
set,O
was,O
called,O
detectable,O
if,O
the,O
result,O
of,O
the,O
Wilcoxon,O
signed,O
rank,O
test,O
applied,O
to,O
its,O
11,O
probe,O
pairs,O
(,O
perfect,O
match,O
versus,O
mismatch,O
oligonucleotide,O
),O
had,O
a,O
significance,O
level,O
of,O
p,O
<,O
0.1,O
and,O
relative,O
expression,O
value,O
(,O
PMQ,O
),O
of,O
>,O
4.0,O
.,O
 , 
We,O
used,O
these,O
constraints,O
for,O
decision,O
whether,O
a,O
gene,O
is,O
expressed,O
or,O
not,O
due,O
to,O
validation,O
results,O
of,O
several,O
gene,O
expression,O
pattern,O
by,O
quantitative,O
RT,O
-,O
PCR,O
and/or,O
Northern,O
Blot,O
analysis,O
in,O
our,O
lab,O
(,O
data,O
not,O
shown,O
),O
.,O
 , 


,O
For,O
each,O
patient,B-cohort-patient
and,O
probeset,O
an,O
expression,O
ratio,O
was,O
calculated,O
according,O
to,O
the,O
following,O
rules,O
:,O
 , 
If,O
expression,O
was,O
detectable,O
in,O
both,O
the,O
normal,O
and,O
tumor,B-disease
sample,O
(,O
Wilcoxon,O
test,O
p,O
<,O
=,O
0.10,O
and,O
relative,O
expression,O
value,O
PMQ,O
>,O
=,O
4,O
),O
,,O
the,O
ratio,O
PMQ(T)/PMQ(N,O
),O
is,O
our,O
expression,O
ratio,O
(,O
hereafter,O
called,O
T,O
/,O
N,O
),O
.,O
 , 
If,O
expression,O
was,O
undetectable,O
in,O
either,O
the,O
normal,O
or,O
the,O
tumor,B-disease
sample,O
,,O
the,O
expression,O
ratio,O
was,O
either,O
set,O
to,O
T,O
/,O
N,O
=,O
2,O
(,O
normal,O
absent,O
),O
or,O
to,O
T,O
/,O
N,O
=,O
0.5,O
(,B-disease
tumor,I-disease
absent,O
),O
.,O
 , 
If,O
expression,O
was,O
undetectable,O
in,O
both,O
the,O
normal,O
and,O
tumor,B-disease
sample,O
,,O
no,O
expression,O
ratio,O
was,O
calculated,O
and,O
we,O
call,O
the,O
probe,O
set,O
not,O
informative,O
.,O
 , 
For,O
each,O
probe,O
set,O
the,O
number,O
of,O
cases,B-cohort-patient
which,O
showed,O
an,O
up,O
-,O
regulation,O
(,O
T,O
/,O
N,O
>,O
=,O
2,O
),O
,,O
a,O
down,O
-,O
regulation,O
(,O
T,O
/,O
N,O
<,O
=,O
0.5,O
),O
or,O
the,O
number,O
of,O
unchanged,O
transcription,O
levels,O
(,O
0.5,O
<,O
T,O
/,O
N,O
<,O
2,O
),O
were,O
counted,O
.,O
 , 
We,O
filtered,O
out,O
those,O
probe,O
sets,O
which,O
are,O
not,O
informative,O
in,O
any,O
patient,B-cohort-patient
,,I-cohort-patient
reducing,O
the,O
number,O
of,O
probe,O
sets,O
to,O
19404,O
.,O
 , 
To,O
eliminate,O
redundancy,O
of,O
probe,O
sets,O
with,O
respect,O
to,O
genes,O
,,O
we,O
kept,O
only,O
the,O
most,O
informative,O
probe,O
set,O
of,O
a,O
single,O
gene,O
,,O
i.e.,O
the,O
probe,O
set,O
which,O
is,O
informative,O
in,O
the,O
highest,O
number,O
of,O
matched,O
sample,O
pairs,O
.,O
 , 
Additionally,O
,,O
only,O
probe,O
sets,O
that,O
could,O
unambiguously,O
be,O
linked,O
to,O
a,O
particular,O
genomic,O
locus,O
were,O
considered,O
(,O
chromosome,O
band,O
and,O
position,O
;,O
see,O
Affymetrix,O
U133A,O
/,O
B,O
annotation,O
files,O
),O
.,O
 , 
Finally,O
,,O
the,O
pre,O
-,O
processing,O
resulted,O
in,O
a,O
total,O
number,O
of,O
10.935,O
probe,O
sets,O
which,O
were,O
the,O
basis,O
of,O
all,O
further,O
analyses,O
.,O
 , 


,O
 , 
#1619718-05-Discussion-p04
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,B-Physiology
MGMT,I-Physiology
inactivation,I-Physiology
predisposes,O
to,O
G,B-mutation
:,I-mutation
T,I-mutation
mismatches,I-mutation
and,O
chromosomal,O
instability,O
through,O
futile,O
cycles,O
of,O
excision,O
and,O
repair,O
as,O
well,O
as,O
to,O
mutation,B-mutation
of,O
KRAS,B-gene
and,O
TP53.9,B-gene
Partial,B-Physiology
methylation,I-Physiology
of,I-Physiology
MLH1,B-gene
may,O
also,O
lead,O
to,O
low,O
-,O
level,O
microsatellite,O
instability.37,O


,O
The,O
interpretation,O
of,O
immunostaining,O
for,O
p53,B-gene
is,O
problematic,O
insofar,O
as,O
increased,O
expression,O
of,O
the,O
wild,O
-,O
type,O
protein,O
occurs,O
in,O
areas,O
of,O
increased,O
proliferation,O
and,O
must,O
be,O
distinguished,O
from,O
the,O
diffuse,O
and,O
strong,O
nuclear,O
staining,O
associated,O
with,O
retained,O
mutant,O
protein,O
.,O
 , 
However,O
,,O
several,O
studies,O
have,O
described,O
low,O
frequencies,O
of,O
p53,O
expression,O
in,O
TAs,B-disease
with,O
low,B-Disorder
-,I-Disorder
grade,I-Disorder
dysplasia45,46,I-Disorder
and,O
even,O
in,O
VAs.47,B-disease
Conversely,O
,,O
there,O
is,O
general,O
agreement,O
that,O
aberrant,B-Physiology
p53,I-Physiology
expression,I-Physiology
is,O
closely,O
associated,O
with,O
the,O
presence,O
of,O
high,B-Disorder
-,I-Disorder
grade,I-Disorder
dysplasia,I-Disorder
amounting,O
to,O
carcinoma,B-disease
in,O
situ.34,46,48,O
Aberrant,B-Physiology
retention,I-Physiology
of,I-Physiology
presumed,I-Physiology
mutant,I-Physiology
nuclear,I-Physiology
p53,I-Physiology
was,O
rarely,O
observed,O
in,O
the,O
present,O
series,O
,,O
although,O
it,O
occurred,O
more,O
frequently,O
in,O
serrated,B-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
(,B-size
12,I-size
%,I-size
),I-size
than,O
in,O
adenomas,B-disease
(,B-size
1,I-size
%,I-size
),I-size
.,O
 , 
One,B-size
of,O
the,O
polyps,B-cohort-patient
with,O
aberrant,B-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
was,O
a,O
mixed,B-Concepts_Ideas
polyp,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
(,O
Figure,O
1B,O
),O
.,O
 , 
Had,O
it,O
not,O
been,O
removed,O
,,O
this,O
polyp,B-disease
may,O
have,O
progressed,O
within,O
a,O
short,O
time,O
frame,O
to,O
the,O
subset,O
of,O
CRC,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
,,I-mutation
DNA,B-Physiology
methylation,I-Physiology
,,I-Physiology
TP53,B-gene
mutation,B-mutation
and,O
DNA,B-Disorder
microsatellite,I-Disorder
stable,I-Disorder
status,I-Disorder
(,O
a,O
‘,O
fusion,O
’,O
pathway,O
shown,O
in,O
Table,O
3).49,50,O


,B-Physiology
Loss,I-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
the,I-Physiology
DNA,I-Physiology
repair,I-Physiology
gene,I-Physiology
MGMT,B-gene
is,O
associated,O
with,O
methylation,O
of,O
the,O
promoter,O
region45,51,52,O
and,O
the,O
latter,O
change,O
has,O
been,O
linked,O
causatively,O
with,O
G,B-mutation
:,I-mutation
C,I-mutation
to,I-mutation
A,I-mutation
:,I-mutation
T,I-mutation
transition,I-mutation
mutations,O
in,O
TP53.53,B-gene
 , 
In,O
the,O
present,O
study,O
,,O
complete,B-Physiology
or,I-Physiology
partial,I-Physiology
loss,I-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,B-gene
coincided,O
with,O
aberrant,B-Physiology
nuclear,I-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
in,O
three,B-size
serrated,B-Concepts_Ideas
polyps,B-cohort-patient
with,O
dysplasia,B-Disorder
(,O
Figure,O
2,O
),O
,,O
but,O
not,O
in,O
the,O
single,B-size
tubular,B-Concepts_Ideas
adenoma,B-disease
with,O
aberrant,B-Physiology
p53,I-Physiology
expression,I-Physiology
.,I-Physiology
 , 
Only,O
one,O
previous,O
study,O
has,O
attempted,O
to,O
correlate,O
MGMT,B-gene
and,O
p53,B-Physiology
expression,I-Physiology
in,O
colorectal,B-body-part
polyps.45,B-disease
 , 
In,O
that,O
study,O
,,O
4.3,B-size
%,I-size
of,O
adenomas,B-disease
showed,O
aberrant,B-Physiology
p53,I-Physiology
expression,I-Physiology
but,O
none,B-Concepts_Ideas
had,I-Concepts_Ideas
loss,I-Concepts_Ideas
of,I-Concepts_Ideas
MGMT,B-gene
.,I-gene
 , 
It,O
is,O
possible,O
that,O
the,O
link,O
between,O
MGMT,B-gene
silencing,I-Physiology
and,O
TP53,B-gene
mutation,B-mutation
is,O
more,O
evident,O
in,O
the,O
serrated,O
pathway,O
than,O
in,O
the,O
adenoma,B-disease
–,I-disease
carcinoma,I-disease
sequence,O
.,O
 , 
The,O
frequency,O
of,O
TP53,B-gene
mutation,B-mutation
in,O
SAs,B-disease
has,O
ranged,O
from,O
5,B-size
to,I-size
50,I-size
%,I-size
in,O
the,O
literature.39,41,54,O
Although,O
a,O
link,O
between,O
MGMT,B-Physiology
loss,I-Physiology
and,O
aberrant,B-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
is,O
supported,O
by,O
the,O
present,O
findings,O
,,O
it,O
should,O
be,O
noted,O
that,O
only,O
a,O
small,O
number,O
of,O
polyps,B-disease
showed,O
these,O
changes,O
concurrently,O
.,O
 , 


,B-gene
KRAS,I-gene
mutation,B-mutation
has,O
been,O
linked,O
to,O
the,O
initiation,O
of,O
hyperplastic,B-Disorder
aberrant,I-Disorder
crypt,I-Disorder
foci,I-Disorder
and,O
small,B-Concepts_Ideas
HPs7,38,55,B-disease
and,O
is,O
therefore,O
closely,O
associated,O
with,O
the,O
development,O
of,O
glandular,B-Concepts_Ideas
serration,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
While,O
the,O
acquisition,O
of,O
KRAS,B-gene
mutation,B-mutation
is,O
also,O
observed,O
in,O
adenomas,B-disease
,,I-disease
this,O
change,O
is,O
correlated,O
with,O
the,O
development,O
of,O
a,O
villous,B-Concepts_Ideas
architecture,I-Concepts_Ideas
and,O
in,O
some,O
cases,O
the,O
presence,O
of,O
epithelial,B-Concepts_Ideas
serration,I-Concepts_Ideas
(,O
see,O
Discussion,O
of,O
Group,B-cohort-patient
B,I-cohort-patient
serrated,B-Concepts_Ideas
polyps,B-disease
above,O
),O
.,O
 , 
It,O
may,O
therefore,O
be,O
conceptually,O
correct,O
to,O
view,O
KRAS,B-gene
mutation,B-mutation
as,O
adding,O
a,O
serrated,O
molecular,O
signature,O
to,O
the,O
traditional,B-Concepts_Ideas
adenoma,B-disease
and,O
hence,O
providing,O
an,O
additional,O
‘,O
fusion,O
’,O
pathway,O
.,O
 , 
However,O
,,O
a,O
mechanistic,O
link,O
between,O
KRAS,B-gene
mutation,B-mutation
and,O
the,O
morphogenesis,O
of,O
serration,O
and,O
villous,O
change,O
remains,O
to,O
be,O
established,O
.,O
 , 
MGMT,B-gene
is,O
again,O
implicated,O
in,O
this,O
second,O
type,O
of,O
‘,O
fusion,O
’,O
since,O
methylation,O
and,O
inactivation,O
of,O
this,O
DNA,O
repair,O
gene,O
has,O
been,O
linked,O
to,O
G,B-mutation
:,I-mutation
C,I-mutation
to,I-mutation
A,I-mutation
:,I-mutation
T,I-mutation
transitions,I-mutation
in,O
KRAS.56–58,B-gene
 , 
In,O
this,O
study,O
there,O
was,O
an,O
association,O
between,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,I-Physiology
and,O
KRAS,B-gene
mutation,B-mutation
among,O
small,B-Concepts_Ideas
TAs,B-disease
(,O
P,O
=,O
0.04,O
),O
but,O
not,O
in,O
the,O
other,O
polyp,B-disease
categories,O
.,O
 , 
Methylation,B-Physiology
of,I-Physiology
MGMT,B-gene
occurs,O
in,O
normal,B-disease
colorectal,B-body-part
mucosa,59,I-body-part
as,O
well,O
as,O
in,O
polyps,B-disease
,,I-disease
and,O
is,O
therefore,O
unlikely,O
to,O
serve,O
as,O
a,O
key,O
rate,O
-,O
limiting,O
step,O
in,O
the,O
transition,O
to,O
malignancy,O
.,O
 , 
A,O
possible,O
third,O
‘,O
fusion,O
’,O
pathway,O
implicating,O
KRAS,B-gene
and,O
methylation,B-Physiology
of,I-Physiology
APC60,I-Physiology
is,O
included,O
in,O
Table,O
3,O
.,O
 , 


,O
 , 
#1601966-06-Methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Methods,O


,B-cohort-patient
Patients,I-cohort-patient


,I-cohort-patient
25,I-size
colorectal,B-disease
cancer,I-disease
patients,B-cohort-patient
undergoing,O
elective,O
standard,O
oncological,O
resection,O
at,O
the,O
department,O
of,O
surgery,O
,,O
Charité,O
,,O
Campus,O
Benjamin,O
Franklin,O
,,O
Berlin,O
,,O
Germany,O
were,O
prospectively,O
recruited,O
for,O
this,O
study,O
.,O
 , 
The,O
study,O
was,O
approved,O
by,O
the,O
local,O
ethical,O
committee,O
and,O
informed,O
consent,O
was,O
obtained,O
from,O
all,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
Rectal,B-body-part
cancer,I-disease
patients,B-cohort-patient
receiving,O
neo,O
-,O
adjuvant,O
radiochemotherapy,O
were,O
excluded,O
from,O
this,O
study,O
.,O
 , 


,O
Tissue,O
samples,O
and,O
UV,O
-,O
laser,O
microdissection,O


,O
Transmural,O
cancer,B-disease
specimens,O
were,O
snap,O
frozen,O
(,O
liquid,O
nitrogen,O
),O
within,O
20,O
minutes,O
following,O
excision,O
and,O
stored,O
at,O
-80,O
°,O
C,O
.,O
 , 
All,O
tissue,O
samples,O
were,O
evaluated,O
by,O
a,O
pathologist,O
before,O
and,O
during,O
laser,O
micro,O
-,O
dissection,O
to,O
ensure,O
an,O
enrichment,O
of,O
vital,O
tumor,B-disease
cells,O
.,O
 , 
Six,O
-,O
micron,O
serial,O
frozen,O
sections,O
were,O
cut,O
on,O
a,O
standard,O
cryostat,O
and,O
mounted,O
on,O
RNase,O
-,O
free,O
foil,O
(,O
2,5,O
μm,O
),O
coated,O
on,O
glass,O
slides,O
followed,O
by,O
immediate,O
fixation,O
(,O
70,O
%,O
ethanol,O
for,O
30s,O
),O
,,O
H&E,O
staining,O
,,O
and,O
ethanol,O
dehydration,O
(,O
70,O
%,O
,,O
95,O
%,O
and,O
finally,O
100,O
%,O
ethanol,O
),O
.,O
 , 
After,O
vacuum,O
drying,O
the,O
membranes,O
carrying,O
the,O
sections,O
were,O
manually,O
turned,O
and,O
coated,O
on,O
new,O
RNase,O
free,O
glass,O
slides,O
.,O
 , 
Optically,O
transparent,O
CapSure,O
LCM,O
caps,O
(,O
ARCTURUS,O
,,O
CA,O
),O
were,O
placed,O
on,O
the,O
foil,O
over,O
a,O
selected,O
field,O
of,O
cells,O
.,O
 , 
Vital,O
colorectal,O
epithelial,O
carcinoma,O
cells,O
(,O
>,O
90,O
%,O
proportion,O
),O
from,O
the,O
invasion,O
front,O
were,O
isolated,O
using,O
UV,O
-,O
LCM,O
Systems,O
from,O
PALM,O
(,O
Microlaser,O
Technologie,O
,,O
Germany,O
),O
and,O
SL,O
(,O
Microtest,O
GmbH,O
,,O
Germany,O
),O
.,O
 , 
After,O
visual,O
control,O
of,O
completeness,O
of,O
dissection,O
the,O
captured,O
cells,O
were,O
immersed,O
in,O
denaturation,O
buffer,O
(,O
GTC,O
Extraction,O
Buffer,O
,,O
2,O
%,O
beta,O
-,O
mercaptoethanol,O
,,O
Promega,O
,,O
WI,O
),O
and,O
stored,O
at,O
-80,O
°,O
C,O
.,O
 , 


,O
mRNA,O
-,O
extraction,O
,,O
cRNA,O
-,O
preparation,O
and,O
-amplification,O


,O
Poly(A)+,O
RNAs,O
were,O
isolated,O
using,O
PolyATtract,O
1000,O
kit,O
(,O
Promega,O
,,O
Heidelberg,O
,,O
Germany,O
),O
according,O
to,O
the,O
manufacturer,O
's,O
recommendations,O
.,O
 , 
For,O
each,O
sample,O
the,O
cDNA,O
synthesis,O
and,O
repetitive,O
in,O
vitro,O
transcription,O
were,O
performed,O
three,O
times,O
,,O
as,O
described,O
previously,O
[,O
38,O
-,O
40,O
],O
.,O
 , 
In,O
brief,O
,,O
the,O
total,O
amount,O
of,O
prepared,O
mRNA,O
from,O
one,O
sample,O
was,O
used,O
.,O
 , 
First,O
strand,O
cDNA,O
synthesis,O
was,O
initiated,O
using,O
the,O
Affymetrix,O
T7,O
-,O
oligo,O
-,O
dT,O
promoter,O
-,O
primer,O
combination,O
.,O
 , 
The,O
second,O
strand,O
cDNA,O
was,O
synthesized,O
by,O
internal,O
priming,O
.,O
 , 
In,O
vitro,O
transcription,O
was,O
performed,O
using,O
Ambion,O
's,O
Megascript,O
kit,O
(,O
Ambion,O
,,O
Huntington,O
,,O
UK,O
),O
as,O
recommended,O
by,O
the,O
manufacturer,O
.,O
 , 
From,O
the,O
generated,O
cRNA,O
a,O
new,O
first,O
strand,O
synthesis,O
was,O
initiated,O
using,O
0.025,O
mM,O
of,O
a,O
random,O
hexamer,O
as,O
primer,O
.,O
 , 
After,O
completion,O
,,O
the,O
second,O
strand,O
synthesis,O
was,O
primed,O
using,O
the,O
Affymetrix,O
T7,O
-,O
oligo,O
-,O
dT,O
promoter,O
-,O
primer,O
combination,O
at,O
a,O
concentration,O
of,O
0.1,O
mM.,O
 , 
A,O
second,O
in,O
vitro,O
transcription,O
was,O
performed,O
and,O
then,O
the,O
procedure,O
was,O
repeated,O
one,O
additional,O
time,O
.,O
 , 
During,O
the,O
third,O
in,O
vitro,O
transcription,O
biotin,O
-,O
labeled,O
nucleotides,O
were,O
incorporated,O
into,O
the,O
cRNA,O
as,O
recommended,O
by,O
the,O
Affymetrix,O
protocol,O
.,O
 , 


,O
Microarray,O
hybridization,O


,O
BIO+cRNAs,O
were,O
hybridized,O
on,O
Affymetrix,O
Human,O
Genome,O
U133A,O
 , 
and,O
U133B,O
 , 
GeneChips,O
,,O
that,O
consist,O
of,O
44.928,O
probe,O
sets,O
(,O
Affymetrix,O
,,O
Santa,O
Clara,O
,,O
CA,O
),O
.,O
 , 
Fragmentation,O
,,O
preparation,O
of,O
hybridization,O
cocktails,O
,,O
hybridization,O
,,O
washing,O
,,O
staining,O
and,O
scanning,O
of,O
Affymetrix,O
GeneChip,O
were,O
performed,O
according,O
to,O
the,O
manufacturer,O
's,O
protocols,O
.,O
 , 


,O
 , 
#1373649-02-Background-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Background,O


,B-disease
Hereditary,I-disease
non,I-disease
-,I-disease
polyposis,I-disease
colorectal,I-disease
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
is,O
an,O
inherited,B-Concepts_Ideas
syndrome,O
predisposing,O
to,O
the,O
early,B-Disorder
development,I-Disorder
of,O
cancers,B-disease
of,O
colon,B-body-part
,,I-body-part
rectum,B-body-part
,,I-body-part
endometrium,B-body-part
,,I-body-part
ovarium,B-body-part
,,I-body-part
small,B-body-part
bowel,I-body-part
,,I-body-part
stomach,B-body-part
and,O
urinary,B-body-part
tract,I-body-part
[,O
1,2,O
],O
.,O
 , 


,O
Since,O
there,O
are,O
no,O
premonitory,O
signs,O
of,O
susceptibility,O
to,O
HNPCC,B-disease
,,I-disease
family,O
history,O
has,O
been,O
the,O
primary,O
method,O
for,O
identifying,O
patients,O
at,O
risk,O
.,O
 , 
Defined,O
by,O
the,O
International,O
Collaborative,O
group,O
on,O
HNPCC,B-disease
,,I-disease
the,O
typical,O
HNPCC,B-disease
family,B-cohort-patient
fulfill,O
the,O
following,O
criteria,O
(,O
referred,O
to,O
as,O
the,O
Amsterdam,O
-,O
I,O
criteria,O
[,O
3,O
],O
):,O
1,O
.,O
 , 
Three,B-size
or,I-size
more,I-size
relatives,B-cohort-patient
with,O
histologically,O
verified,O
colorectal,B-disease
cancer,I-disease
,,I-disease
one,O
of,O
whom,O
is,O
a,O
first,O
-,O
degree,O
relative,O
of,O
the,O
other,O
two,O
;,O
2,O
.,O
 , 
Colorectal,B-disease
cancer,I-disease
affecting,O
at,O
least,O
2,O
successive,O
generations,O
;,O
and,O
3,O
.,O
 , 
At,O
least,O
one,B-cohort-patient
relative,I-cohort-patient
diagnosed,O
with,O
colorectal,B-disease
cancer,B-disease
under,B-age
the,I-age
age,I-age
of,I-age
50,I-age
.,I-age
 , 
The,O
fulfillment,O
of,O
these,O
criteria,O
prompted,O
further,O
genetics,O
investigations,O
.,O
 , 
More,O
recently,O
it,O
has,O
been,O
revised,O
to,O
take,O
into,O
account,O
the,O
prevalence,O
of,O
extracolonic,B-disease
cancer,I-disease
in,O
certain,O
HNPCC,B-cohort-patient
families,I-cohort-patient
[,O
4,O
],O
.,O
 , 


,O
This,O
autosomal,O
dominantly,O
inherited,O
disorder,O
is,O
caused,O
by,O
germline,O
mutations,O
in,O
genes,O
coding,O
proteins,O
responsible,O
for,O
the,O
repair,O
of,O
DNA,O
replication,O
errors,O
,,O
which,O
are,O
referred,O
to,O
as,O
DNA,O
mismatch,O
repair,O
(,O
MMR,O
),O
genes,O
[,O
5,O
],O
.,O
 , 
DNA,O
mismatch,O
repair,O
machinery,O
plays,O
a,O
critical,O
role,O
in,O
genomic,O
stability,O
,,O
including,O
correction,O
of,O
mispaired,O
bases,O
associated,O
with,O
DNA,O
replication,O
and,O
recombination,O
.,O
 , 
Germline,O
mutations,O
in,O
one,O
allele,O
of,O
any,O
of,O
these,O
genes,O
followed,O
by,O
the,O
somatic,O
loss,O
or,O
inactivation,O
of,O
the,O
wild,O
-,O
type,O
allele,O
leads,O
to,O
a,O
defective,O
mismatch,O
repair,O
mechanism,O
.,O
 , 
The,O
current,O
",O
gold,O
standard,O
",O
for,O
assessing,O
tumor,O
DNA,O
MMR,B-gene
activity,O
is,O
molecular,O
microsatellite,O
instability,O
(,O
MSI,O
),O
testing,O
.,O
 , 
In,O
most,O
cases,O
,,O
it,O
involves,O
extracting,O
DNA,O
from,O
both,O
tumor,O
and,O
normal,O
tissue,O
.,O
 , 
The,O
DNA,O
is,O
subjected,O
to,O
polymerase,O
chain,O
reaction,O
(,O
PCR,O
),O
amplification,O
of,O
five,O
or,O
more,O
different,O
chromosomal,O
loci,O
that,O
compare,O
",O
microsatellites,O
",O
,,O
running,O
the,O
PCR,O
products,O
through,O
a,O
gel,O
to,O
separate,O
DNA,O
fragments,O
by,O
size,O
,,O
comparing,O
the,O
tumor,O
-,O
normal,O
pairs,O
,,O
and,O
scoring,O
for,O
differences,O
between,O
the,O
two,O
.,O
 , 
Instability,O
at,O
two,O
or,O
more,O
out,O
of,O
five,O
markers,O
defines,O
a,O
tumor,B-disease
as,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
and,O
prompts,O
further,O
analysis,O
,,O
as,O
sequencing,O
of,O
DNA,O
MMR,O
genes,O
.,O
 , 
A,O
number,O
of,O
them,O
have,O
been,O
associated,O
with,O
HNPCC,B-disease
,,I-disease
including,O
hMSH2,B-gene
,,I-gene
hMLH1,B-gene
,,I-gene
hPMS1,B-gene
,,I-gene
hPMS2,B-gene
,,I-gene
hMSH3,B-gene
,,I-gene
and,O
hMSH6,B-gene
.,I-gene
 , 
Most,O
of,O
the,O
HNPCC,B-disease
families,B-cohort-patient
in,O
which,O
mutations,B-mutation
have,O
been,O
identified,O
involved,O
hMSH2,B-gene
and,O
hMLH1,B-gene
genes,O
[,O
6,O
],O
.,O
 , 


,O
A,O
much,O
less,O
labor,O
-,O
intensive,O
alternative,O
method,O
used,O
to,O
prescreen,O
high,O
-,O
risk,O
individuals,O
for,O
further,O
germline,O
mutation,O
analysis,O
is,O
immunohistochemistry,O
(,O
IHC,O
),O
testing,O
for,O
MLH1,B-gene
and,I-Physiology
MSH2,B-gene
expression,I-Physiology
.,I-Physiology
 , 
IHC,O
testing,O
may,O
identify,O
which,O
gene,O
to,O
target,O
for,O
analysis,O
.,O
 , 


,O
We,O
describe,O
MSI,O
testing,O
in,O
the,O
absence,O
of,O
proband,B-cohort-patient
non,O
-,O
tumor,O
tissue,O
using,O
the,O
Bethesda,O
consensus,O
panel,O
(,O
mononucleotide,O
repeats,O
BAT25,O
and,O
BAT26,O
,,O
and,O
dinucleotide,O
repeats,O
D2S123,O
,,O
D5S346,O
,,O
and,O
D17S250,O
),O
and,O
we,O
report,O
a,O
novel,O
hMSH2,B-gene
germline,B-mutation
mutation,I-mutation
found,O
in,O
the,O
family,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1619718-05-Discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Discussion,O


,O
The,O
scientific,O
basis,O
for,O
the,O
prevention,O
of,O
cancer,B-disease
depends,O
upon,O
an,O
understanding,O
of,O
early,O
events,O
in,O
pathogenesis,O
,,O
including,O
the,O
mechanisms,O
underlying,O
initiation,O
and,O
growth,O
of,O
precancerous,B-Concepts_Ideas
polyps,B-disease
.,I-disease
 , 
Recommendations,O
for,O
the,O
management,O
of,O
patients,B-cohort-patient
with,O
colorectal,B-body-part
polyps,B-disease
currently,O
recognize,O
only,O
a,O
single,O
principal,O
type,O
of,O
clinically,O
important,O
polyp,B-disease
:,I-disease
the,O
adenoma,B-disease
.,I-disease
 , 
The,O
current,O
study,O
includes,O
additional,O
types,O
of,O
polyp,B-disease
that,O
are,O
likely,O
to,O
have,O
malignant,O
potential,O
,,O
namely,O
serrated,B-Concepts_Ideas
polyps,B-disease
with,B-Disorder
(,B-disease
MP,I-disease
and,I-Disorder
SA,I-Disorder
),I-Disorder
and,I-Disorder
without,I-Disorder
(,I-Disorder
SSA,I-Disorder
),I-Disorder
dysplasia,I-Disorder
.,I-Disorder
 , 
This,O
discussion,O
will,O
focus,O
first,O
on,O
adenomas,B-disease
,,I-disease
second,O
on,O
non,B-Disorder
-,I-Disorder
dysplastic,I-Disorder
serrated,B-Concepts_Ideas
polyps,B-disease
and,O
will,O
then,O
conclude,O
with,O
the,O
concept,O
that,O
features,O
of,O
these,O
two,O
types,O
of,O
polyp,B-disease
can,O
co,O
-,O
occur,O
or,O
become,O
‘,O
fused,O
’,O
in,O
subtypes,O
of,O
advanced,B-Concepts_Ideas
polyps,B-disease
with,O
mixed,O
cytomorphology,O
(,B-Disorder
hyperplastic,I-Disorder
and,I-Disorder
dysplastic,I-Disorder
),I-Disorder
and,O
a,O
serrated,B-Disorder
and/or,I-Disorder
villous,I-Disorder
architecture,I-Disorder
.,I-Disorder
 , 


,B-disease
Adenomas,I-disease


,I-disease
The,O
adenomas,B-disease
in,O
this,O
study,O
were,O
grouped,O
as,O
TAs,B-disease
<,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
,,I-Concepts_Ideas
TAs,B-cohort-patient
>,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
and,O
TVAs,B-cohort-patient
/,I-cohort-patient
VAs,I-cohort-patient
.,I-cohort-patient
 , 
Overall,O
,,O
KRAS,B-gene
mutation,B-mutation
occurred,O
in,O
26.5,B-size
%,I-size
of,O
adenomas,B-disease
while,O
BRAF,B-gene
mutation,B-mutation
was,O
detected,O
in,O
only,O
4.8,B-size
%,I-size
.,I-size
 , 
Three,B-size
of,I-size
the,I-size
four,I-size
BRAF,B-gene
mutations,B-mutation
occurred,O
in,O
adenomas,B-disease
that,O
also,O
had,O
KRAS,B-gene
mutation,B-mutation
.,I-mutation
 , 
It,O
is,O
well,O
established,O
that,O
BRAF,B-gene
and,O
KRAS,B-gene
mutation,B-mutation
rarely,O
occur,O
in,O
the,O
same,O
colorectal,B-body-part
neoplasm.12,16,30,O
Furthermore,O
,,O
BRAF,B-gene
mutations,B-mutation
are,O
much,O
more,O
typical,O
of,O
serrated,B-Concepts_Ideas
polyps,B-disease
than,O
adenomas.14,31,B-disease
The,O
assay,O
for,O
BRAF,B-gene
mutation,B-mutation
used,O
in,O
this,O
study,O
was,O
highly,O
sensitive,O
and,O
it,O
is,O
possible,O
that,O
the,O
mutation,O
was,O
being,O
identified,O
in,O
normal,B-disease
mucosa,B-body-part
included,O
with,O
the,O
polyp,B-disease
.,I-disease
 , 
KRAS,B-gene
mutation,B-mutation
may,O
occur,O
within,O
apparently,O
normal,B-disease
colorectal,B-body-part
mucosa,I-body-part
and,O
the,O
same,O
could,O
apply,O
to,O
BRAF.32,B-gene
Therefore,O
,,O
the,O
finding,O
of,O
BRAF,B-gene
mutation,B-mutation
in,O
a,O
small,O
subset,O
of,O
adenomas,B-disease
could,O
be,O
spurious,O
and,O
the,O
true,O
incidence,O
of,O
BRAF,B-gene
mutation,B-mutation
in,O
colorectal,B-body-part
adenomas,B-disease
could,O
be,O
lower,B-size
than,I-size
4.8,I-size
%,I-size
.,I-size
 , 
BRAF,B-gene
mutation,B-mutation
frequencies,O
of,O
0%14,B-size
and,O
3%31,B-size
have,O
been,O
reported,O
in,O
other,O
series,O
of,O
colorectal,B-body-part
adenomas,B-disease
.,I-disease
 , 


,O
In,O
previous,O
studies,O
of,O
KRAS,B-gene
in,O
colorectal,B-body-part
adenomas,B-disease
,,I-disease
mutation,B-mutation
has,O
been,O
associated,O
negatively,O
with,O
flat,B-Concepts_Ideas
and,O
depressed,B-Concepts_Ideas
TAs,B-disease
and,O
positively,O
with,O
polypoid,B-Disorder
appearance,I-Disorder
,,I-Disorder
increasing,B-Concepts_Ideas
size,I-Concepts_Ideas
,,I-Concepts_Ideas
dysplasia,B-Disorder
,,I-Disorder
villous,B-Concepts_Ideas
change,I-Concepts_Ideas
and,O
synchronous,B-Concepts_Ideas
colorectal,B-disease
cancer.6,33–35,I-disease
In,O
by,O
far,O
the,O
largest,O
study,O
,,O
which,O
included,O
738,B-size
adenomas,B-disease
obtained,O
from,O
639,B-size
participants,B-cohort-patient
in,O
a,O
dietary,O
intervention,O
trial,O
,,O
multivariate,O
analysis,O
showed,O
that,O
the,O
independent,O
predictors,O
of,O
KRAS,B-gene
mutation,B-mutation
were,O
age,O
of,O
subject,O
,,O
presence,O
of,O
villous,O
architecture,O
and,O
high,O
-,O
grade,O
dysplasia,O
,,O
but,O
not,O
size,O
of,O
adenoma.6,B-disease
 , 
It,O
is,O
well,O
known,O
that,O
adenoma,B-disease
size,O
,,O
dysplasia,O
and,O
villous,O
architecture,O
are,O
interrelated,O
and,O
account,O
has,O
to,O
be,O
taken,O
of,O
this,O
in,O
assessing,O
results,O
.,O
 , 
In,O
this,O
study,O
KRAS,B-gene
mutation,B-mutation
occurred,O
with,O
the,O
same,O
frequency,O
in,O
small,B-Concepts_Ideas
(,B-size
18,I-size
%,I-size
),I-size
and,O
large,B-Concepts_Ideas
(,B-size
17,I-size
%,I-size
),I-size
adenomas,B-disease
but,O
was,O
significantly,O
more,O
frequent,O
in,O
adenomas,B-disease
that,O
included,O
a,O
villous,B-Concepts_Ideas
architecture,I-Concepts_Ideas
(,B-size
50,I-size
%,I-size
),I-size
.,O
 , 
A,O
previous,O
study,O
showed,O
a,O
very,O
high,O
frequency,O
of,O
KRAS,B-gene
mutation,B-mutation
(,B-size
93,I-size
%,I-size
),I-size
in,O
flat,B-Concepts_Ideas
adenomas,B-disease
with,O
a,O
tubulovillous,B-Disorder
architecture.34,I-Disorder
We,O
would,O
agree,O
with,O
the,O
suggestion,O
that,O
KRAS,B-gene
mutation,B-mutation
is,O
linked,O
with,O
the,O
development,O
of,O
villous,O
change,O
and,O
does,O
not,O
influence,O
adenoma,B-disease
growth,O
in,O
an,O
independent,O
manner.6,O
In,O
this,O
study,O
,,O
high,O
-,O
grade,O
dysplasia,O
was,O
diagnosed,O
only,O
when,O
it,O
amounted,O
to,O
carcinoma,B-disease
in,O
situ,O
.,O
 , 
This,O
was,O
observed,O
in,O
none,B-size
of,I-size
the,I-size
84,I-size
adenomas,B-cohort-patient
but,O
in,O
four,B-size
serrated,B-Concepts_Ideas
polyps,B-cohort-patient
,,I-cohort-patient
of,O
which,O
three,B-size
showed,O
aberrant,B-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
and,O
the,O
fourth,B-cohort-patient
had,O
KRAS,B-gene
mutation,B-mutation
.,I-mutation
 , 
Age,O
was,O
not,O
a,O
predictor,O
of,O
KRAS,B-gene
mutation,B-mutation
in,O
this,O
study,O
.,O
 , 
However,O
,,O
many,O
of,O
the,O
patients,B-cohort-patient
were,O
undergoing,O
continuing,O
colonoscopic,O
surveillance,O
for,O
colorectal,B-body-part
polyps,B-disease
and,O
it,O
is,O
known,O
that,O
after,O
clearance,O
of,O
large,B-Concepts_Ideas
polyps,B-disease
,,I-disease
time,O
is,O
required,O
for,O
the,O
growth,O
of,O
newly,O
initiated,O
polyps.36,B-disease
This,O
could,O
explain,O
why,O
adenomas,B-disease
were,O
smaller,B-Concepts_Ideas
in,O
subjects,O
aged,O
>,B-age
 ,I-age
60,I-age
years,I-age
than,O
in,O
subjects,O
aged,O
<,B-age
 ,I-age
60,I-age
years,I-age
(,O
data,O
not,O
shown,O
),O
.,O
 , 


,O
 , 
#1619718-02-Introduction-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Introduction,O


,O
The,O
traditional,O
view,O
of,O
epithelial,B-body-part
polyps,B-disease
of,O
the,O
colorectum,B-body-part
envisages,O
a,O
larger,O
non,B-Disorder
-,I-Disorder
neoplastic,I-Disorder
category,O
of,O
hyperplastic,B-Disorder
polyps,B-disease
(,B-disease
HPs,I-disease
),I-disease
that,O
can,O
be,O
safely,O
ignored,O
and,O
a,O
smaller,O
category,O
of,O
neoplastic,B-Disorder
polyps,B-disease
or,O
adenomas,B-disease
that,O
are,O
precancerous.1,B-Concepts_Ideas
With,O
respect,O
to,O
adenomas,B-disease
,,I-disease
it,O
is,O
clear,O
that,O
the,O
majority,O
will,O
not,O
progress,O
to,O
colorectal,B-disease
cancer,I-disease
(,B-disease
CRC).2,I-disease
The,O
risk,O
of,O
cancer,B-disease
developing,O
within,O
an,O
adenoma,B-disease
increases,O
with,O
size,O
,,O
grade,O
of,O
dysplasia,O
(,O
synonymous,O
with,O
intraepithelial,O
neoplasia,O
),O
and,O
villosity.3,O
These,O
features,O
,,O
together,O
with,O
polyp,B-disease
numbers,O
,,O
are,O
also,O
predictive,O
of,O
metachronous,B-Concepts_Ideas
neoplasia,B-disease
and,O
may,O
therefore,O
influence,O
the,O
decision,O
to,O
offer,O
follow,O
-,O
up,O
endoscopic,O
surveillance.4,O
However,O
,,O
the,O
grading,O
of,O
dysplasia,O
and,O
estimation,O
of,O
the,O
extent,O
of,O
villous,O
change,O
may,O
not,O
be,O
fully,O
reproducible,O
and,O
it,O
may,O
be,O
difficult,O
to,O
distinguish,O
new,O
from,O
recurrent,O
adenomas,B-disease
.,I-disease
 , 
Establishing,O
a,O
risk,O
profile,O
on,O
the,O
basis,O
of,O
the,O
traditional,O
features,O
of,O
adenoma,B-disease
is,O
therefore,O
not,O
always,O
straightforward,O
.,O
 , 


,O
The,O
addition,O
of,O
molecular,O
profiling,O
to,O
polyp,B-disease
description,O
offers,O
hope,O
of,O
a,O
more,O
objective,O
and,O
therefore,O
reproducible,O
approach,O
to,O
the,O
classification,O
of,O
colorectal,B-body-part
adenomas,B-disease
.,I-disease
 , 
The,O
genetic,O
evolutionary,O
paradigm,O
envisages,O
a,O
linear,O
sequence,O
of,O
changes,O
beginning,O
with,O
bi,B-Physiology
-,I-Physiology
allelic,I-Physiology
inactivation,I-Physiology
of,I-Physiology
APC,B-gene
,,I-gene
followed,O
by,O
oncogenic,B-mutation
KRAS,B-gene
mutation,I-mutation
and,O
culminating,O
in,O
inactivation,B-Physiology
of,I-Physiology
TP53,B-gene
at,O
the,O
transition,O
from,O
adenoma,B-disease
to,O
carcinoma.5,B-disease
While,O
there,O
is,O
good,O
evidence,O
that,O
KRAS,B-gene
mutation,B-mutation
is,O
associated,O
with,O
advanced,B-Concepts_Ideas
adenoma,B-disease
features6,O
and,O
could,O
therefore,O
be,O
used,O
as,O
objective,O
evidence,O
of,O
aggression,O
,,O
this,O
approach,O
has,O
a,O
number,O
of,O
limitations,O
.,O
 , 
First,O
,,O
KRAS,B-gene
mutation,B-mutation
also,O
occurs,O
frequently,O
in,O
dysplastic,B-Disorder
aberrant,I-Disorder
crypt,I-Disorder
foci,I-Disorder
(,B-disease
microadenomas,I-disease
),I-disease
and,O
in,O
some,O
small,B-Concepts_Ideas
tubular,B-Concepts_Ideas
adenomas,B-disease
,,I-disease
suggesting,O
that,O
KRAS,B-gene
mutation,B-mutation
may,O
initiate,O
a,O
subset,O
of,O
small,B-Concepts_Ideas
adenomas,B-disease
with,O
limited,O
potential,O
for,O
progression.6,7,O
Second,O
,,O
around,O
70,B-size
%,I-size
of,O
CRCs,B-disease
lack,B-mutation
mutation,I-mutation
of,O
KRAS.8,B-gene
From,O
this,O
it,O
follows,O
that,O
most,O
of,O
the,O
precancerous,B-Concepts_Ideas
lesions,B-disease
that,O
eventually,O
become,O
cancers,B-disease
do,O
not,O
in,O
fact,O
have,O
KRAS,B-gene
mutation,B-mutation
.,I-mutation
 , 
There,O
is,O
increasing,O
evidence,O
that,O
CRC,B-disease
evolves,O
through,O
a,O
number,O
of,O
pathways,O
and,O
the,O
traditional,O
adenoma,B-disease
–,B-disease
carcinoma,I-disease
sequence,O
,,O
with,O
its,O
accompanying,O
genetic,O
steps,O
,,O
provides,O
a,O
surprisingly,O
narrow,O
window,O
of,O
understanding,O
of,O
this,O
multipathway,O
reality.9,O


,O
In,O
recent,O
years,O
,,O
the,O
fundamental,O
division,O
of,O
colorectal,B-body-part
polyps,B-disease
into,O
precancerous,B-Concepts_Ideas
adenomas,B-disease
and,O
innocent,O
HPs,B-disease
has,O
begun,O
to,O
erode,O
and,O
the,O
concept,O
of,O
an,O
alternative,O
serrated,O
pathway,O
has,O
gained,O
support,O
.,O
 , 
This,O
revision,O
began,O
with,O
the,O
description,O
of,O
an,O
intermediate,B-Concepts_Ideas
lesion,B-disease
described,O
as,O
serrated,B-Concepts_Ideas
adenoma,B-disease
(,B-disease
SA).10,I-disease
Initially,O
,,O
however,O
,,O
SA,B-disease
was,O
not,O
conceived,O
as,O
an,O
intermediate,O
category,O
of,O
polyp,B-disease
but,O
essentially,O
as,O
an,O
adenoma,B-disease
with,O
a,O
superimposed,B-Disorder
serrated,I-Disorder
architecture,I-Disorder
that,O
conferred,O
only,O
a,O
superficial,O
likeness,O
to,O
a,O
HP.10,B-disease
Additionally,O
,,O
the,O
mixed,B-Concepts_Ideas
polyp,B-disease
(,B-disease
MP,I-disease
),I-disease
was,O
perceived,O
as,O
a,O
chance,O
collision,O
between,O
a,O
HP,B-disease
and,O
an,O
adenoma,B-disease
,,I-disease
giving,O
a,O
combined,B-Concepts_Ideas
polyp,B-disease
.,I-disease
 , 
These,O
preliminary,O
interpretations,O
did,O
not,O
represent,O
a,O
major,O
departure,O
from,O
the,O
traditional,O
classification,O
of,O
colorectal,B-body-part
polyps,B-disease
but,O
preserved,O
the,O
fundamental,O
distinction,O
of,O
neoplastic,B-Disorder
adenomas,B-disease
versus,O
non,B-Disorder
-,I-Disorder
neoplastic,I-Disorder
HPs,B-disease
.,I-disease
 , 


,O
 , 
#1557864-05-Discussion-p04
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Since,O
platinum,O
-,O
drug,O
resistance,O
is,O
thought,O
to,O
be,O
multifactorial,O
the,O
involvement,O
of,O
other,O
resistance,O
mechanisms,O
could,O
have,O
overruled,O
the,O
possible,O
contribution,O
of,O
MMR,O
status,O
.,O
 , 
However,O
,,O
platinum,O
treatment,O
does,O
seem,O
to,O
select,O
for,O
MMR,O
deficient,O
cells,O
since,O
in,O
vitro,O
enrichment,O
for,O
MLH1,B-Disorder
deficient,I-Disorder
colon,B-body-part
cancer,B-disease
HCT116,O
cells,O
in,O
a,O
mixed,O
cell,O
population,O
was,O
seen,O
after,O
cisplatin,O
treatment,O
[,O
53,O
],O
.,O
 , 
In,O
addition,O
,,O
several,O
in,O
vivo,O
studies,O
found,O
an,O
increase,O
in,O
the,O
percentage,O
of,O
MSI,O
and,O
MLH1,B-Physiology
methylation,I-Physiology
after,O
platinum,O
-,O
based,O
chemotherapy,O
as,O
well,O
as,O
a,O
decrease,O
in,O
the,O
percentage,O
of,O
cells,O
positive,O
for,O
MLH1,B-gene
and,O
MSH2,B-gene
[,O
14,19,25,52,O
],O
.,O
 , 
Moreover,O
,,O
an,O
increase,B-Physiology
in,I-Physiology
MLH1,I-Physiology
methylation,I-Physiology
after,O
platinum,O
-,O
based,O
chemotherapy,O
was,O
associated,O
with,O
poor,O
survival,O
in,O
ovarian,B-body-part
cancer,I-disease
patients,B-cohort-patient
[,O
19,O
],O
.,O
 , 
These,O
results,O
as,O
well,O
as,O
the,O
in,O
vitro,O
studies,O
mentioned,O
in,O
the,O
introduction,O
,,O
suggest,O
that,O
MMR,B-gene
inactivation,O
causes,O
a,O
low,O
level,O
resistance,O
to,O
platinum,O
-,O
based,O
chemotherapy,O
which,O
does,O
not,O
play,O
a,O
significant,O
role,O
in,O
intrinsic,O
resistance,O
.,O
 , 
However,O
,,O
due,O
to,O
selection,O
during,O
chemotherapy,O
MMR,B-gene
inactivation,O
might,O
play,O
a,O
greater,O
role,O
in,O
the,O
acquired,O
resistance,O
.,O
 , 
We,O
therefore,O
propose,O
that,O
the,O
role,O
of,O
MMR,B-gene
inactivation,O
in,O
acquired,O
resistance,O
in,O
ovarian,B-disease
cancer,I-disease
should,O
be,O
further,O
investigated,O
.,O
 , 


,O
 , 
#2386495-05-Discussion-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
A,O
case,B-cohort-patient
of,O
APC,B-gene
mosaicism,I-Physiology


,I-Physiology
Screening,O
for,O
mosaic,O
mutations,O
in,O
the,O
three,B-size
APC-,B-gene
and,I-Disorder
MUTYH,I-Disorder
-,I-Disorder
negative,I-Disorder
patients,B-cohort-patient
with,O
de,B-mutation
novo,I-mutation
mutations,I-mutation
revealed,O
the,O
c.2700_2701delTC,B-mutation
mutation,O
in,O
patient,B-cohort-patient
C107,B-cohort-patient
.,I-cohort-patient
 , 
This,O
mutation,O
was,O
detected,O
in,O
a,O
very,O
low,O
fraction,O
of,O
the,O
lymphocytes,O
and,O
was,O
only,O
detectable,O
using,O
the,O
SSCP,O
/,O
HD,O
analysis,O
(,O
Figure,O
2A,O
),O
.,O
 , 
Owing,O
to,O
the,O
subtle,O
appearance,O
of,O
this,O
mutation,O
it,O
could,O
easily,O
have,O
been,O
overlooked,O
.,O
 , 


,O
The,O
phenotype,O
of,O
patient,B-cohort-patient
C107,B-cohort-patient
does,O
not,O
fit,O
the,O
generally,O
accepted,O
genotype,O
-,O
phenotype,O
correlation,O
of,O
AFAP,B-disease
,,I-disease
in,O
which,O
the,O
disease,B-disease
-,I-disease
causing,O
mutations,B-mutation
are,I-mutation
situated,I-mutation
either,I-mutation
in,I-mutation
the,I-mutation
5,I-mutation
',I-mutation
or,I-mutation
3,I-mutation
',I-mutation
regions,I-mutation
or,I-mutation
the,I-mutation
alternatively,I-mutation
spliced,I-mutation
part,I-mutation
of,I-mutation
exon,I-mutation
9,I-mutation
(,O
see,O
the,O
introduction,O
),O
.,O
 , 
A,O
speculative,O
reason,O
for,O
the,O
attenuated,O
phenotype,O
could,O
be,O
that,O
the,O
patient,B-cohort-patient
is,O
mosaic,B-Physiology
in,O
the,O
epithelial,O
cells,O
of,O
the,O
colon,B-body-part
.,I-body-part
 , 
The,O
parents,B-cohort-patient
of,I-cohort-patient
patient,I-cohort-patient
C107,B-cohort-patient
of,O
age,B-age
73,I-age
and,O
80,B-age
years,I-age
as,O
well,O
as,O
her,B-gender
three,B-size
children,B-cohort-patient
,,I-cohort-patient
age,O
31–40,B-age
years,I-age
,,I-age
were,O
free,O
of,O
polyps,B-disease
.,I-disease
 , 
No,O
CRC,B-disease
has,O
been,O
diagnosed,O
on,O
either,O
the,O
maternal,B-gender
or,O
paternal,B-gender
side,O
of,O
the,O
family,B-cohort-patient
.,I-cohort-patient
 , 
The,O
mutation,O
was,O
not,O
detected,O
in,O
blood,O
samples,O
from,O
the,O
patient,B-cohort-patient
's,I-cohort-patient
parents,I-cohort-patient
or,O
from,O
her,B-gender
three,B-size
children,B-cohort-patient
.,I-cohort-patient
 , 
It,O
is,O
possible,O
that,O
either,O
gonadal,O
or,O
somatic,O
mosaicism,O
exists,O
in,O
patient,B-cohort-patient
C107,B-cohort-patient
.,I-cohort-patient
 , 


,B-gene
APC,I-gene
mutational,I-Physiology
mosaicism,I-Physiology
could,O
be,O
a,O
reason,O
for,O
the,O
quite,O
large,O
number,O
of,O
de,B-Concepts_Ideas
novo,I-Concepts_Ideas
or,O
sporadic,B-Concepts_Ideas
FAP,B-disease
cases,B-cohort-patient
that,O
exist,O
[,O
23,O
-,O
25,40,O
],O
.,O
 , 
In,O
the,O
family,B-cohort-patient
of,O
C107,B-cohort-patient
the,O
mutation,O
has,O
not,O
been,O
passed,O
on,O
to,O
the,O
offspring,O
of,O
the,O
patient,B-cohort-patient
and,O
,,O
thus,O
,,O
this,O
appears,O
to,O
be,O
a,O
sporadic,B-Concepts_Ideas
case,B-cohort-patient
,,I-cohort-patient
but,O
,,O
generally,O
,,O
the,O
existence,O
of,O
mosaicism,O
is,O
a,O
risk,O
of,O
error,O
in,O
predictive,O
diagnosis,O
in,O
FAP,B-disease
/,B-disease
AFAP,I-disease
families,B-cohort-patient
[,O
43,O
],O
.,O
 , 
In,O
the,O
initial,O
stages,O
,,O
the,O
molecular,O
screening,O
procedure,O
of,O
FAP,B-disease
/,I-disease
AFAP,I-disease
patients,B-cohort-patient
uses,O
mainly,O
PCR,O
-,O
based,O
methods,O
for,O
analysis,O
of,O
the,O
APC,B-gene
gene,O
in,O
DNA,O
from,O
isolated,O
blood,B-body-part
samples,O
.,O
 , 
Therefore,O
,,O
the,O
chances,O
of,O
detecting,O
pathogenic,O
low,O
-,O
frequency,O
APC,B-gene
mutations,B-mutation
that,O
are,O
present,O
only,O
in,O
a,O
small,O
fraction,O
of,O
the,O
peripheral,O
blood,O
cells,O
or,O
only,O
in,O
the,O
colon,B-body-part
are,O
poor,O
.,O
 , 
Approximately,O
25,B-size
%,I-size
of,O
neurofibromatosis,B-disease
type,I-disease
2,I-disease
(,B-disease
NF2,I-disease
),I-disease
patients,B-cohort-patient
have,O
been,O
shown,O
to,O
be,O
cases,B-cohort-patient
of,O
mosaicism,B-Physiology
[,O
44,O
],O
.,O
 , 
When,O
investigating,O
NF2,B-disease
mutational,B-Physiology
mosaicism,I-Physiology
,,I-Physiology
the,O
search,O
for,O
constitutional,O
mutations,O
is,O
preferably,O
carried,O
out,O
initially,O
in,O
tumor,B-disease
cells,O
.,O
 , 
Detected,O
mutations,O
could,O
subsequently,O
be,O
verified,O
in,O
blood,O
leukocyte,O
samples,O
.,O
 , 
However,O
,,O
this,O
approach,O
would,O
not,O
be,O
applicable,O
for,O
FAP,B-disease
mosaisicm,B-Physiology
as,O
somatic,B-mutation
APC,B-gene
mutations,I-mutation
are,O
frequently,O
found,O
in,O
tumors,B-disease
.,I-disease
 , 


,O
Splice,O
-,O
site,O
affecting,O
mutations,O


,B-size
Two,I-size
novel,O
germline,B-mutation
APC,I-mutation
mutations,I-mutation
that,O
introduce,O
different,O
cryptic,O
splice,O
sites,O
are,O
characterized,O
in,O
this,O
study,O
.,O
 , 
Both,O
mutations,O
result,O
in,O
the,O
aberrant,B-mutation
splicing,I-mutation
of,I-mutation
APC,B-gene
exons,I-mutation
7,I-mutation
and,I-mutation
8,I-mutation
and,O
prematurely,O
truncated,O
APC,B-gene
protein,O
,,O
and,O
both,O
are,O
defined,O
as,O
pathogenic,O
.,O
 , 
The,O
aberrant,O
splicing,O
identified,O
in,O
patient,B-cohort-patient
C496,B-cohort-patient
(,B-mutation
c.835,I-mutation
-,I-mutation
7,I-mutation
T,I-mutation
>,I-mutation
G,I-mutation
),I-mutation
is,O
caused,O
by,O
an,O
introduction,B-mutation
of,I-mutation
a,I-mutation
new,I-mutation
active,I-mutation
splice,I-mutation
site,I-mutation
6,I-mutation
bp,I-mutation
upstream,I-mutation
of,I-mutation
the,I-mutation
wildtype,I-mutation
AG,I-mutation
splice,I-mutation
site,I-mutation
of,I-mutation
intron,I-mutation
7,I-mutation
.,I-mutation
 , 
This,O
acceptor,O
site,O
is,O
apparently,O
preferred,O
by,O
the,O
splicing,O
machinery,O
,,O
as,O
shown,O
by,O
the,O
results,O
of,O
the,O
cDNA,O
sequencing,O
(,O
Figure,O
3,O
),O
.,O
 , 
The,O
c.834,B-mutation
G,I-mutation
>,I-mutation
C,I-mutation
substitution,O
at,O
the,O
last,O
nucleotide,O
of,O
exon,O
7,O
in,O
patient,B-cohort-patient
C633,B-cohort-patient
,,I-cohort-patient
would,O
theoretically,O
introduce,O
a,O
missense,B-mutation
mutation,I-mutation
at,I-mutation
codon,I-mutation
278,I-mutation
.,I-mutation
 , 
However,O
,,O
as,O
demonstrated,O
by,O
the,O
cDNA,O
sequencing,O
results,O
(,O
Figure,O
4,O
),O
the,O
mutation,O
leads,O
to,O
the,O
use,O
of,O
a,O
cryptic,O
splice,O
donor,O
site,O
11,O
bp,O
upstream,O
in,O
exon,O
7,O
.,O
 , 
This,O
real,O
outcome,O
of,O
the,O
mutation,O
would,O
easily,O
have,O
been,O
overlooked,O
unless,O
the,O
RNA,O
-,O
based,O
methods,O
had,O
been,O
used,O
.,O
 , 
Other,O
examples,O
of,O
aberrant,O
splicing,O
of,O
the,O
APC,B-gene
gene,O
due,O
to,O
missense,B-mutation
mutations,I-mutation
have,O
recently,O
been,O
described,O
[,O
16,O
],O
.,O
 , 
One,O
case,B-cohort-patient
of,O
use,O
of,O
aberrant,B-mutation
splice,I-mutation
-,I-mutation
acceptor,I-mutation
site,I-mutation
of,I-mutation
APC,B-gene
exon,I-mutation
8,I-mutation
has,O
been,O
reported,O
previously,O
in,O
a,O
patient,B-cohort-patient
with,O
classical,B-Concepts_Ideas
polyposis,B-disease
[,O
15,O
],O
.,O
 , 
However,O
,,O
an,O
alternative,O
acceptor,O
splice,O
site,O
(,B-mutation
c.845,I-mutation
-,I-mutation
17A,I-mutation
>,I-mutation
G,I-mutation
),I-mutation
in,O
intron,O
7,O
has,O
been,O
reported,O
from,O
a,O
patient,B-cohort-patient
with,O
a,O
milder,B-Physiology
phenotype,I-Physiology
,,I-Physiology
multiple,B-Concepts_Ideas
synchronous,B-Concepts_Ideas
colorectal,B-body-part
adenomas,B-disease
[,O
45,O
],O
.,O
 , 


,O
 , 
#1266026-04-Results-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O


,O
The,O
presence,O
or,O
absence,O
of,O
MSI,O
was,O
determined,O
for,O
1,022,B-size
colorectal,B-body-part
cancers,B-cohort-patient
obtained,O
from,O
nine,O
large,O
regional,O
hospitals,O
in,O
southeastern,B-ethnicity
Finland,I-ethnicity
 , 
[,O
9,O
],O
.,O
 , 
There,O
were,O
895,B-size
(,B-size
87.6,I-size
%,I-size
),I-size
MSI-,B-Disorder
cancers,B-cohort-patient
and,O
127,B-size
(,B-size
12.4,I-size
%,I-size
),I-size
MSI+,B-Disorder
cancers,B-disease
.,I-disease
 , 
The,O
MSI+,B-Disorder
cancers,B-disease
were,O
further,O
classified,O
as,O
sporadic,B-Concepts_Ideas
(,O
N,O
=,O
98,B-size
or,O
9.6,B-size
%,I-size
of,O
all,O
cancers,B-cohort-patient
),I-cohort-patient
or,O
HNPCC,B-disease
(,O
N,O
=,O
29,B-size
or,O
2.9,B-size
%,I-size
of,O
all,O
cancers,B-cohort-patient
),I-cohort-patient
based,O
on,O
germline,B-mutation
MLH1,B-gene
or,I-mutation
MSH2,B-gene
mutations,I-mutation
(,O
Table,O
1,O
),O
.,O
 , 


,O
Ages,O
at,O
cancer,B-disease
can,O
be,O
used,O
to,O
estimate,O
likely,O
numbers,O
of,O
oncogenic,O
mutations,O
required,O
before,O
transformation,O
 , 
[,O
3,O
-,O
6,11,O
],O
.,O
 , 
Average,O
ages,O
for,O
sporadic,B-cohort-patient
MSI+,I-cohort-patient
,,I-cohort-patient
MSI-,B-cohort-patient
,,I-cohort-patient
and,O
HNPCC,B-disease
cancers,I-disease
were,O
respectively,O
71.5,B-age
,,I-age
67.5,B-age
,,I-age
and,O
50.3,B-age
years,I-age
(,O
Figure,O
1A,O
),O
.,O
 , 
For,O
HNPCC,B-disease
cancers,I-disease
,,I-disease
estimated,O
numbers,O
of,O
oncogenic,B-mutation
mutations,I-mutation
were,O
between,B-size
four,I-size
and,I-size
seven,I-size
(,O
95,O
%,O
credibility,O
interval,O
),O
,,O
with,O
the,O
most,O
likely,O
value,O
of,O
five,B-size
mutations,B-mutation
(,O
Table,O
1,O
),O
.,O
 , 
For,O
MSI+,B-Disorder
sporadic,B-Concepts_Ideas
cancers,B-cohort-patient
,,I-cohort-patient
estimated,O
numbers,O
of,O
mutations,B-mutation
were,O
between,B-size
six,I-size
and,I-size
nine,I-size
(,O
95,O
%,O
credibility,O
interval,O
),O
with,O
more,O
likely,O
values,O
of,O
seven,B-size
or,I-size
eight,I-size
mutations,B-mutation
.,I-mutation
 , 
The,O
most,O
likely,O
number,O
of,O
mutations,B-mutation
was,O
seven,B-size
for,O
sporadic,B-Concepts_Ideas
MSI-,B-Disorder
cancers,B-cohort-patient
.,I-cohort-patient
 , 


,O
Duke,O
's,O
stage,O
and,O
age,O
at,O
clinical,O
presentation,O
(,O
Figure,O
1B,O
),O
were,O
documented,O
for,O
884,B-size
of,I-size
the,I-size
895,I-size
MSI-,B-Disorder
sporadic,B-Concepts_Ideas
cancers,B-disease
(,O
Table,O
1,O
),O
.,O
 , 
Average,O
ages,O
were,O
68.6,B-age
years,I-age
for,O
stage,B-Concepts_Ideas
A,I-Concepts_Ideas
,,I-Concepts_Ideas
69.0,B-age
years,I-age
for,O
stage,B-Concepts_Ideas
B,I-Concepts_Ideas
,,I-Concepts_Ideas
65.2,B-age
years,I-age
for,O
stage,B-Concepts_Ideas
C,I-Concepts_Ideas
,,I-Concepts_Ideas
and,O
65.4,B-age
years,I-age
for,O
stage,B-Concepts_Ideas
D.,I-Concepts_Ideas
 , 
The,O
most,O
likely,O
numbers,O
of,O
oncogenic,B-mutation
mutations,I-mutation
were,O
seven,B-size
for,O
stage,B-Concepts_Ideas
A,I-Concepts_Ideas
cancers,B-disease
,,I-disease
eight,B-size
for,O
stage,B-Concepts_Ideas
B,I-Concepts_Ideas
cancers,B-cohort-patient
,,I-cohort-patient
and,O
six,B-size
for,O
stage,B-Concepts_Ideas
C,I-Concepts_Ideas
or,I-Concepts_Ideas
D,I-Concepts_Ideas
cancers,B-cohort-patient
(,O
Table,O
1,O
),O
.,O
 , 


,O
Mutation,O
number,O
estimates,O
with,O
respect,O
to,O
clinical,O
stage,O
may,O
be,O
biased,O
with,O
the,O
Finnish,B-ethnicity
data,O
because,O
it,O
includes,O
only,O
specimens,O
with,O
tissue,O
available,O
for,O
molecular,O
analysis,O
.,O
 , 
Advanced,O
cancers,B-disease
may,O
not,O
be,O
removed,O
.,O
 , 
Therefore,O
,,O
a,O
similar,O
analysis,O
was,O
performed,O
on,O
a,O
population,O
-,O
based,O
cancer,B-disease
registry,O
[,O
10,O
],O
from,O
the,O
United,B-ethnicity
States,I-ethnicity
of,I-ethnicity
America,I-ethnicity
(,O
SEER,O
11,O
Regs,O
Public,O
-,O
Use,O
,,O
Nov,O
2001,O
Sub,O
(,O
1992–1999,O
),O
),O
,,O
which,O
records,O
ages,O
and,O
stages,O
at,O
diagnosis,O
regardless,O
of,O
treatment,O
(,O
Table,O
2,O
),O
.,O
 , 
The,O
average,B-age
age,I-age
at,I-age
diagnosis,I-age
was,I-age
70.5,I-age
years,I-age
,,I-age
consistent,O
with,O
an,O
estimate,O
of,O
six,B-size
mutations,B-mutation
to,O
colorectal,B-disease
cancer,I-disease
for,O
the,O
108,275,B-size
white,B-ethnicity
males,B-gender
and,I-cohort-patient
females,B-gender
with,O
stage,O
data,O
.,O
 , 
Like,O
the,O
Finnish,B-ethnicity
cancers,B-disease
,,I-disease
ages,O
were,O
similar,O
for,O
SEER,O
patients,B-cohort-patient
of,O
different,O
clinical,O
stages,O
,,O
with,O
an,O
estimate,O
of,O
six,B-size
mutations,B-mutation
for,O
cancers,B-disease
with,O
localized,B-Concepts_Ideas
,,I-Concepts_Ideas
regional,I-Concepts_Ideas
or,I-Concepts_Ideas
distant,I-Concepts_Ideas
clinical,I-Concepts_Ideas
stages,I-Concepts_Ideas
(,O
Table,O
2,O
and,O
Figure,O
1C,O
),O
.,O
 , 


,O
 , 
#1601966-03-Results-p11
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
5q22.2,O
-,O
5q23.1,O
–,O
the,O
APC,B-gene
region,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
up,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
up,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
7,O
,,O
10,O
,,O
13,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
27,O
and,O
29,O
.,O
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
5q22.2,O
-,O
5q23.1,O
–,O
the,O
APC,B-gene
region,O
(,B-cohort-patient
patient,I-cohort-patient
counts,O
with,O
coordinate,O
down,O
-,O
regulation,O
),O
.,O
 , 
Grayscale,O
cross,O
-,O
comparison,O
plot,O
of,O
down,O
-,O
regulation,O
patterns,O
across,O
patients,B-cohort-patient
(,O
analogous,O
to,O
Figures,O
8,O
,,O
11,O
,,O
14,O
),O
.,O
 , 
View,O
this,O
plot,O
in,O
conjunction,O
with,O
Figures,O
27,O
and,O
28,O
.,O
 , 
Note,O
,,O
that,O
many,O
more,O
patients,B-cohort-patient
show,O
down,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
this,O
plot,O
than,O
up,O
-,O
regulation,O
as,O
indicated,O
by,O
dark,O
spots,O
in,O
Figure,O
28,O
.,O
 , 
This,O
region,O
has,O
been,O
reported,O
in,O
other,O
studies,O
to,O
be,O
frequently,O
deleted,O
in,O
colon,B-body-part
cancer,B-disease
(,O
see,O
Table,O
4,O
),O
.,O
 , 
APC,B-gene
itself,O
is,O
not,O
represented,O
in,O
this,O
plot,O
(,O
no,O
valid,O
expression,O
measures,O
),O
.,O
 , 
It,O
is,O
located,O
down,O
-,O
stream,O
of,O
TIGA1,B-gene
and,O
up,O
-,O
stream,O
of,O
DP1,B-gene
and,O
DCP2,B-gene
.,I-gene
 , 
Note,O
the,O
sharp,O
change,O
from,O
expression,O
up,O
-,O
regulation,O
(,B-gene
TIGA1,I-gene
),I-gene
to,O
expression,O
down,O
-,O
regulation,O
(,B-gene
DCP2,I-gene
to,O
DMXL1,B-gene
),I-gene
in,O
this,O
interval,O
.,O
 , 


,O
14q24.3,O


,O
The,O
chromosomal,O
region,O
14q24.3,O
has,O
been,O
implicated,O
in,O
colorectal,B-body-part
cancer,B-disease
several,O
times,O
(,O
see,O
Table,O
1,O
),O
.,O
 , 
We,O
found,O
coordinated,O
down,O
-,O
regulation,O
of,O
expression,O
of,O
genes,O
in,O
14q24.1,O
-,O
14q24.3,O
(,O
see,O
Figures,O
30,O
,,O
31,O
,,O
32,O
),O
.,O
 , 
The,O
region,O
comprises,O
the,O
MLH3,B-gene
gene,O
that,O
is,O
linked,O
to,O
hereditary,B-disease
non,I-disease
-,I-disease
polyposis,I-disease
colorectal,I-disease
cancer,I-disease
type,I-disease
7,I-disease
(,B-disease
HNPCC7,I-disease
),I-disease
.,O
 , 
We,O
note,O
that,O
also,O
the,O
FOS,B-gene
gene,O
encoding,O
one,O
half,O
of,O
the,O
bZIP,O
dimer,O
activator,O
protein,O
(,O
AP-1,O
),O
at,O
14q24.3,O
is,O
strongly,O
down,O
-,O
regulated,O
.,O
 , 
FOS,B-gene
is,O
known,O
as,O
an,O
oncogene,O
and,O
its,O
down,O
-,O
regulation,O
is,O
therefore,O
unexpected,O
.,O
 , 
However,O
,,O
deletions,O
of,O
14q24.3,O
have,O
been,O
linked,O
to,O
metastatic,O
CRC,B-disease
[,O
36,O
],O
.,O
 , 
In,O
combination,O
,,O
these,O
results,O
suggest,O
that,O
there,O
is,O
a,O
class,O
II,O
tumor,O
metastasis,O
suppressor,O
in,O
this,O
region,O
.,O
 , 
This,O
class,O
II,O
TSG,O
is,O
probably,O
not,O
MLH3,B-gene
,,I-gene
as,O
its,O
protein,O
function,O
is,O
hardly,O
related,O
to,O
cellular,O
functions,O
promoting,O
metastasis,O
.,O
 , 
The,O
functions,O
of,O
several,O
other,O
strongly,O
misregulated,O
proteins,O
,,O
however,O
,,O
make,O
them,O
better,O
candidates,O
for,O
metastasis,O
suppressors,O
.,O
 , 
KIAA0317,O
codes,O
for,O
a,O
predicted,O
transmembrane,O
ubiquitin,O
ligase,O
.,O
 , 
Ubiquitin,O
ligases,O
can,O
help,O
to,O
tag,O
misfolded,O
transmembrane,O
proteins,O
in,O
the,O
ER,O
for,O
destruction,O
via,O
the,O
proteasome,O
system,O
[,O
37,O
],O
.,O
 , 
Absence,O
of,O
such,O
a,O
function,O
could,O
result,O
in,O
misexpressed,O
proteins,O
at,O
the,O
cell,O
surface,O
which,O
could,O
promote,O
metastasis,O
.,O
 , 
Other,O
potential,O
candidates,O
for,O
metastasis,O
suppressor,O
genes,O
in,O
this,O
region,O
code,O
for,O
the,O
transmembrane,O
Alzheimer,O
protein,O
PSEN1,B-gene
,,I-gene
the,O
GTPase,O
activating,O
protein,O
KIAA0440,O
/,O
SIPA1L1,O
,,O
the,O
PDZ,O
-,O
domain,O
synaptojanin,O
2,O
-,O
binding,O
protein,O
SYNJ2BP,B-gene
and,O
the,O
developmental,O
regulator,O
and,O
Notch,O
interaction,O
partner,O
NUMB,B-gene
.,I-gene
 , 


,O
Down,O
-,O
regulation,O
of,O
mRNA,O
expression,O
in,O
human,O
chromosomal,O
region,O
14q24.1,O
-,O
14q24.3,O
–,O
the,O
FOS,O
region,O
(,O
T,O
/,O
N,O
relative,O
expression,O
heat,O
map,O
),O
.,O
 , 
Heat,O
map,O
of,O
fold,O
change,O
of,O
tumor,O
-,O
versus,O
-,O
normal,O
expression,O
.,O
 , 
Genes,O
are,O
given,O
in,O
chromosomal,O
order,O
on,O
the,O
horizontal,O
axis,O
.,O
 , 
Patient,B-cohort-patient
codes,O
are,O
given,O
on,O
the,O
vertical,O
axis,O
.,O
 , 
The,O
legend,O
depicts,O
which,O
colors,O
code,O
for,O
which,O
expression,O
changes,O
on,O
a,O
loge,O
scale,O
(,O
green,O
:,O
down,O
in,O
tumor,B-disease
;,I-disease
red,O
:,O
up,O
in,O
tumor,B-disease
),I-disease
.,O
 , 
View,O
in,O
conjunction,O
with,O
Figures,O
31,O
and,O
32,O
.,O
 , 


,O
 , 
#1373649-03-Methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Methods,O


,O
Patients,O


,B-size
Three,I-size
first,B-cohort-patient
-,I-cohort-patient
degree,I-cohort-patient
relatives,I-cohort-patient
(,B-cohort-patient
mother,I-cohort-patient
and,O
two,B-size
sisters,B-cohort-patient
),I-cohort-patient
of,O
a,O
male,B-cohort-patient
who,O
died,O
of,O
poorly,B-Physiology
differentiated,I-Physiology
colorectal,B-body-part
adenocarcinoma,B-disease
at,O
age,B-age
23,I-age
contacted,O
us,O
for,O
genetic,O
counseling,O
.,O
 , 
A,O
detailed,O
family,O
and,O
medical,O
history,O
was,O
obtained,O
through,O
interview,O
with,O
the,O
proband,B-cohort-patient
relatives,I-cohort-patient
and,O
their,O
consent,O
for,O
release,O
of,O
medical,O
records,O
and,O
use,O
of,O
the,O
pathological,O
tissue,O
blocks,O
still,O
available,O
.,O
 , 


,O
The,O
early,O
onset,O
of,O
the,O
colon,B-disease
cancer,I-disease
in,O
the,O
proband,B-cohort-patient
and,O
the,O
study,O
of,O
the,O
family,O
's,O
pedigree,O
(,O
fig,O
.,O
1,O
),O
,,O
that,O
fulfill,O
the,O
strict,O
Amsterdam-1,O
criteria,O
,,O
prompted,O
genetic,O
analysis,O
with,O
suspicion,O
of,O
HNPCC,B-disease
.,I-disease
 , 
They,O
were,O
informed,O
about,O
the,O
risks,O
,,O
benefits,O
and,O
limitations,O
of,O
the,O
study,O
protocol,O
.,O
 , 


,O
Pedigree,O
showing,O
HNPCC,B-disease
family,B-cohort-patient
.,I-cohort-patient
 , 
An,O
arrow,O
indicates,O
the,O
male,B-gender
index,B-cohort-patient
patient,I-cohort-patient
(,B-cohort-patient
III:3,I-cohort-patient
),I-cohort-patient
diagnosed,O
with,O
colorectal,B-body-part
adenocarcinoma,B-disease
at,O
the,O
age,B-age
of,I-age
23,I-age
years,I-age
.,I-age
 , 
Family,B-cohort-patient
members,I-cohort-patient
suffering,O
from,O
a,O
malignancy,B-disease
are,O
indicated,O
by,O
a,O
shaded,O
circle,O
or,O
square,O
.,O
 , 
The,O
age,O
,,O
type,O
of,O
malignancy,O
,,O
as,O
well,O
as,O
the,O
generation,O
(,O
roman,O
figures,O
),O
,,O
are,O
described,O
below,O
the,O
indicated,O
patient,O
.,O
 , 
The,O
family,B-cohort-patient
fulfill,O
the,O
Amsterdam,O
-,O
I,O
criteria,O
with,O
presence,O
of,O
extracolonic,B-body-part
tumors,B-disease
in,O
the,O
extended,O
pedigree,O
,,O
having,O
more,O
than,O
three,B-size
carcinomas,B-disease
of,O
colon,B-body-part
(,O
C,O
),O
or,O
ovary,B-body-part
(,O
O,O
),O
in,O
the,O
affected,O
members,O
.,O
 , 
The,O
syndrome,O
is,O
present,O
in,O
all,O
three,O
generations,O
(,O
I,O
-,O
III,O
),O
and,O
three,B-size
family,B-cohort-patient
members,I-cohort-patient
are,O
younger,B-age
than,I-age
50,I-age
years,I-age
(,B-cohort-patient
III:3,I-cohort-patient
,,I-cohort-patient
II:1,B-cohort-patient
and,O
I:3,B-cohort-patient
),I-cohort-patient
.,O
 , 
At,O
the,O
moment,O
of,O
the,O
study,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
mother,B-gender
(,B-cohort-patient
II-5,I-cohort-patient
),I-cohort-patient
was,O
an,O
unaffected,B-disease
carrier,I-disease
,,I-disease
but,O
two,O
years,O
later,O
she,B-gender
developed,O
an,O
endometrial,B-body-part
(,O
E,O
),O
adenocarcinoma,B-disease
.,I-disease
 , 


,O
Study,O
protocol,O


,O
As,O
screening,O
method,O
for,O
HNPCC,B-disease
we,O
searched,O
for,O
MSI,O
in,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
primary,O
tumor,B-disease
and,O
metastasis,O
tissue,O
blocks,O
.,O
 , 
The,O
absence,O
of,O
proband,B-cohort-patient
's,I-cohort-patient
non,O
-,O
tumor,O
DNA,O
for,O
MSI,O
testing,O
was,O
overcome,O
studying,O
the,O
alleles,O
carried,O
by,O
his,B-gender
progenitors,O
.,O
 , 
Once,O
the,O
MSI,O
was,O
established,O
,,O
a,O
second,O
blood,O
sample,O
was,O
obtained,O
from,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
mother,I-cohort-patient
(,O
obligate,O
carrier,O
but,O
at,O
the,O
moment,O
of,O
the,O
study,O
still,O
unaffected,B-disease
),I-disease
to,O
full,O
mutation,O
analysis,O
of,O
the,O
hMSH2,B-gene
and,O
hMLH1,B-gene
genes,O
by,O
direct,O
sequencing,O
.,O
 , 
After,O
identifying,O
the,O
family,O
mutation,O
,,O
we,O
searched,O
it,O
in,O
both,O
proband,B-cohort-patient
's,I-cohort-patient
sisters,I-cohort-patient
.,I-cohort-patient
 , 


,O
DNA,O
preparation,O
for,O
genetic,O
testing,O


,O
Peripheral,O
blood,O
was,O
collected,O
from,O
the,O
three,B-size
consulting,O
family,B-cohort-patient
members,I-cohort-patient
and,O
the,O
proband,B-cohort-patient
's,I-cohort-patient
father,I-cohort-patient
.,I-cohort-patient
 , 
Genomic,O
DNA,O
isolation,O
from,O
their,O
lymphocytes,O
was,O
performed,O
using,O
a,O
standard,O
phenol,O
-,O
chloroform,O
extraction,O
.,O
 , 
DNA,O
from,O
the,O
proband,B-cohort-patient
was,O
obtained,O
from,O
the,O
formalin,O
-,O
fixed,O
,,O
paraffin,O
embedded,O
tissue,O
blocks,O
and,O
isolated,O
by,O
microdissection,O
of,O
tumor,B-disease
,,I-disease
deparaffinization,O
,,O
proteinase,O
K,O
treatment,O
,,O
and,O
ethanol,O
precipitation,O
[,O
7,O
],O
.,O
 , 


,O
Determination,O
of,O
MSI,O


,O
The,O
reference,O
panel,O
of,O
5,O
microsatellite,O
markers,O
standardized,O
by,O
the,O
National,O
Cancer,O
Institute,O
for,O
the,O
screening,O
of,O
HNPCC,B-disease
(,O
BAT-25,O
,,O
BAT-26,O
,,O
D2S123,O
,,O
D5S346,O
and,O
D17S250,O
),O
were,O
PCR,O
amplified,O
using,O
the,O
corresponding,O
specific,O
primers,O
for,O
each,O
one,O
[,O
8,O
],O
.,O
 , 
All,O
the,O
PCR,O
products,O
were,O
electrophoresed,O
through,O
a,O
denaturing,O
6,O
%,O
polyacrylamide,O
gels,O
and,O
visualized,O
by,O
silver,O
staining,O
(,O
fig,O
.,O
2,O
),O
.,O
 , 


,O
 , 
#3034663-05-Discussion-p01
Discussion,O


,O
The,O
accelerated,O
development,O
of,O
genetic,O
counselling,O
in,O
cancer,B-disease
during,O
the,O
past,O
few,O
years,O
is,O
due,O
to,O
the,O
feedback,O
and,O
interactive,O
information,O
sharing,O
on,O
genetic,O
studies,O
,,O
clinical,O
management,O
and,O
psychological,O
issues,O
in,O
families,B-cohort-patient
with,O
a,O
high,O
risk,O
of,O
cancer,B-disease
.,I-disease
 , 
Identification,O
of,O
deleterious,O
variants,O
in,O
such,O
families,B-cohort-patient
is,O
essential,O
for,O
accurate,O
assessment,O
of,O
individual,O
risk,O
and,O
,,O
if,O
required,O
,,O
subsequent,O
inclusion,O
into,O
a,O
personalized,O
surveillance,O
programme,O
.,O
 , 


,O
Unfortunately,O
,,O
genetic,O
testing,O
for,O
hereditary,B-Concepts_Ideas
cancer,B-disease
frequently,O
fails,O
to,O
identify,O
unambiguous,O
deleterious,O
variants,O
.,O
 , 
Erroneous,O
classification,O
of,O
a,O
genetic,O
variant,O
may,O
have,O
a,O
great,O
effect,O
on,O
at,O
-,O
risk,O
familial,O
who,O
undergo,O
genetic,O
testing,O
for,O
risk,O
prediction,O
because,O
it,O
results,O
in,O
incorrect,O
clinical,O
recommendations,O
.,O
 , 


,B-disease
LS,I-disease
is,O
the,O
most,O
common,O
hereditary,B-Concepts_Ideas
CRC,B-disease
-,I-disease
predisposing,I-disease
syndrome,I-disease
and,O
accounts,O
for,O
3,O
%,O
of,O
unselected,O
CRC,B-disease
cases,B-cohort-patient
.,I-cohort-patient
 , 
A,O
significant,O
proportion,O
of,O
DNA,O
variations,O
found,O
in,O
patients,B-cohort-patient
suspected,O
of,O
having,O
LS,B-disease
are,O
UVs,O
(,B-size
32,I-size
%,I-size
,,I-size
18,B-size
%,I-size
and,O
38,B-size
%,I-size
for,O
MLH1,B-gene
,,I-gene
MSH2,B-gene
and,O
MSH6,B-gene
,,I-gene
respectively,O
),O
 , 
[,O
6,O
],O
.,O
 , 
The,O
pathogenicity,O
of,O
the,O
MLH1,B-gene
p.,B-mutation
Lys618Ala,I-mutation
variant,O
remains,O
controversial,O
because,O
of,O
conflicting,O
data,O
[,O
InSiGHT,O
,,O
http://www.insight-group.org,O
],O
(,O
Figure,O
5,O
),O
.,O
 , 


,O
Classification,O
of,O
the,O
MLH1,B-gene
p.,B-mutation
Lys618Ala,I-mutation
variant,O
according,O
to,O
the,O
InSiGHT,O
database,O
(,O
accessed,O
on,O
07/2010,O
),O
.,O
 , 


,O
The,O
p.,B-mutation
Lys618Ala,I-mutation
substitution,O
replaces,O
a,O
charged,O
amino,O
acid,O
with,O
a,O
neutral,O
one,O
,,O
and,O
occurs,O
alongside,O
four,O
charged,O
amino,O
acids,O
that,O
are,O
well,O
conserved,O
in,O
mammals,O
.,O
 , 
In,O
silico,O
predictions,O
of,O
the,O
pathogenicity,O
of,O
this,O
variant,O
using,O
the,O
PolyPhen,O
http://genetics.bwh.harvard.edu/pph/,O
and,O
SIFT,O
http://sift.jcvi.org/,O
computational,O
program,O
were,O
discordant,O
;,O
the,O
SIFT,O
analysis,O
classified,O
it,O
as,O
a,O
tolerant,O
variant,O
and,O
the,O
PolyPhen,O
analysis,O
classed,O
it,O
as,O
possibly,O
damaging,O
[,O
9,O
],O
.,O
 , 
It,O
has,O
been,O
shown,O
that,O
this,O
variant,O
may,O
reduce,O
the,O
binding,O
ability,O
of,O
MLH1,B-gene
to,O
PMS2,B-gene
in,O
HCT116,O
cells,O
co,O
-,O
transfected,O
with,O
mutated,O
MLH1,B-gene
and,O
wild,O
-,O
type,O
PMS2,B-gene
[,O
10,O
],O
.,O
 , 
In,O
contrast,O
,,O
it,O
had,O
no,O
effect,O
on,O
the,O
ability,O
of,O
MLH1,B-gene
to,O
bind,O
PMS2,B-gene
in,O
a,O
co,O
-,O
immunoprecipitation,O
assay,O
 , 
[,O
9,O
],O
.,O
 , 
Functional,O
analysis,O
using,O
the,O
pCAS,O
ex,O
vivo,O
splicing,O
assay,O
and,O
RNA,O
analysis,O
also,O
demonstrated,O
no,O
effect,O
[,O
11,O
],O
.,O
 , 
Moreover,O
,,O
a,O
significant,O
decrease,B-Disorder
in,I-Disorder
MLH1,I-Disorder
protein,I-Disorder
stability,I-Disorder
has,O
been,O
found,O
for,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
[,O
9,O
],O
.,O
 , 


,O
The,O
results,O
of,O
in,O
silico,O
prediction,O
and,O
functional,O
assays,O
alone,O
are,O
insufficient,O
to,O
determine,O
whether,O
this,O
variant,O
is,O
deleterious,O
or,O
a,O
rare,O
functional,O
polymorphism,O
.,O
 , 
For,O
this,O
purpose,O
,,O
it,O
is,O
necessary,O
to,O
integrate,O
indirect,O
evidence,O
with,O
direct,O
genetic,O
evidence,O
involving,O
clinical,O
observations,O
of,O
disease,O
occurrence,O
.,O
 , 


,O
The,O
frequency,O
of,O
variants,O
in,O
unaffected,B-disease
controls,B-cohort-patient
is,O
used,O
often,O
to,O
distinguish,O
between,O
neutral,O
and,O
potentially,O
deleterious,O
variants,O
.,O
 , 
If,O
the,O
frequency,O
of,O
a,O
variant,O
among,O
a,O
few,O
hundred,O
controls,O
is,O
≥1,O
%,O
,,O
it,O
is,O
highly,O
unlikely,O
to,O
be,O
a,O
high,O
-,O
risk,O
variant,O
.,O
 , 
In,O
such,O
cases,O
,,O
it,O
is,O
still,O
possible,O
that,O
the,O
variant,O
will,O
be,O
associated,O
with,O
a,O
modest,O
risk,O
of,O
the,O
disease,O
 , 
[,O
3,O
],O
.,O
 , 
Case,O
-,O
control,O
studies,O
enable,O
quantification,O
of,O
the,O
disease,O
risk,O
associated,O
with,O
the,O
variant,O
.,O
 , 
The,O
main,O
disadvantage,O
of,O
such,O
analyses,O
is,O
that,O
a,O
large,O
sample,O
size,O
is,O
required,O
to,O
obtain,O
sufficient,O
power,O
to,O
detect,O
the,O
lower,O
risk,O
level,O
.,O
 , 
The,O
sample,O
size,O
required,O
is,O
related,O
inversely,O
to,O
the,O
frequency,O
of,O
the,O
variant,O
in,O
the,O
population,O
.,O
 , 
The,O
sample,O
size,O
used,O
in,O
the,O
present,O
study,O
resulted,O
in,O
80,O
%,O
power,O
to,O
detect,O
an,O
OR,O
of,O
3.0,O
(,O
two,O
-,O
sided,O
test,O
;,O
alpha,O
level,O
,,O
5,O
%,O
),O
.,O
 , 
The,O
frequency,O
of,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
in,O
our,O
control,B-cohort-patient
series,O
was,O
2.7,B-size
%,I-size
and,O
no,O
significant,O
differences,O
were,O
observed,O
in,O
the,O
sporadic,B-cohort-patient
and,O
familial,B-cohort-patient
groups,B-cohort-patient
,,I-cohort-patient
indicating,O
that,O
a,O
high,O
penetrance,O
effect,O
for,O
colorectal,B-body-part
carcinogenesis,B-disease
can,O
be,O
excluded,O
.,O
 , 
Similar,O
results,O
were,O
reported,O
in,O
case,O
-,O
control,O
studies,O
on,O
Scottish,B-ethnicity
and,O
Danish,B-ethnicity
populations,B-cohort-patient
[,O
12,13,O
],O
.,O
 , 


,O
 , 
#1266026-03-Methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Methods,O


,O
Specimens,O


,O
MSI,O
status,O
was,O
determined,O
for,O
1,022,B-size
colorectal,B-body-part
cancers,B-cohort-patient
sampled,O
from,O
nine,O
large,O
regional,O
hospitals,O
in,O
southeastern,B-ethnicity
Finland,I-ethnicity
as,O
part,O
of,O
a,O
study,O
to,O
characterize,O
genetic,O
alterations,O
in,O
a,O
well,O
-,O
defined,O
population,O
[,O
9,O
],O
.,O
 , 
The,O
cancers,B-disease
represent,O
approximately,O
60,O
%,O
of,O
all,O
colorectal,B-body-part
cancers,I-disease
removed,O
from,O
this,O
population,O
in,O
1994,O
to,O
1998,O
[,O
9,O
],O
.,O
 , 
Germline,B-mutation
mutations,I-mutation
in,O
MLH1,B-gene
or,O
MSH2,B-gene
were,O
detected,O
by,O
allelic,O
specific,O
PCR,O
assays,O
(,O
for,O
the,O
two,O
common,O
Finnish,B-ethnicity
MLH1,B-gene
germline,B-mutation
mutations,I-mutation
),I-mutation
or,O
by,O
direct,O
genomic,O
sequencing,O
of,O
coding,O
exons,O
[,O
9,O
],O
.,O
 , 
The,O
data,O
can,O
be,O
downloaded,O
from,O
the,O
following,O
website,O
:,O
.,O
 , 
Approval,O
for,O
this,O
research,O
was,O
obtained,O
from,O
the,O
appropriate,O
ethics,O
committees,O
,,O
which,O
are,O
in,O
compliance,O
with,O
the,O
Helsinki,O
Declaration,O
.,O
 , 


,O
A,O
second,O
data,O
set,O
(,O
SEER,O
11,O
Regs,O
 , 
Public,O
-,O
Use,O
,,O
Nov,O
2001,O
Sub,O
(,O
1992–1999,O
),O
),O
was,O
obtained,O
from,O
the,O
Surveillance,O
,,O
Epidemiology,O
,,O
and,O
End,O
Results,O
(,O
SEER,O
),O
Program,O
,,O
a,O
population,O
-,O
based,O
registry,O
in,O
the,O
United,B-ethnicity
States,I-ethnicity
of,I-ethnicity
America,I-ethnicity
that,O
records,O
all,O
cancers,B-disease
regardless,O
of,O
clinical,O
treatment,O
[,O
10,O
],O
.,O
 , 
A,O
total,O
of,O
108,275,B-size
records,B-cohort-patient
were,O
analyzed,O
for,O
ages,O
at,O
cancer,B-disease
selected,O
by,O
site,O
(,B-body-part
colon,I-body-part
and,O
rectum,B-body-part
),I-body-part
,,O
race,O
(,B-ethnicity
white,I-ethnicity
),I-ethnicity
,,O
histology,O
(,B-disease
adenocarcinoma,I-disease
,,I-disease
ICD-0,O
-,O
2,O
codes,O
8000–8500,O
),O
,,O
and,O
stage,O
(,O
localized,O
,,O
regional,O
,,O
or,O
distant,O
),O
.,O
 , 
These,O
cancers,B-disease
were,O
not,O
characterized,O
with,O
respect,O
to,O
HNPCC,B-disease
or,O
MSI,O
.,O
 , 


,O
Quantitative,O
analysis,O


,O
Numbers,O
of,O
oncogenic,O
alterations,O
(,O
genetic,O
mutations,O
or,O
epigenetic,O
alterations,O
),O
required,O
for,O
transformation,O
were,O
estimated,O
from,O
ages,O
at,O
cancer,B-disease
using,O
a,O
Bayesian,O
approach,O
as,O
previously,O
described,O
[,O
11,O
],O
.,O
 , 
This,O
method,O
requires,O
the,O
use,O
of,O
a,O
life,O
table,O
from,O
census,O
data,O
:,O
for,O
the,O
Finnish,B-ethnicity
data,O
set,O
we,O
used,O
a,O
Finnish,B-ethnicity
life,O
table,O
from,O
the,O
World,O
Health,O
Organization,O
website,O
,,O
for,O
the,O
SEER,O
dataset,O
we,O
used,O
a,O
United,B-ethnicity
States,I-ethnicity
life,O
table,O
as,O
described,O
previously,O
[,O
11,O
],O
.,O
 , 
The,O
model,O
assumes,O
the,O
first,O
visible,O
clonal,O
expansion,O
occurs,O
at,O
the,O
time,O
of,O
transformation,O
and,O
ignores,O
the,O
interval,O
after,O
transformation,O
.,O
 , 
The,O
analysis,O
ignores,O
temporal,O
trends,O
,,O
which,O
may,O
influence,O
our,O
mutation,O
estimates,O
.,O
 , 


,O
For,O
the,O
SEER,O
dataset,O
,,O
we,O
also,O
fit,O
our,O
model,O
for,O
cancer,B-disease
progression,O
[,O
11,O
],O
with,O
the,O
inferential,O
method,O
described,O
in,O
reference,O
12,O
.,O
 , 
This,O
method,O
does,O
not,O
require,O
a,O
life,O
table,O
,,O
but,O
unlike,O
our,O
method,O
it,O
does,O
require,O
information,O
on,O
all,O
the,O
cancer,B-disease
cases,B-cohort-patient
for,O
the,O
population,O
at,O
risk,O
.,O
 , 
Therefore,O
this,O
method,O
is,O
appropriate,O
for,O
analysing,O
the,O
SEER,O
dataset,O
but,O
not,O
the,O
Finnish,B-ethnicity
dataset,O
.,O
 , 
Our,O
method,O
[,O
11,O
],O
is,O
appropriate,O
for,O
analysing,O
both,O
datasets,O
.,O
 , 
For,O
the,O
SEER,O
dataset,O
,,O
the,O
two,O
methods,O
inferred,O
the,O
same,O
number,O
of,O
mutations,O
required,O
for,O
cancer,B-disease
.,I-disease
 , 


,O
 , 
#1619718-03-Materials-and-methods-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Statistics,O


,O
Data,O
were,O
analysed,O
by,O
χ2,O
test,O
,,O
Fisher,O
's,O
exact,O
test,O
or,O
T,O
-,O
test,O
,,O
as,O
appropriate,O
,,O
using,O
SAS,O
software,O
,,O
version,O
8.2,O
(,O
Cary,O
,,O
NC,O
,,O
USA,O
),O
.,O
 , 
P,O
-,O
values,O
<,O
 ,O
0.05,O
were,O
interpreted,O
as,O
significant,O
.,O
 , 


,O
 , 
#2386495-04-Results-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Splice,O
-,O
site,O
affecting,O
mutations,O


,O
When,O
investigating,O
patient,B-cohort-patient
C496,B-cohort-patient
with,O
RNA,O
-,O
based,O
PTT,O
,,O
an,O
aberrant,O
APC,B-gene
polypeptide,O
pattern,O
was,O
detected,O
(,O
data,O
not,O
shown,O
),O
.,O
 , 
Sequencing,O
of,O
the,O
corresponding,O
cDNA,O
fragment,O
identified,O
a,O
change,O
in,O
the,O
beginning,O
of,O
exon,O
8,O
(,O
Figure,O
3,O
),O
.,O
 , 
Genomic,O
sequencing,O
of,O
exon,O
8,O
and,O
the,O
flanking,O
intron,O
sequences,O
lead,O
to,O
the,O
discovery,O
of,O
the,O
c.835,B-mutation
-,I-mutation
7,I-mutation
T,I-mutation
>,I-mutation
G,I-mutation
mutation,O
(,O
Figure,O
3A,O
),O
.,O
 , 
The,O
base,O
substitution,O
introduces,O
a,O
new,B-mutation
AG,I-mutation
splice,I-mutation
-,I-mutation
acceptor,I-mutation
site,I-mutation
eight,I-mutation
bases,I-mutation
upstream,I-mutation
of,I-mutation
exon,I-mutation
8,I-mutation
.,I-mutation
 , 
Owing,O
to,O
the,O
use,O
of,O
this,O
new,O
splice,O
site,O
the,O
last,O
six,O
bases,O
of,O
intron,O
7,O
are,O
included,O
in,O
the,O
transcript,O
,,O
resulting,O
in,O
premature,O
truncation,O
(,O
Figure,O
3B,O
),O
.,O
 , 
The,O
entire,O
APC,B-gene
coding,O
region,O
of,O
the,O
patient,B-cohort-patient
was,O
sequenced,O
and,O
no,O
other,O
pathogenic,O
variants,O
were,O
detected,O
.,O
 , 
A,O
search,O
for,O
deletion,O
or,O
duplication,O
of,O
one,O
or,O
more,O
exon,O
in,O
the,O
APC,B-gene
gene,O
by,O
MLPA,O
was,O
also,O
carried,O
out,O
with,O
negative,O
result,O
.,O
 , 


,O
Characterization,O
of,O
the,O
mutation,O
in,O
patient,B-cohort-patient
C496,B-cohort-patient
.,I-cohort-patient
 , 
(,O
A,O
),O
Genomic,O
sequence,O
of,O
the,O
patient,B-cohort-patient
showing,O
the,O
c.835,B-mutation
-,I-mutation
7,I-mutation
T,I-mutation
>,I-mutation
G,I-mutation
mutation,O
.,O
 , 
The,O
new,O
splice,O
site,O
generated,O
by,O
the,O
T,O
>,O
G,O
substitution,O
is,O
indicated,O
with,O
a,O
dashed,O
line,O
,,O
the,O
wildtype,O
acceptor,O
-,O
splice,O
site,O
is,O
underlined,O
,,O
and,O
the,O
regular,O
start,O
of,O
exon,O
8,O
is,O
indicated,O
with,O
an,O
arrow,O
.,O
 , 
(,O
B,O
),O
cDNA,O
sequence,O
covering,O
the,O
exon,O
7–8,O
boundary,O
,,O
indicated,O
with,O
a,O
dashed,O
line,O
.,O
 , 
Shown,O
below,O
the,O
sequence,O
diagram,O
is,O
the,O
interpretation,O
of,O
the,O
sequence,O
reflecting,O
the,O
two,O
mRNA,O
species,O
present,O
in,O
the,O
sample,O
.,O
 , 
The,O
insertion,O
of,O
6,O
bp,O
owing,O
to,O
the,O
introduction,O
of,O
a,O
new,O
splice,O
site,O
in,O
the,O
mutant,O
allele,O
is,O
shown,O
as,O
a,O
shaded,O
area,O
.,O
 , 
Predicted,O
amino,O
-,O
acid,O
sequence,O
of,O
translation,O
products,O
are,O
shown,O
above,O
and,O
below,O
the,O
respective,O
cDNA,O
sequence,O
.,O
 , 


,O
The,O
APC,B-gene
mutation,B-mutation
in,O
patient,B-cohort-patient
C633,B-cohort-patient
was,O
also,O
detected,O
by,O
RNA,O
-,O
based,O
PTT,O
,,O
followed,O
by,O
cDNA,O
sequencing,O
and,O
genomic,O
sequencing,O
of,O
APC,B-gene
exon,O
7,O
(,O
Figure,O
4,O
),O
.,O
 , 
The,O
c.834,B-mutation
G,I-mutation
>,I-mutation
C,I-mutation
mutation,O
changes,O
the,O
normal,O
splice,O
donor,O
site,O
of,O
exon,O
7,O
.,O
 , 
This,O
substitution,O
reduces,O
the,O
score,O
for,O
usage,O
of,O
the,O
wild,O
-,O
type,O
splice,O
donor,O
site,O
according,O
to,O
[,O
37,O
],O
.,O
 , 
An,O
alternative,O
cryptic,O
splice,O
donor,O
site,O
11,O
bp,O
upstream,O
in,O
exon,O
7,O
is,O
used,O
in,O
the,O
mutant,O
allele,O
,,O
leading,O
to,O
the,O
aberrant,B-mutation
splicing,I-mutation
of,I-mutation
exon,I-mutation
7,I-mutation
.,I-mutation
 , 
The,O
resulting,O
APC,B-gene
mRNA,O
carries,O
a,O
frameshift,B-mutation
,,I-mutation
caused,I-mutation
by,I-mutation
the,I-mutation
11,I-mutation
-,I-mutation
bp,I-mutation
deletion,I-mutation
in,I-mutation
the,I-mutation
3,I-mutation
',I-mutation
end,I-mutation
of,I-mutation
exon,I-mutation
7,I-mutation
,,I-mutation
which,I-mutation
leads,I-mutation
to,I-mutation
the,I-mutation
premature,I-mutation
truncation,I-mutation
of,I-mutation
the,I-mutation
protein,I-mutation
in,I-mutation
exon,I-mutation
8,I-mutation
.,I-mutation
 , 
A,O
third,O
novel,O
mutation,B-mutation
affecting,I-mutation
splicing,I-mutation
of,O
the,O
APC,B-gene
gene,O
was,O
detected,O
by,O
PTT,O
analysis,O
and,O
genomic,O
sequencing,O
of,O
patient,B-cohort-patient
C232,B-cohort-patient
.,I-cohort-patient
 , 
A,O
complex,O
deletion,B-mutation
/,I-mutation
insertion,I-mutation
was,O
detected,O
that,O
affects,O
the,O
splicing,O
of,O
APC,B-gene
intron,O
3,O
,,O
APC,B-gene
c.423,B-mutation
-,I-mutation
6del8ins13,I-mutation
(,O
in,O
detail,O
APC,B-gene
c.,B-mutation
423,I-mutation
-6delAAATAGGTinsGAAGCAAGATCAG,I-mutation
),I-mutation
.,O
 , 


,O
 , 
#1360090-05-Conclusion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Conclusion,O


,O
Findings,O
from,O
the,O
present,O
study,O
and,O
from,O
previous,O
work,O
indicate,O
that,O
BRAF,B-gene
mutation,B-mutation
is,O
likely,O
to,O
be,O
a,O
convenient,O
marker,O
for,O
the,O
identification,O
of,O
a,O
subset,O
of,O
CRCs,B-disease
with,O
distinctive,O
clinical,O
,,O
pathological,O
and,O
molecular,O
features,O
and,O
which,O
may,O
originate,O
in,O
hyperplastic,B-Disorder
polyps,B-disease
and,O
serrated,B-Concepts_Ideas
adenomas,B-disease
[,O
7,14,15,O
],O
.,O
 , 
In,O
view,O
of,O
the,O
strong,O
associations,O
between,O
BRAF,B-gene
mutation,B-mutation
and,O
specific,O
pathological,O
(,O
site,O
,,O
grade,O
,,O
mucinous,O
,,O
infiltrating,O
lymphocytes,O
),O
and,O
molecular,O
(,O
methylated,O
MSI+,O
,,O
CIMP+,O
,,O
wildtype,O
KRAS,B-gene
),I-gene
features,O
,,O
it,O
will,O
be,O
interesting,O
in,O
future,O
studies,O
to,O
determine,O
the,O
predictive,O
significance,O
of,O
this,O
marker,O
for,O
response,O
to,O
adjuvant,O
therapies,O
in,O
CRC,B-disease
.,I-disease
 , 


,O
 , 
#2275286-04-Results-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Comparisons,O
of,O
clinical,O
features,O
between,O
MSS,B-Disorder
and,O
MSI,B-Disorder
group,B-cohort-patient


,I-cohort-patient
*,O
Statistical,O
analysis,O
was,O
made,O
between,O
MSI,B-Disorder
and,O
MSS,B-Disorder
group,B-cohort-patient
only,O


,O
MSI,O
state,O
,,O
germline,O
mutations,O
,,O
and,O
consequential,O
changes,O
in,O
amino,O
-,O
acid,O
sequence,O


,O
The,O
MSI,O
state,O
,,O
mutation,O
sites,O
,,O
and,O
consequential,O
changes,O
in,O
amino,O
-,O
acid,O
sequences,O
of,O
MMR,B-gene
genes,O
are,O
summarized,O
in,O
Table,O
4,O
.,O
 , 
In,O
34,B-size
MSI,B-Disorder
CRCs,B-disease
and,O
one,B-size
MSS,B-Disorder
CRC,B-disease
with,O
MLH1,B-gene
negative,I-Phenomena
staining,I-Phenomena
,,I-Phenomena
8,B-size
had,O
MMR,B-gene
gene,O
germline,B-mutation
mutations,I-mutation
,,I-mutation
accounting,O
for,O
22.9,B-size
%,I-size
of,O
MSI,B-Disorder
colorectal,B-disease
cancers,B-disease
and,O
5.5,B-size
%,I-size
of,O
all,O
colorectal,B-disease
cancers,B-cohort-patient
.,I-cohort-patient
 , 
Three,B-size
patients,B-cohort-patient
had,O
MSH6,B-gene
germline,B-mutation
mutations,I-mutation
and,O
5,B-cohort-patient
had,O
MSH2,B-gene
germline,B-mutation
mutations,I-mutation
;,I-mutation
the,O
clinical,O
features,O
of,O
these,O
patients,B-cohort-patient
are,O
summarized,O
in,O
Table,O
5,O
.,O
 , 
None,B-size
of,O
the,O
patients,B-cohort-patient
had,O
MLH1,B-gene
gene,O
mutations,B-mutation
.,I-mutation
 , 
Seven,B-size
patients,B-cohort-patient
in,O
the,O
MSI,B-Disorder
group,B-cohort-patient
had,O
A,B-mutation
/,I-mutation
T,I-mutation
heterozygosis,I-mutation
in,I-mutation
MSH6,B-gene
codon,I-mutation
380,I-mutation
of,I-mutation
exon,I-mutation
5,I-mutation
,,I-mutation
but,I-mutation
it,I-mutation
did,I-mutation
not,I-mutation
cause,I-mutation
changes,I-mutation
in,I-mutation
the,I-mutation
amino,I-mutation
acid,I-mutation
sequence,I-mutation
.,I-mutation
 , 
The,O
germline,B-mutation
mutations,I-mutation
of,O
the,O
MSI,B-Disorder
-,I-Disorder
L,I-Disorder
and,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
CRCs,B-disease
are,O
summarized,O
in,O
Table,O
6,O
.,O
 , 
Six,B-size
CRCs,B-disease
with,O
mutations,B-mutation
were,O
MSI,B-Disorder
-,I-Disorder
H,I-Disorder
and,O
two,B-size
patients,B-cohort-patient
with,O
mutations,B-mutation
were,O
MSI,B-Disorder
-,I-Disorder
L.,I-Disorder


,O
Details,O
of,O
the,O
8,B-size
patients,B-cohort-patient
in,O
MSS,B-Disorder
group,B-cohort-patient
identified,O
to,O
have,O
MMR,B-gene
gene,O
germline,B-mutation
mutation,I-mutation


,I-mutation
Clinical,O
features,O
of,O
patients,B-cohort-patient
in,O
MSI,B-Disorder
group,B-cohort-patient
with,O
MMR,B-gene
gene,O
mutations,B-mutation


,I-mutation
*,O
Amsterdam,O
criteria,O
II,O


,O
The,O
mutation,O
between,O
the,O
MSI,O
-,O
L,O
and,O
MSI,O
-,O
H,O


,O
P,O
=,O
0.112,O


,O
Clinical,O
features,O
of,O
patients,B-cohort-patient
in,O
the,O
MSI,B-Disorder
group,B-cohort-patient
with,O
MMR,B-gene
gene,O
mutations,B-mutation


,I-mutation
The,O
clinical,O
features,O
of,O
MSI,B-Disorder
patients,B-cohort-patient
with,O
MMR,B-gene
gene,O
mutations,B-mutation
are,O
shown,O
in,O
Table,O
5,O
.,O
 , 
Mean,O
age,O
was,O
58.8,B-age
years,I-age
(,I-age
range,I-age
:,I-age
34–78,I-age
),I-age
.,I-age
 , 
Six,B-size
were,O
female,B-cohort-patient
and,O
2,B-size
were,O
male,B-cohort-patient
.,I-cohort-patient
 , 
Only,O
one,O
patient,B-cohort-patient
had,O
right,B-body-part
side,I-body-part
colonic,I-body-part
lesion,B-disease
and,O
2,B-cohort-patient
had,O
mucinous,B-Disorder
carcinoma,B-disease
.,I-disease
 , 
There,O
were,O
no,B-size
patients,B-cohort-patient
in,O
Dukes,B-Phenomena
',I-Phenomena
A,I-Phenomena
or,O
with,O
synchronous,B-Concepts_Ideas
/,I-Concepts_Ideas
metachronous,I-Concepts_Ideas
disease,B-disease
.,I-disease
 , 
Only,O
one,O
patient,B-cohort-patient
fulfilled,O
the,O
Amsterdam,O
Criteria,O
(,O
II,O
),O
.,O
 , 


,O
 , 
#2386495-04-Results-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Seven,O
of,O
the,O
identified,O
APC,B-gene
mutations,B-mutation
were,O
large,B-mutation
deletions,I-mutation
,,I-mutation
ranging,O
from,O
a,O
deletion,B-mutation
of,I-mutation
86,I-mutation
bp,I-mutation
in,I-mutation
exon,I-mutation
15,I-mutation
to,O
a,O
deletion,B-mutation
of,I-mutation
the,I-mutation
whole,I-mutation
APC,I-mutation
gene,I-mutation
(,O
Figure,O
1C,O
),O
.,O
 , 
Three,O
of,O
these,O
deletions,O
have,O
not,O
,,O
to,O
the,O
best,O
of,O
the,O
authors,O
',O
knowledge,O
,,O
been,O
described,O
earlier,O
.,O
 , 
The,O
deletion,B-mutation
encompassing,I-mutation
APC,B-gene
exon,I-mutation
4,I-mutation
in,O
patient,B-cohort-patient
3765,B-cohort-patient
,,I-cohort-patient
c.423,B-mutation
-,I-mutation
1662_531,I-mutation
+,I-mutation
1825del3595,I-mutation
,,I-mutation
was,O
detected,O
by,O
RNA,O
-,O
based,O
PTT,O
with,O
subsequent,O
cDNA,O
sequencing,O
and,O
verified,O
by,O
long,O
-,O
range,O
PCR,O
on,O
genomic,O
DNA,O
.,O
 , 
We,O
could,O
not,O
detect,O
this,O
deletion,O
with,O
MLPA,O
even,O
though,O
a,O
probe,O
for,O
exon,O
4,O
is,O
included,O
in,O
the,O
MLPA,O
kit,O
(,O
see,O
the,O
discussion,O
),O
.,O
 , 
Detection,O
of,O
the,O
large,B-mutation
deletion,I-mutation
in,O
patient,B-cohort-patient
C591,B-cohort-patient
,,I-cohort-patient
encompassing,O
APC,B-gene
exons,B-mutation
13,I-mutation
through,I-mutation
the,I-mutation
5,I-mutation
',I-mutation
part,I-mutation
of,I-mutation
exon,I-mutation
15,I-mutation
,,I-mutation
was,O
carried,O
out,O
with,O
MLPA,O
.,O
 , 
The,O
deletion,B-mutation
in,O
patient,B-cohort-patient
2136,B-cohort-patient
was,O
identified,O
by,O
PTT,O
and,O
subsequent,O
DNA,O
sequencing,O
.,O
 , 


,O
A,O
case,B-cohort-patient
of,O
APC,B-gene
mosaicism,B-mutation


,B-size
Three,I-size
patients,B-cohort-patient
(,B-cohort-patient
C107,I-cohort-patient
,,I-cohort-patient
C257,B-cohort-patient
,,I-cohort-patient
and,O
C505,B-cohort-patient
),I-cohort-patient
,,O
negative,O
for,O
mutations,B-mutation
in,O
APC,B-gene
,,I-gene
were,O
reported,O
as,O
de,O
novo,O
cases,B-cohort-patient
with,O
no,B-Concepts_Ideas
known,I-Concepts_Ideas
family,I-Concepts_Ideas
history,I-Concepts_Ideas
of,I-Concepts_Ideas
FAP,B-disease
.,I-disease
 , 
These,O
patients,B-cohort-patient
where,O
all,O
screened,O
for,O
APC,B-gene
mutations,B-mutation
present,O
as,O
low,O
-,O
frequency,O
alleles,O
using,O
SSCP,O
/,O
HD,O
.,O
 , 
We,O
did,O
not,O
detect,O
any,O
signs,O
of,O
low,O
-,O
frequency,O
mutations,O
in,O
patients,B-cohort-patient
C257,B-cohort-patient
and,O
C505,B-cohort-patient
.,I-cohort-patient
 , 
However,O
,,O
in,O
patient,B-cohort-patient
C107,B-cohort-patient
,,I-cohort-patient
aberrant,O
bands,O
,,O
possibly,O
originating,O
from,O
formation,O
of,O
heteroduplexes,O
,,O
was,O
detected,O
by,O
SSCP,O
/,O
HD,O
in,O
a,O
very,O
low,O
fraction,O
of,O
her,B-gender
blood,B-body-part
lymphocytes,I-body-part
.,I-body-part
 , 
The,O
c.2700_2701delTC,B-mutation
mutation,O
,,O
which,O
results,O
in,O
frame,B-mutation
shift,I-mutation
at,I-mutation
codon,I-mutation
900,I-mutation
,,I-mutation
was,O
found,O
by,O
sequencing,O
of,O
the,O
aberrant,O
bands,O
excised,O
from,O
the,O
SSCP,O
/,O
HD,O
gel,O
(,O
Figure,O
2A,O
),O
.,O
 , 
The,O
mutation,O
was,O
detected,O
in,O
approximately,O
one,O
-,O
third,O
of,O
the,O
analyzed,O
tumor,B-disease
-,I-disease
derived,O
cells,O
extracted,O
from,O
paraffin,O
-,O
embedded,O
tissue,O
by,O
DNA,O
sequencing,O
(,O
Figure,O
2B,O
),O
.,O
 , 
The,O
mutation,O
was,O
not,O
detectable,O
at,O
all,O
in,O
the,O
sequence,O
determination,O
of,O
DNA,O
extracted,O
from,O
blood,B-body-part
lymphocytes,I-body-part
from,O
the,O
patient,B-cohort-patient
(,O
Figure,O
2C,O
),O
.,O
 , 


,O
Detection,O
of,O
the,O
mosaic,B-mutation
c.2700_2701delTC,I-mutation
mutation,O
in,O
patient,B-cohort-patient
C107,B-cohort-patient
.,I-cohort-patient
 , 
Nucleotide,O
2700,O
is,O
indicated,O
with,O
an,O
arrow,O
.,O
 , 
(,O
A,O
),O
 , 
The,O
aberrant,O
bands,O
indicated,O
by,O
the,O
bracket,O
were,O
excised,O
from,O
the,O
SSCP,O
/,O
HD,O
gel,O
.,O
 , 
The,O
resulting,O
DNA,O
sequence,O
is,O
shown,O
to,O
the,O
right,O
.,O
 , 
(,O
B,O
),O
DNA,O
sequence,O
from,O
DNA,O
extracted,O
from,O
tumor,B-disease
-,I-disease
derived,O
cells,O
from,O
the,O
patient,B-cohort-patient
.,I-cohort-patient
 , 
(,O
C,O
),O
The,O
DNA,O
sequence,O
from,O
DNA,O
isolated,O
from,O
the,O
patient,B-cohort-patient
's,I-cohort-patient
blood,B-body-part
lymphocytes,I-body-part
.,I-body-part
 , 


,O
Mutation,O
at,O
the,O
far,O
5'end,O


,O
DNA,O
sequencing,O
of,O
APC,B-gene
exon,O
1,O
in,O
patient,B-cohort-patient
C157,B-cohort-patient
revealed,O
the,O
c.70C,B-mutation
>,I-mutation
T,I-mutation
substitution,I-mutation
which,I-mutation
introduces,I-mutation
a,I-mutation
nonsense,I-mutation
mutation,I-mutation
in,I-mutation
codon,I-mutation
24,I-mutation
(,O
Figure,O
1,O
),O
.,O
 , 
The,O
mutation,O
was,O
also,O
detectable,O
by,O
SSCP,O
/,O
HD,O
analysis,O
but,O
was,O
not,O
detectable,O
by,O
PTT,O
due,O
to,O
its,O
localization,O
close,O
to,O
the,O
5,O
',O
end,O
of,O
the,O
PTT,O
fragment,O
.,O
 , 
However,O
,,O
indication,O
for,O
a,O
mutation,O
was,O
observed,O
as,O
lowered,O
intensity,O
of,O
the,O
full,O
-,O
length,O
fragment,O
.,O
 , 


,O
 , 
#2275286-03-Methods-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Detection,O
of,O
methylation,O
of,O
MLH1,B-gene
promoter,O
by,O
quantitative,O
MSP,O


,O
DNA,O
was,O
chemically,O
modified,O
by,O
sodium,O
bisulfite,O
to,O
convert,O
all,O
unmethylated,O
cytosines,O
to,O
uracils,O
,,O
while,O
leaving,O
methylcytosines,O
unaltered,O
(,O
EZ,O
DNA,O
methylation,O
gold,O
kit,O
;,O
Zymo,O
Research,O
,,O
Orange,O
,,O
CA,O
),O
,,O
and,O
eluted,O
in,O
50,O
μL,O
of,O
elution,O
buffer,O
[,O
10,11,O
],O
.,O
 , 
The,O
bisulfite,O
-,O
modified,O
DNA,O
was,O
then,O
used,O
as,O
a,O
template,O
for,O
the,O
fluorescence,O
-,O
based,O
real,O
-,O
time,O
PCR,O
assay,O
 , 
[,O
12,O
],O
.,O
 , 


,O
The,O
sequences,O
of,O
primers,O
and,O
the,O
fluorogenic,O
probe,O
were,O
designed,O
by,O
MethPrimer,O
software,O
.,O
 , 
Primer,O
sequence,O
for,O
hMLH1,B-gene
was,O
:,O
CGTTATATATCGTTCGTAGTATTCGTGTTT(Forward,O
),O
,,O
and,O
CTATCGCCGCCTCATCGT,O
(,O
Reverse,O
),O
,,O
probe,O
sequence,O
was,O
6FAM,O
-,O
CGCGACGTCAAACGCCACTACG,O
-,O
TAMRA,O
.,O
 , 
For,O
the,O
MSP,O
,,O
5,O
μL,O
of,O
bisulfite,O
-,O
converted,O
DNA,O
was,O
used,O
in,O
each,O
amplification,O
.,O
 , 
PCR,O
was,O
performed,O
in,O
a,O
reaction,O
volume,O
of,O
25,O
μL,O
consisting,O
of,O
5,O
pmol,O
of,O
each,O
primer,O
,,O
250,O
pmol,O
of,O
probe,O
,,O
200,O
μM,O
each,O
of,O
dATP,O
,,O
dCTP,O
,,O
and,O
dGTP,O
,,O
400,O
μM,O
dUTP,O
,,O
3.5,O
mM,O
MgCl2,O
,,O
1×,O
TaqMan,O
Buffer,O
A,O
,,O
and,O
2,O
units,O
of,O
AmpliTaq,O
Gold,O
polymerase,O
(,O
Applied,O
Biosystem,O
Shanghai,O
Division,O
,,O
Shanghai,O
,,O
China,O
),O
at,O
the,O
following,O
condition,O
:,O
95,O
°,O
C,O
for,O
10,O
min,O
,,O
followed,O
by,O
50,O
cycles,O
at,O
95,O
°,O
C,O
for,O
15,O
s,O
,,O
and,O
60,O
°,O
C,O
for,O
1,O
min,O
.,O
 , 
All,O
PCR,O
was,O
performed,O
in,O
the,O
ABI-7000,O
Real,O
-,O
Time,O
PCR,O
Detection,O
system,O
(,O
Applied,O
Biosystem,O
Shanghai,O
Division,O
,,O
Shanghai,O
,,O
China,O
),O
.,O
 , 
CpGenomeTM,O
Universal,O
methylated,O
DNA,O
(,O
Chemicon,O
International,O
Inc.,O
,,O
city,O
,,O
CA,O
,,O
USA,O
),O
was,O
included,O
as,O
positive,O
control,O
in,O
all,O
amplifications,O
and,O
glyceraldehyde-3,O
-,O
phosphate,O
dehydrogenase,O
(,O
GAPDH,O
),O
quantification,O
of,O
all,O
untreated,O
DNA,O
was,O
used,O
as,O
loading,O
control,O
.,O
 , 


,O
Extraction,O
of,O
genomic,O
DNA,O
from,O
blood,O


,O
Blood,O
from,O
peripheral,O
veins,O
(,O
2,O
mL,O
),O
was,O
taken,O
from,O
patients,B-cohort-patient
with,O
MSI,B-Disorder
colorectal,B-body-part
cancer,B-disease
,,I-disease
and,O
genomic,O
DNA,O
was,O
extracted,O
using,O
a,O
kit,O
from,O
Beijing,O
Bio,O
-,O
Lab,O
Materials,O
Institute,O
.,O
 , 
The,O
extracted,O
genomic,O
DNA,O
was,O
stored,O
at,O
-80,O
°,O
C,O
until,O
further,O
analysis,O
.,O
 , 


,B-mutation
Mutation,I-mutation
of,O
MSH2,B-gene
,,I-gene
MLH1,B-gene
and,O
MSH6,B-gene
genes,O


,O
Primers,O
for,O
all,O
exons,O
of,O
MSH2,B-gene
,,I-gene
MLH1,B-gene
and,O
MSH6,B-gene
were,O
designed,O
for,O
PCR,O
amplification,O
as,O
previously,O
reported,O
.,O
 , 
PCR,O
amplification,O
was,O
performed,O
using,O
the,O
reagents,O
from,O
ABI,O
Company,O
,,O
following,O
the,O
protocol,O
provided,O
by,O
the,O
company,O
.,O
 , 
After,O
amplification,O
,,O
the,O
PCR,O
products,O
were,O
purified,O
by,O
electrophoresis,O
through,O
a,O
1.5,O
%,O
low,O
melting,O
point,O
agarose,O
gel,O
,,O
and,O
then,O
were,O
sequenced,O
on,O
an,O
AB13100,O
-,O
Avant,O
sequencer,O
(,O
Applied,O
Biosystem,O
Shanghai,O
Division,O
),O
using,O
fluorescently,O
labeled,O
primers,O
,,O
following,O
the,O
protocols,O
supplied,O
by,O
the,O
manufacturer,O
.,O
 , 
By,O
comparing,O
the,O
obtained,O
sequence,O
with,O
the,O
known,O
sequence,O
,,O
nonsense,O
,,O
missense,O
,,O
and,O
frameshift,O
mutations,O
were,O
identified,O
.,O
 , 
Nonsense,O
and,O
frameshift,O
mutations,O
were,O
considered,O
pathogenic,O
.,O
 , 
All,O
missense,O
mutations,O
were,O
screened,O
in,O
50,B-size
patients,B-cohort-patient
with,O
MSS,B-Disorder
colorectal,B-disease
cancer,I-disease
and,O
50,B-size
people,B-cohort-patient
without,B-disease
cancer,I-disease
or,O
a,O
family,O
history,O
of,O
cancer,B-disease
.,I-disease
 , 
They,O
were,O
judged,O
as,O
pathogenic,O
if,O
they,O
could,O
not,O
be,O
found,O
in,O
MSS,B-Disorder
patients,B-cohort-patient
and,O
normal,B-disease
people,B-cohort-patient
,,I-cohort-patient
otherwise,O
,,O
they,O
were,O
judged,O
as,O
polymorphisms,O
.,O
 , 


,O
 , 
#3034663-03-Methods-p02
Microsatellite,O
instability,O
and,O
MLH1,B-gene
immunohistochemical,I-Physiology
expression,I-Physiology


,I-Physiology
A,O
subset,O
of,O
colorectal,B-body-part
tumour,B-disease
DNA,O
samples,O
from,O
17,B-size
patients,B-cohort-patient
carrying,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
(,B-size
eight,I-size
from,O
the,O
familial,B-cohort-patient
group,I-cohort-patient
and,O
nine,B-size
from,O
the,O
sporadic,B-Concepts_Ideas
CRC,B-disease
group,B-cohort-patient
),I-cohort-patient
was,O
screened,O
for,O
MSI,O
status,O
using,O
five,O
mononucleotide,O
markers,O
(,O
BAT26,O
,,O
BAT25,O
,,O
NR21,O
,,O
NR24,O
and,O
NR27,O
),O
and,O
multiplex,O
PCR,O
as,O
previously,O
described,O
by,O
Buhard,O
et,O
al,O
 , 
[,O
8,O
],O
.,O
 , 


,B-disease
Tumours,I-disease
from,O
p.,B-mutation
Lys618Ala,I-mutation
carrier,B-cohort-patient
cases,I-cohort-patient
in,O
the,O
familial,B-Concepts_Ideas
group,I-cohort-patient
(,B-size
seven,I-size
index,B-cohort-patient
subjects,I-cohort-patient
and,O
one,O
relative,B-cohort-patient
),I-cohort-patient
were,O
also,O
analysed,O
for,O
MLH1,B-gene
protein,O
expression,O
using,O
immunohistochemistry,O
and,O
anti,O
-,B-gene
MLH1,I-gene
antibodies,O
(,O
PharMingen,O
,,O
CA,O
,,O
USA,O
),O
as,O
described,O
elsewhere,O
[,O
7,O
],O
.,O
 , 
Tumour,B-disease
cells,O
were,O
judged,O
negative,O
for,O
protein,O
expression,O
only,O
if,O
they,O
lacked,O
staining,O
in,O
a,O
sample,O
in,O
which,O
normal,O
colonocytes,O
and,O
stroma,O
cells,O
were,O
stained,O
.,O
 , 
If,O
no,O
immunostaining,O
of,O
normal,O
tissue,O
could,O
be,O
demonstrated,O
,,O
the,O
results,O
were,O
considered,O
unreliable,O
.,O
 , 


,B-Physiology
MLH1,I-Physiology
promoter,I-Physiology
hypermethylation,I-Physiology
by,O
Methylation,O
Sensitive,O
Multiplex,O
Ligation,O
-,O
dependent,O
Probe,O
Amplification,O
(,O
MS,O
-,O
MLPA,O
),O
,,O
and,O
BRAF,B-gene
p.,B-mutation
Val600Glu,I-mutation
 , 
mutation,O
by,O
direct,O
sequencing,O
from,O
tumor,B-disease
DNA,O
was,O
also,O
assess,O
when,O
MLH1,B-gene
loss,I-Physiology
of,I-Physiology
expression,I-Physiology
was,O
detected,O
.,O
 , 


,O
Statistical,O
analysis,O


,O
Hardy,O
-,O
Weinberg,O
equilibrium,O
was,O
calculated,O
for,O
the,O
control,B-cohort-patient
,,I-cohort-patient
sporadic,B-Concepts_Ideas
CRC,B-disease
and,O
familial,B-Concepts_Ideas
CRC,B-disease
groups,B-cohort-patient
.,I-cohort-patient
 , 
Allelic,O
and,O
genotype,O
frequencies,O
were,O
calculated,O
.,O
 , 
In,O
the,O
case,O
-,O
control,O
study,O
of,O
sporadic,B-Concepts_Ideas
CRC,B-disease
,,I-disease
we,O
estimated,O
the,O
odds,O
ratio,O
(,O
OR,O
),O
and,O
95,O
%,O
confidence,O
interval,O
(,O
95,O
%,O
CI,O
),O
for,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
using,O
unconditional,O
logistic,O
regression,O
adjusted,O
for,O
age,O
and,O
sex,O
.,O
 , 
We,O
analysed,O
for,O
potential,O
effect,O
modification,O
by,O
age,O
using,O
an,O
analysis,O
stratified,O
according,O
to,O
median,O
age,O
at,O
diagnosis,O
for,O
the,O
sporadic,B-Concepts_Ideas
CRC,B-disease
cases,B-cohort-patient
(,B-age
≤70,I-age
years,I-age
or,I-age
>,I-age
70,I-age
years,I-age
),I-age
.,O
 , 
A,O
χ2,O
test,O
was,O
used,O
to,O
evaluate,O
differences,O
in,O
p.,B-mutation
Lys618Ala,I-mutation
carrier,O
frequencies,O
between,O
the,O
tumour,B-disease
and,O
control,B-cohort-patient
groups,I-cohort-patient
.,I-cohort-patient
 , 
A,O
probability,O
level,O
of,O
<,O
0.05,O
was,O
considered,O
significant,O
.,O
 , 


,O
 , 
#1619718-04-Results-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Loss,O
of,O
expression,O
of,O
mgmt,O


,B-Physiology
Loss,I-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,I-Physiology
was,O
distributed,O
differently,O
(,O
P,O
<,O
0.001,O
),O
across,O
the,O
different,O
types,O
of,O
polyps,B-disease
,,I-disease
being,O
observed,O
most,O
frequently,O
among,O
MPs,B-disease
,,I-disease
TA,B-disease
>,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
and,O
TVAs,B-disease
/,B-disease
VAs,I-disease
(,O
Table,O
1,O
),O
.,O
 , 
There,O
was,O
no,O
correlation,O
between,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,B-gene
and,O
either,O
KRAS,B-gene
or,O
BRAF,B-gene
mutation,B-mutation
across,O
the,O
full,O
range,O
of,O
polyp,B-disease
types,O
.,O
 , 
However,O
,,O
among,O
TAs,B-disease
<,B-Concepts_Ideas
 ,I-Concepts_Ideas
10,I-Concepts_Ideas
mm,I-Concepts_Ideas
,,I-Concepts_Ideas
KRAS,B-gene
mutation,B-mutation
occurred,O
in,O
3/25,B-size
(,B-size
12,I-size
%,I-size
),I-size
adenomas,B-disease
with,O
no,B-Physiology
MGMT,B-gene
loss,I-Physiology
but,O
in,O
4/8,B-size
(,B-size
50,I-size
%,I-size
),I-size
adenomas,B-disease
with,O
MGMT,B-gene
loss,I-Physiology
(,O
P,O
<,O
0.04,O
),O
.,O
 , 
Since,O
there,O
were,O
few,O
KRAS,B-gene
mutations,B-mutation
in,O
this,O
subset,O
and,O
most,B-mutation
KRAS,B-gene
mutations,I-mutation
(,I-mutation
5/7,I-mutation
),I-mutation
were,I-mutation
G→A,B-cohort-patient
,,I-cohort-patient
it,O
was,O
not,O
possible,O
to,O
demonstrate,O
an,O
association,O
between,O
MGMT,B-gene
loss,I-Physiology
and,O
G→A,B-mutation
mutation,O
in,O
KRAS,B-gene
.,I-gene
 , 


,O
Aberrant,O
expression,O
of,O
p53,B-gene
and,O
correlation,O
with,O
MGMT,B-gene
loss,O


,B-size
Sixty,I-size
-,I-size
two,I-size
TAs,B-cohort-patient
,,I-cohort-patient
22,B-size
TVAs,B-cohort-patient
/,I-cohort-patient
VAs,I-cohort-patient
,,I-cohort-patient
15,B-size
SAs,B-cohort-patient
and,O
10,B-size
MPs,B-disease
were,O
immunostained,O
for,O
p53,B-gene
.,I-gene
 , 
Weak,B-Physiology
expression,I-Physiology
of,I-Physiology
nuclear,I-Physiology
p53,B-gene
occurred,O
frequently,O
within,O
the,O
proliferative,O
compartment,O
in,O
all,O
types,O
of,O
polyps,B-disease
and,O
was,O
ignored,O
.,O
 , 
Aberrant,B-Physiology
p53,B-gene
expression,I-Physiology
was,O
observed,O
in,O
only,O
four,B-size
polyps,B-disease
:,I-disease
one,B-size
TA,B-disease
,,I-disease
one,B-size
MP,B-disease
(,O
Figure,O
1B,O
),O
and,O
two,B-size
SAs,B-cohort-patient
(,O
Figure,O
2,O
),O
.,O
 , 
Overall,O
,,O
only,O
1/84,B-size
(,B-size
1,I-size
%,I-size
),I-size
conventional,B-Concepts_Ideas
adenomas,B-disease
showed,O
aberrant,B-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
compared,O
with,O
3/25,B-size
(,B-size
12,I-size
%,I-size
),I-size
serrated,B-Concepts_Ideas
polyps,B-cohort-patient
with,O
dysplasia,B-Disorder
(,O
P,O
<,O
0.04,O
),O
.,O
 , 
In,O
the,O
latter,O
,,O
aberrant,O
p53,O
expression,O
coincided,O
with,O
high,O
-,O
grade,O
dysplasia,O
and,O
reduced,B-Physiology
or,I-Physiology
complete,I-Physiology
loss,I-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MGMT,B-gene
(,O
Figures,O
1B,O
and,O
2,O
),O
.,O
 , 
The,O
TA,B-disease
with,O
aberrant,B-Physiology
p53,I-Physiology
expression,I-Physiology
had,O
normal,B-Disorder
expression,I-Disorder
of,I-Disorder
MGMT,B-gene
.,I-gene
 , 


,O
High,O
-,O
power,O
field,O
of,O
a,O
serrated,B-Concepts_Ideas
adenoma,B-disease
with,O
high,B-Disorder
-,I-Disorder
grade,I-Disorder
dysplasia,I-Disorder
(,O
A,O
),O
in,O
which,O
there,O
is,O
aberrant,B-Physiology
nuclear,I-Physiology
expression,I-Physiology
of,I-Physiology
p53,I-Physiology
(,O
B,O
),O
and,O
loss,B-Physiology
of,I-Physiology
nuclear,I-Physiology
expression,I-Physiology
of,I-Physiology
O-6,I-Physiology
-,I-Physiology
methylguanine,I-Physiology
DNA,I-Physiology
methyltransferase,I-Physiology
(,O
C,O
),O
.,O
 , 


,O
 , 
#1557864-03-Methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Methods,O


,O
Cell,O
culture,O


,O
All,O
cell,B-cohort-patient
lines,I-cohort-patient
were,O
cultured,O
in,O
medium,O
supplemented,O
with,O
100,O
U,O
/,O
ml,O
penicillin,O
,,O
100,O
μg,O
/,O
ml,O
streptomycin,O
and,O
50,O
μg,O
/,O
ml,O
gentamycin,O
at,O
37,O
°,O
C,O
in,O
humidified,O
air,O
with,O
5,O
%,O
CO2,O
(,O
except,O
for,O
SW48,O
which,O
was,O
cultured,O
with,O
10,O
%,O
CO2,O
),O
.,O
 , 
The,O
human,O
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
SKOV6,B-cohort-patient
,,I-cohort-patient
HOC7,B-cohort-patient
,,I-cohort-patient
SKOV3,B-cohort-patient
,,I-cohort-patient
2774,B-cohort-patient
,,I-cohort-patient
KB3.1,B-cohort-patient
and,O
CAOV3,B-cohort-patient
were,O
cultured,O
in,O
DMEM,O
/,O
HAMF12,O
medium,O
with,O
10,O
%,O
fetal,O
calf,O
serum,O
,,O
A2780,O
in,O
RPMI,O
1640,O
medium,O
with,O
10,O
%,O
fetal,O
calf,O
serum,O
and,O
OVCAR3,O
in,O
RPMI,O
1640,O
with,O
20,O
%,O
fetal,O
calf,O
serum,O
and,O
0.01,O
mg,O
/,O
ml,O
insulin,O
.,O
 , 
The,O
human,O
colon,B-disease
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
SW480,B-cohort-patient
and,O
SW48,B-cohort-patient
,,I-cohort-patient
included,O
as,O
controls,O
,,O
were,O
cultured,O
in,O
RPMI,O
1640,O
with,O
5,O
%,O
fetal,O
calf,O
serum,O
and,O
DMEM,O
/,O
HAMF12,O
with,O
10,O
%,O
fetal,O
calf,O
serum,O
respectively,O
.,O
 , 
The,O
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
line,I-cohort-patient
A2780,B-cohort-patient
has,O
been,O
cultured,O
separately,O
in,O
two,O
different,O
research,O
laboratories,O
at,O
our,O
department,O
.,O
 , 
The,O
isolated,O
DNA,O
and,O
RNA,O
from,O
each,O
culture,O
were,O
used,O
for,O
further,O
analysis,O
.,O
 , 


,O
The,O
MTT,O
colorimetric,O
assay,O
,,O
which,O
measures,O
the,O
number,O
of,O
viable,O
cells,O
capable,O
of,O
reducing,O
the,O
tetrazolium,O
compound,O
(,O
Sigma,O
-,O
Aldrich,O
,,O
Zwijndrecht,O
,,O
The,O
Netherlands,O
),O
to,O
a,O
blue,O
formazan,O
product,O
,,O
was,O
used,O
to,O
quantitate,O
the,O
chemosensitivity,O
of,O
the,O
ovarian,B-body-part
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
to,O
cisplatin,O
.,O
 , 
The,O
assay,O
was,O
performed,O
as,O
described,O
previously,O
by,O
us,O
[,O
38,O
],O
.,O
 , 


,O
Patients,O


,O
The,O
study,O
design,O
was,O
approved,O
by,O
the,O
medical,O
ethical,O
committee,O
of,O
the,O
Erasmus,O
MC,O
Rotterdam,O
,,O
the,O
Netherlands,O
(,O
MEC,O
02.949,O
),O
.,O
 , 
Tissue,O
of,O
75,B-size
ovarian,B-body-part
cancer,I-disease
patients,B-cohort-patient
and,O
four,B-size
normal,B-Disorder
stromal,I-Disorder
ovarian,B-body-part
tissues,B-cohort-patient
collected,O
at,O
the,O
Erasmus,O
MC,O
in,O
Rotterdam,B-ethnicity
were,O
included,O
in,O
this,O
study,O
.,O
 , 
The,O
patient,B-cohort-patient
and,O
tumor,B-disease
characteristics,O
are,O
listed,O
in,O
Table,O
1,O
.,O
 , 
Forty,B-size
-,I-size
six,I-size
patients,B-cohort-patient
received,O
platinum,O
-,O
based,O
chemotherapy,O
of,O
whom,O
34,B-cohort-patient
responded,O
to,O
treatment,O
defined,O
as,O
complete,O
response,O
,,O
partial,O
response,O
,,O
stable,O
disease,B-disease
or,O
no,O
relapse,O
within,O
6,O
months,O
after,O
chemotherapy,O
,,O
whereas,O
eleven,B-size
patients,B-cohort-patient
had,O
progressive,O
disease,B-disease
or,O
a,O
relapse,O
within,O
6,O
months,O
after,O
chemotherapy,O
.,O
 , 
In,O
one,O
patient,B-cohort-patient
the,O
response,O
was,O
not,O
known,O
.,O
 , 
The,O
response,O
rate,O
of,O
74,O
%,O
(,O
34/46,O
),O
is,O
comparable,O
with,O
the,O
response,O
rate,O
of,O
80,O
%,O
seen,O
in,O
the,O
clinic,O
.,O
 , 
A,O
more,O
detailed,O
description,O
of,O
the,O
response,O
definitions,O
has,O
been,O
previously,O
described,O
by,O
us,O
[,O
5,O
],O
.,O
 , 
The,O
median,O
age,O
at,O
the,O
time,O
of,O
surgery,O
was,O
52,B-age
years,I-age
(,B-age
range,I-age
27–83,I-age
),I-age
.,O
 , 


,O
DNA,O
isolation,O
:,O
microsatellite,O
analysis,O
and,O
methylation,O
specific,O
PCR,O


,O
Microsatellite,O
analysis,O
and,O
methylation,O
specific,O
PCR,O
(,O
MSP,O
),O
were,O
performed,O
on,O
DNA,O
from,O
eight,B-size
ovarian,B-disease
cancer,I-disease
cell,B-cohort-patient
lines,I-cohort-patient
,,I-cohort-patient
75,B-size
ovarian,B-disease
cancer,I-disease
specimens,B-cohort-patient
(,O
part,O
of,O
a,O
collection,O
of,O
ovarian,B-body-part
tumor,B-disease
specimens,B-cohort-patient
described,O
by,O
us,O
previously,O
[,O
39,O
],O
),O
and,O
the,O
four,B-size
normal,B-Disorder
stromal,I-Disorder
ovarian,B-body-part
specimens,B-cohort-patient
(,O
see,O
study,O
design,O
in,O
Figure,O
2,O
),O
.,O
 , 


,O
 , 
#1266026-05-Discussion-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Discussion,O


,O
The,O
exact,O
identities,O
and,O
numbers,O
of,O
mutations,O
required,O
for,O
transformation,O
are,O
uncertain,O
.,O
 , 
With,O
simple,O
multistage,O
models,O
[,O
3,O
-,O
6,11,O
],O
,,O
all,O
cancers,B-disease
of,O
a,O
given,O
type,O
require,O
the,O
same,O
number,O
of,O
oncogenic,O
mutations,O
,,O
but,O
stochastic,O
differences,O
in,O
the,O
times,O
to,O
accumulate,O
these,O
mutations,O
allow,O
individual,O
cancers,B-disease
to,O
appear,O
at,O
different,O
ages,O
.,O
 , 
Precisely,O
when,O
and,O
how,O
quickly,O
mutations,O
accumulate,O
are,O
unknown,O
,,O
but,O
a,O
basic,O
premise,O
is,O
that,O
cancer,B-disease
types,O
requiring,O
more,O
mutations,O
will,O
tend,O
to,O
appear,O
later,O
in,O
life,O
.,O
 , 
Therefore,O
,,O
numbers,O
of,O
mutations,O
may,O
be,O
estimated,O
from,O
cancer,B-disease
epidemiology,O
.,O
 , 
Colorectal,B-body-part
cancer,I-disease
frequencies,O
increase,O
with,O
age,O
,,O
and,O
the,O
pattern,O
of,O
this,O
increase,O
is,O
consistent,O
with,O
approximately,O
five,B-size
to,I-size
seven,I-size
oncogenic,B-mutation
mutations,I-mutation
[,O
3,O
-,O
6,O
],O
.,O
 , 


,O
In,O
this,O
study,O
numbers,O
of,O
mutations,O
were,O
estimated,O
for,O
well,O
-,O
defined,O
subgroups,O
of,O
colorectal,B-disease
cancers,I-disease
because,O
biological,O
heterogeneity,O
may,O
confound,O
this,O
type,O
of,O
quantitative,O
analysis,O
.,O
 , 
Such,O
estimates,O
should,O
be,O
considered,O
rough,O
guides,O
rather,O
than,O
absolute,O
values,O
because,O
our,O
model,O
does,O
not,O
account,O
for,O
all,O
factors,O
.,O
 , 
Cancers,B-disease
were,O
classified,O
as,O
MSI+,B-Disorder
or,O
MSI-,B-Disorder
,,I-Disorder
and,O
MSI+,B-Disorder
cancers,B-disease
were,O
further,O
sub,O
-,O
classified,O
as,O
either,O
hereditary,B-Concepts_Ideas
(,B-disease
HNPCC,I-disease
),I-disease
or,O
sporadic,B-Concepts_Ideas
.,I-Concepts_Ideas
 , 
As,O
expected,O
because,O
one,O
MMR,O
mutation,O
is,O
inherited,O
,,O
estimated,O
numbers,O
of,O
critical,O
mutations,O
were,O
less,O
for,O
MSI+,B-Disorder
 , 
HNPCC,B-disease
cancers,I-disease
compared,O
to,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
.,I-disease
 , 
However,O
,,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
required,O
more,O
than,O
one,B-size
additional,O
somatic,B-mutation
mutation,I-mutation
compared,O
to,O
HNPCC,B-disease
cancers,B-cohort-patient
.,I-cohort-patient
 , 
Of,O
interest,O
,,O
a,O
difference,O
of,O
more,O
than,O
a,O
single,O
mutation,O
has,O
also,O
been,O
inferred,O
between,O
sporadic,B-Concepts_Ideas
and,O
FAP,B-disease
cancers,B-disease
,,I-disease
with,O
estimates,O
of,O
three,B-size
to,I-size
four,I-size
mutations,B-mutation
for,O
FAP,B-disease
cancers,I-disease
versus,O
six,B-size
for,O
sporadic,B-Concepts_Ideas
cancers,B-disease
[,O
6,13,O
],O
,,O
although,O
another,O
analysis,O
was,O
consistent,O
with,O
a,O
difference,O
of,O
only,O
a,O
single,O
mutation,O
[,O
14,O
],O
.,O
 , 
Therefore,O
,,O
germline,B-mutation
mutations,I-mutation
(,B-gene
APC,I-gene
and,O
MMR,B-gene
loci,O
),O
in,O
both,O
common,O
colorectal,B-body-part
familial,B-Concepts_Ideas
cancer,B-disease
syndromes,O
(,B-disease
FAP,I-disease
and,O
HNPCC,B-disease
),I-disease
appear,O
to,O
advance,O
progression,O
by,O
more,O
than,O
a,O
single,O
mutation,O
relative,O
to,O
their,O
sporadic,O
counterparts,O
.,O
 , 


,O
An,O
epigenetic,O
mechanism,O
may,O
help,O
explain,O
why,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
require,O
more,O
than,O
one,O
additional,O
somatic,O
alteration,O
relative,O
to,O
HNPCC,B-disease
cancers,I-disease
.,I-disease
 , 
Inactivation,B-Concepts_Ideas
of,I-Concepts_Ideas
the,I-Concepts_Ideas
normal,I-Concepts_Ideas
MMR,I-Concepts_Ideas
allele,I-Concepts_Ideas
occurs,O
through,O
mutation,O
(,O
usually,O
LOH,B-Physiology
[,O
15,O
],O
),O
in,O
HNPCC,B-disease
whereas,O
MMR,B-Physiology
loss,I-Physiology
in,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
is,O
associated,O
with,O
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
[,O
16,17,O
],O
.,O
 , 
CpG,O
islands,O
may,O
be,O
",O
protected,O
",O
from,O
methylation,O
because,O
most,O
are,O
unmethylated,O
at,O
birth,O
and,O
usually,O
remain,O
unmethylated,O
throughout,O
life,O
[,O
18,O
],O
.,O
 , 
Epigenetic,B-Physiology
MLH1,B-gene
inactivation,I-Physiology
may,O
require,O
at,O
least,O
two,O
cis,O
acting,O
somatic,O
alterations,O
---,O
loss,O
of,O
a,O
mechanism,O
that,O
normally,O
prevents,O
methylation,O
,,O
followed,O
by,O
the,O
accumulation,O
of,O
methylation,O
at,O
sufficient,O
numbers,O
of,O
CpG,O
sites,O
to,O
silence,O
expression,O
.,O
 , 


,O
In,O
agreement,O
with,O
prior,O
studies,O
,,O
there,O
were,O
seven,B-size
mutations,B-mutation
estimated,O
for,O
sporadic,B-Concepts_Ideas
MSI-,B-Disorder
Finnish,B-ethnicity
cancers,B-cohort-patient
[,O
4,O
],O
,,O
and,O
seven,B-size
or,I-size
eight,I-size
mutations,B-mutation
for,O
MSI+,B-Disorder
cancers,B-cohort-patient
.,I-cohort-patient
 , 
A,O
requirement,O
for,O
more,O
alterations,O
before,O
tranformation,O
for,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
compared,O
to,O
sporadic,B-Concepts_Ideas
MSI-,B-Disorder
cancers,B-disease
may,O
help,O
explain,O
why,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
cancers,B-disease
are,O
a,O
minority,O
of,O
all,O
colorectal,B-body-part
cancers,I-disease
and,O
occur,O
in,O
slightly,O
older,O
patients,B-cohort-patient
[,O
19,20,O
],O
.,O
 , 
Although,O
numbers,O
of,O
oncogenic,O
mutations,O
before,O
transformation,O
are,O
similar,O
between,O
sporadic,B-Concepts_Ideas
MSI+,B-Disorder
and,O
MSI-,B-Disorder
cancers,B-disease
,,I-disease
their,O
identities,O
likely,O
differ,O
[,O
7,8,O
],O
.,O
 , 


,O
 , 
#1601966-03-Results-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Results,O


,O
Evaluation,O
of,O
data,O
set,O
quality,O
by,O
tissue,O
-,O
wise,O
hierarchical,O
clustering,O


,O
Prior,O
to,O
the,O
analysis,O
of,O
chromosomal,O
expression,O
domains,O
,,O
we,O
aimed,O
to,O
check,O
whether,O
the,O
quality,O
of,O
our,O
complete,O
array,O
expression,O
data,O
set,O
(,O
>,O
44,O
k,O
genes,O
),O
allows,O
to,O
extract,O
discrepancies,O
between,O
tumor,B-disease
samples,O
and,O
normal,B-disease
epithelial,O
tissues,O
.,O
 , 
Purely,O
unsupervised,O
hierarchical,O
clustering,O
of,O
tissue,O
samples,O
based,O
on,O
gene,O
expression,O
vectors,O
can,O
provide,O
such,O
information,O
.,O
 , 
The,O
use,O
of,O
the,O
full,O
set,O
of,O
44,O
k,O
genes,O
for,O
clustering,O
is,O
not,O
desirable,O
,,O
because,O
of,O
high,O
signal,O
-,O
noise,O
ratios,O
and,O
computational,O
considerations,O
.,O
 , 
Therefore,O
,,O
we,O
pre,O
-,O
selected,O
potentially,O
informative,O
genes,O
for,O
hierarchical,O
clustering,O
.,O
 , 
We,O
selected,O
only,O
genes,O
which,O
had,O
reliable,O
information,O
about,O
genomic,O
localization,O
and,O
for,O
which,O
probe,O
sets,O
exceeded,O
a,O
minimum,O
expression,O
threshold,O
in,O
at,O
least,O
20,O
%,O
of,O
the,O
experiments,O
.,O
 , 
To,O
enrich,O
informative,O
genes,O
for,O
tissue,O
distinction,O
,,O
we,O
required,O
a,O
minimum,O
standard,O
deviation,O
across,O
all,O
50,B-size
samples,B-cohort-patient
.,I-cohort-patient
 , 
The,O
pre,O
-,O
selection,O
resulted,O
in,O
514,O
probe,O
sets,O
.,O
 , 
Note,O
that,O
we,O
avoided,O
to,O
pre,O
-,O
select,O
genes,O
based,O
on,O
differential,O
expression,O
between,O
tumor,O
and,O
normal,O
tissue,O
.,O
 , 
We,O
applied,O
three,O
rounds,O
of,O
normalization,O
to,O
genes,O
and,O
arrays,O
.,O
 , 
Finally,O
,,O
we,O
applied,O
standard,O
centroid,O
hierarchical,O
clustering,O
(,O
Pearson,O
correlation,O
),O
to,O
this,O
dataset,O
.,O
 , 
Two,O
large,O
clusters,O
were,O
revealed,O
(,O
Figure,O
1,O
),O
.,O
 , 
18,B-size
out,I-size
of,I-size
25,I-size
normal,B-disease
tissues,B-cohort-patient
formed,O
one,O
single,O
cluster,O
.,O
 , 
The,O
remaining,O
8,B-size
normal,B-disease
tissues,B-cohort-patient
mainly,O
clustered,O
together,O
with,O
matching,O
tumor,B-disease
samples,B-cohort-patient
from,O
same,O
patients,B-cohort-patient
.,I-cohort-patient
 , 
This,O
suggests,O
that,O
coalescence,O
between,O
tumor,B-disease
and,O
normal,B-disease
samples,B-cohort-patient
from,O
the,O
same,O
patients,B-cohort-patient
could,O
be,O
due,O
to,O
patient,B-cohort-patient
-,I-cohort-patient
specific,O
gene,O
expression,O
characteristics,O
.,O
 , 
As,O
the,O
majority,O
of,O
normal,B-disease
samples,B-cohort-patient
could,O
be,O
clearly,O
separated,O
from,O
tumors,B-disease
,,I-disease
we,O
concluded,O
that,O
our,O
data,O
set,O
is,O
well,O
suited,O
to,O
explore,O
differences,O
in,O
gene,O
expression,O
between,O
normal,B-disease
and,O
tumor,B-disease
cells,O
of,O
colorectal,B-body-part
origin,O
.,O
 , 


,O
Hierarchical,O
clustering,O
of,O
samples,B-cohort-patient
from,O
colorectal,B-body-part
tumors,B-disease
and,O
normal,B-disease
colon,B-body-part
epithelia,O
.,O
 , 
On,O
the,O
right,O
,,O
you,O
find,O
the,O
chromosomal,O
localization,O
of,O
the,O
genes,O
and,O
the,O
official,O
HUGO,O
symbol,O
or,O
prospective,O
Affymetrix,O
cluster,O
ID,O
.,O
 , 
On,O
the,O
top,O
,,O
the,O
binary,O
tree,O
of,O
tissue,O
samples,O
based,O
on,O
gene,O
expression,O
is,O
given,O
.,O
 , 
The,O
tissue,O
denominators,O
either,O
contain,O
TR,O
for,O
tumor,B-disease
or,O
E,O
for,O
epithelium,O
and,O
a,O
code,O
reflecting,O
the,O
identity,O
of,O
each,O
patient,B-cohort-patient
.,I-cohort-patient
 , 
In,O
the,O
center,O
,,O
the,O
expression,O
values,O
after,O
normalization,O
have,O
been,O
color,O
-,O
coded,O
:,O
light,O
blue,O
means,O
high,O
expression,O
,,O
black,O
means,O
low,O
(,O
or,O
no,O
),O
expression,O
.,O
 , 
Note,O
that,O
only,O
a,O
representative,O
fraction,O
of,O
the,O
514,O
genes,O
is,O
visualized,O
here,O
(,O
white,O
bars,O
replace,O
some,O
portions,O
of,O
original,O
heat,O
map,O
),O
.,O
 , 
The,O
right,O
cluster,O
contains,O
only,O
samples,O
from,O
normal,B-disease
colon,B-body-part
epithelia,O
,,O
the,O
left,O
cluster,O
is,O
composed,O
primarily,O
of,O
tumors,B-disease
along,O
with,O
some,O
interspersed,O
normal,B-disease
epithelial,O
samples,O
.,O
 , 
Note,O
that,O
misplaced,O
normal,B-disease
tissue,O
(,O
E,O
),O
samples,O
often,O
cluster,O
along,O
with,O
matching,O
tumor,B-disease
(,O
TR,O
),O
samples,B-cohort-patient
from,O
the,O
same,O
patient,B-cohort-patient
.,I-cohort-patient
 , 


,O
 , 
#1360090-06-Methods-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Methods,O


,O
The,O
275,B-size
colorectal,B-body-part
tumors,B-cohort-patient
investigated,O
in,O
this,O
study,O
were,O
obtained,O
from,O
the,O
Colorectal,O
Unit,O
of,O
the,O
Royal,O
Adelaide,O
Hospital,O
.,O
 , 
These,O
were,O
snap,O
frozen,O
in,O
liquid,O
nitrogen,O
within,O
20–40,O
min,O
after,O
resection,O
and,O
stored,O
at,O
-70,O
°,O
C,O
prior,O
to,O
extraction,O
of,O
DNA,O
.,O
 , 
Clinical,O
data,O
available,O
for,O
this,O
series,O
included,O
patient,O
age,O
,,O
sex,O
and,O
family,O
history,O
of,O
CRC,B-disease
.,I-disease
 , 
Only,O
one,O
case,B-cohort-patient
was,O
confirmed,O
as,O
HNPCC,B-disease
-,I-disease
related,I-Disorder
.,I-Disorder
 , 
Pathological,O
data,O
included,O
nodal,O
involvement,O
,,O
tumor,O
site,O
,,O
histological,O
grade,O
,,O
mucinous,O
appearance,O
and,O
the,O
presence,O
of,O
infiltrating,O
lymphocytes,O
.,O
 , 
Evaluation,O
of,O
MSI+,O
 , 
[,O
21,O
],O
,,O
CIMP+,O
[,O
18,O
],O
,,O
KRAS,B-gene
mutation,B-mutation
[,O
22,O
],O
and,O
TP53,B-gene
mutation,B-mutation
[,O
23,O
],O
were,O
performed,O
as,O
described,O
previously,O
by,O
our,O
group,O
.,O
 , 
Mutations,B-mutation
in,I-mutation
exon,I-mutation
15,I-mutation
of,O
BRAF,B-gene
including,O
the,O
V600E,B-mutation
hotspot,O
were,O
detected,O
using,O
the,O
PCR,O
primer,O
sequences,O
reported,O
earlier,O
[,O
1,O
],O
,,O
the,O
F,O
-,O
SSCP,O
method,O
[,O
22,23,O
],O
and,O
confirmed,O
by,O
direct,O
sequencing,O
.,O
 , 


,O
Statistical,O
analyses,O
were,O
performed,O
using,O
SPSS,O
Version,O
12.0,O
(,O
Chicago,O
,,O
Illinois,O
,,O
USA,O
),O
.,O
 , 
Associations,O
between,O
BRAF,B-gene
mutation,B-mutation
and,O
clinical,O
,,O
pathological,O
or,O
molecular,O
features,O
were,O
evaluated,O
using,O
Fisher,O
's,O
exact,O
or,O
Pearson,O
's,O
chi,O
-,O
squared,O
tests,O
as,O
appropriate,O
.,O
 , 
Multivariate,O
analysis,O
was,O
performed,O
using,O
binary,O
logistic,O
regression,O
with,O
BRAF,B-gene
mutation,B-mutation
as,O
the,O
dependent,O
variable,O
.,O
 , 


,O
 , 
#1334229-04-Results-p01
Results,O


,B-disease
Tumours,I-disease
from,O
464,B-size
of,I-size
656,I-size
patients,B-cohort-patient
,,I-cohort-patient
which,O
did,O
not,O
harbour,O
a,O
truncating,B-mutation
APC,B-gene
mutation,I-mutation
or,O
lacked,B-Physiology
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
were,O
analysed,O
for,O
mutations,B-mutation
in,I-mutation
exon,I-mutation
3,I-mutation
of,O
the,O
CTNNB1,B-gene
gene,O
.,O
 , 
Table,O
1,O
describes,O
the,O
tumour,B-disease
and,O
patient,B-cohort-patient
characteristics,O
of,O
seven,B-size
colorectal,B-body-part
tumours,B-cohort-patient
that,O
harboured,O
a,O
mutation,B-mutation
in,I-mutation
CTNNB1,I-mutation
exon,I-mutation
3,I-mutation
.,I-mutation
 , 
In,O
five,B-size
colorectal,B-body-part
cancers,B-disease
,,I-disease
a,O
CTNNB1,B-gene
mutation,O
that,O
would,O
lead,O
to,O
loss,B-mutation
of,I-mutation
one,I-mutation
of,I-mutation
the,I-mutation
Ser,I-mutation
/,I-mutation
Thr,I-mutation
phosphorylation,I-mutation
sites,I-mutation
and,I-mutation
subsequent,I-mutation
stabilisation,I-mutation
of,I-mutation
the,I-mutation
protein,I-mutation
,,I-mutation
occurred,I-mutation
at,I-mutation
codons,I-mutation
37,I-mutation
and,I-mutation
45,I-mutation
,,I-mutation
all,I-mutation
were,I-mutation
C→T,I-mutation
transitions,I-mutation
,,I-mutation
leading,I-mutation
to,I-mutation
Ser→Phe,I-mutation
amino,I-mutation
acid,I-mutation
changes,I-mutation
and,O
occurred,O
in,O
the,O
proximal,B-body-part
colon,I-body-part
.,I-body-part
 , 
All,O
bar,O
one,O
also,O
had,O
an,O
activating,B-mutation
mutation,I-mutation
in,O
the,O
K,B-gene
-,I-gene
ras,I-gene
gene,O
.,O
 , 
Three,B-size
of,I-size
these,I-size
five,I-size
tumours,B-cohort-patient
showed,O
hMLH1,B-gene
deficiency,I-Physiology
.,I-Physiology
 , 
Two,B-size
colorectal,B-body-part
cancer,I-disease
patients,B-cohort-patient
harboured,O
a,O
mutation,B-mutation
in,O
the,O
CTNNB1,B-gene
gene,O
,,O
that,O
did,O
not,O
occur,O
at,O
the,O
Ser,O
/,O
Thr,O
phosphorylation,O
sites,O
,,O
but,O
would,O
result,O
in,O
an,O
amino,B-mutation
acid,I-mutation
alteration,I-mutation
at,I-mutation
codons,I-mutation
22,I-mutation
and,I-mutation
29,I-mutation
,,I-mutation
the,O
effects,O
of,O
which,O
are,O
unknown,O
.,O
 , 
Because,O
of,O
the,O
very,O
low,O
frequency,O
of,O
tumours,B-disease
harbouring,O
a,O
CTNNB1,B-gene
mutation,B-mutation
,,I-mutation
these,O
mutations,O
were,O
not,O
included,O
in,O
further,O
analyses,O
.,O
 , 
In,O
addition,O
,,O
mutation,O
analysis,O
of,O
remaining,O
samples,B-cohort-patient
was,O
abandoned,O
,,O
since,O
this,O
was,O
deemed,O
irrelevant,O
as,O
these,O
harboured,O
truncating,B-mutation
APC,B-gene
mutations,I-mutation
and,O
are,O
considered,O
to,O
be,O
unlikely,O
to,O
also,O
have,O
CTNNB1,B-gene
mutations,B-mutation
[,O
7,O
],O
.,O
 , 


,O
Of,O
656,B-size
tumours,B-cohort-patient
for,O
which,O
the,O
other,O
molecular,O
alterations,O
,,O
i.e.,O
mutations,B-mutation
in,O
the,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
genes,O
and,O
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
were,O
all,O
successfully,O
and,O
completely,O
analysed,O
,,O
103,B-size
colorectal,B-body-part
tumours,B-cohort-patient
did,O
not,O
harbour,O
a,O
truncating,B-mutation
or,I-mutation
missense,I-mutation
APC,B-gene
mutation,I-mutation
,,I-mutation
an,O
activating,B-mutation
K,B-gene
-,I-gene
ras,I-gene
mutation,I-mutation
or,O
showed,O
lack,B-Physiology
of,I-Physiology
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
as,O
depicted,O
in,O
figure,O
1,O
.,O
 , 
Truncating,B-mutation
as,I-mutation
well,I-mutation
as,I-mutation
missense,I-mutation
APC,B-gene
mutations,I-mutation
and,O
activating,B-mutation
K,B-gene
-,I-gene
ras,I-gene
mutations,I-mutation
were,O
relatively,O
common,O
.,O
 , 
Truncating,B-mutation
APC,I-mutation
mutations,I-mutation
alone,O
and,O
activating,B-mutation
K,I-mutation
-,I-mutation
ras,I-mutation
mutations,I-mutation
in,I-mutation
codons,I-mutation
12,I-mutation
and,I-mutation
13,I-mutation
only,O
,,O
occurred,O
at,O
similar,O
frequencies,O
(,B-size
20,I-size
%,I-size
(,B-size
130/656,I-size
),I-size
and,O
18,B-size
%,I-size
(,B-size
121/656,I-size
),I-size
,,O
respectively,O
),O
.,O
 , 
A,O
combination,O
of,O
a,O
truncating,B-mutation
mutation,I-mutation
in,I-mutation
APC,B-gene
and,O
an,O
activating,B-mutation
mutation,I-mutation
in,I-mutation
K,I-mutation
-,I-mutation
ras,I-mutation
occurred,O
less,O
often,O
than,O
the,O
sole,O
occurrences,O
of,O
mutations,O
in,O
both,O
genes,O
.,O
 , 
However,O
,,O
as,O
shown,O
in,O
table,O
2,O
,,O
the,O
simultaneous,O
occurrence,O
of,O
mutations,O
in,O
both,O
genes,O
occurred,O
more,O
frequently,O
than,O
expected,O
on,O
the,O
basis,O
of,O
chance,O
alone,O
.,O
 , 
A,O
χ2,O
test,O
for,O
the,O
occurrence,O
of,O
a,O
truncating,B-mutation
APC,B-gene
mutation,I-mutation
and,O
an,O
activating,B-mutation
K,I-mutation
-,I-mutation
ras,I-mutation
mutation,I-mutation
revealed,O
that,O
the,O
occurrence,O
of,O
these,O
mutations,O
was,O
not,O
independent,O
(,O
χ2,O
=,O
8.7,O
,,O
P,O
<,O
0.001,O
),O
,,O
but,O
the,O
correlation,O
was,O
weak,O
(,O
Cramérs,O
V,O
=,O
0.138,O
),O
.,O
 , 
Finally,O
,,O
although,O
11,B-size
tumours,B-cohort-patient
that,O
harboured,O
a,O
mutation,B-mutation
in,O
the,O
APC,B-gene
or,O
K,B-gene
-,I-gene
ras,I-gene
gene,O
also,O
lacked,B-Physiology
hMLH1,B-gene
expression,I-Physiology
,,I-Physiology
hMLH1,B-Physiology
deficiency,I-Physiology
occurred,O
more,O
frequently,O
in,O
tumours,B-disease
that,O
did,O
not,O
harbour,O
these,O
mutations,O
(,O
χ2,O
=,O
36.6,O
,,O
P,O
<,O
0.001,O
),O
.,O
 , 


,O
 , 
#1266026-05-Discussion-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Progression,O
to,O
cancer,B-disease
has,O
been,O
modeled,O
by,O
a,O
number,O
of,O
investigators,O
with,O
different,O
approaches,O
and,O
assumptions,O
[,O
3,O
-,O
6,11,O
-,O
14,29,30,O
],O
.,O
 , 
In,O
our,O
previously,O
reported,O
approach,O
there,O
is,O
no,O
growth,O
until,O
after,O
the,O
last,O
required,O
mutation,O
has,O
been,O
acquired,O
[,O
11,O
],O
.,O
 , 
In,O
this,O
paper,O
we,O
apply,O
this,O
model,O
to,O
cancer,B-disease
subtypes,O
instead,O
of,O
considering,O
colorectal,B-disease
cancers,I-disease
as,O
a,O
single,O
uniform,O
disease,O
.,O
 , 
Modeling,O
is,O
potentially,O
more,O
informative,O
and,O
specific,O
when,O
applied,O
to,O
distinct,O
cancer,B-disease
subtypes,O
because,O
their,O
progression,O
pathways,O
can,O
differ,O
.,O
 , 
The,O
ability,O
to,O
apply,O
a,O
simple,O
multistage,O
model,O
to,O
different,O
colorectal,B-disease
cancer,I-disease
subtypes,O
that,O
have,O
marked,O
differences,O
in,O
final,O
types,O
of,O
mutations,O
and,O
clinical,O
outcomes,O
suggests,O
its,O
basic,O
underlying,O
premise,O
(,O
most,O
critical,O
alterations,O
first,O
accumulate,O
in,O
normal,B-disease
colon,B-body-part
),I-body-part
may,O
be,O
correct,O
.,O
 , 


,O
 , 
#1360090-02-Background-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Background,O


,B-gene
BRAF,I-gene
is,O
a,O
member,O
of,O
the,O
RAF,B-gene
family,O
of,O
kinases,O
that,O
acts,O
upstream,O
of,O
the,O
MEK1/2,B-gene
kinases,O
in,O
response,O
to,O
RAS,B-gene
signals,O
.,O
 , 
Activating,B-mutation
mutations,I-mutation
in,O
BRAF,B-gene
have,O
been,O
reported,O
in,O
5–15,B-size
%,I-size
of,O
colorectal,B-body-part
carcinomas,B-cohort-patient
(,B-disease
CRC,I-disease
),I-disease
,,O
with,O
by,O
far,O
the,O
most,O
common,O
mutation,O
being,O
a,O
1796,B-mutation
T,I-mutation
to,I-mutation
A,I-mutation
transversion,O
leading,O
to,O
a,O
V600E,B-mutation
substitution,O
 , 
[,O
1,O
-,O
3,O
],O
.,O
 , 
The,O
BRAF,B-gene
V600E,B-mutation
hotspot,O
mutation,O
is,O
strongly,O
associated,O
with,O
the,O
microsatellite,O
instability,O
(,O
MSI+,O
),O
phenotype,O
but,O
is,O
mutually,O
exclusive,O
with,O
KRAS,B-gene
mutations,B-mutation
 , 
[,O
4,O
-,O
7,O
],O
.,O
 , 
Interestingly,O
,,O
BRAF,B-gene
mutations,B-mutation
are,O
found,O
only,O
in,O
MSI+,B-Disorder
sporadic,B-Concepts_Ideas
tumors,B-disease
that,O
result,O
from,O
aberrant,O
MLH1,B-gene
promoter,I-Physiology
methylation,I-Physiology
and,O
do,O
not,O
occur,O
in,O
MSI+,B-Disorder
tumors,B-disease
from,O
hereditary,B-disease
non,I-disease
-,I-disease
polyposis,I-disease
colorectal,I-disease
cancer,I-disease
(,B-disease
HNPCC,I-disease
),I-disease
patients,B-cohort-patient
[,O
5,8,O
-,O
10,O
],O
,,O
thus,O
providing,O
a,O
convenient,O
discriminator,O
between,O
sporadic,B-Concepts_Ideas
and,O
familial,B-Concepts_Ideas
cases,B-cohort-patient
.,I-cohort-patient
 , 
The,O
majority,O
of,O
MSI+,B-Disorder
sporadic,B-Concepts_Ideas
tumors,B-disease
belong,O
to,O
a,O
larger,O
CRC,B-disease
group,B-cohort-patient
referred,O
to,O
as,O
the,O
CpG,B-Physiology
island,I-Physiology
methylator,I-Physiology
phenotype,I-Physiology
(,B-Physiology
CIMP+,I-Physiology
),I-Physiology
that,O
is,O
characterised,O
by,O
widespread,O
hypermethylation,O
of,O
CpG,O
islands,O
located,O
with,O
gene,O
promoter,O
regions,O
[,O
11,O
],O
.,O
 , 
Both,O
MSI+,B-Disorder
and,O
CIMP+,B-Physiology
tumors,B-disease
are,O
thought,O
to,O
arise,O
from,O
large,B-Disorder
hyperplastic,I-Disorder
polyps,B-disease
and,O
serrated,B-Concepts_Ideas
adenomas,B-disease
[,O
12,13,O
],O
and,O
recent,O
work,O
has,O
demonstrated,O
a,O
high,O
frequency,O
of,O
BRAF,B-gene
mutations,B-mutation
in,O
these,O
lesions,B-disease
[,O
7,14,15,O
],O
.,O
 , 


,O
Although,O
the,O
positive,O
association,O
with,O
MSI+,O
and,O
inverse,O
association,O
with,O
KRAS,B-gene
mutation,B-mutation
have,O
been,O
well,O
documented,O
,,O
little,O
is,O
known,O
about,O
the,O
other,O
properties,O
of,O
tumors,B-disease
with,O
BRAF,B-gene
mutation,B-mutation
.,I-mutation
 , 
In,O
the,O
present,O
study,O
we,O
analysed,O
for,O
BRAF,B-gene
V600E,B-mutation
mutations,O
in,O
a,O
consecutive,O
series,O
of,O
275,B-size
CRCs,B-cohort-patient
that,O
were,O
well,O
characterised,O
for,O
the,O
major,O
pathological,O
and,O
molecular,O
features,O
of,O
this,O
disease,O
.,O
 , 
Our,O
results,O
demonstrate,O
that,O
oncogenic,B-mutation
BRAF,B-gene
mutation,I-mutation
occurs,O
preferentially,O
within,O
a,O
subgroup,O
of,O
CRCs,B-disease
that,O
have,O
distinctive,O
features,O
.,O
 , 
It,O
could,O
therefore,O
be,O
used,O
as,O
a,O
convenient,O
marker,O
for,O
the,O
further,O
characterisation,O
of,O
these,O
tumors,B-disease
,,I-disease
particularly,O
in,O
relation,O
to,O
their,O
prognosis,O
and,O
response,O
to,O
adjuvant,O
chemotherapy,O
.,O
 , 


,O
 , 
#1619718-05-Discussion-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,B-Disorder
Non,I-Disorder
-,I-Disorder
dysplastic,I-Disorder
serrated,B-Concepts_Ideas
polyps,B-disease
:,I-disease
HP,B-disease
and,O
SSA,B-disease


,B-Disorder
Non,I-Disorder
-,I-Disorder
dysplastic,I-Disorder
serrated,B-Concepts_Ideas
polyps,B-disease
comprise,O
conventional,O
HPs,B-disease
and,O
the,O
variant,O
lesion,B-disease
which,O
has,O
been,O
described,O
as,O
SSA,B-disease
.,I-disease
 , 
In,O
this,O
study,O
,,O
SSAs,B-disease
accounted,O
for,O
approximately,O
3,B-size
%,I-size
of,O
the,O
overall,O
series,O
of,O
polyps,B-disease
and,O
were,O
more,O
age,O
-,O
related,O
than,O
HPs,B-disease
.,I-disease
 , 
Importantly,O
,,O
SSAs,B-disease
have,O
been,O
linked,O
with,O
the,O
subset,O
of,O
colorectal,B-disease
cancer,I-disease
with,O
BRAF,B-gene
mutation,B-mutation
,,I-mutation
DNA,B-Physiology
methylation,I-Physiology
,,I-Physiology
MSI,B-Disorder
and,O
serrated,B-Disorder
architecture.14,18,37,I-Disorder
 , 
In,O
this,O
study,O
there,O
was,O
a,O
high,O
frequency,O
of,O
BRAF,B-gene
mutation,B-mutation
in,O
conventional,B-Concepts_Ideas
HPs,B-cohort-patient
(,B-size
67,I-size
%,I-size
),I-size
as,O
well,O
as,O
in,O
SSAs,B-cohort-patient
(,B-size
81,I-size
%,I-size
),I-size
.,O
 , 
Previous,O
reports,O
have,O
shown,O
very,O
similar,O
results,O
for,O
BRAF,B-gene
mutation,B-mutation
in,O
SSA,16,B-disease
but,O
higher,O
frequencies,O
of,O
KRAS,B-gene
mutation,B-mutation
and,O
lower,O
frequencies,O
of,O
BRAF,B-gene
mutation,B-mutation
in,O
HPs.12,16,38,B-disease
As,O
mentioned,O
in,O
Materials,O
and,O
methods,O
,,O
there,O
had,O
been,O
selection,O
of,O
larger,B-Concepts_Ideas
HPs,B-disease
in,O
an,O
earlier,O
cell,O
kinetic,O
study,O
involving,O
the,O
same,O
material,O
.,O
 , 
Large,B-Concepts_Ideas
HPs,B-disease
are,O
more,O
likely,O
to,O
include,O
the,O
subset,O
described,O
as,O
‘,B-body-part
microvesicular,I-body-part
’,I-body-part
,,O
in,O
which,O
the,O
columnar,O
cells,O
contain,O
apical,O
mucin,O
droplets,O
within,O
small,O
vesicles,O
while,O
goblet,O
cells,O
are,O
rendered,O
inconspicuous.25BRAF,B-gene
mutation,B-mutation
occurs,O
more,O
frequently,O
in,O
the,O
microvesicular,B-body-part
variant,I-body-part
of,O
HP.16,B-disease
 , 
By,O
contrast,O
,,O
KRAS,B-gene
mutation,B-mutation
occurs,O
much,O
more,O
commonly,O
in,O
the,O
goblet,B-Concepts_Ideas
cell,I-Concepts_Ideas
variant,I-Concepts_Ideas
of,O
HP,B-disease
,,I-disease
which,O
is,O
usually,O
small,B-Concepts_Ideas
,,I-Concepts_Ideas
located,O
in,O
the,O
left,B-body-part
colon,I-body-part
or,O
rectum,B-body-part
and,O
deviates,O
minimally,O
from,O
normal,B-disease
colorectal,B-body-part
mucosa,I-body-part
in,O
terms,O
of,O
differentiation,O
and,O
architecture.16,25,O
The,O
latter,O
were,O
under,O
-,O
represented,O
in,O
this,O
series,O
(,O
details,O
not,O
shown,O
),O
.,O
 , 


,B-Disorder
dysplastic,I-Disorder
serrated,B-Concepts_Ideas
polyps,B-disease
:,I-disease
MP,B-disease
and,O
SA,B-disease


,I-disease
Serrated,I-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
,,I-Disorder
i.e.,O
MPs,B-disease
and,O
SAs,B-disease
,,I-disease
together,O
comprised,O
only,O
2,B-size
%,I-size
of,O
the,O
overall,O
consecutive,O
series,O
of,O
1250,B-size
polyps,B-cohort-patient
.,I-cohort-patient
 , 
While,O
mutation,B-mutation
of,O
KRAS,B-gene
and,O
BRAF,B-gene
was,O
associated,O
with,O
conventional,B-Concepts_Ideas
adenoma,B-disease
and,O
SSA,B-disease
,,I-disease
respectively,O
(,O
see,O
above,O
),O
,,O
BRAF,B-gene
and,O
KRAS,B-gene
mutation,B-mutation
occurred,O
with,O
similar,O
frequency,O
in,O
both,O
MPs,B-cohort-patient
(,B-size
40,I-size
%,I-size
and,O
50,B-size
%,I-size
,,I-size
respectively,O
),O
and,O
SAs,B-disease
(,B-size
33,I-size
%,I-size
and,O
27,B-size
%,I-size
,,I-size
respectively,O
),O
.,O
 , 
In,O
the,O
literature,O
,,O
the,O
frequency,O
of,O
BRAF,B-gene
and,O
KRAS,B-gene
mutation,B-mutation
in,O
MP,B-disease
or,O
SA,B-cohort-patient
has,O
ranged,O
from,O
36,B-size
to,I-size
100,I-size
%,I-size
and,O
from,O
0,B-size
%,I-size
to,I-size
60,I-size
%,I-size
,,I-size
respectively.12,16,39–42,O
These,O
findings,O
indicate,O
that,O
this,O
subset,O
of,O
colorectal,B-body-part
polyps,B-disease
is,O
likely,O
to,O
be,O
heterogeneous,B-Concepts_Ideas
in,O
terms,O
of,O
its,O
molecular,O
origins,O
.,O
 , 
These,O
polyps,B-disease
were,O
therefore,O
reclassified,O
according,O
to,O
their,O
resemblance,O
to,O
HP,B-disease
or,O
SSA,B-disease
(,B-cohort-patient
Group,I-cohort-patient
A,I-cohort-patient
),I-cohort-patient
(,O
Figure,O
1A,O
,,O
B,O
,,O
E,O
,,O
F,O
),O
or,O
to,O
conventional,B-Concepts_Ideas
adenoma,B-disease
(,B-cohort-patient
Group,I-cohort-patient
B,I-cohort-patient
),I-cohort-patient
(,O
Figure,O
1C,O
,,O
D,O
),O
.,O
 , 
Particular,O
histological,O
features,O
among,O
the,O
Group,B-cohort-patient
A,I-cohort-patient
polyps,B-disease
were,O
:,O
marked,B-Concepts_Ideas
serration,I-Concepts_Ideas
,,I-Concepts_Ideas
a,O
papillary,B-Disorder
or,I-Disorder
villous,I-Disorder
architecture,I-Disorder
,,I-Disorder
a,O
relatively,O
abundant,B-body-part
eosinophilic,I-body-part
cytoplasm,I-body-part
,,I-body-part
columnar,O
cells,O
with,O
apical,O
mucin,O
droplets,O
,,O
nuclei,B-body-part
that,I-body-part
were,I-body-part
enlarged,I-body-part
,,I-body-part
ovoid,I-body-part
,,I-body-part
vesicular,I-body-part
and,I-body-part
contained,I-body-part
a,I-body-part
prominent,I-body-part
nucleolus,I-body-part
,,I-body-part
and,O
adjacent,B-body-part
non,I-body-part
-,I-body-part
dysplastic,I-body-part
serrated,I-body-part
polyp,I-body-part
.,I-body-part
 , 
Particular,O
histological,O
features,O
among,O
the,O
Group,B-cohort-patient
B,I-cohort-patient
polyps,B-disease
were,O
:,O
some,O
glandular,B-Concepts_Ideas
serration,I-Concepts_Ideas
,,I-Concepts_Ideas
frequent,O
villous,B-Concepts_Ideas
change,I-Concepts_Ideas
and,O
epithelial,B-body-part
dysplasia,I-Disorder
that,I-Disorder
appeared,I-Disorder
adenomatous,I-Disorder
(,O
cytoplasmic,O
basophilia,O
and,O
nuclei,O
that,O
were,O
elongated,O
,,O
pseudostratified,O
and,O
hyperchromatic,O
without,O
a,O
prominent,O
nucleolus,O
),O
.,O
 , 
Importantly,O
,,O
BRAF,B-gene
mutation,B-mutation
occurred,O
more,O
frequently,O
among,O
Group,B-cohort-patient
A,I-cohort-patient
polyps,B-disease
(,O
P,O
<,O
0.03,O
),O
,,O
whereas,O
there,O
was,O
a,O
trend,O
for,O
KRAS,B-gene
to,O
be,O
more,O
frequent,O
among,O
Group,B-cohort-patient
B,I-cohort-patient
polyps,B-disease
(,O
P,O
=,O
0.06,O
),O
.,O
 , 


,O
 , 
#2386495-01-Abstract-p01
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Clinical,O
characterization,O
and,O
the,O
mutation,O
spectrum,O
in,O
Swedish,B-ethnicity
adenomatous,B-Disorder
polyposis,I-disease
families,B-cohort-patient


,I-cohort-patient
Abstract,O


,O
Background,O


,O
The,O
dominantly,B-Concepts_Ideas
inherited,I-Concepts_Ideas
condition,O
familial,B-disease
adenomatous,I-disease
polyposis,I-disease
(,B-disease
FAP,I-disease
),I-disease
is,O
caused,O
by,O
germline,B-mutation
mutations,I-mutation
in,O
the,O
APC,B-gene
gene,O
.,O
 , 
Finding,O
the,O
causative,O
mutations,O
has,O
great,O
implications,O
for,O
the,O
families,B-cohort-patient
.,I-cohort-patient
 , 
Correlating,O
the,O
genotypes,O
to,O
the,O
phenotypes,O
could,O
help,O
to,O
improve,O
the,O
diagnosis,O
and,O
follow,O
-,O
up,O
of,O
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
Methods,O


,O
Mutation,O
screening,O
of,O
APC,B-gene
and,O
the,O
clinical,O
characterization,O
of,O
96,B-size
unrelated,B-cohort-patient
FAP,I-cohort-patient
patients,I-cohort-patient
from,O
the,O
Swedish,B-ethnicity
Polyposis,B-disease
Registry,O
was,O
performed,O
.,O
 , 
In,O
addition,O
to,O
generally,O
used,O
mutation,O
screening,O
methods,O
,,O
analyses,O
of,O
splicing,O
-,O
affecting,O
mutations,O
and,O
investigations,O
of,O
the,O
presence,O
of,O
low,O
-,O
frequency,O
mutation,O
alleles,O
,,O
indicating,O
mosaics,O
,,O
have,O
been,O
performed,O
,,O
as,O
well,O
as,O
quantitative,O
real,O
-,O
time,O
polymerase,O
chain,O
reaction,O
to,O
detect,O
lowered,B-Physiology
expression,I-Physiology
of,I-Physiology
APC,B-gene
.,I-gene
 , 


,O
Results,O


,B-size
Sixty,I-size
-,I-size
one,I-size
different,O
APC,B-gene
mutations,B-mutation
in,O
81,B-size
of,I-size
the,I-size
96,I-size
families,B-cohort-patient
were,O
identified,O
and,O
27,B-mutation
of,O
those,O
are,O
novel,O
.,O
 , 
We,O
have,O
previously,O
shown,O
that,O
6,B-size
of,I-size
the,I-size
96,I-size
patients,B-cohort-patient
carried,O
biallelic,B-mutation
MUTYH,B-gene
mutations,I-mutation
.,I-mutation
 , 
The,O
9,B-size
mutation,B-cohort-patient
-,I-cohort-patient
negative,I-cohort-patient
cases,I-cohort-patient
all,O
display,O
an,O
attenuated,O
or,O
atypical,O
phenotype,O
.,O
 , 
Probands,B-cohort-patient
with,I-cohort-patient
a,I-cohort-patient
genotype,I-cohort-patient
(,I-cohort-patient
codon,I-cohort-patient
1250–1464,I-cohort-patient
),I-cohort-patient
predicting,O
a,O
severe,O
phenotype,O
had,O
a,O
median,B-age
age,I-age
at,I-age
diagnosis,I-age
of,I-age
21.8,B-age
(,I-age
range,I-age
,,I-age
11–49,I-age
),I-age
years,I-age
compared,O
with,O
34.4,B-age
(,I-age
range,I-age
,,I-age
14–57,I-age
),I-age
years,I-age
among,O
those,B-cohort-patient
with,I-cohort-patient
mutations,I-cohort-patient
outside,I-cohort-patient
this,I-cohort-patient
region,I-cohort-patient
(,O
P,O
<,O
0.017,O
),O
.,O
 , 
Dense,B-Disorder
polyposis,B-disease
(,O
>,O
1000,O
),O
occurred,O
in,O
75,B-size
%,I-size
of,O
the,O
probands,B-cohort-patient
with,I-cohort-patient
a,I-cohort-patient
severe,I-cohort-patient
phenotype,I-cohort-patient
compared,O
with,O
30,B-size
%,I-size
in,O
those,B-cohort-patient
with,I-cohort-patient
mutations,I-cohort-patient
outside,I-cohort-patient
this,I-cohort-patient
region,I-cohort-patient
.,I-cohort-patient
 , 
The,O
morbidity,B-Concepts_Ideas
in,O
colorectal,B-body-part
cancer,B-disease
among,O
probands,B-cohort-patient
was,O
25,B-size
%,I-size
at,O
a,O
mean,B-age
age,I-age
of,I-age
37.5,I-age
years,I-age
and,O
29,B-size
%,I-size
at,O
a,O
mean,B-age
age,I-age
of,I-age
46.6,I-age
years,I-age
.,I-age
 , 


,O
Conclusion,O


,O
Using,O
a,O
variety,O
of,O
mutation,O
-,O
detection,O
techniques,O
,,O
we,O
have,O
achieved,O
a,O
100,O
%,O
detection,O
frequency,O
in,O
classical,B-Concepts_Ideas
FAP,B-disease
.,I-disease
 , 
Probands,B-cohort-patient
with,O
APC,B-gene
mutations,B-mutation
outside,I-mutation
codon,I-mutation
1250–1464,I-mutation
,,I-mutation
although,O
exhibiting,O
a,O
less,B-Physiology
-,I-Physiology
severe,I-Physiology
phenotype,I-Physiology
,,I-Physiology
are,O
at,O
high,B-Concepts_Ideas
risk,I-Concepts_Ideas
of,I-Concepts_Ideas
having,I-Concepts_Ideas
a,I-Concepts_Ideas
colorectal,B-disease
cancer,I-disease
at,O
diagnosis,O
indicating,O
that,O
age,O
at,O
diagnosis,O
is,O
as,O
important,O
as,O
the,O
severity,O
of,O
the,O
disease,B-disease
for,O
colorectal,B-disease
cancer,B-disease
morbidity,B-Concepts_Ideas
.,I-Concepts_Ideas
 , 


,O
 , 
#1619718-05-Discussion-p03
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
 , 
The,O
preceding,O
findings,O
indicate,O
that,O
serrated,B-Concepts_Ideas
polyps,B-disease
with,O
dysplasia,B-Disorder
evolve,O
through,O
at,O
least,O
two,O
independent,O
histogenetic,O
pathways,O
.,O
 , 
Group,B-cohort-patient
A,I-cohort-patient
polyps,B-disease
are,O
likely,O
to,O
be,O
initiated,O
by,O
BRAF,B-gene
mutation,B-mutation
and,O
are,O
serrated,B-Concepts_Ideas
lesions,B-disease
at,O
the,O
outset,O
.,O
 , 
Group,B-cohort-patient
B,I-cohort-patient
polyps,B-disease
may,O
begin,O
as,O
conventional,B-Concepts_Ideas
adenomas,B-disease
and,O
then,O
become,O
serrated,B-Concepts_Ideas
and,O
villous,B-Concepts_Ideas
following,O
mutation,B-mutation
of,O
KRAS,B-gene
.,I-gene
 , 
There,O
may,O
be,O
instances,O
in,O
which,O
KRAS,B-gene
mutation,B-mutation
can,O
initiate,O
lesions,B-disease
which,O
are,O
serrated,B-Concepts_Ideas
at,O
the,O
outset,O
and,O
become,O
dysplastic,B-Disorder
.,I-Disorder
 , 
While,O
this,O
suggestion,O
remains,O
speculative,O
,,O
it,O
may,O
apply,O
to,O
the,O
Group,B-cohort-patient
A,I-cohort-patient
serrated,B-Concepts_Ideas
polyps,B-disease
that,O
show,O
a,O
distinct,O
likeness,O
to,O
the,O
goblet,B-Concepts_Ideas
cell,I-Concepts_Ideas
variant,I-Concepts_Ideas
of,O
HP,B-disease
in,O
which,O
columnar,O
cells,O
are,O
eosinophilic,O
and,O
lack,O
mucin,O
-,O
filled,O
microvesicles,O
and,O
KRAS,B-gene
mutation,B-mutation
is,O
frequent,O
(,O
Figure,O
1E,O
,,O
F).16,25,O
 , 
The,O
literature,O
refers,O
to,O
the,O
concept,O
of,O
‘,B-Concepts_Ideas
traditional,I-Concepts_Ideas
’,I-Concepts_Ideas
SA.43,B-disease
Based,O
on,O
the,O
current,O
findings,O
,,O
it,O
is,O
likely,O
that,O
several,O
mechanisms,O
can,O
account,O
for,O
adenomatous,B-Disorder
lesions,B-disease
with,O
glandular,B-Concepts_Ideas
serration,I-Concepts_Ideas
and,O
that,O
‘,B-Concepts_Ideas
traditional,I-Concepts_Ideas
’,I-Concepts_Ideas
SA,B-disease
is,O
not,O
a,O
single,O
entity,O
.,O
 , 


,O
Concept,O
of,O
‘,O
fusion,O
’,O
pathways,O
to,O
crc,B-disease


,I-disease
Colorectal,I-body-part
polyps,B-disease
have,O
traditionally,O
been,O
classified,O
into,O
distinct,O
histogenetic,O
types,O
that,O
may,O
progress,O
to,O
CRC,B-disease
through,O
independent,O
pathways,O
of,O
colorectal,B-body-part
tumorigenesis,B-disease
(,O
Table,O
2,O
),O
.,O
 , 
However,O
,,O
in,O
addition,O
to,O
the,O
two,O
‘,O
classical,O
’,O
pathways,O
to,O
CRC,B-disease
shown,O
in,O
Table,O
2,O
,,O
there,O
may,O
be,O
‘,O
fusion,O
’,O
pathways,O
that,O
combine,O
mechanisms,O
associated,O
with,O
both,O
adenomas,B-disease
and,O
serrated,B-Concepts_Ideas
polyps,B-disease
.,I-disease
 , 
This,O
would,O
explain,O
why,O
many,O
CRCs,B-disease
display,O
phenotypes,O
associated,O
with,O
serrated,B-Concepts_Ideas
polyps,B-disease
as,O
well,O
as,O
adenomas.44,B-disease
Three,O
possible,O
examples,O
of,O
such,O
fusion,O
pathways,O
are,O
shown,O
in,O
Table,O
3,O
.,O
 , 
It,O
is,O
difficult,O
to,O
observe,O
directly,O
the,O
actual,O
point,O
of,O
transition,O
from,O
benign,O
to,O
malignant,B-Concepts_Ideas
colorectal,B-body-part
lesions,B-disease
.,I-disease
 , 
Once,O
the,O
key,O
rate,O
-,O
limiting,O
step,O
is,O
achieved,O
it,O
is,O
likely,O
that,O
the,O
transition,O
to,O
cancer,B-disease
occurs,O
rapidly,O
and,O
the,O
precursor,B-Concepts_Ideas
lesion,B-disease
is,O
then,O
overtaken,O
by,O
the,O
malignancy,O
.,O
 , 
Changes,O
leading,O
to,O
inactivation,B-mutation
of,I-Physiology
either,I-Physiology
TP535,B-gene
or,I-Physiology
the,I-Physiology
DNA,I-Physiology
mismatch,I-Physiology
repair,I-Physiology
gene,I-Physiology
MLH113,B-gene
are,O
likely,O
to,O
be,O
two,O
such,O
rate,O
-,O
limiting,O
mechanisms,O
.,O
 , 
Only,O
a,O
single,O
instance,O
of,O
loss,B-Physiology
of,I-Physiology
expression,I-Physiology
of,I-Physiology
MLH1,B-gene
was,O
observed,O
in,O
the,O
present,O
series,O
of,O
polyps,B-disease
and,O
the,O
adenoma,B-disease
in,O
question,O
was,O
inferred,O
to,O
be,O
from,O
a,O
patient,B-cohort-patient
with,O
Lynch,B-disease
syndrome.24,I-disease


,O
Concept,O
of,O
discrete,O
colorectal,B-body-part
lesions,B-disease
and,O
progression,O
to,O
colorectal,B-disease
cancer,B-disease
via,O
independent,O
pathways,O


,B-disease
ACF,I-disease
,,I-disease
Aberrant,B-Concepts_Ideas
crypt,B-body-part
foci,B-disease
(,B-Disorder
hyperplastic,I-Disorder
or,O
dysplastic,B-Disorder
),I-Disorder
;,O
HP,B-disease
,,I-disease
hyperplastic,B-Disorder
polyp,B-disease
;,I-disease
SSA,B-disease
,,I-disease
sessile,B-Concepts_Ideas
serrated,B-Concepts_Ideas
adenoma,B-disease
;,I-disease
SA,B-disease
,,I-disease
serrated,B-Concepts_Ideas
adenoma,B-disease
;,I-disease
TA,B-disease
,,I-disease
tubular,B-Concepts_Ideas
adenoma,B-disease
.,I-disease
 , 


,B-Physiology
Inactivation,I-Physiology
of,I-Physiology
MLH1,I-Physiology
and,I-Physiology
TP53,I-Physiology
is,O
associated,O
with,O
malignant,O
progression,O
.,O
 , 


,O
‘,O
Fusion,O
’,O
pathways,O
brought,O
about,O
by,O
the,O
sequential,O
alteration,O
of,O
genes,O
(,O
linked,O
to,O
separate,O
lesions,B-disease
and,O
pathways,O
in,O
Table,O
2,O
),O
and,O
with,O
the,O
second,O
alteration,O
associated,O
with,O
a,O
superimposed,O
morphology,O


,O
 , 
#1619718-02-Introduction-p02
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Subsequently,O
,,O
it,O
was,O
argued,O
that,O
HP,B-disease
and,O
SA,B-disease
are,O
related,O
lesions.11,B-disease
 , 
The,O
latter,O
could,O
arise,O
within,O
the,O
former,O
(,O
giving,O
a,O
MP,B-disease
),I-disease
or,O
could,O
develop,O
as,O
de,O
novo,O
SA,B-disease
but,O
through,O
mechanisms,O
shared,O
with,O
HPs,B-disease
.,I-disease
 , 
This,O
proposal,O
subsequently,O
received,O
strong,O
support,O
through,O
the,O
demonstration,O
of,O
molecular,O
alterations,O
common,O
to,O
both,O
types,O
of,O
serrated,B-Concepts_Ideas
polyp,B-disease
,,I-disease
notably,O
mutation,B-mutation
of,O
BRAF,B-gene
and,O
extensive,O
DNA,B-Physiology
methylation.12,I-Physiology
 , 
This,O
viewpoint,O
was,O
consolidated,O
through,O
the,O
formal,O
recognition,O
of,O
two,O
largely,O
independent,O
pathways,O
of,O
colorectal,B-body-part
tumorigenesis,B-disease
:,I-disease
(,O
i,O
),O
the,O
traditional,O
adenoma,B-disease
–,I-disease
carcinoma,I-disease
sequence,O
associated,O
with,O
chomosomally,B-Disorder
unstable,I-Disorder
CRCs,13,B-disease
and,O
(,O
ii,O
),O
the,O
‘,B-Concepts_Ideas
serrated,I-Concepts_Ideas
pathway,O
’,O
culminating,O
in,O
CRCs,B-disease
with,O
DNA,O
microsatellite,B-Disorder
instability,I-Disorder
(,B-Disorder
MSI,I-Disorder
),I-Disorder
,,O
mutation,B-mutation
of,O
BRAF,B-gene
and,O
extensive,O
DNA,B-Physiology
methylation.12,14–20,I-Physiology


,O
This,O
paper,O
explores,O
the,O
possibility,O
that,O
the,O
early,O
evolution,O
of,O
colorectal,B-disease
cancer,I-disease
is,O
not,O
limited,O
to,O
two,O
essentially,O
independent,O
pathways,O
,,O
but,O
often,O
combines,O
components,O
of,O
these,O
pathways,O
.,O
 , 
Indeed,O
,,O
the,O
successful,O
‘,O
fusion,O
’,O
of,O
the,O
hyperproliferation,B-Disorder
and,O
crypt,B-Disorder
fission,I-Disorder
that,O
characterize,O
adenomas21,B-disease
with,O
the,O
inhibition,B-Physiology
of,I-Physiology
apoptosis,I-Physiology
that,O
has,O
been,O
linked,O
with,O
serrated,B-Concepts_Ideas
polyps22,23,B-disease
may,O
generate,O
lesions,B-disease
with,O
enhanced,B-Concepts_Ideas
aggressiveness,I-Concepts_Ideas
.,I-Concepts_Ideas
 , 
Specifically,O
,,O
it,O
is,O
suggested,O
that,O
methylation,B-Physiology
of,I-Physiology
the,I-Physiology
DNA,I-Physiology
repair,I-Physiology
gene,I-Physiology
O-6,B-gene
-,I-gene
methylguanine,I-gene
DNA,I-gene
methyltransferase,I-gene
(,B-gene
MGMT,I-gene
),I-gene
,,O
mutation,B-mutation
of,O
KRAS,B-gene
and,O
inactivation,B-mutation
of,I-Physiology
TP53,B-gene
provide,O
critical,O
combinations,O
of,O
molecular,O
‘,O
cross,O
-,O
over,O
’,O
between,O
the,O
two,O
pathways,O
that,O
occur,O
at,O
the,O
stage,O
of,O
precancerous,B-Concepts_Ideas
polyps,B-disease
.,I-disease
 , 


,O
 , 
#1334229-06-Conclusion-p01
Conclusion,O


,O
In,O
conclusion,O
,,O
this,O
study,O
shows,O
that,O
mutations,B-mutation
in,O
the,O
CTNNB1,B-gene
gene,O
are,O
presumably,O
of,O
minor,O
importance,O
in,O
sporadic,B-Concepts_Ideas
colorectal,B-body-part
cancer,B-disease
.,I-disease
 , 
Although,O
APC,B-gene
and,O
K,B-gene
-,I-gene
ras,I-gene
mutations,B-mutation
are,O
often,O
observed,O
seperately,O
in,O
a,O
tumour,B-disease
,,I-disease
these,O
mutations,O
seem,O
to,O
also,O
occur,O
in,O
a,O
co,O
-,O
dependent,O
manner,O
.,O
 , 
Tumours,B-disease
that,O
display,O
mismatch,B-Physiology
repair,I-Physiology
deficiency,I-Physiology
,,I-Physiology
may,O
form,O
a,O
distinct,O
sub,O
-,O
group,O
as,O
they,O
differ,O
from,O
tumours,B-disease
with,O
APC,B-gene
and/or,O
K,B-gene
-,I-gene
ras,I-gene
mutations,B-mutation
with,O
regard,O
to,O
age,O
,,O
sex,O
,,O
tumour,B-disease
sub,O
-,O
localisation,O
and,O
differentiation,O
.,O
 , 


,O
 , 
#2275286-03-Methods-p04
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
*,O
*,O
IGNORE,O
LINE,O
*,O
*,O

,O
Statistical,O
methods,O


,O
The,O
data,O
are,O
presented,O
as,O
mean,O
and,O
standard,O
deviation,O
(,O
x,O
±,O
SD,O
),O
or,O
percentage,O
.,O
 , 
Student,O
t,O
-,O
test,O
,,O
chi,O
-,O
square,O
test,O
or,O
Log,O
-,O
rank,O
test,O
were,O
used,O
for,O
statistic,O
analysis,O
as,O
appropriate,O
(,O
SPSS,O
Inc.,O
,,O
Chicago,O
,,O
IL,O
,,O
USA,O
),O
,,O
with,O
p,O
<,O
0.05,O
indicating,O
statistical,O
significance,O
.,O
 , 


,O
 , 
#3034663-05-Discussion-p02
As,O
most,O
disease,O
pedigrees,O
are,O
small,O
,,O
it,O
is,O
difficult,O
to,O
obtain,O
a,O
sufficient,O
number,O
of,O
samples,O
from,O
affected,B-disease
and,O
informative,O
unaffected,B-disease
individuals,B-cohort-patient
.,I-cohort-patient
 , 
Moreover,O
,,O
LS,B-disease
deleterious,O
variants,O
are,O
not,O
completely,O
penetrant,O
.,O
 , 
For,O
these,O
reasons,O
,,O
it,O
is,O
rarely,O
possible,O
to,O
categorize,O
variants,O
as,O
deleterious,O
based,O
on,O
segregation,O
alone,O
.,O
 , 
The,O
co,O
-,O
occurrence,O
of,O
another,O
known,O
deleterious,O
variant,O
reduces,O
the,O
likelihood,O
that,O
an,O
UV,O
is,O
truly,O
deleterious,O
,,O
especially,O
when,O
both,O
variants,O
are,O
located,O
in,O
trans,O
[,O
3,O
],O
.,O
 , 
To,O
our,O
knowledge,O
,,O
co,O
-,O
occurrence,O
of,O
a,O
deleterious,O
variant,O
in,O
one,O
of,O
the,O
LS,B-disease
genes,O
with,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
has,O
been,O
observed,O
in,O
only,O
two,B-size
families,B-cohort-patient
.,I-cohort-patient
 , 
Liu,O
et,O
 , 
al,O
 , 
[,O
14,O
],O
described,O
an,O
index,B-cohort-patient
subject,I-cohort-patient
from,O
a,O
LS,B-disease
family,B-cohort-patient
with,O
two,O
heterozygous,O
variants,O
(,B-mutation
c.546,I-mutation
-,I-mutation
2A,I-mutation
>,I-mutation
G,I-mutation
and,O
c.1852_1853AA,B-mutation
>,I-mutation
GC,I-mutation
),I-mutation
;,O
only,O
the,O
former,O
segregated,O
with,O
LS,B-disease
in,O
the,O
family,B-cohort-patient
.,I-cohort-patient
 , 
Similarly,O
,,O
Steinke,O
et,O
al,O
 , 
[,O
15,O
],O
,,O
described,O
the,O
co,O
-,O
occurrence,O
of,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
 , 
(,B-mutation
c.1852_1853AA,I-mutation
>,I-mutation
GC,I-mutation
),I-mutation
variant,O
with,O
the,O
MSH6,B-gene
p.,B-mutation
Arg1068X,I-mutation
(,B-mutation
c.3202C,I-mutation
>,I-mutation
T,I-mutation
),I-mutation
deleterious,O
variant,O
.,O
 , 


,O
Herein,O
,,O
we,O
describe,O
the,O
coexistence,O
of,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
with,O
deleterious,O
variants,O
in,O
another,O
two,B-size
unrelated,O
LS,B-disease
families,B-cohort-patient
.,I-cohort-patient
 , 
In,O
one,B-size
family,B-cohort-patient
,,I-cohort-patient
the,O
allele,O
distribution,O
of,O
the,O
pathogenic,O
and,O
unclassified,O
variant,O
was,O
in,O
trans,O
,,O
in,O
the,O
other,O
family,B-cohort-patient
the,O
pathogenic,O
variant,O
was,O
detected,O
in,O
the,O
MSH6,B-gene
gene,O
and,O
only,O
the,O
deleterious,O
variant,O
co,O
-,O
segregated,O
with,O
the,O
disease,O
in,O
both,O
families,O
.,O
 , 
This,O
evidence,O
indicates,O
that,O
the,O
p.,B-mutation
Lys618Ala,I-mutation
variant,O
is,O
not,O
deleterious,O
.,O
 , 


,O
The,O
molecular,O
hallmark,O
of,O
LS,B-disease
tumours,I-disease
is,O
an,O
MSI,B-Disorder
phenotype,O
,,O
a,O
functional,O
consequence,O
of,O
MMR,B-Physiology
deficiency,I-Physiology
.,I-Physiology
 , 
It,O
is,O
expected,O
that,O
the,O
putative,O
germ,B-mutation
-,I-mutation
line,I-mutation
mutation,I-mutation
responsible,O
for,O
LS,B-disease
would,O
confer,O
the,O
MSI,B-Disorder
phenotype,O
.,O
 , 
We,O
tested,O
the,O
MSI,O
status,O
of,O
17,B-size
tumours,B-cohort-patient
from,O
p.,B-mutation
Lys618Ala,I-mutation
carriers,O
and,O
detected,O
only,O
two,B-size
cases,B-cohort-patient
of,O
MSI,O
(,B-size
11.8,I-size
%,I-size
),I-size
.,O
 , 
Taking,O
into,O
consideration,O
the,O
bias,O
caused,O
by,O
the,O
over,O
-,O
representation,O
of,O
Bethesda,B-Concepts_Ideas
Criteria,I-Concepts_Ideas
-,I-Concepts_Ideas
positive,I-Concepts_Ideas
tumours,B-disease
in,O
this,O
subset,O
of,O
cases,B-cohort-patient
(,B-size
8/17,I-size
),I-size
,,O
the,O
MSI,O
frequency,O
was,O
not,O
significantly,O
different,O
from,O
that,O
in,O
the,O
unselected,O
CRC,B-disease
group,B-cohort-patient
[,O
7,O
],O
.,O
 , 
This,O
is,O
further,O
proof,O
that,O
the,O
presence,O
of,O
this,O
variant,O
is,O
irrelevant,O
to,O
the,O
functional,O
inactivation,O
of,O
MLH1,B-gene
in,O
CRC,B-disease
patients,B-cohort-patient
.,I-cohort-patient
 , 


,O
Nonetheless,O
,,O
we,O
can,O
not,O
exclude,O
the,O
possibility,O
that,O
this,O
variant,O
may,O
result,O
in,O
a,O
small,O
increase,O
in,O
susceptibility,O
to,O
CRC,B-disease
or,O
adenomas,B-disease
,,I-disease
as,O
was,O
suggested,O
by,O
Fearnhead,O
et,O
al,O
 , 
[,O
16,O
],O
.,O
 , 
Further,O
studies,O
with,O
appropriate,O
sample,O
sizes,O
are,O
required,O
to,O
address,O
the,O
low,O
penetrance,O
effect,O
of,O
this,O
variant,O
in,O
CRC,B-disease
.,I-disease
 , 


,O
Finally,O
,,O
we,O
hypothesize,O
that,O
the,O
clinical,O
significance,O
of,O
a,O
genetic,O
variant,O
may,O
differ,O
according,O
to,O
genetic,O
background,O
.,O
 , 
Gene,O
functionality,O
may,O
be,O
the,O
net,O
result,O
of,O
the,O
effects,O
of,O
allelic,O
structures,O
and,O
their,O
interactions,O
with,O
environmental,O
factors,O
.,O
 , 
It,O
is,O
possible,O
that,O
low,O
-,O
penetrance,O
variants,O
behave,O
differently,O
in,O
different,O
populations,O
,,O
making,O
it,O
difficult,O
to,O
make,O
predictions,O
in,O
terms,O
of,O
conferred,O
risk,O
.,O
 , 


,O
 , 
